PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40640119,DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.,2025-Jul-10,,,imdoctor@snu.ac.kr.
40631774,First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.,2025-Jul-04,Hoyle; Dong; Cheng; Chen; Janik; Bourayou,"Incyte Corporation, Wilmington, DE 19803, United States.; Incyte Corporation, Wilmington, DE 19803, United States.; Incyte Corporation, Wilmington, DE 19803, United States.; Incyte Corporation, Wilmington, DE 19803, United States.; Incyte Corporation, Wilmington, DE 19803, United States.; Incyte Biosciences International Sàrl, 1110 Morges, Switzerland.",
40631773,First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.,2025-Jul-04,Hoyle; Dong; Cheng; Gong; Janik; Bourayou,"Incyte Corporation, Wilmington, DE 19803, USA.; Incyte Corporation, Wilmington, DE 19803, USA.; Incyte Corporation, Wilmington, DE 19803, USA.; Incyte Corporation, Wilmington, DE 19803, USA.; Incyte Corporation, Wilmington, DE 19803, USA.; Incyte Biosciences International Sàrl, 1110 Morges, Switzerland.",
40629017,Relationship between programmed cell death ligand 1 expression and the number of biopsy specimens in advanced gastric cancer.,2025-Jul-08,,,yukiya.narita@aichi-cc.jp.
40623176,Acyl-CoA-binding protein as a driver of pathological aging.,2025-Jul-15,Abdellatif,"BioTechMed-Graz, Graz 8010, Austria.",
40621463,Thyroid disorders as predictors of cemiplimab efficacy in recurrent/metastatic cervical cancer: real-world evidence from Poland.,2025,,,
40613596,"Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer.",2025-Dec,,,
40604351,Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma.,2025-Jul,Yamada; Takeuchi; Komatsu; Bonate; Poondru; Yang,"Astellas Pharma, Inc., Tokyo, Japan.; Astellas Pharma, Inc., Tokyo, Japan.; Astellas Pharma, Inc., Tokyo, Japan.; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.",
40590326,Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.,2025-Jul,,,elena.biagioli@marionegri.it.
40588371,Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort.,2025-Jun-30,,,spatel@ucsd.edu.
40563593,Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials.,2025-Jun-11,,,
40561062,Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice.,2025,Hemmi; Yamashita; Shimizu; Nakao,"Immuno-Oncology, Astellas Pharma Inc., Ibaraki, Japan.; Immuno-Oncology, Astellas Pharma Inc., Ibaraki, Japan.; Immuno-Oncology, Astellas Pharma Inc., Ibaraki, Japan.; Immuno-Oncology, Astellas Pharma Inc., Ibaraki, Japan.",
40554682,Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma.,2025-Jul-04,,,
40536766,First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.,2025-Jul-01,Efuni; Ikawa; Shiue; Liu; Hruska; Zhao; Tokunaga,"Kyowa Kirin Inc, Princeton, New Jersey, USA.; Kyowa Kirin Inc, Princeton, New Jersey, USA.; Kyowa Kirin Inc, Princeton, New Jersey, USA.; Kyowa Kirin Inc, Princeton, New Jersey, USA.; Kyowa Kirin Inc, Princeton, New Jersey, USA.; Kyowa Kirin Inc, Princeton, New Jersey, USA.; Kyowa Kirin Co, Ltd, Shizuoka, Japan.",
40527893,Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis.,2025-Jun-17,Kanno; Kanno; Kito; Maeda; Maeda; Yamaki; Amano; Shimomura; Suzuki; Razai; Mihara; Kubo; Shimada; Nakamura; Nomura; Kondo; Okimoto; Sugiyama; Kazimi; Eastman; Snipas; Mitchell; Maurer; Jefson; Lichter; Yamajuku; Shirai; Adachi; Hoeppner; Kubo; Kubo; Flynn; Matsumoto; Matsumoto,"Arialys Therapeutics, Inc., La Jolla, CA, USA.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.; Arialys Therapeutics, Inc., La Jolla, CA, USA.; Arialys Therapeutics, Inc., La Jolla, CA, USA. mmatsumoto@arialysrx.com.; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan. mmatsumoto@arialysrx.com.",mmatsumoto@arialysrx.com.
40523369,"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.",2025-Jul,,,neeraj.agarwal@hci.utah.edu.
40523368,"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.",2025-Jul,Wang; Wang; Wang; Dai; Shi; Yang,"CStone Pharmaceuticals (Suzhou), Suzhou, China.; CStone Pharmaceuticals (Suzhou), Suzhou, China.; CStone Pharmaceuticals (Suzhou), Suzhou, China.; CStone Pharmaceuticals (Suzhou), Suzhou, China.; CStone Pharmaceuticals (Suzhou), Suzhou, China.; CStone Pharmaceuticals (Suzhou), Suzhou, China.",caicunzhoudr@163.com.
40516378,"Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study.",2025-Jun-13,,,yunda@fredhutch.org.
40514070,Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.,2025-Jun-12,,,movvas@mskcc.org.
40511820,LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.,2025-Jul,Siu,"Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, Canada.",
40501309,Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma.,2025-Jul,,,
40500415,T and B cell responses against Epstein-Barr virus in primary sclerosing cholangitis.,2025-Jun-11,Pesesky; May; Howie; Robins,"Adaptive Biotechnologies, Seattle, WA, USA.; Adaptive Biotechnologies, Seattle, WA, USA.; Adaptive Biotechnologies, Seattle, WA, USA.; Adaptive Biotechnologies, Seattle, WA, USA.",a.franke@ikmb.uni-kiel.de.
40481574,Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies.,2025-Jun-06,Liu; Li; Ge; Chartash; Akala,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",ym.yin@hotmail.com.
40476844,A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G.,2025-Jul,,,
40473449,"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.",2025-Jun-14,Chakrabarti; Bhatt; Cai; Iannone,"Jazz Pharmaceuticals, Dublin, Ireland.; Jazz Pharmaceuticals, Dublin, Ireland.; Jazz Pharmaceuticals, Dublin, Ireland.; Jazz Pharmaceuticals, Dublin, Ireland.",lpazaresr@seom.org.
40473445,"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.",2025-Jul,Elimova; Yang; Ozog; Garfin,"Department of Gastrointestinal Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: elena.elimova@uhn.ca.; Jazz Pharmaceuticals, Palo Alto, CA, USA.; Jazz Pharmaceuticals, Palo Alto, CA, USA.; Jazz Pharmaceuticals, Palo Alto, CA, USA.",elena.elimova@uhn.ca.
40471801,"CD20×CD3 Bispecific Antibodies in B-NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research.",2025-Jun,Zhu; Guan; Ganguly; Welf; Welf; Davis,"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Orion Corporation, Espoo, Finland.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.",
40468744,Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report.,2025-Jun,,,
40466467,Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer.,2025-Jun-25,,,lorenzo.gervaso@ieo.it.
40465055,Personalized drug stratification using endoscopic samples to assess ex vivo gastric cancer tissue susceptibility to chemotherapy and immune checkpoint inhibitors.,2025-Jun-04,,,sonja.kallendrusch@hmu-potsdam.de.
40461266,Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease.,2025-Jun-03,Wick-Urban; Garrison; Gao; Fish; Strengholt,"AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.",gerd.burmester@charite.de.
40456667,Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL).,2025-Jun-25,,,roger.olofsson.bagge@gu.se.
40455688,Cancer incidence in patients with ulcerative colitis naïve to or treated with thiopurine and targeted therapies-a cohort study 2007 to 2022 with comparison to the general population.,2025-Jun-04,,,
40449509,"Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.",2025-Jul,Fjällskog; Jalkanen; Aakko; Pawlitzky,"Faron Pharmaceuticals, Boston, MA, USA.; Faron Pharmaceuticals, Turku, Finland.; Faron Pharmaceuticals, Turku, Finland.; Faron Pharmaceuticals, Turku, Finland.",mika.kontro@helsinki.fi.
40449498,"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.",2025-Jun,Dillon; Shetty; Moreno,"Global Health Economics and Outcomes Research, Astellas Pharma, Northbrook, IL, USA.; Global Health Economics and Outcomes Research, Astellas Pharma, Northbrook, IL, USA.; Department of Health Economics and Outcomes Research, Merck & Co, Inc, Rahway, NJ, USA.",guptas5@ccf.org.
40449497,Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF,2025-Jun,,,caroline.robert@gustaveroussy.fr.
40447351,"Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.",2025-Jun,Lawniczek; Mahajan; Solar-Yohay; Kerloëguen; Ferber; Thorburn; Dahlke,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Limited, London, UK.; Novartis Pharma AG, Basel, Switzerland.",amrisita@unina.it.
40446185,Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis: A Multicenter Cohort Study.,2025-Jul,,,
40441807,"Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial.",2025-Jun,,,kelly.seaton@duke.edu.
40435872,Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.,2025-Jun,Kamble; Norquist; Mody; Wang; Dubrovsky,"Merck & Co., Inc., Rahway, USA.; Merck & Co., Inc., Rahway, USA.; Eisai Inc., Nutley, USA.; Merck & Co., Inc., Rahway, USA.; Merck & Co., Inc., Rahway, USA.",rfinn@mednet.ucla.edu.
40432369,Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators.,2025-Jun,Cassoli; Wu; Jani; Biondo; Lin,"Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.",
40427499,Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering.,2025-Apr-22,Pougoue Ketchemen; Fonge,"Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.; Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.",
40423982,"Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.",2025-May-27,,,
40413024,Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.,2025-May-24,,,n.martinezchanza@hubruxelles.be.
40412417,Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study.,2025-Jul,,,s.savic@leeds.ac.uk.
40409025,A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer.,2025-Jun,,,snomura@m.u-tokyo.ac.jp.
40391586,Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study.,2025-Jun,,,
40383966,Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy.,2025-Jun,Bullement; Naik,"Radiological, Oncological, Pathological Sciences, Delta Hat, Ltd, Nottingham, UK.; Radiological, Oncological, Pathological Sciences, Delta Hat, Ltd, Nottingham, UK.",
40382973,"An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study).",2025-Jul,,,andres.redondos@uam.es.
40380283,Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience.,2025-May-17,,,sohrezaei64@gmail.com.
40372585,"A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901).",2025-Jul,,,kshitara@east.ncc.go.jp.
40366333,Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.,2025-May-08,,,
40361510,Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.,2025-May-07,,,
40360544,Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).,2025-May-13,Montesion,"Foundation Medicine Inc., Boston, MA, USA.",sara_tolaney@dfci.harvard.edu.
40355425,Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.,2025-May-12,,,cp4ys@uvahealth.org.
40354065,First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.,2025-Jun-01,Abdul Razak; Hood,"Phase 1 Program, Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.; Clinical Pharmacology, AstraZeneca, Cambridge, United Kingdom.",
40354013,Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.,2025-Jul,Diels; van Sanden; Mendes; Burnett; Cichewicz; Lee; Hernando; Schecter; Lendvai; Patel,"The Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium.; The Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium.; The Janssen Pharmaceutical Companies of Johnson & Johnson, Lisbon, Portugal. jmendes6@ITS.JNJ.com.; Evidera Inc., Wilmington, NC, USA.; Evidera Inc., Wilmington, NC, USA.; The Janssen Pharmaceutical Companies of Johnson & Johnson, Lisbon, Portugal.; The Janssen Pharmaceutical Companies of Johnson & Johnson, Madrid, Spain.; The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USA.; The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USA.; Legend Biotech USA Inc., Somerset, NJ, USA.",jmendes6@ITS.JNJ.com.
40349714,"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.",2025-May-24,Wang; Stromko; Neely; Singh; Jimenez Exposito,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",peter.galle@unimedizin-mainz.de.
40349417,Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.,2025-Jun,,,ksaruwat@kuh.kumamoto-u.ac.jp.
40349139,Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.,2025-May-08,Xiao,"Biostatistics and Data Management, Daiichi Sankyo, Inc., Basking Ridge, NJ, 07920, United States.",
40346992,"EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.",2025-Jun,Maciag; Hong; Amatangelo; Chen,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",
40346041,"Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.",2025-May-09,Qu; Hamidi; Johnson; Sokol; Lin; Sivakumar; Kaplan; de Sousa E Melo; Mancini; Wongchenko; Shi; Shames; Yan; Bais,"Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Foundation Medicine, Inc, Boston, MA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Foundation Medicine, Inc, Boston, MA, USA.; Foundation Medicine, Inc, Boston, MA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA. baiscarlos@gmail.com.",baiscarlos@gmail.com.
40341029,Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab.,2025-May-07,,,michor@jimmy.harvard.edu
40339592,"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.",2025-Jun,Shpektor; Salim; Harvey,"Jazz Pharmaceuticals, Palo Alto, CA, USA.; Jazz Pharmaceuticals, Palo Alto, CA, USA.; Jazz Pharmaceuticals, Palo Alto, CA, USA.",sescriva@vhio.net.
40338596,Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.,2025-Jun-01,McKevitt; Struemper,"Now with Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, United Kingdom.; Clinical Pharmacology Modeling & Simulation, GSK, Durham, North Carolina.",
40334315,Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON.,2025-May,,,Solange.Peters@chuv.ch.
40334245,Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab.,2025,,,
40323277,DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.,2025-Jun,,,
40318646,"Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.",2025-May,Depenbusch,"Onkodok GmbH, Guetersloh, Germany.",s.kuemmel@kem-med.com.
40316348,"A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.",2025-May-02,Shi; Wong; Kistler,"Amgen Inc San Francisco, South San Francisco, California, USA.; Amgen Inc San Francisco, South San Francisco, California, USA.; Amgen Inc San Francisco, South San Francisco, California, USA.",timothy.price@sa.gov.au.
40311141,Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.,2025-Jul-10,,,
40306831,"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.",2025-May,,,michael.northend@nhs.net.
40306121,The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.,2025-Jun-03,,,chiaracremolini@gmail.com.
40304209,"Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312.",2025-May-01,Wang; Sun; He; Kang; Liu; Liu; Li; Yang; Lin; Li; Wang; Wang,"Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio (US) Pharmaceuticals, Inc., Burlington, Massachusetts.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Group Co., Ltd., Beijing, China.; Jacobio Pharmaceuticals Co., Ltd., Beijing, China.",
40300079,"INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.",2025-Jul-01,Siu; Serrano,"Princess Margaret Cancer Centre, Toronto, Canada.; Cytel Inc., AstraZeneca, Paris, France.",
40298385,"CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target.",2025-Jun-04,Luo; Wang; Wang,"Tmunity Therapeutics/Kite Pharma, Philadelphia, Pennsylvania.; Tmunity Therapeutics/Kite Pharma, Philadelphia, Pennsylvania.; Tmunity Therapeutics/Kite Pharma, Philadelphia, Pennsylvania.",
40293658,A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study.,2025-Jun,Katayama; Shiosakai,"Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo Co., Ltd., Tokyo, Japan.",t-aoyama@lilac.plala.or.jp.
40293376,Pretargeting: Bridging the Two Worlds of Radiopharmaceutical Probes.,2025-Jul-01,,,
40293180,Zongertinib in Previously Treated ,2025-Jun-19,Sadrolhefazi; von Wangenheim,"Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT.; Boehringer Ingelheim Pharma, Biberach an der Riss, Germany.",
40286540,Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.,2025-Jun,,,benoit.you@chu-lyon.fr.
40285403,Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria.,2025-Aug,Hillmen,"Apellis Pharmaceuticals, Boston, Massachusetts, USA.",
40280867,Associations between early tumor shrinkage/depth of response and survival from the ARCAD database.,2025-Apr-30,,,
40277744,Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study.,2025-Mar-24,Morris; Bhanegaonkar; Ike,"EMD Serono, Inc., Boston, MA 02210, USA, an affiliate of Merck KGaA.; EMD Serono, Inc., Boston, MA 02210, USA, an affiliate of Merck KGaA.; EMD Serono, Inc., Boston, MA 02210, USA, an affiliate of Merck KGaA.",
40262400,Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.,2025-May-15,Lin; Gumuscu; Lerman,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",matahara@east.ncc.go.jp.
40261555,Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy.,2025-Jul,Rouvet,"Department of Pharmacy, Centre Henri Becquerel, Rouen, France.",florian.clatot@chb.unicancer.fr.
40260947,"Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study.",2025-May,,,
40259818,Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression.,2025-Jun,,,
40253945,"Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).",2025-May,,,shiraishi.yoshimasa.258@m.kyushu-u.ac.jp.
40252634,Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin.,2025-Jun-03,,,samy.belkaid@chu-lyon.fr.
40252208,Real-World Clinical Outcomes in Patients With HER2+ Metastatic Breast Cancer Receiving Tucatinib-Based Therapy After 2 or More Prior Metastatic HER2-Directed Regimens.,2025,Neuberger; Bartley; Pittner,"Pfizer Inc, South San Francisco, CA, USA.; Pfizer Inc, South San Francisco, CA, USA.; Pfizer Inc, South San Francisco, CA, USA.",
40248950,STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.,2025-May,He; Jew; Andrianov,"Exelixis, Inc, Alameda, CA, USA.; Exelixis, Inc, Alameda, CA, USA.; Exelixis, Inc, Alameda, CA, USA.",
40245453,Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes.,2025-May-15,,,maria.varela.calvo@gmail.com.
40241307,Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.,2025-Apr,,,
40233040,Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.,2025,,,
40232811,"Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.",2025-Dec,,,
40220771,"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.",2025-May,,,mvmateos@usal.es.
40211538,DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets.,2025-Jun-04,,,dweiner@wistar.org.
40198940,"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.",2025-May-02,Odeleye-Ajakaye; Fukunaga-Kalabis; Krepler,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",lukejj@upmc.edu.
40192715,"Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.",2025-Jun-13,,,
40186886,Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.,2025-May,,,jmaroto@santpau.cat.
40184872,"Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.",2025-Jun,,,yshinno@ncc.go.jp.
40181694,Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort.,2025-Jun,,,
40180420,Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors.,2025-Apr-02,,,hwada@gesurg.med.osaka-u.ac.jp.
40179908,"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.",2025-Apr,,,hilpert@mammazentrum.eu.
40179821,FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.,2025-May-02,Stintzing; Stahler; Kiani; Link; Modest,"Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin and German Cancer Research Centre (DKFZ), Heidelberg, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin and German Cancer Research Centre (DKFZ), Heidelberg, Germany.; Klinikum Bayreuth GmbH, Bayreuth, Germany and CCC Erlangen-EMN, Germany.; Department of Medicine I, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany.",julian.holch@med.uni-muenchen.de.
40179327,Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.,2025-Apr,,,
40175211,Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial Carcinoma: A Real-world Analysis From a Multicenter Study.,2025-Jun,,,makitomiyake@yahoo.co.jp.
40172786,Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer.,2025-Jul,,,hiromina@east.ncc.go.jp.
40168999,"TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.",2025-Apr-15,Hodgson; Ryan; Raulf; Voutila; Sinigaglia; Habib,"MiNA Therapeutics Ltd, W12 0BZ London, UK.; MiNA Therapeutics Ltd, W12 0BZ London, UK.; MiNA Therapeutics Ltd, W12 0BZ London, UK.; MiNA Therapeutics Ltd, W12 0BZ London, UK.; MiNA Therapeutics Ltd, W12 0BZ London, UK.; MiNA Therapeutics Ltd, W12 0BZ London, UK.",nagy.habib@imperial.ac.uk.
40163686,Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study.,2025-Mar-10,,,
40159282,Poor outcome of older patients with diffuse large B-cell lymphoma after progression.,2025,,,
40156871,Real-world safety and effectiveness of alemtuzumab for relapsed or refractory chronic lymphocytic leukaemia: results from postmarketing surveillance in Japan.,2025-Jul-06,,,
40156118,Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma.,2025-Mar-10,Chaney; Hippenmeyer; Lawrence; Liu; Hamidi,"Merck & Co., Inc., Rahway, NJ 07065, United States.; Amgen Inc., Thousand Oaks, CA 91320, United States.; Amgen Inc., Thousand Oaks, CA 91320, United States.; Amgen Inc., Thousand Oaks, CA 91320, United States.; Amgen Inc., Thousand Oaks, CA 91320, United States.",
40154210,Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial.,2025-May-02,,,paolo.bossi@hunimed.eu.
40154184,Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.,2025-May,Melief; Hooftman; Jamil; Boersma; Yoo; Seebach; Lowy; Fury; Mathias,"ISA Pharmaceuticals, Oegstgeest, the Netherlands.; ISA Pharmaceuticals, Oegstgeest, the Netherlands.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",domenica.lorusso@hunimed.eu.
40152791,"A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.",2025-Jun-13,,,
40148195,Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy.,2025-Jun,,,charles.geyer@NSABP.org.
40143674,Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis.,2025-Jun,,,
40140364,Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.,2025-Mar-26,,,Timothy.Voorhees@osumc.edu.
40140179,A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.,2025-May,Chao; Shihadeh; Lee; Song; Jin; Huo; Howland,"Forty Seven, Inc, Menlo Park, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.",cathy.eng@vumc.org.
40139261,"A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies.",2025-Mar-10,,,
40136373,Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer.,2025-Mar-15,Dasgupta; Kaushik; Verret,"Gilead Sciences, Inc., Foster City, CA 94404, USA.; Gilead Sciences, Inc., Foster City, CA 94404, USA.; Gilead Sciences, Inc., Foster City, CA 94404, USA.",
40136372,Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study.,2025-Mar-15,,,
40136348,Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma.,2025-Feb-28,,,
40131851,Therapeutic advances for cutaneous T-cell lymphoma.,2025-Jun-20,,,
40124489,"Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.",2025-Mar-21,Gibbs; Kouekam; Esser,"Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.",
40121972,Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.,2025-Apr,,,ocearbhr@mskcc.org.
40121197,Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.,2025-Mar-22,,,k9288090@kadai.jp.
40120068,"INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.",2025-Apr-01,,,
40118215,Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.,2025-Jul,Li; Zhu; Kaul; Perez; Seebach; Lowy; Pouliot; Kim; Magnan,"Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.",skilickap@yahoo.com.
40116970,Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study.,2025-Mar-21,,,ayone@keio.jp.
40114329,ABO-Blood Group Associates With Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.,2025-Mar,,,
40112923,Influence of high-fiber diet on ipilimumab-induced gastrointestinal toxicity in metastatic melanoma.,2025-Jun,,,Jessica.Hassel@med.uni-heidelberg.de.
40105996,Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.,2025-Mar-19,,,vera.bril@utoronto.ca.
40102759,Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).,2025-Mar-18,Marbach; Brouer-Visser; Brennan; Wilson; Davydov; Staedler; Duarte; Martinez Quetglas; Nüesch; Cañamero; Chesné; Gomes; Franjkovic; DeMario; Kornacker; Lechner,"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. daniel.marbach.dm1@roche.com.; Roche Pharma Research and Early Development, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd, New York, NY, USA.; Roche Pharma Research and Early Development, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd, New York, NY, USA.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development, Data Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, F. Hoffmann-La Roche Ltd, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, F. Hoffmann-La Roche Ltd, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd, New York, NY, USA.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, F. Hoffmann-La Roche Ltd, Penzberg, Germany.",daniel.marbach.dm1@roche.com.
40102029,"Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).",2025-Mar-18,Beck; Schuetz; Poch,"Oncocyte Corporation, Irvine, California, USA.; Oncocyte Corporation, Irvine, California, USA.; Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA.",Sumati.Gupta@hci.utah.edu.
40097400,Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.,2025-Mar-17,Bouquet; Bustillos,"Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.",antonin.levy@gustaveroussy.fr.
40087402,Emerging importance of HER3 in tumorigenesis and cancer therapy.,2025-May,,,joan.garrett@uc.edu.
40085955,Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.,2025-May-27,Chohan; Kothari; Lee Batlevi; Hirata; Sahin; Lee; Sugidono,"Hoffmann-La Roche Ltd, Mississauga, ON, Canada.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.",
40082588,Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy.,2025-Mar-13,Chang; Lin; Wen; Wu; Wei; Huang; Tsao; Chen; Tang; Wu; Lee; Huang; Kuo; Li; Lai,"OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan.; OBI Pharma, Inc., 6F, No. 508, Section 7 Zhongxiao East Road, Nangang District, Taipei, Taiwan. mingtainlai@obipharma.com.",mingtainlai@obipharma.com.
40081941,Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.,2025-Mar-13,,,iwiner@med.wayne.edu.
40080442,Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes.,2025-May-15,Siu,"Princess Margaret Cancer Centre, Toronto, Canada.",
40079944,Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.,2025-May-13,Lau; Jiang; Yan; Ballinger; Kaul; Matheny; Cuchelkar,"Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.",
40079483,"Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post-marketing surveillance.",2025-May,,,
40075025,First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.,2025-May,Xu; Sheng; Yang; Kadva,"Clinical Development, BeiGene (Shanghai) Co., Ltd, Shanghai, China.; Biostatistics, BeiGene USA, Inc., Emeryville, CA, USA.; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., Beijing, China.; Clinical Development, BeiGene USA, Inc., San Mateo, CA, USA.",xurh@sysucc.org.cn.
40075024,First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.,2025-May,Wu; Wang; Yan; Shi; Kadva,"Biostatistics, BeiGene USA, Inc., Ridgefield Park, NJ, USA.; Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China.; Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China.; Clinical Biomarker, BeiGene (Beijing) Co., Ltd., Beijing, China.; Clinical Development, BeiGene USA, Inc., San Mateo, CA, USA.",yoon.harry@mayo.edu.
40072824,Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.,2025-Jul,Rossiter; Jansson; Nakaya,"Takeda Development Center Americas, Inc. (at the time of the study), Cambridge, MA, USA.; Takeda Development Center Americas, Inc. (at the time of the study), Cambridge, MA, USA.; Takeda Pharmaceutical Company Limited, Tokyo, Japan.",teshima@med.hokudai.ac.jp.
40069763,"Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.",2025-Mar-11,Yearley; Wang; Nebozhyn; Huang; Cristescu; Jelinic; Karantza,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",Rebecca.dent@duke-nus.edu.sg.
40069616,"Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma.",2025-Mar-11,Hamano,"Head office, P4 Statistics Co. Ltd., 5-11-14, Todoroki, Setagaya-Ku, Tokyo, 158-0082, Japan.",m-kudo@med.kindai.ac.jp.
40067419,Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice.,2025-Jul,,,takuro_kameda@med.miyazaki-u.ac.jp.
40058642,Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON).,2025-Jul,,,t-hakozaki@akane.waseda.jp.
40057343,"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.",2025-Mar-08,Yang; Lu; Hu; Wang; Li; Xia,"Akeso Biopharma, Zhongshan, China.; Akeso Biopharma, Zhongshan, China.; Akeso Biopharma, Zhongshan, China.; Akeso Biopharma, Zhongshan, China.; Akeso Biopharma, Zhongshan, China.; Akeso Biopharma, Zhongshan, China.",caicunzhoudr@163.com.
40055759,"Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.",2025-Mar-07,,,telonishi@gmail.com.
40055521,Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.,2025-May,Yao; Wang; Wang; Chhibber; Pandya; Elimova; Doshi; Li; Lei,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Daiichi Sankyo Inc, Basking Ridge, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA. ming.lei1@bms.com.",janjigiy@mskcc.org.
40055288,Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.,2025-Jun,,,m-kudo@med.kindai.ac.jp.
40054461,"Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.",2025-Apr-15,,,juanita.lopez@icr.ac.uk.
40052634,Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer.,2025-Mar,Abousaud,"Astellas Pharma Global Development Inc, Northbrook, Illinois, USA.",
40052589,Immune checkpoint inhibitors for children with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma: A case presentation and brief review.,2025-Mar,,,
40049198,"Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.",2025-Mar,,,sherene.loi@petermac.org.
40049197,"Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial.",2025-Mar,,,tshukuya@juntendo.ac.jp.
40048689,Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.,2025-May-10,,,
40044930,Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.,2025-May,Hope; Musa; Cantuaria; Baghdadi,"Pacific Cancer Research Consortium, NCORP, Alaska Women's Cancer Care and Providence Alaska Cancer Center, Anchorage, AK, USA.; Pacific Cancer Research Consortium, NCORP, Swedish Medical Center-First Hill, Seattle, WA, USA.; Georgia NCORP, Atlanta, GA, USA.; Michigan Cancer Research Consortium, NCORP, Trinity Health IHA Medical Group, Ypsilanti, MI, USA.",reskander@health.ucsd.edu.
40040557,"Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study.",2025-Jun,Mucha; Quicquaro; Xie; Young,"Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.",
40038334,Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies.,2025-Mar-04,,,luca.gianni@fondazionemichelangelo.org.
40038004,Cost-Effectiveness Analysis of SOX Plus Bevacizumab Versus SOX Plus Cetuximab for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer in Japan.,2025-May,,,morimta2@keio.jp.
40037029,Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials.,2025-Apr,Moreno; Bavle; Xu,"Merck & Co., Inc., Rahway, NJ.; Merck & Co., Inc., Rahway, NJ.; Merck & Co., Inc., Rahway, NJ.",Patrizia.Giannatempo@istitutotumori.mi.it.
40036608,Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomas.,2025-Apr-28,Costanza; Janz; Mathas,"Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.; Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.; Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.",
40033991,Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions.,2025-Mar,,,
40030008,Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.,2025-May-13,,,
40024743,Prognostic predictors of newly diagnosed Diffuse large B-cell lymphoma treated with R-THP-COP regimen.,2025-Mar-28,,,
40023002,Effectiveness and safety of Atezolizumab in patients with locally-advanced or metastatic non-small cell lung cancer after prior chemotherapy under real-life conditions in Germany: The Non-interventional Study HYPERION.,2025,Zortel; Zerbes,"Biometrics & Epidemiology, Roche Pharma AG, Grenzach-Wyhlen, Germany.; Medical Affairs, Roche Pharma AG, Grenzach-Wyhlen, Germany.",n.reinmuth@asklepios.com.
40021433,Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients.,2025-Jun,,,biagio_ricciuti@dfci.harvard.edu.
40020696,"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.",2025-Apr,Song; Li; Yang; Shi,"Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals, Shanghai, China.",shunlu@sjtu.edu.cn.
40019482,Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.,2025-May-01,,,
40018758,TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.,2025-Apr,,,
40017103,High Antigenicity for T,2025-May,,,
40016302,Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.,2025-Apr,,,Kumar.Shaji@mayo.edu.
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025-Jul,Thomas; Aksyuk; Clegg; Currie; Yang; Flyrin; Gibbs; Perez; Chang; Cohen,"Biometrics, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK.; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Mölndal, Sweden.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA. Electronic address: taylor.cohen@astrazeneca.com.",haidarg@upmc.edu.
40013724,Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real-World Study of Patients Ineligible for Combination Immunotherapy.,2025-Mar,,,
40010775,Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.,2025-Feb-25,Tang; Dolfi; Warad; Garnett-Benson,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",paolo.ascierto@gmail.com.
40010764,Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer.,2025-Feb-25,,,sara_tolaney@dfci.harvard.edu.
40008409,STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma.,2025-Mar,Bhatt; Wang; Nandoskar,"Clinical Development, Exelixis, Inc., Alameda, CA, USA.; Biometrics, Exelixis, Inc., Alameda, CA, USA.; Clinical Development, Exelixis, Inc., Alameda, CA, USA.",
40006675,Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer.,2025-Jan-27,,,
39999590,Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians.,2025-Mar,,,egrande@oncomadrid.com.
39997358,"Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study).",2025-Jun-05,,,
39987772,"Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.",2025-Mar,Previs,"LabCorp, Chapel Hill, NC, United States of America.",Swestin@mdanderson.org.
39980145,Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience.,2025-Feb,,,
39979665,Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.,2025-Feb,Yao; Jin; Gozman,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",AURELIEN.MARABELLE@gustaveroussy.fr.
39976819,Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2,2025-Feb-20,,,fialao@fnplzen.cz.
39975549,Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase.,2025,,,
39972124,RNA neoantigen vaccines prime long-lived CD8,2025-Mar,,,balachav@mskcc.org.
39972105,Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).,2025-Mar,,,hbando@east.ncc.go.jp.
39970730,"Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.",2025-Mar,,,tayamada@koto.kpu-m.ac.jp.
39967671,Discovery and ,2025,Almagro; Pérez-Tapia,"GlobalBio, Inc., Cambridge, MA, United States.; National Laboratory for Specialized Services of Investigation, Development and Innovation (I+D+i) for Pharma Chemicals and Biotechnological Products, LANSEIDI-FarBiotec-CONAHCYT, Mexico City, Mexico.",
39964352,"Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.",2025-Apr-14,Chen; Lata; Skolnik; Keler; Yellin,"Personalis, Inc., Menlo Park, California.; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.; Celldex Therapeutics, Inc., Hampton, New Jersey.; Celldex Therapeutics, Inc., Hampton, New Jersey.",
39955432,Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.,2025-Apr,Desai; Chen; Li; Rotibi; Syed; Vusirikala,"Actinium Pharmaceuticals, New York, NY, USA.; Actinium Pharmaceuticals, New York, NY, USA.; Actinium Pharmaceuticals, New York, NY, USA.; Actinium Pharmaceuticals, New York, NY, USA.; Actinium Pharmaceuticals, New York, NY, USA.; Actinium Pharmaceuticals, New York, NY, USA.",sabedin@mcw.edu.
39952926,The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.,2025-Feb-14,,,jaume.mora@sjd.es.
39952901,"Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.",2025-May,,,
39951918,"A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.",2025-Mar,,,stephanie.gaillard@jhmi.edu.
39948608,First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.,2025-Feb-14,Dwivedi; Kothari,"Cell Transplant Therapy, CareDx Inc, Brisbane, CA, USA.; Cell Transplant Therapy, CareDx Inc, Brisbane, CA, USA.",glenn_hanna@dfci.harvard.edu.
39945382,A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.,2025-Feb,,,
39939142,Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma.,2025-Feb-12,,,ntannir@mdanderson.org.
39937961,Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.,2025-Mar,,,
39937271,"AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.",2025-Apr-14,Siu,"Princess Margaret Cancer Centre, Toronto, Canada.",
39934514,Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification.,2025-Apr,Ito; Kajita,"Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, 1-8-1 Shimomeguro, Meguro-ku, Tokyo, 153-8926, Japan.; Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, 1-8-1 Shimomeguro, Meguro-ku, Tokyo, 153-8926, Japan.",huemura@med.kindai.ac.jp.
39933529,"Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers.",2025-Feb-18,Podzimkova; Schoenenberger; Kiemle-Kallee; Tillmanns; Sachse; Moebius; Spisek; Bechard,"SOTIO Biotech a.s., 170 00 Prague, Czech Republic.; SOTIO Biotech a.s., 170 00 Prague, Czech Republic.; SOTIO Biotech AG, 4056 Basel, Switzerland.; SOTIO Biotech AG, 4056 Basel, Switzerland.; SOTIO Biotech AG, 4056 Basel, Switzerland.; SOTIO Biotech a.s., 170 00 Prague, Czech Republic.; SOTIO Biotech a.s., 170 00 Prague, Czech Republic.; Cytune Pharma, 44300 Nantes, France.",schampiat@mdanderson.org.
39928953,Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.,2025-May-13,Patel,"Servier Pharmaceuticals, LLC, Boston, MA.",
39927885,Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer.,2025-Apr-14,,,
39927513,Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors.,2025-Mar-01,Huang; Chaturvedi; Weispfenning; Hiemeyer; Morcos; Mongay Soler; Childs; Hansen,"Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey.; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey.; Pharmaceuticals Division, Bayer AG, Berlin, Germany.; Pharmaceuticals Division, Bayer AG, Berlin, Germany.; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey.; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey.; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey.; Princess Margaret Cancer Centre, Toronto, Canada.",
39924521,AXL signaling in cancer: from molecular insights to targeted therapies.,2025-Feb-10,Yadav,"Laboratory of Nanotechnology and Chemical Biology, Regional Center for Biotechnology, Faridabad, Haryana, India.",soumitro.pal@childrens.harvard.edu.
39922974,Second-line anti-CD38 monoclonal antibody therapy mitigates the negative impact of functional high-risk status in myeloma patients.,2025-Jun,,,kaz-suzuki@jikei.ac.jp.
39920159,The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.,2025-Feb-07,Trudel,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",sloni01@emory.edu.
39919737,Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer.,2025-Mar-10,,,zhangyy@cicams.ac.cn.
39916320,"Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.",2025-Feb-15,,,
39915004,Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality.,2025-Feb-06,,,cbonifa2@jhmi.edu
39913118,Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.,2025-Apr-01,,,
39910301,A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.,2025-Mar,,,david.braun@yale.edu.
39910273,"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.",2025-Apr,Ahmadi,"Genmab US, Inc., Plainsboro, NJ, USA.",usmanis@mskcc.org.
39908481,Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.,2025-May-27,Wei; Wang; Bucher; Sit; Penuel; Purev; Yee,"Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",
39908461,Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.,2025-Apr-08,,,
39907793,Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review.,2025-Feb-05,,,loredanaamoroso@gaslini.org.
39905373,"Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE).",2025-Feb-04,,,hshouji@ncc.go.jp.
39900053,[Dose banding. Observational study on cost optimization in chemotherapy].,2025,Sanguinetti,"Laboratorio Integrador de Soluciones Pharma, Villa Lynch, Buenos Aires, Argentina. E-mail: sanguinetti.josema@gmail.com.",sanguinetti.josema@gmail.com.
39899878,IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.,2025-Jun-05,Amann; Klein; Umaña,"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.",
39895413,Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.,2025-Feb-01,Habigt; Evers; Sleiman; Dejardin; Ardeshir; Martin; Boetsch; Charo; Teichgräber; Kraxner; Keshelava,"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.",
39893774,First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.,2025-Mar,Takahashi,"Oncology Clinical Development Planning 1, Ono Pharmaceutical Co., Ltd., 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan. Electronic address: shig.takahashi@ono-pharma.com.",kihlee@chungbuk.ac.kr.
39893343,"Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.",2025-Apr,Zhao; Fukunaga-Kalabis; Krepler,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",cyoon@bwh.harvard.edu.
39891883,A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.,2025-Mar,,,oki.eiji.857@m.kyushu-u.ac.jp.
39890560,"Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.",2025-Jun,,,erica_mayer@dfci.harvard.edu.
39889250,"Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.",2025-Mar-20,Elias; Srirangam; Garnett-Benson; Lee,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
39883948,Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.,2025-Apr-08,,,
39880580,Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02.,2025-Feb,Qi; Tokuhiro; Karnoub; Feng; Shiga; Pereira; Khambata-Ford,"Daiichi Sankyo, Inc., Basking Ridge, New Jersey. Electronic address: zhenhao.qi@daiichisankyo.com.; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey.",zhenhao.qi@daiichisankyo.com.
39874977,"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.",2025-Feb-01,Cela; Chen; Lei; Jin; Blum,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",thierry.andre@aphp.fr.
39874912,Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.,2025-Feb-25,,,ines.silva@melanoma.org.au.
39869830,Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.,2025-Apr-10,Delepine; Chand; Avagyan; Wu; Johnson; Grossman; O'Day,"Agenus Inc, Lexington, MA.; Agenus Inc, Lexington, MA.; Agenus Inc, Lexington, MA.; Agenus Inc, Lexington, MA.; Agenus Inc, Lexington, MA.; Agenus Inc, Lexington, MA.; Agenus Inc, Lexington, MA.",
39865401,Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.,2025-Feb,,,
39863775,"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.",2025-Mar,Beyzarov; Zhang; Ferrier; Zhang,"Pfizer, Inc., New York, NY, USA.; Pfizer, Inc., New York, NY, USA.; Pfizer, Inc., New York, NY, USA.; Pfizer, Inc., South San Francisco, CA, USA.",SKopetz@mdanderson.org.
39862880,"Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.",2025-Feb,,,aahabib@hs.uci.edu.
39862879,"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.",2025-Feb,Hoffmann,"Department of Neurology, Neuroscience Clinical Research Center (NCRC) and Integrated Myasthenia Gravis Centre, Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",sramcha4@its.jnj.com.
39853764,Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.,2025-Jun,Hayato; Hamuro; Miura; Nomoto; Zhao; Zhu; Yasuda,"Eisai Co. Ltd., Tokyo, Japan.; Bristol Myers Squibb, Princeton, NJ, USA.; Eisai Co. Ltd., Tokyo, Japan.; Eisai Co. Ltd., Tokyo, Japan.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Eisai Inc., Nutley, NJ, USA.",
39853679,"A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers.",2025-Feb-01,,,
39853385,[T-cell large granular lymphocytic leukemia and Felty's syndrome in rheumatoid arthritis].,2025-Feb,Schwaneck,"Medizinisches Versorgungszentrum Rheumatologie und Autoimmunmedizin Hamburg GmbH, Mönckebergstr. 27, 20095, Hamburg, Deutschland.",gernert_m1@ukw.de.
39853272,Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.,2025-Mar-25,,,
39851917,The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.,2024-Dec-24,,,
39849293,"Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab-a polish multicenter, observational study.",2025-Jan-23,,,Renata.pacholczak@uj.edu.pl.
39847999,Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.,2025-Feb,Hansen; Yao; Gozman; Jin,"Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: Aaron.R.Hansen@health.qld.gov.au.; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: lili.yao@merck.com.; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: alexander.gozman@merck.com.; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: fan.jin@merck.com.",malley@osumc.edu.
39847172,Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.,2025-Feb,,,kaneda.hiroyasu@omu.ac.jp.
39846984,Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.,2025-Jan-17,,,
39846804,"Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.",2025-Apr-01,Khilnani; Huang; Zhao; Jemielita,"Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.",
39841198,"Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.",2025-Jan,,,austin.kulasekararaj@nhs.net.
39840727,Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.,2025-Jan,,,
39838118,Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.,2025-Feb,Ades; Pacius; Chhibber; Chandra; Nathani; Spires; Wu,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",sherene.loi@petermac.org.
39838117,"Pembrolizumab and chemotherapy in high-risk, early-stage, ER",2025-Feb,Ding; Jia; Karantza; Tryfonidis,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",fcardoso@abcglobalalliance.org.
39836408,Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).,2025-Mar-17,Alqaisi; Dhani; Madariaga; Grant; Malaguti; Lee; Bowering; Wong; Poothullil; Speers; Bedard; Oza; Lheureux,"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.",
39835421,"Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.",2025-May,Cosson; Beveridge; Gotanda; Jaminion; Lundberg; Shi; Sreckovic; Benkali; Buatois,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, United States.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, United States.; Certara, Inc., Paris, France.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
39832211,"A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.",2025-Apr,Ogawa; Taoka,"Chiome Bioscience Inc, Tokyo, Japan.; Chiome Bioscience Inc, Tokyo, Japan.",
39825152,Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.,2025-Mar,,,prpohlmann@mdanderson.org.
39824531,"Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.",2025-Jan-16,O'Brien; Zhang; Xu; Hamuro; Suryawanshi; McKinley; Novosiadly,"Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Early Clinical Development, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, USA.",spihapau@mdanderson.org.
39821700,Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer.,2025-Jan-17,Abegesah; Lim; Fan; Chen; Kim; Ren; Phipps; Gibbs; Zhou,"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA. aburough.abegesah1@astrazeneca.com.; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA.; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, USA.; Integrated Bioanalysis, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.",aburough.abegesah1@astrazeneca.com.
39820359,Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.,2025-Apr-22,,,
39815052,Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.,2025-Mar,,,philippe.moreau@chu-nantes.fr.
39809837,Targeted dual biologic therapy for erythroderma of unknown etiology guided by high-parameter peripheral blood immunophenotyping.,2025-Jan-14,,,skwatra@som.umaryland.edu.
39800379,Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma.,2025-Jan-11,,,luigi.formisano1@unina.it.
39798981,"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.",2025-Jan-11,,,arminghobadi@wustl.edu.
39798960,C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.,2025-Mar-24,Gerischer; Gerischer; Herdick; Herdick; Stascheit; Stascheit; Hoffmann; Hoffmann; Lehnerer; Lehnerer; Stein; Stein; Meisel; Meisel; Meisel,"Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.",tobias.ruck@uni-duesseldorf.de.
39798579,"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.",2025-Jan-18,,,bsangro@unav.es.
39798578,"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.",2025-Jan-18,Peng; Dubrovsky; Siegel,"Merck & Co, Inc, Rahway, NJ, USA.; Merck & Co, Inc, Rahway, NJ, USA.; Merck & Co, Inc, Rahway, NJ, USA.",josep.llovet@mountsinai.org.
39798514,Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.,2025-Feb-05,Perez; Yoo; Gao; Jamil; Seebach; Lowy; Mathias; Fury,"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",aoaknin@vhio.net.
39788967,Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.,2025-Jan-09,Banbury; Sherry,"Adaptive Biotechnologies Corp, Seattle, USA.; Adaptive Biotechnologies Corp, Seattle, USA.",jmayadev@health.ucsd.edu.
39787453,Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.,2025-Apr-10,Hasegawa; Uchida,"Medical HQs, Eisai Co, Ltd, Tokyo, Japan.; Medical HQs, Eisai Co, Ltd, Tokyo, Japan.",
39786525,Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.,2025-Jan,,,tess_omeara@dfci.harvard.edu.
39786401,"OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.",2025-Feb-04,Li; Chiang; Weng; Yang; Wu; Wu; Chen; Lu; Tu; Hsu; Shia; Huang; Lai,"OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.; OBI Pharma, Inc., Taipei, Taiwan.",
39781908,Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).,2024,,,
39779412,AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG).,2025-Jun,,,Matthew.burge@health.qld.gov.au.
39778121,Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.,2025-Apr-20,Gharpure; Neely; Balli; Hu,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
39776016,The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.,2025-Mar,,,ttsuka@koto.kpu-m.ac.jp.
39775043,Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.,2025-Jan,Webber; Ren; Fukunaga-Kalabis; Krepler,"Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.",reinhard.dummer@usz.ch.
39774681,[Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma].,2025-Jan,,,margitta.retz@tum.de.
39772655,Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.,2025-Mar-20,Patterson; Ho; Rustia; Fanale; Jie,"Pfizer Inc, Bothell, WA.; Pfizer Inc, Bothell, WA.; Pfizer Inc, Bothell, WA.; Pfizer Inc, Bothell, WA.; Pfizer Inc, Bothell, WA.",
39762422,Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.,2025-Jan,Siu; Wong; Sabado; Rhee; Mancuso; Muller; Yadav; Leveque; Robert; Darwish; Qi; Zhu; Zhang; Zhang; Twomey; Twomey; Rao; Low; Petry; Lo; Schartner; Delamarre; Mellman,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Seagen, Inc., Bothell, WA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA. mancuso.michael@gene.com.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Artera, Inc., Los Altos, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; AbbVie, Inc., Santa Clara, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.",juanita.lopez@icr.ac.uk.
39757000,Successful Treatment of Methotrexate-associated Lymphoproliferative Disorder with the Pola-R-CHP Regimen.,2025,,,
39755168,Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03.,2025-Jun,Patel; Mekan; Wu,"Gilead Sciences, Inc., Foster City, California.; Gilead Sciences, Inc., Foster City, California.; Gilead Sciences, Inc., Foster City, California.",Afshin.dowlati@uhhospitals.org.
39753814,Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.,2025-Jan,,,iznakaya@east.ncc.go.jp.
39747856,Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.,2025-Jan-02,,,jeffrey.clarke@duke.edu.
39747534,Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients.,2025-Jan-02,,,iwamoto.g@med.kawasaki-m.ac.jp.
39739622,Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.,2025-Apr-01,Burgents; Xie; Okpara,"Global Clinical Development, Merck & Co., Inc., Rahway, New Jersey, USA.; Biostatistics, Eisai Inc., Nutley, New Jersey, USA.; Clinical Research, Eisai Ltd., Hatfield, UK.",
39730000,Hormone therapy enhances anti-PD1 efficacy in premenopausal estrogen receptor-positive and HER2-negative advanced breast cancer.,2025-Jan-21,,,yslu@ntu.edu.tw.
39729222,Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan.,2025-Apr,,,iida@med.nagoya-cu.ac.jp.
39725778,A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer.,2025-Feb,Wiley; Ghalie,"MEI Pharma, San Diego, CA, USA.; MEI Pharma, San Diego, CA, USA.",Pb564@cinj.rutgers.edu.
39724246,Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.,2025-Feb-01,,,
39723687,Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany.,2025-Mar,,,
39723627,MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.,2025-Feb,Ramos; Guan,"Oncology Research and Development, Pfizer Inc, Bothell, WA, USA.; Oncology Biostatistics, Pfizer Inc, Bothell, WA, USA.",
39721833,Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma.,2025-Feb,,,Umang.Swami@hci.utah.edu.
39719711,Durable lymphocyte subset elimination upon a single dose of AAV-delivered depletion antibody dissects immune control of chronic viral infection.,2025-Feb-11,Künzli,"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.",daniel.pinschewer@unibas.ch.
39719418,Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database.,2025-Jan-07,,,
39715697,"Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.",2025-Jan,,,
39709655,Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.,2025-Jan,,,schettini@recerca.clinic.cat.
39707623,Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial.,2025-Apr,Lau; Mhatre; Ci; Machado; Li; Bretscher; Reyes-Rivera; Zhu; Zhang; Patel,"Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Roche Products Ltd, Welwyn Garden City, UK.; Genentech, Inc., South San Francisco, California, USA.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.",
39703511,Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma.,2024,,,
39686589,T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice.,2025-Dec,O'Brien; Mueller; Bröske; Attig; Osl; Crisand; Wolf; Rae; Lechner; Pöschinger; Klein; Umaña; Colombetti; Eckmann,"Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.",
39679910,The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer.,2025-Jan-01,Suto; Koga; Inaki; Kuwahara; Arita; Hirata; Goto; Wada; Kobayashi; Shibutani; Okabayashi; Nakamaru,"Translational Science Department, Precision Medicine Function, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Translational Science Department I, Precision Medicine Function, Daiichi Sankyo, Co., Ltd., Tokyo, Japan.; Oncology Medical Science Department, Medical Affairs Division, Daiichi Sankyo, Co., Ltd., Tokyo, Japan.; Translational Science Department, Precision Medicine Function, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Translational Science Department I, Precision Medicine Function, Daiichi Sankyo, Co., Ltd., Tokyo, Japan.; Translational Science Department, Precision Medicine Function, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; Clinical Development Department I, Development Function, Daiichi Sankyo, Co., Ltd., Tokyo, Japan.; Translational Science Department I, Precision Medicine Function, Daiichi Sankyo, Co., Ltd., Tokyo, Japan.",
39679430,Scoping Review: The Effects of Interrupted Onabotulinumtoxin A Treatment for Chronic Migraine Prevention During the COVID-19 Pandemic.,2024,,,
39671533,Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.,2025-May,Ratto; Rodriguez; Mazzei; Dolfi,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
39667721,Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).,2025-Mar,Kridel,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",
39663572,Autophagy-dependent hepatocyte secretion of DBI/ACBP induced by glucocorticoids determines the pathogenesis of Cushing syndrome.,2025-Mar,,,
39663448,Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.,2025-Jan,,,imelero@unav.es.
39662152,Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab.,2025-Feb,Shih; Wright; Hepp; Willmon; Chang; Mucha,"Pfizer Inc., Bothell, WA.; Pfizer Inc., Bothell, WA.; Pfizer Inc., Bothell, WA.; Pfizer Inc., Bothell, WA.; Pfizer Inc., Bothell, WA.; Astellas Pharma Inc., Northbrook, IL.",aliciak_morgans@dfci.harvard.edu.
39654382,A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibody.,2025-Mar,Thiele; Montaseri; Pérez-Pitarch; Busse,"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.",
39654063,A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.,2024,Jung; Glaser; Popa; Pisarsky; Geyer; Haderk; Alpar; Schmittner; Traexler; Poehn; Fiorelli; Budano; Martin; Albrecht; Drobits-Handl; Anand; Kasturirangan; Trapani; Schweifer; Tontsch-Grunt; Pearson; Kraut; García-Martínez,"Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Global Computational Biology and Digital Sciences, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Translational Medicine & Clinical Pharmacology, Oncology Translational Science, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.; Translational Medicine & Clinical Pharmacology, Oncology Translational Science, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.; Translational Medicine & Clinical Pharmacology, Oncology Translational Science, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Translational Medicine & Clinical Pharmacology, Oncology Translational Science, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Boehringer Ingelheim Pharmaceuticals, Inc., Nonclinical Drug Safety, Ridgefield, CT, USA.; Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, CT, USA.; Translational Medicine & Clinical Pharmacology, Oncology Translational Science, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Translational Medicine & Clinical Pharmacology, Oncology Translational Science, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Cancer Research Therapeutic Area, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.",
39652594,"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.",2025-Apr-10,,,
39652156,Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1.,2025-Feb,Kuroe; Kawasaki; Sato,"Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.",hidekigt@med.hokudai.ac.jp.
39647999,Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.,2025-Mar,Tian; Liu; Korolkiewicz; Szeto,"BeiGene USA, Inc, San Mateo, CA.; BeiGene USA, Inc, San Mateo, CA.; BeiGene USA, Inc, San Mateo, CA.; BeiGene USA, Inc, San Mateo, CA.",
39645590,"Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.",2025-Jan-01,,,
39645236,"Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.",2025-Mar,,,
39644032,Nontransplant treatment approaches for myeloid neoplasm with mutated TP53.,2024-Dec-06,,,
39644004,BV and beyond: how to incorporate novel agents into PTCL management.,2024-Dec-06,,,
39632797,Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.,2024-Dec-05,,,maximilian.merz@medizin.uni-leipzig.de.
39632711,"Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.",2025-Mar-04,,,
39630848,Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study.,2025-Feb,Baraniskin; Held; Kaiser; Kahl,"Department of Hematology, Oncology and Palliative Care, Evangelisches Krankenhaus Hamm gGmbH, Germany.; ClinAssess GmbH, Leverkusen, Germany.; VK&K Studien GmbH, Landshut, Germany.; Klinikum Magdeburg gGmbH, Department of Hematology, Oncology and Palliative Care Magdeburg, Germany.",
39627139,"Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia.",2024-Dec-03,,,zamachi@um.edu.my.
39622410,"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.",2025-Apr,Chacko Varughese,"Statistics, Eli Lilly Services India Pvt. Ltd., Bengaluru, India.",nakagawa@med.kindai.ac.jp.
39620653,Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape.,2024,,,
39613746,Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.,2024-Nov-29,Izquierdo,"Novartis Pharma AG, Basel, Switzerland.",christos.sotiriou@hubruxelles.be.
39612757,Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.,2025-Jan,Durani; Pe Benito; Wang,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",caroline.robert@gustaveroussy.fr.
39608979,Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.,2024-Nov-27,Wang; Ma; Shi,"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.",caicunzhou_dr@163.com.
39607603,"A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.",2025-Feb,Nishikawa; Shibayama; Aida; Yamazaki; Inagaki; Kobayashi,"Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan. hkobaya1@its.jnj.com.",hkobaya1@its.jnj.com.
39605282,The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.,2025-May-19,,,
39602677,Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study.,2025-Jan,,,
39602301,Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium.,2025-Mar-11,,,
39596506,ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma.,2024-Nov-19,Cesano; Warren,"ESSA Pharma, South San Francisco, CA 94080, USA.; ESSA Pharma, South San Francisco, CA 94080, USA.",
39594670,BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia.,2024-Nov-20,,,
39591551,"First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.",2025-Mar-20,Lheureux; Okpara; McKenzie; Yao; Orlowski; Khemka,"Princess Margaret Cancer Centre, Medical Oncology, Toronto, ON, Canada.; Eisai Ltd, Hatfield, United Kingdom.; Eisai Inc, Nutley, NJ.; Merck & Co, Inc, Rahway, NJ.; Merck & Co, Inc, Rahway, NJ.; Merck & Co, Inc, Rahway, NJ.",
39587053,Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.,2024-Nov-25,,,y.suna0825@gmail.com.
39585341,Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.,2025-Feb-03,Maejima; Karibe; Tang; Okajima,"Daiichi Sankyo Co. Ltd., Tokyo, Japan.; Daiichi Sankyo Co. Ltd., Tokyo, Japan.; Daiichi Sankyo Co. Ltd., Tokyo, Japan.; Daiichi Sankyo Co. Ltd., Tokyo, Japan.",
39584789,"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.",2025-Jan-01,,,
39577421,Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.,2024-Dec-09,,,banchereau.romain@gene.com.
39576965,"MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.",2025-Feb-11,,,
39576208,Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.,2025-Feb-03,Chisamore,"Merck & Co., Inc., Rahway, New Jersey.",
39575618,Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma.,2024-Nov,,,
39574956,Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction.,2024,,,
39572927,High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy.,2024-Dec-31,,,
39571250,Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.,2024-Dec,Iwasawa; Nakagawa,"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",mitsudom@med.kindai.ac.jp.
39571171,Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.,2025-Feb-25,Penuel; Wei; Wu; Yin,"Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",
39570583,First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.,2025-Jan-01,,,
39567211,"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).",2024-Nov-20,Dalal,"Mural Oncology, Inc, Waltham, Massachusetts, USA.",vaishamu@med.umich.edu.
39566464,Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.,2024-Nov-19,Rey; Weber; Rachakonda; Zahm; Felder; Nekljudova; Loibl,"German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany.; German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany.; German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany.; SRH Waldklinikum Gera GmbH, Gera, Germany.; German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany.; German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany.; German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany. Electronic address: sibylle.loibl@gbg.de.",carsten.denkert@uni-marburg.de.
39565570,Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone.,2025-Jan,,,mrobertson@bwh.harvard.edu.
39560862,"Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors.",2025-Jan,Miah; Mugundu,"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Boston, MA, USA.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Boston, MA, USA.",mpatel@flcancer.com.
39558820,Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19.,2024-Nov,Arroyo-Hernandez; Arrieta,"Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.",
39557586,Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction.,2025-Feb,,,
39557058,"Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.",2024-Dec,,,filippo.pietrantonio@istitutotumori.mi.it.
39551600,"Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.",2024-Nov-17,Chen; Fan; Tu; Durham,"Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (CPSS), BioPharmaceuticals R&D, AstraZeneca R&D Gaithersburg, Gaithersburg, Maryland, USA.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences (CPSS), BioPharmaceuticals R&D, AstraZeneca R&D Gaithersburg, Gaithersburg, Maryland, USA.; Translational Medicine, Cell Therapy and Oncolytic Viruses, BioPharmaceuticals R&D, AstraZeneca R&D Gaithersburg, Gaithersburg, Maryland, USA.; Translational Medicine, Cell Therapy and Oncolytic Viruses, BioPharmaceuticals R&D, AstraZeneca R&D Gaithersburg, Gaithersburg, Maryland, USA.",davard@upmc.edu.
39550516,ACBP/DBI neutralization for the experimental treatment of fatty liver disease.,2025-Mar,,,omar.motino@uva.es.
39549280,Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825.,2025-Mar-07,,,
39549218,Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study.,2025-Jan,Ito; Kajita,"Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, 1-8-1 Shimomeguro, Meguro-ku, Tokyo, 153-8926, Japan.; Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, 1-8-1 Shimomeguro, Meguro-ku, Tokyo, 153-8926, Japan.",huemura@med.kindai.ac.jp.
39548483,Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland.,2024-Nov-15,,,Renata.pacholczak@uj.edu.pl.
39547252,"Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.",2024-Nov-23,,,david.kirsch@uhn.ca.
39541202,Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.,2025-Jan-01,Luo; Gu; Yu; Xu; Zhang; Yu,"Shanghai Junshi Biosciences Co Ltd, Shanghai, China.; Shanghai Junshi Biosciences Co Ltd, Shanghai, China.; Shanghai Junshi Biosciences Co Ltd, Shanghai, China.; Shanghai Junshi Biosciences Co Ltd, Shanghai, China.; TopAlliance Biosciences Inc, Rockville, Maryland.; TopAlliance Biosciences Inc, Rockville, Maryland.",
39540661,"Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial.",2025-Jan-01,,,
39537648,The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.,2024-Nov-13,,,scolla@mdanderson.org.
39536390,Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.,2024,,,h.kenmotsu@scchr.jp.
39533016,Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma.,2025-Feb,,,lihmd@163.com.
39532835,Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.,2024-Nov-12,,,nazad2@jhu.edu.
39531903,"Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).",2025-Jan,,,mpowell@wustl.edu.
39530615,Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.,2025-Feb,Wang; Xu,"ADC Therapeutics America, Inc., Murray Hill, NJ, USA.; ADC Therapeutics America, Inc., Murray Hill, NJ, USA.",
39530574,Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.,2024-Nov,Kim; Zhang; Li; Xu; Kadeerbai; Lee; Gorla,"Pfizer Inc, Bothell, Washington, USA.; Astellas (China) Investment co., Ltd., Beijing, China.; Astellas (China) Investment co., Ltd., Beijing, China.; Astellas (China) Investment co., Ltd., Beijing, China.; Astellas (China) Investment co., Ltd., Beijing, China.; Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Inc., Northbrook, Illinois, USA.",
39527097,Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy.,2025-Feb-03,,,
39522333,Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.,2024-Dec,,,xyghx335@mail.com.
39521884,Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.,2025-Jan,,,Roger.Li@moffitt.org.
39521434,The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC.,2025-Feb,Aggarwal; Zimmer; Zhao; Shamoun,"Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.",jhanelle.gray@moffitt.org.
39521279,Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy.,2025-May,,,aakenroye@bwh.harvard.edu.
39521008,"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.",2024-Dec,,,p.chowdary@ucl.ac.uk.
39520979,[,2024-Nov-08,,,neeraj.agarwal@hci.utah.edu.
39520771,Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.,2025-Jan,Walder; Burton,"FIECON Ltd, London, UK.; FIECON Ltd, London, UK.",cmathews@wihri.org.
39520048,Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.,2025-Mar,,,
39495153,Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort.,2024-Nov-01,,,
39494690,"Preclinical Characterization of XB002, an Anti-Tissue Factor Antibody-Drug Conjugate for the Treatment of Solid Tumors.",2025-Feb-04,Kantak; Faggioni; Li; Vainshtein; Cheng; Mendelsohn,"Discovery Biotherapeutics, Exelixis, Inc., Alameda, California.; Clinical Pharmacology and Toxicology, Exelixis, Inc., Alameda, California.; Clinical Pharmacology and Toxicology, Exelixis, Inc., Alameda, California.; Clinical Pharmacology and Toxicology, Exelixis, Inc., Alameda, California.; Clinical Pharmacology and Toxicology, Exelixis, Inc., Alameda, California.; Discovery Biotherapeutics, Exelixis, Inc., Alameda, California.",
39488171,"A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors.",2024-Dec-01,,,yogita_pharma@pbi.ac.in.
39481054,Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.,2025-Feb-10,Wozniak; Zhao; Mihm; Kaplan; Gorla,"Astellas Pharma, Inc, Northbrook, IL.; Astellas Pharma, Inc, Northbrook, IL.; Astellas Pharma, Inc, Northbrook, IL.; Astellas Pharma, Inc, Northbrook, IL.; Astellas Pharma, Inc, Northbrook, IL.",
39486766,Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments.,2024-Dec-15,,,stefano.fogli@unipi.it.
39486410,Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma.,2024-Nov-11,,,smithyj@mskcc.org.
39475591,Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of ,2025-Mar,Ridinger; Samuëlsz; Karki; Subramanian; Yemane; Kim; Wu; Croucher; Smeal; Kabbinavar,"Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.; Cardiff Oncology Inc, San Diego, CA.",
39475359,Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.,2024-Dec-02,Ma; Rajasagi; Vajdi; Lunceford; Cristescu; Imai; Homet Moreno,"Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.",
39472976,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,2024-Oct-29,Frost; Mattson-Hoss; Sarnoff,"Infixion Bioscience, Inc., San Diego, CA, USA.; Infixion Bioscience, Inc., San Diego, CA, USA.; Infixion Bioscience, Inc., San Diego, CA, USA.",ksolt1@jhmi.edu.
39470879,Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.,2024-Dec,Qi; Yang; Du; Chen; Gelinas; Brauer; Phillips,"Argenx, Inc., Boston, MA, USA. cqi@argenx.com.; Analysis Group, Inc., Boston, MA, USA.; Analysis Group, Inc., Boston, MA, USA.; Analysis Group, Inc., Boston, MA, USA.; Argenx, Inc., Boston, MA, USA.; Argenx, Inc., Boston, MA, USA.; Argenx, Inc., Boston, MA, USA.",cqi@argenx.com.
39469838,TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.,2024,Pan; Ren; Chen; Rajagopalan,"Daiichi Sankyo, Inc., Global Research & Development, Basking Ridge, NJ 07920, USA.; Daiichi Sankyo, Inc., Clinical Development, Basking Ridge, NJ 07921, USA.; Daiichi Sankyo Inc., Biostatics and Data Management, Basking Ridge, NJ 0792 1, USA.; Daiichi Sankyo, Inc., Clinical Safety and Pharmacovigilance, London UB8 1DH, UK.",
39466716,Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.,2024-Dec,,,
39465550,Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011.,2025-Jan-01,Zhao; O'Hara; Okpara; Franco; Homet Moreno,"Merck & Co, Inc, Rahway, New Jersey, USA.; Eisai, Ltd, Hatfield, UK.; Eisai, Ltd, Hatfield, UK.; Merck & Co, Inc, Rahway, New Jersey, USA.; Merck & Co, Inc, Rahway, New Jersey, USA.",
39461270,Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.,2024-Dec,Method; Wang,"ImmunoGen, Inc., Waltham, MA, USA.; ImmunoGen, Inc., Waltham, MA, USA.",kathleen-moore@ouhsc.edu.
39451736,Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.,2024-Sep-27,,,
39448966,"Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.",2024-Oct-24,Shepherd; Cai; Eddy; McCulloch,"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.",armando.santoro@cancercenter.humanitas.it.
39448084,Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.,2025-Jul,,,japfidalgo@msn.com.
39442018,Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.,2025-Apr-28,Trivedi; Barragan; Chow; Mytych; Franklin,"Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.",
39437778,EGFR-directed antibodies promote HER2 ADC internalization and efficacy.,2024-Nov-19,Ghafourian; Thyparambil,"mProbe Inc, Rockville, MD, USA.; mProbe Inc, Rockville, MD, USA.",chandars@mskcc.org.
39437708,"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.",2025-Jan-30,,,
39428126,Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.,2024-Oct-20,,,alberto.cruz.bermudez@gmail.com.
39427441,First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study.,2024-Dec,,,dirk.schadendorf@uk-essen.de.
39423355,Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.,2025-Feb-10,Hack; Wu; Liu; Guan; Lu; Wang,"Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.",
39422604,Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.,2024-Dec-16,Hansen; Habigt; Schneider; Evers; Sleiman; Dejardin; Ardeshir; Schmid; Boetsch; Charo; Kraxner; Teichgräber; Keshelava,"Division of Medical Oncology, Princess Margaret Cancer Center, Toronto, Canada.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.",
39422602,"Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-09).",2025-Jan-01,Kim,"Bioinformatics, Geninus Inc., Seoul, South Korea.",
39422598,"First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.",2024-Dec-16,Chen; Gonzalez Ortiz; Jankovic; Paccaly; Masinde; Mani; Lowy; Gullo; Sims; Kroog,"Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.",
39417832,Novel use of Siltuximab in a patient with VEXAS Syndrome.,2025-Feb,,,samuel_rubinstein@med.unc.edu.
39417680,"Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma.",2024-Dec-02,Canton,"OncoSec Medical Incorporated, San Diego, California.",
39415563,Real-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study.,2024-Oct-16,,,outi.isomeri@gmail.com.
39415562,Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study.,2024-Oct-16,Roebuck,"GSK, Brentford, Middlesex, UK; ImmunoGen, Inc.",outi.isomeri@gmail.com.
39414520,Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan.,2025-May,Fukasawa; Uenaka,"Research and Analytics Department, Real World Data Co. Ltd., Kyoto, Japan.; Research and Analytics Department, Real World Data Co. Ltd., Kyoto, Japan.",toshihiko.minegishi@merck.com.
39405648,Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome.,2024-Nov,,,Inge.marie.svane@regionh.dk.
39405343,Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.,2024-Dec-16,Li; Tsuchihashi; Suto; Cheng; Kandil; Barrios,"Quantitative Clinical Pharmacology, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Department of Translational Science, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Department of Translational Science, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Biostatistics and Data Management, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; CSPV, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Department of Global Oncology R&D, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.",
39405335,Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.,2024-Dec-16,,,
39387986,Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).,2025-Jan,Kume; Yamaguchi; Hashimoto,"Oncology Medical Science Department I, Daiichi Sankyo Co. Ltd., Tokyo, Japan.; Oncology Medical Science Department I, Daiichi Sankyo Co. Ltd., Tokyo, Japan.; Data Intelligence Department, Daiichi Sankyo Co. Ltd., Tokyo, Japan.",kawakami_h@med.kindai.ac.jp.
39395231,Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.,2024-Nov,Habigt; Marbach; Boetsch; Evers; Richard; Ardeshir; Charo; Kraxner; Teichgräber; Keshelava,"Roche Pharma Research and Early Development, Penzburg, Germany.; Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.; Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.; Roche Pharma Research and Early Development, Discovery & Translational Area Oncology, Roche Innovation Center, Basel, Switzerland.; Roche Pharma Research and Early Development, Discovery & Translational Area Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Products Ltd, Welwyn Garden City, UK.; Roche Pharma Research and Early Development, Discovery & Translational Area Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Discovery & Translational Area Oncology, Roche Innovation Center, Basel, Switzerland.; Roche Pharma Research and Early Development, Discovery & Translational Area Oncology, Roche Innovation Center, Basel, Switzerland.; Roche Pharma Research and Early Development, Discovery & Translational Area Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.",rafal.dziadziuszko@gumed.edu.pl.
39392339,Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.,2024-Nov-01,Iwasawa; Nakagawa,"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",
39390209,Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy.,2024-Dec,,,tkatou@nagasaki-u.ac.jp.
39387946,Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel.,2024-Oct-10,,,kkaehler@dermatology.uni-kiel.de.
39385434,Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.,2024-Dec-02,,,
39385035,CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.,2024-Nov,Sacher; Leighl,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",fskoulidis@mdanderson.org.
39384194,Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies.,2024-Oct-09,,,jychang@mdanderson.org
39382718,First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048.,2024-Dec,Gumuscu; Lerman,"Merck & Co., Inc, 126 E. Lincoln Avenue, Rahway, NJ, 07033, USA.; Merck & Co., Inc, 126 E. Lincoln Avenue, Rahway, NJ, 07033, USA.",matahara@east.ncc.go.jp.
39381588,Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance.,2024,,,
39378386,A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve ,2025-Feb,,,
39377880,"Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.",2024-Nov,Das; Krepler; Grebennik,"Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, USA.; Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, USA.; Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, USA.",laurent.mortier@chru-lille.fr.
39374583,"PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.",2024-Dec-24,Sloss,"Translational Sciences, Immunogen Inc, Waltham, MA.",
39373062,"Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.",2024-Dec,,,
39354179,Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2,2024-Nov,,,fialao@fnplzen.cz.
39352553,Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study.,2024-Oct-01,,,florentia.dimitriou@usz.ch.
39348118,Calibrating Observational Health Record Data Against a Randomized Trial.,2024-Sep-03,Bruno; Lunacsek,"Bayer Pharmaceuticals, Philadelphia, Pennsylvania.; Bayer Pharmaceuticals, Whippany, New Jersey.",
39343173,CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity.,2025-Feb,Calatroni; Lussier; David,"Rho Inc, Durham, NC.; Rho Inc, Durham, NC.; Rho Inc, Durham, NC.",lisa_beck@urmc.rochester.edu.
39330050,Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer.,2024-Sep-21,,,
39325020,Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.,2024-Sep,Li; Jamil; Paccaly; Seebach; Lowy; Mathias; Fury,"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.",
39324726,Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer.,2024,Shah; Phan,"Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.",
39322802,Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.,2024-Nov,Denis; Foulley; Habauzit; Benkhalifa,"Medical Affairs, Celltrion Healthcare France S.A.S., 9-15 rue Rouget de Lisle, 92130, Issy-les-Moulineaux, France.; Medical Affairs, Celltrion Healthcare France S.A.S., 9-15 rue Rouget de Lisle, 92130, Issy-les-Moulineaux, France.; Medical Affairs, Celltrion Healthcare France S.A.S., 9-15 rue Rouget de Lisle, 92130, Issy-les-Moulineaux, France. Caroline.Habauzit@celltrionhc.com.; Medical Affairs, Celltrion Healthcare France S.A.S., 9-15 rue Rouget de Lisle, 92130, Issy-les-Moulineaux, France.",Caroline.Habauzit@celltrionhc.com.
39321197,Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.,2024,,,
39320414,Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study.,2024-Dec,,,kawakami.koji.4e@kyoto-u.ac.jp.
39316716,The current landscape of frontline large B-cell lymphoma trials.,2025-Jan-09,,,
39313594,Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.,2024-Nov,,,SKopetz@mdanderson.org.
39312871,"Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.",2024-Oct,,,daichianzen14@gmail.com.
39311947,"Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.",2024-Dec,Xu; Saville,"OBI Pharma USA, Inc, San Diego, CA, USA.; OBI Pharma USA, Inc, San Diego, CA, USA.",atsimber@mdanderson.org.
39308141,The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.,2024-Nov-01,Seitz; Nielsen; Schweitzer; Ross,"Oncocyte Corp., Irvine, California.; Oncocyte Corp., Irvine, California.; Oncocyte Corp., Irvine, California.; Oncocyte Corp., Irvine, California.",
39308028,Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.,2024-Dec,,,
39306923,Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.,2024-Oct,Morris; Kaul,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Oncology Product Development Safety, Genentech Inc, South San Francisco, CA, USA.",m.reck@lungenclinic.de.
39304364,VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG).,2025-Feb,,,ekastritis@gmail.com.
39304280,Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.,2024-Oct,,,sebastian.stintzing@charite.de.
39303200,"Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.",2025-Jan-10,Simsek; Spiridigliozzi; Lee; van Kooten Losio,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
39302614,Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors.,2024-Nov,Lai; Zhang; Gary; Huynh,"Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.",ynaito@east.ncc.go.jp.
39293083,Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.,2024-Nov-26,Hacohen-Kleiman; Huo; Zhang; Renard,"Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.",
39288781,"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.",2024-Sep-28,,,jonathan.spicer@mcgill.ca.
39288779,"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.",2024-Oct-05,,,domenica.lorusso@hunimed.eu.
39288737,Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.,2024-Nov,Grebennik; Kreplere,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",alexander.eggermont@prinsesmaximacentrum.nl.
39288227,Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.,2024-Aug-23,,,
39287821,"A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.",2024-Nov-15,Wang; Zha; Li; Robinson; Hingorani; Jeng,"AbbVie, Inc., North Chicago, Illinois.; AbbVie, Inc., North Chicago, Illinois.; AbbVie, Inc., North Chicago, Illinois.; AbbVie, Inc., North Chicago, Illinois.; AbbVie, Inc., North Chicago, Illinois.; AbbVie, Inc., North Chicago, Illinois.",
39284329,Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.,2024-Oct-05,,,toni_choueiri@dfci.harvard.edu.
39282934,Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.,2024-Sep-26,Nakajima; Matsangou; Cao; Li; Moran; Pophale; Oh; Ranganath,"Astellas Pharma Global Development, Northbrook, IL.; Astellas Pharma Global Development, Northbrook, IL.; Astellas Pharma Global Development, Northbrook, IL.; Astellas Pharma Global Development, Northbrook, IL.; Astellas Pharma Global Development, Northbrook, IL.; Astellas Pharma Global Development, Northbrook, IL.; Astellas Pharma Global Development, Northbrook, IL.; Astellas Pharma Global Development, Northbrook, IL.",xurh@sysucc.org.cn.
39279181,Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products.,2024,Green,"Chesapeake Pharma LLC, Weehawken, NJ, USA.",
39277672,Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.,2024-Dec,,,laura.esserman@ucsf.edu.
39277671,Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.,2024-Dec,,,laura.esserman@ucsf.edu.
39276176,A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors.,2024-Oct,Huang; Chen; Siu,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Princess Margaret Cancer Centre, Toronto, ON, Canada.",nehal.lakhani@startmidwest.com.
39271844,Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.,2024-Dec,,,nadia.harbeck@med.uni-muenchen.de.
39265579,The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis.,2025-Jan-10,,,antoniollombart@medsir.org.
39264730,A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.,2024,Standifer,"Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA.",
39261417,Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.,2024-Nov,,,fmeric@mdanderson.org.
39258976,Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin.,2024,Ortiz Nunez; Gonzalez Portela,"HEOR Established Markets, Astellas Pharma Europe, Madrid, Spain.; HEOR Established Markets, Astellas Pharma Europe, Madrid, Spain.",
39249605,Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study.,2024-Sep-09,,,chihhunghsu@ntu.edu.tw.
39245360,"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.",2025-Jan,Booth; Yoo; Seebach; Lowy; Fury,"Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.",brett.hughes@health.qld.gov.au.
39244180,Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma.,2024-Dec,,,jabramson@mgh.harvard.edu.
39243945,Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.,2025-Jan,Alatorre-Alexander; Araujo,"Health Pharma Professional Research, Mexico City, Mexico.; Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil.",solange.peters@chuv.ch.
39236649,Efficacy of tocilizumab in highly relapsing MOGAD with an inadequate response to intravenous immunoglobulin therapy: A case series.,2024-Nov,,,hojinkim@ncc.re.kr.
39236226,An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024.,2024-Nov-18,,,
39235868,"A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.",2025-Jan-17,Olwill; Wurzenberger; Hasenkamp; Hansbauer; Kumar; Duerr; Zettl; Aviano; Matis; Bruns,"Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts.; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts.; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts.",
39235489,Clinical characteristics and management of paroxysmal nocturnal haemoglobinuria in Latin America: a narrative review.,2025-Feb,,,hematologia.vg@gmail.com.
39227409,Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.,2024-Nov,,,jshen8@mdanderson.org.
39226397,"A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer.",2024-Nov-01,,,
39222408,B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity.,2024-Oct,Patterson; Smith; Gunsior; Mittereder; Rees; Cimbora,"Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA.; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA.; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA.; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA.; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA.; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA.",
39213421,Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.,2024-Nov-26,Hacohen-Kleiman; Huo; Su-Feher; Renard,"Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.",
39209782,Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study.,2024-Aug-29,Xyrafas; Gutzwiller,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",cclin1@ntu.edu.tw.
39209453,Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.,2024-Aug-28,,,elizabeth_buchbinder@dfci.harvard.edu.
39207194,A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.,2024-Sep-01,,,
39201700,Circular RNA Profile in Atherosclerotic Disease: Regulation during ST-Elevated Myocardial Infarction.,2024-Aug-19,,,
39200906,High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy.,2024-Aug-13,,,
39197119,Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.,2024-Dec,Nicholas; Hernandez,"Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",
39190534,Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.,2024-Oct-07,Velichko; Chen,"Natera Inc. , Austin, TX, USA.; Personalis Inc. , Fremont, CA, USA.",
39187558,Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.,2024-Aug-27,,,rizzo.mimma@gmail.com.
39186707,TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.,2024-Oct-10,Tonelli; Vance; Zhou,"Gilead Sciences, Inc, Parsippany, NJ.; Gilead Sciences, Inc, Parsippany, NJ.; Gilead Sciences, Inc, Parsippany, NJ.",
39179598,Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer.,2024-Aug-23,,,kaneda.hiroyasu@omu.ac.jp.
39177967,"Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns.",2024-Nov-01,,,
39177945,Omalizumab for Treatment of Anti-GD2 Antibody-related Urticaria.,2024-Oct-01,,,
39173098,"Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, ",2024-Dec,Luo; Chirovsky; Pietanza; Bhagwati,"Merck & Co, Inc, Rahway, NJ.; Merck & Co, Inc, Rahway, NJ.; Merck & Co, Inc, Rahway, NJ.; Merck & Co, Inc, Rahway, NJ.",
39167703,Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma.,2024-Dec-06,Morris; Michaud,"EMD Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA.; EMD Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA.",
39167621,KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.,2024-Oct-15,,,
39167179,The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.,2024-Dec,,,yshimazu@kuhp.kyoto-u.ac.jp.
39162872,"Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.",2024-Nov,Nakada; Hagihara; Makino; Nishiyama,"Department of Oncology Clinical Development Planning, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Department of Statistical Analysis, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Department of Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Department of Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.",ykkang@amc.seoul.kr.
39159638,"Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.",2024-Nov,,,okamoto.isamu.290@m.kyushu-u.ac.jp.
39153900,Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors.,2024-Oct,,,matteo.silberg@elisabethgruppe.de.
39151421,Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial.,2025-Jan-10,,,jahow@mdanderson.org.
39147327,IL-2 family cytokines IL-9 and IL-21 differentially regulate innate and adaptive type 2 immunity in asthma.,2024-Nov,,,Martijn.schuijs@irc.vib-ugent.be.
39147210,Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report.,2025-Jan-01,,,yuanyuan.zhang@utsouthwestern.edu.
39146951,"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.",2024-Sep,,,emanuel.buhrer@bluewin.ch.
39142718,"Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.",2024-Aug-13,Enstrom; LeBlanc; Schmalz; Thomas; Chisamore; Peng; Naumovski,"Alpine Immune Sciences Inc, Seattle, Washington, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.; Adaptive Biotechnologies Corp, Seattle, Washington, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.; Merck & Co Inc, Rahway, New Jersey, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.",ludi.cavalcante@gmail.com.
39140264,Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors.,2024-Sep-01,Imaizumi; Enomoto; Seki,"Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.",
39138106,Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).,2024-Nov,,,kwhat@koto.kpu-m.ac.jp.
39134652,Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.,2025-Jun,Poehlein; Qiu; Suttner; Schloss,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",graffj@ohsu.edu.
39134526,A roadmap towards improving outcomes in multiple myeloma.,2024-Aug-12,,,mohamad.mohty@inserm.fr.
39133378,Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).,2024-Nov,Takiguchi; Takata; Bastanfard; Shiosakai,"Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.",nniikura@tokai.ac.jp.
39122726,"Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.",2024-Aug-09,,,harshabad_singh@dfci.harvard.edu.
39121849,Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8,2024-Aug-08,,,arc85@pitt.edu.
39117670,Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).,2024-Aug-08,,,rgcarbonero@gmail.com.
39116902,"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.",2024-Sep,,,kpraghav@mdanderson.org.
39116683,Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study.,2024-Oct,,,jealesm@seom.org.
39114870,A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.,2024,Boyken; Garfin,"Zymeworks Inc., Vancouver, BC, Canada.; Jazz Pharmaceuticals, Palo Alto, CA, USA.",
39112504,Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.,2024-Aug-07,,,ejabbour@mdanderson.org.
39107131,"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.",2024-Aug-06,Tschaika; Konduru; Vemula; Slepetis; Kollia; Pacius; Duong; Huang; Doshi; Baden,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",massimo.dinicola@istitutotumori.mi.it.
39106708,Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer.,2024-Sep,,,h.vanlaarhoven@amsterdamumc.nl.
39106081,A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.,2024-Oct-15,,,
39102832,"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.",2024-Sep,,,elena.biagioli@marionegri.it.
39100528,Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center.,2024-Aug,Craig,"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.",
39098455,Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.,2024-Nov,Jiang; Desilva; Fedorov; Lee,"Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton.; Late Clinical Development, Bristol Myers Squibb, Princeton.; Oncology Late Clinical Development, Bristol Myers Squibb, Princeton.; Department of Clinical Trials, Bristol Myers Squibb, Princeton.",ntannir@mdanderson.org.
39097500,"Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study.",2024-Sep,Maenz; Leidig; Bauer,"Cermed Contract Research GmbH, Friedrichstr. 94, 10117 Berlin, Germany.; CROLLL GmbH, Woernitzstraße 115A, 90449 Nuremberg, Germany.; Staburo GmbH, Aschauer Straße 26a, 81549 Munich, Germany.",nicolai.haertel@medma.uni-heidelberg.de.
39097413,"Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).",2024-Aug-03,Voskoboynik; Enstrom; Blanchfield; LeBlanc; Thomas; Chisamore; Peng; Naumovski,"Nucleus Network Ltd, Melbourne, Victoria, Australia.; Alpine Immune Sciences Inc, Seattle, Washington, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.; Merck & Co Inc, Rahway, New Jersey, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.; Alpine Immune Sciences Inc, Seattle, Washington, USA.",davard@upmc.edu.
39095234,"Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.",2024-Dec,,,ksaruwat@kuh.kumamoto-u.ac.jp.
39093952,Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.,2024-Dec-10,Mukherjee,"Department of Hematology and Oncology, Oncology Hematology Care, Cincinnati, OH.",
39088783,"Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.",2024-Nov-10,,,
39083724,Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.,2024-Oct-10,Patel; Mekan; Wu; Lin; Kuo,"Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.",
39082675,Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.,2024,Diver,"Medical Affairs, ImmunoGen, Inc., Waltham, MA 02451, USA.",
39082340,"Molecular Regulation of Bone Turnover in Juvenile Idiopathic Arthritis: Animal Models, Cellular Features and TNFα.",2024-Jul-10,McCall; Barnett,"ExesaLibero Pharma, Morgantown, WV 26505, USA.; ExesaLibero Pharma, Morgantown, WV 26505, USA.",
39079873,Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy.,2024-Nov,,,hhorinou@ncc.go.jp.
39073799,Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.,2024,Chen; Harnett; Mastey; Yoo; Mohan; Coates; Bowler; Fury,"Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.",
39072867,Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.,2024-Jul,,,
39068951,Chronic lymphocytic leukaemia.,2024-Aug-17,,,obrien@hs.uci.edu.
39067902,Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.,2024-Jul-27,,,hope.rugo@ucsf.edu.
39067465,"Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.",2024-Oct,,,kwee.yong@ucl.ac.uk.
39067464,"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.",2024-Sep,,,aherrera@coh.org.
39060019,Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.,2024-Jul-25,Rosenblatt,"Bristol Myers Squibb, Princeton, New Jersey, USA.",mregan@jimmy.harvard.edu.
39059062,Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trials.,2024-Aug,Pan; Tian; Men; Wang; Liang; Wang; Zhai,"Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China.; Ascentage Pharma Group Inc., Rockville, USA.; Ascentage Pharma Group Inc., Rockville, USA.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China; Ascentage Pharma Group Inc., Rockville, USA. Electronic address: yzhai@ascentage.com.",yzhai@ascentage.com.
39058951,CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.,2024-Sep-24,Yanez; Phelps; Chaturvedi; Morcos; Buvaylo; Childs,"Sociedad de Investigaciones Medicas Ltda, Temuco, Chile.; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ.; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ.; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ.; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ.; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ.",
39056237,Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies.,2024-Aug-05,,,
39055889,Pharmacological methods for ovarian function and fertility preservation in women with cancer: A literature review.,2024,,,
39054491,Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.,2024-Jul-25,Clark; Munteanu; Kataria; Jia,"Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",necchi.andrea@hsr.it.
39054485,Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.,2024-Jul-25,Clark; Munteanu; Kataria; Jia,"Incyte Corporation, Wilmington, DE, USA.; Incyte Corporation, Wilmington, DE, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",irfancicin@trakya.edu.tr.
39054476,"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.",2024-Jul-25,Leopold; Daniel; Munteanu; Samkari; Xu,"Incyte Corporation, Wilmington, DE, United States.; Incyte Corporation, Wilmington, DE, United States.; Incyte Corporation, Wilmington, DE, United States.; Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.",tokitou_takaaki@kurume-u.ac.jp.
39054467,"Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.",2024-Jul-25,Leopold; Munteanu; Ge; Swaby,"Incyte Corporation, Wilmington, DE, 19803, USA.; Incyte Corporation, Wilmington, DE, 19803, USA.; Merck & Co., Inc., P.O. Box 2000, 126 East Lincoln Ave., Rahway, NJ, 07065, USA.; Merck & Co., Inc., P.O. Box 2000, 126 East Lincoln Ave., Rahway, NJ, 07065, USA.",cbc1971@yuhs.ac.
39053945,Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.,2024-Jul-24,Narikiyo; Yamaguchi; Ishida; Takubo; Ogami; Sekiya; Nakagawa,"Chugai Pharmaceutical Co Ltd, Chuo-ku, Tokyo, Japan.; Chugai Pharmaceutical Co Ltd, Chuo-ku, Tokyo, Japan.; Chugai Pharmaceutical Co Ltd, Chuo-ku, Tokyo, Japan.; Chugai Pharmaceutical Co Ltd, Chuo-ku, Tokyo, Japan.; Chugai Pharmaceutical Co Ltd, Chuo-ku, Tokyo, Japan.; Chugai Pharmaceutical Co Ltd, Chuo-ku, Tokyo, Japan.; Chugai Pharmaceutical Co Ltd, Chuo-ku, Tokyo, Japan.",nbryamam@ncc.go.jp.
39052039,"United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.",2024-Sep,Parthan,"FibroGen Inc., San Francisco, CA, USA.",howardj@neurology.unc.edu.
39051558,Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.,2024-Jul,,,
39048638,COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.,2024-Oct,Chen,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",jtabernero@vhio.net.
39041200,STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.,2024,Wang; Wang; Smith,"Exelixis, Inc.Alameda, CA, USA.; Exelixis, Inc.Alameda, CA, USA.; Exelixis, Inc.Alameda, CA, USA.",
39039666,Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.,2024-Dec,,,
39039635,Population Pharmacokinetic Modeling and Exposure-Response Analysis for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma.,2024-Nov,Zuo; Bonate; Garg; Matsangou; Tang,"Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.; Pfizer Inc., South San Francisco, California, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.",
39037800,Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.,2024-Sep-17,Siegmund; Levine; Kalabic; Chen; Cheng; Shu; Duan; Pivorunas; Sanchez Gonzalez; D'Cunha; Neimark; Wallace,"Department of Gastroenterology, Infectiology and Rheumatology, Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; AbbVie Inc, North Chicago, Illinois.; AbbVie Deutschland GmbH and Co KG, Ludwigshafen, Germany.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.",
39034992,Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.,2024,,,
39033764,Renal cell carcinoma.,2024-Aug-03,,,thomas.powles1@nhs.net.
39031963,Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial.,2024-Jul,Inocencio; Lewis; Fury; Chen; Quek,"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.",
39028923,Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).,2025-Mar,Abbass; Fung; Sussell; Cortazar,"Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",
39023864,Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.,2024-Sep-01,,,
39023740,A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape.,2024-Sep,,,jun.gong@cshs.org.
39023287,PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.,2024,,,
39021272,Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy.,2024-Jul,,,
39020051,"Development of a first-in-class antibody and a specific assay for α-1,6-fucosylated prostate-specific antigen.",2024-Jul-17,Halldórsson; Hillringhaus; Hojer; Schraeml; Lange; Tabarés,"Pharma Research and Early Development, F. Hoffmann-La Roche AG, Basel, Switzerland.; Roche Diagnostics GmbH, Nonnenwald, Penzberg, Germany.; Roche Diagnostics GmbH, Nonnenwald, Penzberg, Germany.; Roche Diagnostics GmbH, Nonnenwald, Penzberg, Germany.; Roche Diagnostics GmbH, Nonnenwald, Penzberg, Germany. magdalena.swiatek-de_lange@roche.com.; Roche Diagnostics GmbH, Nonnenwald, Penzberg, Germany.",magdalena.swiatek-de_lange@roche.com.
39013870,Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.,2024-Jul-16,,,isabelle.ray-coquard@lyon.unicancer.fr.
39003289,Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.,2024-Jul-13,,,eiji.shinozaki@jfcr.or.jp.
39003185,MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC.,2024-Sep,,,m.reck@lungenclinic.de.
39002348,Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.,2024-Sep,,,lorenzo.fornaro@gmail.com.
39001619,Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers.,2024-Oct,Gomes; Stern; Neubert; Bruno; Mercier; Vatakuti; Jamois,"Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland.; Pharma Research and Early Development, Data & Analytics, Roche Innovation Center Basel, Basel, Switzerland.; Modeling and Simulation, Clinical Pharmacology, Genentech Research and Early Development, Marseille, France.; Modeling and Simulation, Clinical Pharmacology, Genentech Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Predictive Modeling and Data Analytics, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Translational PKPD and Clinical Pharmacology, Roche Innovation Center Basel, Basel, Switzerland.",
38995291,HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.,2024-Sep-13,,,
38990554,Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.,2024-Sep-03,Nazeer; Squires,"Novartis Pharmaceuticals, Cambridge, Massachusetts.; Novartis Pharmaceuticals, Cambridge, Massachusetts.",
38979893,Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.,2024-Sep,Egorov; Nishijima; Nakatani; Nishiyama; Sugihara,"Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.",
38977707,Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.,2024-Jul-08,,,ajai.chari@ucsf.edu.
38971950,PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.,2024-Sep,Chui; Seiller; Liste-Hermoso; Willis; Shemesh; Molinero; Guan,"Product Development Oncology, Genentech Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Safety, Roche Products Ltd, Welwyn Garden City, UK.; Clinical Pharmacology Oncology, Genentech Inc, South San Francisco, CA, USA.; Translational Medicine, Genentech Inc., South San Francisco, CA, USA.; Translational Medicine, Genentech Inc., South San Francisco, CA, USA.",rebecca.kristeleit@gstt.nhs.uk.
38971175,"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.",2024-Jul-27,Zum Büschenfelde,"Clinic for Hematology, Oncology, Immunology and Palliative Medicine, Vincentius-Deaconry Clinics gAG, Karslruhe, Germany.",peter.borchmann@uk-koeln.de.
38967883,Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion.,2024-Dec,,,mantegazza.renato@gmail.com.
38967717,Zolbetuximab: First Approval.,2024-Aug,,,dru@adis.com.
38960696,Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan.,2024-Sep-28,,,
38956747,"Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée).",2024-Oct-03,,,
38954785,Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.,2024-Sep-01,,,
38954006,Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.,2024-Jul-02,,,giandomenico.roviello@unifi.it.
38949888,"Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.",2024-Sep-03,,,
38945791,The Management of older patients with Hodgkin lymphoma: implications of S1826.,2024-Aug,,,andrew.evens@rutgers.edu.
38942693,Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer.,2024-Sep,Giranda; Suttner; Liu; Chatterjee,"Merck & Co., Inc., Rahway, NJ.; Merck & Co., Inc., Rahway, NJ. Electronic address: leah.suttner@merck.com.; Merck & Co., Inc., Rahway, NJ.; Merck & Co., Inc., Rahway, NJ.",leah.suttner@merck.com.
38942173,Current and emerging intralesional immunotherapies in cutaneous oncology.,2024-Nov,,,mrmigden@mdanderson.org.
38942046,"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.",2024-Aug,,,naomi.haas@pennmedicine.upenn.edu.
38941962,Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.,2024-Sep,,,grishamr@mskcc.org.
38937403,Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study.,2024-Jul,,,Arpitkumar.Prajapati@curateqbio.com.
38937025,"Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial.",2024-Jul,,,alessandro.pulsoni@uniroma1.it.
38932316,Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine.,2024-May-28,,,
38916448,Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.,2024-Jul-01,,,
38914019,Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases.,2025-Mar-01,,,
38913881,Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.,2024-Oct-01,Haiderali; Jia; Nguyen; Pan,"Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ, USA.; Biostatistics and Research Division Sciences, Merck & Co., Inc., Rahway, NJ, USA.; Biostatistics and Research Decision Sciences-Epidemiology, Patient-Centered Endpoints & Strategy, Merck & Co., Inc., Rahway, NJ, USA.; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, USA.",
38911570,Twenty-five years with HER2 targeted therapy.,2024-Jun-10,,,
38907948,Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.,2024-Jul,Wu; Pennesi; Bautista; Garrett; Brivio; Ammerlaan; van der Sluis; Zwaan; Huitema,"Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Pfizer Global Pharmacometrics, San Diego, CA, USA.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. c.m.zwaan-2@prinsesmaximacentrum.nl.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.",c.m.zwaan-2@prinsesmaximacentrum.nl.
38906514,The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies.,2024-Aug,,,r.daher@studenti.unisr.it.
38906161,"Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.",2024-Aug,Hirashima; Hagihara; Nakada,"Ono Pharmaceutical, Osaka, Japan.; Ono Pharmaceutical, Osaka, Japan.; Ono Pharmaceutical, Osaka, Japan.",msasako2010@yahoo.co.jp.
38904892,"Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.",2024-Nov,Ntalla; Lai; Sjekloca; Stwalley; Taylor,"Real-World Evidence, Gilead Sciences Europe Ltd., Stockley Park, UK.; Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.; Global Medical Affairs, Gilead Sciences Europe Ltd., Stockley Park, UK.; US Medical Affairs, Gilead Sciences, Inc., Foster City, CA, USA.; Real-World Evidence, Gilead Sciences Europe Ltd., Stockley Park, UK.",kevin.michael.kalinsky@emory.edu.
38901425,QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.,2024-Sep-13,,,takeh1977@gmail.com.
38899745,Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real-world analysis.,2024-Jun,,,
38898592,"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.",2024-Jun,,,
38896212,Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.,2024-Jul,,,nathan.fowler@bostongene.com.
38895886,Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.,2024-Jun,,,
38889737,"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.",2024-Aug,,,kim.m.linton@manchester.ac.uk.
38886836,Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.,2024-Jun-17,,,Thibault.Mazard@icm.unicancer.fr.
38884900,Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.,2024-Sep,Nishijima; Nishiyama; Sugihara,"Daiichi Sankyo, Co., Ltd, Tokyo, Japan.; Daiichi Sankyo, Co., Ltd, Tokyo, Japan.; Daiichi Sankyo, Co., Ltd, Tokyo, Japan.",tsurutaj@med.showa-u.ac.jp.
38879802,Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.,2024-Aug-01,Cassady; DeVeaux; Chokshi; Boyapati; Hazra; Yancopoulos; Sirulnik; Rodriguez Lorenc; Kroog; Houvras,"Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.",
38879608,"Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab based allogeneic hematopoietic cell transplantation in adults with severe aplastic anemia.",2024-Sep,Gilmore,"Cleveland Clinic, Department of Pharmacy, Cleveland, OH, USA. gilmorr4@ccf.org.",gilmorr4@ccf.org.
38878486,"IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer.",2024-Aug-20,Qian; Xu; Dou; Yang; Liu; Liu; Pan; Wang; Bai; Gao; Xu,"Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.; Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China. Electronic address: xuqinzhi@immunoah.cn.",zhougx@ntu.edu.cn.
38871975,Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.,2024-Sep,Grossman; Patel; Wu; Chand; Rosenthal; Mednick; Delepine; O'Day,"Agenus, Inc., Lexington, MA, USA.; Agenus, Inc., Lexington, MA, USA.; Agenus, Inc., Lexington, MA, USA.; Agenus, Inc., Lexington, MA, USA.; Agenus, Inc., Lexington, MA, USA.; Agenus, Inc., Lexington, MA, USA.; Agenus, Inc., Lexington, MA, USA.; Agenus, Inc., Lexington, MA, USA.",justin.stebbing@aru.ac.uk.
38867006,Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.,2024-Sep,,,kho@soton.ac.uk.
38866528,Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks Is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors.,2025-Jan-15,,,
38861666,Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.,2024-Sep-26,,,
38861301,"IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.",2024,Badhrinarayanan; Cotter; Zhu; Lin,"Clinical Development Oncology, Genentech Inc., South San Francisco, CA, USA.; Clinical Development Oncology, Genentech Inc., South San Francisco, CA, USA.; Clinical Development Oncology, Genentech Inc., South San Francisco, CA, USA.; Clinical Development Oncology, Genentech Inc., South San Francisco, CA, USA.",
38858106,"A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).",2024-Aug-05,Hu; Krishnan; Molinero; Feng; Kim; Castro; Lin,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc, South San Francisco, California, USA.; Genentech, Inc, South San Francisco, California, USA.; Genentech, Inc, South San Francisco, California, USA.; Genentech, Inc, South San Francisco, California, USA.; Genentech, Inc, South San Francisco, California, USA.; Genentech, Inc, South San Francisco, California, USA.",rsalani@mednet.ucla.edu.
38858103,Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.,2024-Aug-05,Wang; Esteves; Method,"ImmunoGen Inc, Waltham, Massachusetts, USA.; ImmunoGen Inc, Waltham, Massachusetts, USA.; ImmunoGen Inc, Waltham, Massachusetts, USA.",rcoledude@mac.com.
38856863,"Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.",2024-Jun-10,Roider; Hoff; Tseng; Berndt; Trautwein; Filarsky; Filarsky; Gritzan; Camps; Nadler; Grudzinska-Goebel; Ellinger; Pesch; Soon; Geyer; Gluske; Stelte-Ludwig; Stelte-Ludwig; Gorjánácz,"Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, San Francisco, USA.; Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Current address: Roche Diagnostics GmbH, Penzberg, Germany.; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Current address: Vincerx Pharma, Monheim am Rhein, Germany.; Bayer AG, Pharmaceuticals, Berlin, Germany. matyas.gorjanacz@bayer.com.",matyas.gorjanacz@bayer.com.
38855109,Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.,2024,,,
38851207,"Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.",2024-Jul,,,dadkins@wustl.edu.
38850448,Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.,2024-Aug,,,kawashima@uro.med.osaka-u.ac.jp.
38850335,Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.,2024-Jun-08,,,p.ascierto@istitutotumori.na.it.
38849283,"Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study.",2024-Oct,Wang; Perumal,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",aoriol@iconcologia.net.
38844797,Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.,2024-Aug,,,ychen6@mgb.org.
38844668,Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan.,2024-Jul,Hiraizumi; Honda; Watanabe; Nakao; Sakamoto,"Oncology Medical Affairs, Ono Pharmaceutical Co., Ltd., 1-8-2 Kyutaromachi, Chuo-ku, Osaka, 541-8564, Japan.; PV Data Strategy, Pharmacovigilance Department, Ono Pharmaceutical Co., Ltd., 2-1-5 Dosho-machi, Chuo-ku, Osaka, 541-8526, Japan.; Safety Management Pharmacovigilance Department, Ono Pharmaceutical Co., Ltd., 2-1-5 Dosho-machi, Chuo-ku, Osaka, 541-8526, Japan.; Safety Management Pharmacovigilance Department, Ono Pharmaceutical Co., Ltd., 2-1-5 Dosho-machi, Chuo-ku, Osaka, 541-8526, Japan.; Safety Management Pharmacovigilance Department, Ono Pharmaceutical Co., Ltd., 2-1-5 Dosho-machi, Chuo-ku, Osaka, 541-8526, Japan. t.sakamoto@ono-pharma.com.",t.sakamoto@ono-pharma.com.
38844309,Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.,2024-Jun,Knox; Soleymani; Yao; Neely; Tschaika,"Princess Margaret Cancer Centre, Toronto, Canada.; Bristol Myers Squibb, Princeton, USA.; Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, USA.; Translational Medicine, Bristol Myers Squibb, Princeton, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA.",imelero@unav.es.
38838502,"A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.",2024-Jun,James; Gangl,"Medical Statistics Consultancy Ltd, London, UK.; BioPharma R&D, AstraZeneca, Boston.",talonso@salud.madrid.org.
38838446,"Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.",2024-Aug,Leiby; Lin; Zhao; Krepler; Perini; Catherine Pietanza; Samkari; Gruber; Ibrahim,"Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.",lukejj@upmc.edu.
38834744,Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.,2024-Jul,,,yutsukad@east.ncc.go.jp.
38834087,"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.",2024-Jul,,,jean-luc.vanlaethem@hubruxelles.be.
38833968,A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.,2024-Jun,,,nkiyota@med.kobe-u.ac.jp.
38833658,"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.",2024-Aug-20,Jain; Adelberg,"Merck & Co, Inc, Rahway, NJ.; Merck & Co, Inc, Rahway, NJ.",
38833206,Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.,2024-Jun-04,,,wongcl@sunmed.com.my.
38833158,A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.,2024-Oct-17,,,
38833067,"A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.",2024-Aug,Hagiwara; Suzuki; Fujikawa; Toyoizumi; Mukai,"Research and Development Division, Janssen Pharmaceutical K.K., Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K., Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K., Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K., Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K., Tokyo, Japan.",tdoi@east.ncc.go.jp.
38830895,Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.,2024-Jun-03,,,yukiya.narita@aichi-cc.jp.
38825627,Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.,2024-Aug,Nakatani; Ashfaque; Liang; Egorov,"Daiichi Sankyo Co, Ltd., Tokyo, Japan.; Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.; Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.; Daiichi Sankyo, Inc., Rueil-Malmaison, France.",javier.cortes@maj3.health.
38823511,Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.,2024-Sep,Bavle; Homet Moreno; Markensohn; Edmondson; Chen; Cristescu; Peña; Lunceford,"Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.; Merck & Co. Inc., Rahway, NJ, USA.",thomas.powles1@nhs.net.
38823398,Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.,2024-Aug,,,ohdoyoun@snu.ac.kr.
38821718,Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.,2024-May-31,Hill; McCraith; He; Lei,"Tasman Oncology Research, Ltd, Southport, Queensland, Australia.; Department of Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Department of Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Global Biostatistics and Data Science, Bristol Myers Squibb Co, Princeton, New Jersey, USA.",moverman@mdanderson.org.
38820549,Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.,2024-Aug-20,Li; Lu; Hu; Wang; Li; Xia,"Akeso Biopharma, Inc, Zhongshan, China.; Akeso Biopharma, Inc, Zhongshan, China.; Akeso Biopharma, Inc, Zhongshan, China.; Akeso Biopharma, Inc, Zhongshan, China.; Akeso Biopharma, Inc, Zhongshan, China.; Akeso Biopharma, Inc, Zhongshan, China.",
38815637,Exosome-mediated delivery platform of biomacromolecules into the brain: Cetuximab in combination with doxorubicin for glioblastoma therapy.,2024-Jul-20,,,wangaipingytu@163.com.
38815152,Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.,2024-Oct-03,Joo; Norquist; Suryawanshi; Shah,"Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.",
38811560,"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.",2024-May-29,,,ajakubowiak@bsd.uchicago.edu.
38811413,Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan.,2024-Aug,,,iida@med.nagoya-cu.ac.jp.
38810600,"Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.",2024-Jul,,,Glen.Frick@alexion.com.
38807589,Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab.,2024,,,
38806195,"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.",2024-May-28,,,xurh@sysucc.org.cn.
38805668,Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.,2024-Aug-10,,,
38797537,Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.,2024-Jul,Nishibata; Weng; Omori; Sato; Nakazawa; Suzuki; Yamada; Nakajo; Kinugasa; Yoshida,"Astellas Pharma, Inc., Ibaraki, Japan. Electronic address: toshihide.nishibata@astellas.com.; Astellas Pharma, Inc., Ibaraki, Japan.; Formerly of Astellas Pharma, Inc., Ibaraki, Japan.; Astellas Pharma, Inc., Ibaraki, Japan.; Astellas Pharma, Inc., Ibaraki, Japan.; Astellas Pharma, Inc., Ibaraki, Japan.; Astellas Pharma, Inc., Ibaraki, Japan.; Astellas Pharma, Inc., Ibaraki, Japan.; Astellas Pharma, Inc., Ibaraki, Japan.; Astellas Pharma, Inc., Ibaraki, Japan.",toshihide.nishibata@astellas.com.
38797190,"Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA.",2024-Jul,,,drkhurram2000@gmail.com.
38796287,Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.,2024-May,Hegg; Verma,"Gynecological and Breast Oncology, Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda., Avenida Brigadeiro Luís Antônio, São Paolo, Brazil.; Global Oncology Research and Development, AstraZeneca Pharmaceuticals, Gaithersburg, USA.",shurvitz@fredhutch.org.
38794892,Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.,2024-Sep-04,,,
38782061,Efficient intracellular drug delivery by co-administration of two antibodies against cell adhesion molecule 1.,2024-Jul,,,azusa618@med.kindai.ac.jp.
38781315,Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.,2024-Sep-10,,,
38780965,Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease: A Phase 1 Nonrandomized Controlled Trial.,2024-Jul-01,,,
38780927,Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.,2024-Jul-01,Abousaud,"Astellas Pharma Global Development Inc, Northbrook, Illinois.",
38777726,Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.,2024-Jul,,,filippo.pietrantonio@istitutotumori.mi.it.
38777578,Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study.,2024-Nov-18,,,herena20@ncc.re.kr.
38775718,Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).,2024-Sep-01,Faller,"Missouri Baptist Medical Center Heartland NCORP, St Louis, MO, USA.",
38772416,Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.,2024-Aug-01,,,
38767786,Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).,2024-Aug,,,nmasuda@alpha.ocn.ne.jp.
38767650,"Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.",2024-Aug-15,,,
38763104,Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.,2024-Jun,Tiedt,"Novartis Pharma AG, Basel, Switzerland.",efelip@vhio.net.
38763053,Agnostic drug development revisited.,2024-Jul,,,egarralda@vhio.net.
38760098,Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.,2024-Jun,,,bruce.cree@ucsf.edu.
38759667,"Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.",2024-Jun,,,joel.guigay@gortec.fr.
38758239,The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.,2024-May-17,,,jkanda16@kuhp.kyoto-u.ac.jp.
38758119,Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.,2024-Jul-01,,,
38757410,The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation.,2024-Jul,,,
38755971,Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis.,2025-Feb,,,
38750034,CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.,2024-May-15,Waterkamp; Leutgeb; Bouseida; Flinn; Das Thakur; Elze; Koeppen; Jamois; Martin-Facklam,"Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.",segaln@mskcc.org.
38749213,Anti-Netrin-1 decorated nanoparticles combined with chemotherapy for the treatment of triple-negative breast cancer.,2024-Jul,Mehlen,"Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS, Université de Lyon1, 69008 Lyon, France; Netris Pharma, Lyon, France.",david.kryza@univ-lyon1.fr.
38749110,Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.,2024-Jul,Li; Jain; Adelberg,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",jtaieb75@gmail.com.
38748596,Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.,2024-Sep-06,Shi; Verret; Shah; Gharaibeh,"Department of Evidence Synthesis, Modeling and Communication, Evidera Inc., Bethesda, MD, United States.; Department of Clinical Development, Gilead Sciences, Inc., Foster City, CA, United States.; Department of Health Economics and Outcomes Research, Gilead Sciences, Inc., Foster City, CA, United States.; Department of Health Economics and Outcomes Research, Gilead Sciences, Inc., Foster City, CA, United States.",
38745009,"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.",2024-Jul,Inaki; Kuwahara; Wada; Suto; Arita; Sugihara; Tsuchihashi; Saito; Kojima,"Daiichi Sankyo Co. Ltd, Tokyo, Japan.; Daiichi Sankyo Inc., Basking Ridge, NJ, USA.; Daiichi Sankyo RD Novare Co. Ltd, Tokyo, Japan.; Daiichi Sankyo Inc., Basking Ridge, NJ, USA.; Daiichi Sankyo Co. Ltd, Tokyo, Japan.; Daiichi Sankyo Co. Ltd, Tokyo, Japan.; Daiichi Sankyo Inc., Basking Ridge, NJ, USA.; Daiichi Sankyo Inc., Basking Ridge, NJ, USA.; Daiichi Sankyo Co. Ltd, Tokyo, Japan.",kshitara@east.ncc.go.jp.
38743766,"Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.",2024-Aug-01,Feldsien; Lefebvre; Reilly,"Development Sciences, AbbVie Inc., North Chicago, Illinois.; Development Sciences, AbbVie Inc., North Chicago, Illinois.; Discovery Oncology, AbbVie Inc., North Chicago, Illinois.",
38740030,"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.",2024-Jun,,,necchi.andrea@hsr.it.
38734670,"Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions.",2024-May-11,,,nshort@mdanderson.org.
38731936,"Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.",2024-Apr-26,,,
38728337,Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.,2024,Porte; Granghaud; Morel; Solbes; Lambert,"Health Economics Department, Merck Santé S.A.S., Lyon, France.; Health Economics department, Pfizer S.A.S., Paris, France.; Health Economics department, Pfizer S.A.S., Paris, France.; Medical Department, Merck Santé S.A.S., Lyon, France.; Medical Department, Pfizer S.A.S., Paris, France.",
38722641,Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.,2024-Jun-01,,,
38722221,"J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.",2024-Aug,Ito; Kajita,"Medical Department, Merck Biopharma Co., Ltd. (an affiliate of Merck KGaA), Tokyo, Japan.; Oncology Medical Affairs, Merck Biopharma Co., Ltd. (an affiliate of Merck KGaA), Tokyo, Japan.",
38716626,"Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.",2024-May,Amaya-Chanaga; Patel; Hu; Matsumura,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Ono Pharmaceutical Company Ltd., Osaka, Japan.",
38714474,Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.,2024-Aug,,,kathryn.lurain@nih.gov.
38710187,"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.",2024-Jun,,,lib1@mskcc.org.
38709220,Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.,2024-Jul-15,Evers; Boetsch; Marbach; Ardeshir; Richard; Charo; Kraxner; Keshelava; Teichgräber,"Roche Pharma Research and Early Development, Discovery and Translational Area Oncology, Roche Innovation Center, Basel, Switzerland.; Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.; Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.; Roche Products Ltd., Welwyn Garden City, United Kingdom.; Roche Pharma Research and Early Development, Discovery and Translational Area Oncology, Roche Innovation Center, Basel, Switzerland.; Roche Pharma Research and Early Development, Discovery and Translational Area Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Discovery and Translational Area Oncology, Roche Innovation Center, Basel, Switzerland.; Roche Pharma Research and Early Development, Discovery and Translational Area Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Discovery and Translational Area Oncology, Roche Innovation Center, Basel, Switzerland.",
38709212,Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.,2024-Jul-15,,,
38709114,"Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.",2024-May-06,,,mc.sorigue@zoho.com.
38705160,"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.",2024-May-25,,,Martin.Dreyling@med.uni-muenchen.de.
38704241,Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.,2024-Aug-14,,,
38702147,Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.,2024-May-03,Combarel; Combarel; Delahousse; Broutin; Broutin,"Laboratoire de pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, Île-de-France, France.; Faculté de pharmacie, Université Paris-Saclay, Orsay, France.; Laboratoire de pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, Île-de-France, France.; Laboratoire de pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, Île-de-France, France.; Faculté de pharmacie, Université Paris-Saclay, Orsay, France.",Francois-xavier.danlos@gustaveroussy.fr.
38698758,Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.,2024-Jun,,,
38697156,"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.",2024-May,,,howard.burris@sarahcannon.com.
38697155,"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.",2024-May,,,tanja.fehm@med.uni-duesseldorf.de.
38696168,Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.,2024-May-01,,,
38689194,Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.,2024-Jul,,,marapersano@alice.it.
38689060,Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.,2024-Jun,,,martin.schuler@uk-essen.de.
38683200,A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.,2024-Jul-01,,,
38682560,A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.,2024,Tonelli; Sierecki; Zhou,"Gilead Sciences, Inc., Parsippany, NJ, USA.; Gilead Sciences, Inc., Parsippany, NJ, USA.; Gilead Sciences, Inc., Parsippany, NJ, USA.",
38664577,First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.,2024-Jun,,,a.h.ree@medisin.uio.no.
38660294,A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma.,2024,,,
38658336,Primary Extranodal Diffuse Large B-cell Lymphoma Presenting in the Lips: A Case Report and Literature Review.,2024-Dec-15,,,
38657187,,2024-Jul-10,,,
38653864,Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.,2024-May,,,friedmac@mskcc.org.
38653033,Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.,2024-Jun,Jiang; Lee; de Silva,"Bristol Myers Squibb, Princeton, USA.; Bristol Myers Squibb, Princeton, USA.; Bristol Myers Squibb, Princeton, USA.",carrilajuria.lucia@gmail.com.
38652877,Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.,2024-Jul-01,Greenberg; Greenberg; Kobayashi; Zebger-Gong; Wong; Kawasaki; Nakamura,"Global Oncology Clinical Development, Daiichi Sankyo, Inc, Basking Ridge, NJ.; Global Oncology Clinical Development, Daiichi Sankyo Europe GmbH, Munich, Germany.; Data Intelligence, Daiichi Sankyo, Co, Ltd, Tokyo, Japan.; Global Oncology Clinical Development, Daiichi Sankyo Europe GmbH, Munich, Germany.; Global Oncology Clinical Development, Daiichi Sankyo, Co, Ltd, Tokyo, Japan.; Global Oncology Clinical Development, Daiichi Sankyo, Inc, Basking Ridge, NJ.; Data Intelligence, Daiichi Sankyo, Co, Ltd, Tokyo, Japan.",
38651187,PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.,2024-Apr,Gu; Mita; Chen; Ueda,"Incyte Corporation, Wilmington, Delaware, USA.; Incyte Biosciences Japan G.K., Tokyo, Japan.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Biosciences Japan G.K., Tokyo, Japan.",
38649340,Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.,2024-Apr-22,,,nsc@medicine.wisc.edu.
38642912,Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?,2024-Jun-20,Schuler,"Roche Innovation Center Basel, Roche Pharma Research and Early Development, Schlieren, Switzerland.",
38642257,Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.,2024-Oct,Lloansí Vila,"AMGEN S.A., Barcelona, Spain.",mvalaye@icloud.com.
38642198,Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.,2024-Jun,,,cvansteen93@gmail.com.
38640937,"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.",2024-Jun,,,nick.kennedy1@nhs.net.
38640773,"Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.",2024-Jul,,,gardnerg@mskcc.org.
38640349,Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.,2024-Jul-09,,,
38634928,Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.,2024-Apr-18,,,francesco.massari@aosp.bo.it.
38629963,Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy.,2024-Jun-03,,,
38627238,Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.,2024-Apr-30,Bernat; Häckl; Marszewska; McKernan; Saulay; Scaleia; Engelhardt,"Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.",
38609704,Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.,2024-Apr,Tang; Garg; Bonate; Matsangou; Kadokura; Yamada; Choules; Pavese; Nagata; Tenmizu; Koibuchi; Heo; Wang; Wojtkowski; Hanley; Poondru,"Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., 2375 Waterview Drive, Northbrook, IL, 60062-6111, USA.; Clinical Pharmacology Oncology, Pfizer Inc., 181 Oyster Point Boulevard, South San Francisco, CA, 94080, USA. amit.garg@pfizer.com.; Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., 2375 Waterview Drive, Northbrook, IL, 60062-6111, USA.; Therapeutic Area-Oncology, Astellas Pharma Global Development, Astellas Pharma, Inc., Northbrook, IL, USA.; Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., Tokyo, Japan.; Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., Tokyo, Japan.; Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., 2375 Waterview Drive, Northbrook, IL, 60062-6111, USA.; Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., 2375 Waterview Drive, Northbrook, IL, 60062-6111, USA.; Analysis and Pharmacokinetics Research Laboratories, Drug Discovery Research, Astellas Pharma, Inc, Tsukuba, Japan.; Analysis and Pharmacokinetics Research Laboratories, Drug Discovery Research, Astellas Pharma, Inc, Tsukuba, Japan.; Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., Tokyo, Japan.; Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., 2375 Waterview Drive, Northbrook, IL, 60062-6111, USA.; Statistical and Real-World Data Science, Astellas Pharma Global Development Inc, Northbrook, IL, USA.; Data Science Development, Astellas Pharma Global Development Inc., Northbrook, IL, USA.; Clinical Pharmacology Oncology, Pfizer Inc., 181 Oyster Point Boulevard, South San Francisco, CA, 94080, USA.; Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., 2375 Waterview Drive, Northbrook, IL, 60062-6111, USA. Srinivasu.Poondru@astellas.com.",amit.garg@pfizer.com.
38608691,"Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.",2024-May,Khan; Copigneaux; Lee; Garnett-Benson; Wang,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA; Syneos Health, Morrisville, NC, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",aoaknin@vhio.net.
38607538,First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.,2024-Jul,,,kenkato@ncc.go.jp.
38607410,Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.,2024-Jun-25,Laird; Yafawi; Liu; Vandendries,"Translational Oncology, Late Development, Pfizer Inc, South San Francisco, CA.; Clinical Data Acquisition, Pfizer Inc, La Jolla, CA.; Biostatistics, Pfizer Inc, Groton, CT.; Global Product Development, Pfizer Inc, Cambridge, MA.",
38600471,Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.,2024-Apr-11,Alkuzweny; Zhang,"Formerly Pfizer, Inc, San Diego, CA, USA.; Pfizer, Inc, New York, NY, USA.",meelez@vhio.net.
38598745,An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.,2024-Jun-11,James,"Polaris Biostatistics Ltd, Edinburgh, United Kingdom.",
38597986,"A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.",2024-Jul,Hatayama; Inagaki; Fujikawa,"Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.; Research and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.",kizutsu@ncc.go.jp.
38593241,Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.,2024-Jun-11,Tan; Yeh,"Lisa Tan Pharma Consulting Ltd, Cambridge, United Kingdom.; Apellis Pharmaceuticals, Inc, Waltham, MA.",
38591098,Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).,2024-Apr,Danenberg,"Liquid Genomics, Inc., Torrance, California, USA.",
38587856,Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.,2024-Jun-03,,,
38584069,A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.,2024-May,Alatorre-Alexander; Araujo,"Health Pharma Professional Research, Mexico City, Mexico.; Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil.",egaron@mednet.ucla.edu.
38582092,3-year invasive disease-free survival with chemotherapy de-escalation using an ,2024-Apr-27,,,antonio.llombart@maj3.health.
38581687,Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).,2024-Aug-05,,,
38576344,A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer.,2024-Nov,,,htanabe@east.ncc.gp.jp.
38574742,Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis.,2024-May,,,specks.ulrich@mayo.edu.
38572524,Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.,2024-May,,,
38568692,Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.,2024-Apr-01,,,
38561010,"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.",2024-May,,,jean-pascal.machiels@saintluc.uclouvain.be.
38554625,"The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.",2024-Jul,Molinero; Khor; Lin,"Genentech, Inc., South San Francisco, CA, United States.; Genentech, Inc., South San Francisco, CA, United States.; Genentech, Inc., South San Francisco, CA, United States. Electronic address: LIN-LIU.YVONNE@gene.com.",LIN-LIU.YVONNE@gene.com.
38554156,"Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.",2024-Mar-30,Duffy; Ge; Elgadi,"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.",mpatel@flcancer.com.
38553360,"Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF",2024-Jun,Ushida; Oizaki; Inoue,"Ono Pharmaceutical, Co., Ltd., Osaka, Japan.; Ono Pharmaceutical, Co., Ltd., Osaka, Japan.; Ono Pharmaceutical, Co., Ltd., Osaka, Japan.",tyoshino@east.ncc.go.jp.
38552197,CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.,2024-Jul-10,Antic; Chun; Lin; Huseni; Ballinger; Graupner,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
38551807,Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.,2024-Jul-04,,,
38551806,"Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.",2024-Jun-11,,,
38547891,"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.",2024-Apr,,,e.f.smit@LUMC.nl.
38546551,Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.,2024-May-01,,,
38542278,Targeting ,2024-Mar-14,,,
38538861,Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.,2024-May,,,Hans.eich@ukmuenster.de.
38538574,"Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.",2024-Mar-27,,,Filipa_Lynce@dfci.harvard.edu.
38537065,A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.,2024-May-28,,,
38533127,Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.,2024-May,Omrani; Hoenigl,"Hamad Medical Corporation, Doha, Qatar.; BioTechMed, Graz, Austria.",
38532079,Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.,2024-Jun,Smith; Ristuccia; Dwyer,"Medical Affairs Oncology, Kyowa Kirin, Inc, Princeton, NJ, USA.; Medical Affairs Oncology, Kyowa Kirin, Inc, Princeton, NJ, USA. robert.ristuccia.bt@kyowakirin.com.; Medical Sciences, Kyowa Kirin, Inc, Princeton, NJ, USA.",robert.ristuccia.bt@kyowakirin.com.
38531863,"How comparable are patient outcomes in the ""real-world"" with populations studied in pivotal AML trials?",2024-Mar-26,,,andrew.wei@petermac.org.
38530846,A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.,2024-Jun-14,Finnes,"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota.",
38530565,"KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.",2024-Jun,Leopold; Munteanu,"Incyte Corporation, Clinical Development, Wilmington, DE, USA.; Incyte Corporation, Clinical Development, Wilmington, DE, USA.",nbryamam@ncc.go.jp.
38529706,Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.,2024-May,,,
38527096,Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.,2024-Oct-03,,,
38521840,Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan.,2024-Jun,Kawasaki; Hoshino; Akamatsu; Kakuuchi,"Ono Pharmaceutical Co., Ltd, 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan. ak.kawasaki@ono-pharma.com.; Ono Pharmaceutical Co., Ltd, 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan.; Ono Pharmaceutical Co., Ltd, 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan.; Ono Pharmaceutical Co., Ltd, 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan.",ak.kawasaki@ono-pharma.com.
38521086,"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.",2024-Apr-06,,,domenica.lorusso@policlinicogemelli.it.
38520847,Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.,2024-Apr,Ebi; Aono,"Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Chiyoda-ku, Tokyo.; Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Chiyoda-ku, Tokyo.",hgyoshioka@gmail.com.
38519705,Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.,2024-May,,,haratani_k@med.kindai.ac.jp.
38519053,Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.,2024-Mar-21,,,yankelevic@gmail.com
38508135,"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial.",2024-Mar-19,Xu; Liu; Wang,"Jiangsu Alphamab Biopharmaceuticals, Suzhou, Jiangsu, China.; Department of Clinical Medicine, Jiangsu Alphamab Biopharmaceuticals, Suzhou, Jiangsu, China.; Department of Biostatistics, Jiangsu Alphamab Biopharmaceuticals, Suzhou, Jiangsu, China.",zhangli@sysucc.org.cn.
38505718,Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.,2024-Feb,,,
38503592,"Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.",2024-Jun,Elsouda; Mucha; Fuldeore,"Astellas Pharma Inc., Northbrook, IL.; Astellas Pharma Inc., Northbrook, IL.; Astellas Pharma Inc., Northbrook, IL.",Ronac.Mamtani@pennmedicine.upenn.edu.
38502947,"Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer.",2024-Mar-19,,,
38502365,Pregnancy and delivery in an advanced cancer survivor with immune checkpoint inhibitor-induced type 1 diabetes: a case report.,2024-Aug,,,suzukir@tokyo-med.ac.jp.
38502227,Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.,2024-Jun-11,,,
38494542,Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.,2024-May,,,bdurie@myeloma.org.
38492020,Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.,2024-Dec,,,n_nakamura@kuhp.kyoto-u.ac.jp.
38489858,Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?,2024-May,Ndounga-Diakou; Laghouati,"Pharmacovigilance Unit, Clinical Research Direction, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94805 Villejuif, France.; Pharmacovigilance Unit, Clinical Research Direction, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94805 Villejuif, France.",Pablo.Berlanga@gustaveroussy.fr.
38485190,Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.,2024-Mar-13,Cullen; Kang; Hammell; Yao,"Oncology Clinical Science, Bristol Myers Squibb, Princeton, New Jersey, USA.; Biostatistics, Bristol Myers Squibb, Princeton, New Jersey, USA.; Precision Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA.; Translational Bioinformatics, Bristol Myers Squibb, Princeton, New Jersey, USA.",lenz@med.usc.edu.
38485189,"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.",2024-Mar-13,Zhao; Kalabis; Krepler,"Merck & Co Inc, Rahway, New Jersey, USA.; Merck & Co Inc, Rahway, New Jersey, USA.; Merck & Co Inc, Rahway, New Jersey, USA.",dirk.schadendorf@uk-essen.de.
38478197,Biodistribution of Drug/ADA Complexes: The Impact of Immune Complex Formation on Antibody Distribution.,2024-Mar-13,Opolka-Hoffmann; Edelmann; Otteneder; Hauri; Jordan; Schrag; Lechmann; Staack,"Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany. Eugenia.opolka-hoffmann@roche.com.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Therapeutic Modalities, CH-4070, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany.",Eugenia.opolka-hoffmann@roche.com.
38471711,High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.,2024-Mar-11,Yoo; Paccaly; Papachristos; Nguyen; Okoye; Seebach; Booth; Lowy; Fury,"Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.",danny.rischin@petermac.org.
38471416,Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.,2024-Apr,,,kimdw@snu.ac.kr.
38468564,Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.,2024-Jul,Asakawa; Waratani; Kondo; Saito,"Department of Global Medical Affairs Japan, Astellas Pharma, Inc., Tokyo, Japan.; Department of Global Medical Affairs Japan, Astellas Pharma, Inc., Tokyo, Japan.; Department of Global Medical Affairs Japan, Astellas Pharma, Inc., Tokyo, Japan.; Department of Global Medical Affairs Japan, Astellas Pharma, Inc., Tokyo, Japan.",
38468231,Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.,2024-Mar-11,,,niina.maenpaa@tuni.fi.
38465614,A pivotal decade for bispecific antibodies?,2024,Surowka; Klein,"Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Roche Glycart AG, Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Roche Glycart AG, Schlieren, Switzerland.",
38458639,"Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.",2024-Mar-07,,,segaln@mskcc.org.
38453922,"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.",2024-Mar-07,Schlothauer,"Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany.",j.t.andersen@medisin.uio.no.
38447347,"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.",2024-Jun,Stec; Wang; Method,"ImmunoGen, Inc., Waltham, MA, United States. Electronic address: james.stec@immunogen.com.; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: yuemei.wang@immunogen.com.; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: michael.method@immunogen.com.",debra-richardson@ouhsc.edu.
38446675,Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.,2024-Mar-07,,,
38446087,An Unusual Presentation of MuSK-Myasthenia Gravis With Bladder Incontinence Responding to Rituximab Treatment: A Case Report and Review of the Literature.,2024-Mar-01,,,
38445082,Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.,2024,,,
38443333,"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.",2024-Mar-05,,,gilles.freyer@univ-lyon1.fr.
38442645,A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.,2024-May,Younan; Soeda; Mezzi; Chia; Rehn,"Center for Observational Research, Amgen Inc, Thousand Oaks, CA, United States.; Oncology Medical Affairs Department, Takeda Pharmaceutical Company Limited, Tokyo, Japan.; Research and Development Department, Amgen Inc, Thousand Oaks, CA, United States.; Center for Observational Research, Amgen Inc, Thousand Oaks, CA, United States.; Medical Department, Amgen Inc, Thousand Oaks, CA, United States.",sebastian.stintzing@charite.de.
38442452,Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B).,2024-Mar,,,Sara_Tolaney@DFCI.HARVARD.EDU.
38437908,Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults.,2024-Apr,,,ciprian.tomuleasa@umfcluj.ro.
38433375,Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance.,2024-Apr,Kambe; Sato; Tanaka,"Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA.; Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA.; Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA.",
38432967,Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer.,2024-Oct-01,,,
38432247,"Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.",2024-Mar,,,joel.guigay@gortec.fr.
38430375,Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.,2024-Mar-02,,,sophie.wildsmith@astrazeneca.com.
38427280,A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.,2024-Mar,,,makoharutaro2015@gmail.com.
38418879,Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T,2024-Mar,Guan; Hu; Choi; Srivats; Nabet; Silva; McGinnis; Hendricks; Nutsch; Banta; Duong; Dunkle; Chang; Han; Mittman; Molden; Daggumati; Connolly; Mellman; Mariathasan; Shames; Meng; Chiang; Johnston; Patil,"Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA.; Genentech Inc., South San Francisco, CA, USA. johnston.robert@gene.com.; Genentech Inc., South San Francisco, CA, USA. patil.namrata@gene.com.",johnston.robert@gene.com.
38418343,Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.,2024-Jun,Sridhar; Matsangou; Wu; McKay,"Princess Margaret Cancer Center, Toronto, Canada.; Astellas Pharma, Northbrook, IL, USA.; Astellas Pharma, Northbrook, IL, USA.; Astellas Pharma, Northbrook, IL, USA.",rosenbj1@mskcc.org.
38402895,"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.",2024-May,,,mp372@cam.ac.uk.
38402687,Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.,2024-Apr,,,sara.valpione@nhs.net.
38402342,"Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.",2024-May,,,c.karapetis@flinders.edu.au.
38402179,Primary endobronchial melanoma: a case report and clinical management indications.,2024-Feb-24,,,boutros.andrea@gmail.com.
38401247,"A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).",2024-Mar,Cornfeld; Ranganathan; Lou,"Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.",dr.cstibor@freemail.hu.
38396877,Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.,2024-Feb-12,,,
38392050,"Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions.",2024-Jan-29,,,
38388927,Ravulizumab in myasthenic crisis: the first case report.,2024-May,,,Skripuletz.thomas@mh-hannover.de.
38383419,First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.,2024-Feb-22,Soll; Frisch; Jensen; Mogl; Penzkofer; Spranger; Keilholz; Mai,"Department of Endocrinology and Metabolism, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Luisenstr. 13, 10117, Berlin, Germany. dominik.soll@charite.de.; Department of Radiology (CVK), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, 13353, Berlin, Germany.; Department of Endocrinology and Metabolism, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, 10117, Berlin, Germany.; Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Germany.; Department of Radiology (CVK), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, 13353, Berlin, Germany.; Department of Endocrinology and Metabolism, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Department of Endocrinology and Metabolism, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, 10117, Berlin, Germany.",dominik.soll@charite.de.
38382875,Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.,2024-May,Thungappa,"Health Care Global Enterprises Ltd, Bangalore, India.",bsangro@unav.es.
38382153,Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.,2024-Apr,,,laurence.albiges@gustaveroussy.fr.
38382001,"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.",2024-Jun-10,Elimova; Kowalyszyn; Wang; Lei; Chen; Nathani,"Princess Margaret Cancer Centre, Toronto, Canada.; Clinica Viedma S.A., Viedma, Argentina.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
38378868,Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.,2024-Feb-20,,,saeeda3@upmc.edu.
38378673,Update on the management of relapsed/refractory chronic lymphocytic leukemia.,2024-Feb-21,,,john.seymour@petermac.org.
38372949,"A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.",2024-Apr,Chamberlain,"Starlight/Lantern Pharma, 7700 Windrose Ave. Office 3-187, Piano, TX, USA.",brian.rini@vumc.org.
38369013,Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.,2024-May,Su; Sato; Fan; Fujimura; Tanaka; Patel; Sternberg; Sellami,"Daiichi Sankyo, Inc., Basking Ridge, USA.; Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo, Inc., Basking Ridge, USA.; Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo, Inc., Basking Ridge, USA.; Daiichi Sankyo, Inc., Basking Ridge, USA.; Daiichi Sankyo, Inc., Basking Ridge, USA.; Daiichi Sankyo, Inc., Basking Ridge, USA.",YuH@mskcc.org.
38367127,"Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.",2024-Apr,,,mark.barok@helsinki.fi.
38366864,Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.,2024-May-03,,,
38362837,Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.,2024-Feb,,,
38360906,Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.,2024-Feb-15,,,ouyamagu@saitama-med.ac.jp.
38358050,Long-term survival with systemic therapy in the last decade: Can melanoma be cured?,2024-Mar,,,
38354535,"Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.",2024-Mar,Mookerjee; Portella; Zhu; Wu; Demanse; Dharan,"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",lpazaresr@seom.org.
38351187,Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.,2024-Mar,,,jheymach@mdanderson.org.
38349570,"INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.",2024-Feb-13,Hansen,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",zandbergdp@upmc.edu.
38347302,Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.,2024-Mar,Mori; Yamanaka; Hihara; Soeda,"Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd, Tokyo, Japan.; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Kanagawa, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd, Tokyo, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd, Tokyo, Japan.",kshitara@east.ncc.go.jp.
38346853,Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.,2024-Feb-12,Zhang; Mahmood; Hu; Penrod; Yuan; Lee,"Global Drug Development, Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Global Drug Development, Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.; Global Drug Development, Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Global Drug Development, Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Global Drug Development, Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.",david.carbone@osumc.edu.
38345769,RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.,2024-Apr-15,Lee; Quintanilha; Schrock,"Foundation Medicine, Inc., Cambridge, Massachusetts.; Foundation Medicine, Inc., Cambridge, Massachusetts.; Foundation Medicine, Inc., Cambridge, Massachusetts.",
38340704,Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?,2024-Feb-09,,,neeraj.agarwal@hci.utah.edu.
38338343,Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.,2024-Jan-25,Lin,"Drug Discovery, Hangzhou Haolu Pharma Co., Hangzhou 311121, China.",
38336371,Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.,2024-Feb-08,,,akawazoe@east.ncc.go.jp
38330766,"First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.",2024-Mar,,,michael.mark@ksgr.ch.
38324085,CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.,2024-Feb,Hansen; Giranda; Ren; Liu; Kandala; Freshwater,"Princess Margaret Cancer Centre, Toronto, ON, Canada.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.",andrew.armstrong@duke.edu.
38321005,Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.,2024-Feb-06,,,ekastritis@med.uoa.gr.
38320431,Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.,2024-Feb,Liao,"Merck Serono Co., Ltd. (An Affiliate of Merck KGaA), Beijing, China.",scott.antonia@duke.edu.
38319973,Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis.,2024-Feb-13,,,
38316517,Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).,2024-Feb-05,Meadows Shropshire; O'Brien; Tschaika,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",mcallahan@uchc.edu.
38315872,Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH.,2024-Apr-09,Tan; Yeh,"Lisa Tan Pharma Consulting Ltd, Cambridge, UK.; Apellis Pharmaceuticals, Inc, Waltham, MA.",
38310035,STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.,2024-May,Yu; Mohammad; Chen; Kim,"Gilead Sciences, Inc., Foster City, CA.; Gilead Sciences, Inc., Foster City, CA.; Gilead Sciences, Inc., Foster City, CA.; Gilead Sciences, Inc., Foster City, CA.",drodabr@gobiernodecanarias.org.
38309282,"Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.",2024-Mar,,,susan.prockop@childrens.harvard.edu.
38308771,Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.,2024-May,Zahlten-Kümeli; Taylor,"Amgen Inc, Thousand Oaks, CA, USA.; Amgen Inc, Uxbridge, UK.",ZWainberg@mednet.ucla.edu.
38302725,Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.,2024-Mar,McKenzie; Orlowski; Miura,"Eisai Inc., Nutley, NJ, USA.; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, USA.; Clinical Oncology, Eisai Co., Ltd., Tokyo, Japan.",kyonemor@ncc.go.jp.
38302221,"Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.",2024-Feb,,,hartmut.goldschmidt@med.uni-heidelberg.de.
38301693,Pembrolizumab plus chemotherapy for advanced gastric cancer.,2024-Feb,,,t.schutte@amsterdamumc.nl.
38301670,"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial.",2024-Mar,Mathas,"Charité-Universitätsmedizin Berlin, Haematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Group Biology of Malignant Lymphomas, Berlin, Germany; Experimental and Clinical Research Center, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.",elisabeth.schorb@uniklinik-freiburg.de.
38296594,Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.,2024-Jan-31,,,alexander.menzies@sydney.edu.au.
38295889,The treatment of advanced melanoma: Current approaches and new challenges.,2024-Apr,,,boutros.andrea@gmail.com.
38280218,The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.,2024-Jun-03,Hamilton; Blum; Ejzykowicz,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",
38272561,Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.,2024-Jan-25,Kumar; Del Vecchio Fitz; Kuperwasser,"Naveris, Inc, Waltham, Massachusetts, USA.; Naveris, Inc, Waltham, Massachusetts, USA.; Naveris, Inc, Waltham, Massachusetts, USA.",James_Cleary@dfci.harvard.edu
38271621,Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.,2024-May-14,,,
38271158,First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.,2024-Apr-06,Suzuki,"Oncology Medical Affairs, Ono Pharmaceutical Co, Ltd, Osaka, Japan.",
38271157,A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma.,2024-Apr-06,Kamiyama,"Department of Prescription Products Development, Zenyaku Kogyo Co., Ltd, 5-6-15, Otsuka, Bunkyo-ku,Tokyo 112-8650, Japan.",
38266541,Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.,2024-Mar,,,angela.lamarca@quironsalud.es.
38266151,Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.,2024-Mar-26,,,
38261316,"Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.",2024-Jan-02,,,
38254266,Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.,2024-Apr-01,,,
38251532,"Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.",2023-Nov,,,c.pitzalis@qmul.ac.uk.
38247820,Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma.,2024-Jan-10,,,
38247115,The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.,2024-Apr,,,
38246698,Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD.,2024-Apr,,,
38246194,"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.",2024-Feb-17,,,Jeffrey.Weber@nyulangone.org.
38246047,"Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.",2024-Mar,Chung,"Geninus Inc., Seoul, Republic of Korea.",bgkim@skku.edu.
38242717,Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.,2024-Jan-19,Cao; Suttner; Loboda; Cristescu; Jelinic; Orlowski; Dutta; Matsui; Dutcus; Minoshima,"Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.; Eisai Inc, Nutley, New Jersey, USA.; Eisai Inc, Nutley, New Jersey, USA.; Eisai Inc, Nutley, New Jersey, USA.; Eisai Co. Ltd, Tsukuba, Japan.",makkerv@mskcc.org.
38241181,Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.,2024-May-03,,,
38240916,Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.,2024-Apr,Ding; Wu; Li; Yu; Barnes,"BeiGene, Ltd, Zhongguancun Life Science Park, Beijing, China.; BeiGene, Ltd, Ridgefield Park, NJ, USA.; BeiGene, Ltd, Zhongguancun Life Science Park, Beijing, China.; Clinical Pharmacology, BeiGene USA, Inc., San Mateo, CA, USA.; BeiGene, Ltd, Ridgefield Park, NJ, USA.",kenkato@ncc.go.jp.
38233099,Corticosteroid-resistant immune-related adverse events: a systematic review.,2024-Jan-17,,,heinz.laeubli@unibas.ch.
38218660,Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma.,2024-Apr,,,Viktor.Gruenwald@uk-essen.de.
38215395,Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.,2024-Apr-18,,,
38215358,"Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With ",2024-Apr-01,,,
38215355,Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.,2024-Apr-20,Wright; Hepp; Carret; Yu; Dillon; Kataria; Beaumont; Purnajo,"Seagen Inc, Bothell, WA.; Seagen Inc, Bothell, WA.; Seagen Inc, Bothell, WA.; Seagen Inc, Bothell, WA.; Astellas Pharma Inc, Northbrook, IL.; Merck & Co, Inc, Rahway, NJ.; Clinical Outcomes Solutions Ltd, Tucson, AZ.; Clinical Outcomes Solutions Ltd, Tucson, AZ.",
38212321,The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.,2024-Jan-11,Leipold; Kamath,"Preclinical and Translational Pharmacokinetics, Genentech, South San Francisco, CA, USA.; Preclinical and Translational Pharmacokinetics, Genentech, South San Francisco, CA, USA.",gdl@gene.com.
38207206,"MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.",2024-Feb-27,,,
38206370,Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.,2024-Jul,Kawasaki; Satake; Shibata,"Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome Chuo-Ku, Tokyo, 103-8324, Japan.; Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome Chuo-Ku, Tokyo, 103-8324, Japan.; Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome Chuo-Ku, Tokyo, 103-8324, Japan.",nbryamam@ncc.go.jp.
38195781,Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies.,2024-Jan-09,,,bhupen27@gmail.com.
38194915,Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.,2024-Jan-08,,,stephen.shiao@cshs.org.
38194163,"Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.",2024-Jan,Takenaka; Ozawa,"Clinical Development and Medical Affairs Division, Taiho Pharmaceutical Co., Ltd, Tokyo, Japan.; Clinical Development and Medical Affairs Division, Taiho Pharmaceutical Co., Ltd, Tokyo, Japan.",y.sunakawa@marianna-u.ac.jp.
38190588,Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.,2024-Mar,,,
38190578,"Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.",2024-Apr-01,Zwaan; van Eijkelenburg; Bautista,"Princess Maxima Center, Utrecht, the Netherlands.; Princess Maxima Center, Utrecht, the Netherlands.; Princess Maxima Center, Utrecht, the Netherlands.",
38181795,A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).,2024-Feb-12,Arkania; Kang; Wang; Yu; Li; Zhu,"LTD Israeli-Georgian Medical Research Clinic ""Helsicore"", Tbilisi 0112, Georgia.; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.",caicunzhoudr@163.com.
38181782,IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.,2024-Mar-26,,,
38175294,Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study.,2024-Jan-04,,,takayuki.s12@hotmail.co.jp.
38170160,"A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.",2024,Samant; Chowdhury,"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",
38167503,Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.,2024-Jan-02,,,p.ascierto@istitutotumori.na.it.
38165333,Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study.,2024-Jan-23,,,
38163317,"Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.",2024-Feb-27,,,
38159809,"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.",2024-Jun,Okpara; Dutcus; Zimmer; Samkari; Bhagwati,"Eisai Ltd., Hatfield, United Kingdom.; Eisai Inc., Nutley, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.",chihyang@ntu.edu.tw.
38150586,Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.,2024-Feb-13,,,
38149256,The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.,2023,Sato; Suminaka; Yamaki,"Central Research Laboratories, Sysmex Corporation, Kobe, Japan.; Central Research Laboratories, Sysmex Corporation, Kobe, Japan.; Business Strategy Development, Sysmex Corporation, Kobe, Japan.",
38135713,NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.,2024-Feb,,,Michael.cecchini@yale.edu.
38134948,"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.",2024-Feb,,,kshitara@east.ncc.go.jp.
38127362,Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.,2024-Mar-01,,,
38114481,Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.,2023-Dec-20,,,sara.a.scott@emoryhealthcare.org.
38113470,MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.,2024-Jan-23,,,
38110838,"Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).",2024-Mar,Osada; Matsui,"Oncology Medical Affairs, Pfizer Japan, Inc., Tokyo, Japan.; Oncology Medical Affairs, Pfizer Japan, Inc., Tokyo, Japan.",
38108214,"GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.",2024-Apr-15,Kinsey; Ragsdale,"Partner Therapeutics, Inc, Lexington, Massachusetts, USA.; Partner Therapeutics, Inc, Lexington, Massachusetts, USA.",
38105153,Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.,2024-May,,,lmezquita@clinic.cat.
38103912,Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer.,2024-Apr-15,,,kenneth.mangion@glasgow.ac.uk.
38102374,Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.,2024-Jun,,,bpvalderrama@gmail.com.
38102212,Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.,2024-Mar,Teranishi,"Alexion Pharma GK, 3-1-1 Shibaura Minato-ku, Tokyo, 108-0023, Japan.",itoshu@yokohama-cu.ac.jp.
38101816,Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.,2024-Apr-01,,,bogani.giorgio@gmail.com.
38100555,Cancer drugs with high repositioning potential for Alzheimer's disease.,2023-Dec,,,
38098261,Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.,2024-Feb,Ntambwe; Mahmood; Cai,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",
38095881,"Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.",2024-Feb-01,Tekin; Li; Toker; Keefe,"Oncology, Merck & Co, Inc, Rahway, New Jersey.; Oncology, Merck & Co, Inc, Rahway, New Jersey.; Oncology, Merck & Co, Inc, Rahway, New Jersey.; Oncology, Merck & Co, Inc, Rahway, New Jersey.",
38092229,Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).,2024-Mar,Mathias; Liu; Cathcart; Singh,"Daiichi Sankyo, Inc., Basking Ridge, USA.; Daiichi Sankyo, Inc., Basking Ridge, USA.; Daiichi Sankyo, Inc., Basking Ridge, USA.; Daiichi Sankyo, Inc., Basking Ridge, USA.",csaura@vhio.net.
38092228,Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.,2024-Mar,,,Bardia.Aditya@mgh.harvard.edu.
38084840,"Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer.",2023,Davies; Dedi; Jones; Kevorkian; McMillan; Ottone; Schulze; Scott-Tucker; Tewari; West; Wright; Rowley,"UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.",
38072960,Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.,2024-Jan,Jia; Pham; Huw; Jing; Wu; Ead; To; Batlevi; Wei,"Roche (China) Holding Ltd, Shanghai, China.; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.",ebudde@coh.org.
38071748,Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.,2024-Mar-04,,,
38067257,,2023-Nov-23,Thiele,"Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.",
38061214,"A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).",2024-Jan,,,satoshi7@med.niigata-u.ac.jp.
38056464,Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.,2023-Dec-19,Mandelin; Karvonen; Jalkanen,"Faron Pharmaceuticals Ltd, Turku, Finland.; Faron Pharmaceuticals Ltd, Turku, Finland.; Faron Pharmaceuticals Ltd, Turku, Finland.",maijal@utu.fi.
38052910,Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.,2024-Jan,,,jayesh.desai@petermac.org.
38049158,Use of denosumab in castration sensitive prostate cancer.,2023-Dec-04,,,
38048793,"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.",2024-Jan-06,,,aoaknin@vhio.net.
38048391,Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.,2024-Jan-23,Reece; Ahmadi,"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Genmab US, Inc, Plainsboro, NJ.",
38039427,Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.,2024-Jan-10,Brase; Bury-Maynard; Passos; Deudon; Dharan; Song; Caparica,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, Cambridge, MA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharma AG, Basel, Switzerland.",
38030303,"Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.",2023-Nov-29,,,tdoi@east.ncc.go.jp.
38016249,Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study.,2023-Dec,,,kmuro@aichi-cc.jp.
38011864,Management of Brain Metastases: A Review of Novel Therapies.,2023-Dec,,,
38008109,Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.,2024-Jan-13,Ukhanova; Burciu; Barve; Modi; Scosyrev; Letzelter; Patekar; Severin,"Scientific Medical Center of General Therapy and Pharmacology, Stavropol, Russia.; Novartis Pharma, Basel, Switzerland.; Novartis Pharmaceuticals, East Hanover, New Jersey, NJ, USA.; Novartis Pharmaceuticals, East Hanover, New Jersey, NJ, USA.; Novartis Pharmaceuticals, East Hanover, New Jersey, NJ, USA.; Novartis Pharma, Basel, Switzerland.; Novartis Pharma, Basel, Switzerland.; Novartis Pharma, Basel, Switzerland.",marcus.maurer@charite.de.
38008033,A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.,2024-Jan,Lammer; Meurer; Unteroberdörster; Capper; Heppner; Chapuy; Janz; Schwartz; Vajkoczy; Korfel; Keller,"Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neuropathology, Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany; Cluster of Excellence, NeuroCure, Berlin, Germany.; Department of Neuropathology, Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany; Cluster of Excellence, NeuroCure, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Berlin, Germany.; Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Berlin, Germany. Electronic address: ulrich.keller@charite.de.",ulrich.keller@charite.de.
38007239,Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.,2023-Nov-24,,,sneelapu@mdanderson.org.
38001657,Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice.,2023-Nov-13,,,
37996986,R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.,2024-Mar,,,
37995519,Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).,2023,Garate,"Roche Pharma Spain, Calle de la Ribera del Loira, 50, 28042 Madrid, Spain.",silvia.antolin.novoa@sergas.es.
37994649,A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.,2024-Mar,Sasse; Moreno; Yu; Carret,"Astellas Pharma Global Development, Northbrook, IL, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Seagen Inc., Bothell, WA, USA.; Seagen Inc., Bothell, WA, USA.",
37988976,"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.",2024-Jan,,,matthew.meriggioli@novartis.com.
37987139,Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.,2023-Dec,,,
37986911,Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.,2023-Nov-09,,,
37971722,Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.,2024-Jan-01,,,
37971411,Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.,2024-Apr-04,,,
37966841,Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.,2023-Nov-01,Jia; Li; Tryfonidis; Karantza,"Merck & Co Inc, Rahway, New Jersey.; Merck & Co Inc, Rahway, New Jersey.; Merck & Co Inc, Rahway, New Jersey.; Merck & Co Inc, Rahway, New Jersey.",
37965350,Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.,2023,,,
37964379,"A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.",2023-Nov-14,Hsu,"Apexigen, Inc., San Carlos, CA, USA.",Harriet.Kluger@yale.edu.
37964066,"Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.",2024-Jan,Fujimura; Sato; Yamazaki; Wakabayashi; Sugihara; Kamio,"Daiichi Sankyo Co., Ltd, Chuo-ku, Tokyo, 103-8426, Japan.; Daiichi Sankyo Co., Ltd, Chuo-ku, Tokyo, 103-8426, Japan.; Daiichi Sankyo Co., Ltd, Chuo-ku, Tokyo, 103-8426, Japan.; Daiichi Sankyo Co., Ltd, Chuo-ku, Tokyo, 103-8426, Japan.; Daiichi Sankyo Co., Ltd, Chuo-ku, Tokyo, 103-8426, Japan.; Daiichi Sankyo, Inc, Basking Ridge, New Jersey, 07920, USA.",kshitara@east.ncc.go.jp.
37950903,Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).,2024-Mar-04,,,
37950901,A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.,2024-Apr-04,,,
37949705,A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.,2024-Jan,,,caimip@ccf.org.
37945755,Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.,2023-Dec,,,fxm557@med.miami.edu.
37945286,"MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.",2023-Nov,Lippe; Khan; Shmagel; Palac; Suboticki,"AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.",ccharles@mednet.ucla.edu.
37941549,Acute low back pain as infusion-related reaction to monoclonal antibodies.,2023,,,
37941436,Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.,2024-Apr-23,,,
37940878,"Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.",2023-Nov-08,,,h_fujii@gifu-u.ac.jp.
37938495,The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.,2024-Feb,Izquierdo,"Novartis Pharma AG, Basel, Switzerland.",evandro.deazambuja@hubruxelles.be.
37935524,AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.,2023-Dec-04,Heitz; de Gregorio; Gropp-Meier; Harter,"AGO Studygroup and Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany florian.heitz@gmx.net.; Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany.; Oberschwabenklinik gGmbH, Ravensburg, Baden-Württemberg, Germany.; AGO Studygroup and Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.",florian.heitz@gmx.net.
37932204,Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).,2024-Apr,,,saraelena89@hotmail.it.
37926672,"Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.",2024-Feb,,,carrho@uw.edu.
37925894,"Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.",2023-Dec,Swaby; Lin; Ge; Lerman,"90 E Scott Ave, Merck & Co., Inc., Rahway, NJ 07065, United States.; 90 E Scott Ave, Merck & Co., Inc., Rahway, NJ 07065, United States.; 90 E Scott Ave, Merck & Co., Inc., Rahway, NJ 07065, United States.; 90 E Scott Ave, Merck & Co., Inc., Rahway, NJ 07065, United States.",Kevin.Harrington@icr.ac.uk.
37922632,Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial.,2023-Dec,,,david.malka@imm.fr.
37924647,Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.,2023-Dec,,,sara.lonardi@iov.veneto.it.
37907221,"First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.",2023-Oct,Lee; Lewis,"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.",jat@uw.edu.
37905372,Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.,2024-Feb,,,
37902990,Development and Characterization of a Novel Neuropilin-2 Antibody for Immunohistochemical Staining of Cancer and Sarcoidosis Tissue Samples.,2023-Oct,Chong; Siefker; Escobedo; Qing; Rauch; Burman; Burkart; Kainz; Cubitt; Muders; Nangle,"aTyr Pharma, San Diego, California, USA.; aTyr Pharma, San Diego, California, USA.; aTyr Pharma, San Diego, California, USA.; aTyr Pharma, San Diego, California, USA.; aTyr Pharma, San Diego, California, USA.; aTyr Pharma, San Diego, California, USA.; aTyr Pharma, San Diego, California, USA.; KML Vision GmbH, Graz, Austria.; aTyr Pharma, San Diego, California, USA.; MVZ Pathologie Bethesda GmbH, Duisburg, Germany.; aTyr Pharma, San Diego, California, USA.",
37899039,"Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.",2024,Shin; Ju; Jang,"Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.; Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.; Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.",
37891002,APR-246 increases tumor antigenicity independent of p53.,2024-Jan,Michels; Venkatesh; Liu; Budhu; Zhong; George; Thach; Campesato; Wolchok; Merghoub,"Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA jwolchok@med.cornell.edu.; Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA tmerghoub@med.cornell.edu.",jwolchok@med.cornell.edu.
37889520,"Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.",2023-Nov-01,,,
37880788,The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.,2023-Oct-25,,,paolo.ascierto@gmail.com.
37878202,Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer.,2023-Nov,,,elsenkus@gumed.edu.pl.
37875771,A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.,2023-Nov,Razak; Quadt; Bootle; Blumenstein; Demanse,"Princess Margaret Cancer Centre, Toronto, Canada. albiruni.razak@uhn.ca.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",albiruni.razak@uhn.ca.
37872381,Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia.,2023-Dec,,,ravetch@mail.rockefeller.edu.
37871898,The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.,2024-Apr,,,
37871703,The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.,2024-Jan,,,Bradley_mcgregor@dfci.harvard.edu.
37871702,Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.,2024-Jan,,,asiefker@mdanderson.org.
37871608,"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.",2023-Nov-18,,,pierce.chow@duke-nus.edu.sg.
37871604,Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.,2023-Dec-09,,,janjigiy@mskcc.org.
37871303,Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.,2024-Jan-09,Liao; Chen; Wang; Qin; Xu,"ADC Therapeutics America Inc, Murray Hill, NJ.; ADC Therapeutics America Inc, Murray Hill, NJ.; ADC Therapeutics America Inc, Murray Hill, NJ.; ADC Therapeutics America Inc, Murray Hill, NJ.; ADC Therapeutics America Inc, Murray Hill, NJ.",
37870536,Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.,2024-Jan-01,,,
37867418,Siltuximab administration results in spurious IL-6 elevation in peripheral blood.,2024-Jan,,,
37866811,SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.,2024-Jan,Shazer; Yan; Harrigan,"Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.",Hossein.Borghaei@fccc.edu.
37864520,"Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.",2024-Feb-01,,,
37862791,Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.,2023-Nov,Kobie; Nebozhyn; Edmondson; Sun; Cristescu; Jelinic; Keefe,"Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.; Merck & Co., Inc., Rahway, NJ, United States.",j.ledermann@ucl.ac.uk.
37857998,Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.,2024-Jun,Garrido; Ghambire; Karnoub; Feng; Hsu; Khambata-Ford; Vitazka; Vitazka,"Daiichi Sankyo, Inc, Basking Ridge, NJ, USA. rgarrido@dsi.com.; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.; Teva Pharmaceuticals, Parsippany, NJ, USA.",rgarrido@dsi.com.
37857711,The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.,2023-Nov,,,lukejj@upmc.edu.
37851898,TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.,2023-Dec-12,,,
37848259,"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.",2023-Oct,Malan; Oliviero,"Phoenix Pharma, Port Elizabeth, South Africa.; Checkpoint Therapeutics Inc, Waltham, Massachusetts, USA jfo@checkpointtx.com.",jfo@checkpointtx.com.
37845511,"Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.",2023-Nov,Durani; Lobo; Campigotto,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",kirkwoodjm@upmc.edu.
37844597,"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.",2023-Nov,,,marc-oliver.grimm@med.uni-jena.de.
37840148,Phospholipase D4 as a signature of toll-like receptor 7 or 9 signaling is expressed on blastic T-bet + B cells in systemic lupus erythematosus.,2023-Oct-16,,,hfujii@med.tohoku.ac.jp.
37839734,"Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.",2024-Feb,Yoo; Okoye; Inocencio; Chen; Seebach; Lowy; Fury,"Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.",alstrat2@gmail.com.
37833451,Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.,2024-Jan,,,lacoutum@mskcc.org.
37813699,Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab.,2024-Feb,,,shiota.masaki.101@m.kyushu-u.ac.jp.
37804003,Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.,2023-Dec,Paul,"Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.",
37802653,Exploring dual effects of dinutuximab beta on cell death and proliferation of insulinoma.,2024-Jan,,,
37801674,"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.",2023-Dec-20,Ohwada; Koyama; Inoue; Li; Patel; Mostillo; Tanaka; Sternberg; Sellami,"Daiichi Sankyo Co, Ltd, Tokyo, Japan.; Daiichi Sankyo Co, Ltd, Tokyo, Japan.; Daiichi Sankyo RD Novare Co, Ltd, Tokyo, Japan.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.",
37798175,Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.,2024-Mar,,,boutros.andrea@gmail.com.
37790943,Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes.,2023,Lenka; Pitschi; Kuhne; Reusch; Knaupp; Izadi; Schlothauer,"Pharmaceutical Development, Genentech, A Member of The Roche Group, South San Francisco, CA, United States.; Pharma Technical Development Europe, Roche Diagnostics GmbH, Penzberg, Germany.; Pharma Technical Development Europe, Roche Diagnostics GmbH, Penzberg, Germany.; Pharma Technical Development Europe, Roche Diagnostics GmbH, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharmaceutical Development, Genentech, A Member of The Roche Group, South San Francisco, CA, United States.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.",
37787906,The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.,2023-Sep,,,Johannes.weller@ukbonn.de.
37787866,Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.,2023-Dec,Hirata; Katagiri; Saito,"Clinical Safety and Pharmacovigilance Division, Medical Safety Department, Daiichi Sankyo Co., Ltd., 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426, Japan.; Clinical Safety and Pharmacovigilance Division, Medical Safety Department, Daiichi Sankyo Co., Ltd., 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426, Japan.; Clinical Safety and Pharmacovigilance Division, Medical Safety Department, Daiichi Sankyo Co., Ltd., 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426, Japan.",baba.19049@kanagawa-pho.jp.
37783966,Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.,2023-Nov,,,matthew.galsky@mssm.edu.
37769428,Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.,2023-Nov,Nagano; Totsuka; Iizuka; Kido; Terata; Okumura; Hirota,"Medical Affairs Department, Mitsubishi Tanabe Pharma Corporation, 3-2-10 Dosho-machi, Chuo-ku, Osaka 541-8505, Japan.; Clinical Research & Development II Department, Mitsubishi Tanabe Pharma Corporation, 1-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-8205, Japan.; Data Science Department, Mitsubishi Tanabe Pharma Corporation, 1-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-8205, Japan.; Clinical Research & Development II Department, Mitsubishi Tanabe Pharma Corporation, 1-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-8205, Japan.; Clinical Research & Development II Department, Mitsubishi Tanabe Pharma Corporation, 1-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-8205, Japan.; Global Pharmacovigilance Department, Mitsubishi Tanabe Pharma Corporation, 3-2-10 Dosho-machi, Chuo-ku, Osaka 541-8505, Japan.; Medical Intelligence Department, Mitsubishi Tanabe Pharma Corporation, 3-2-10 Dosho-machi, Chuo-ku, Osaka 541-8505, Japan.",fujikazu@med.tohoku.ac.jp.
37768658,Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.,2023-Nov-01,Bedard; Bendell; Wu; Patil; Jin; Hoang; Mendus; Wen; Meng,"Princess Margaret Cancer Center, Toronto, Ontario, Canada.; now with F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Clinical Pharmacology, Genentech Inc, South San Francisco, California.; Biomarkers, Genentech Inc, South San Francisco, California.; Biostatistics, F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.; Clinical Science, Genentech Inc, South San Francisco, California.; Clinical Science, Genentech Inc, South San Francisco, California.; Safety Science, Genentech Inc, South San Francisco, California.; Clinical Science, Genentech Inc, South San Francisco, California.",
37760506,Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.,2023-Sep-13,,,
37754515,A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC).,2023-Sep-07,,,
37754485,Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic.,2023-Aug-25,,,
37752582,Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.,2023-Sep-26,,,c.rodriguezmogeda@amsterdamumc.nl.
37741273,Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.,2023-Dec,Ades; Filian; Huang,"Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, Princeton, NJ, USA. Electronic address: felipe.ades@bms.com.; Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, Princeton, NJ, USA. Electronic address: jeiry.filian@bms.com.; Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, Princeton, NJ, USA. Electronic address: ning.huang@bms.com.",g.jerusalem@chuliege.be.
37731056,Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.,2023-Oct,,,pmk4001@med.cornell.edu.
37729719,Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.,2023-Nov,,,jan.cerny@umassmemorial.org.
37729621,Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.,2023-Dec-12,,,
37722354,Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.,2023-Nov-28,,,
37713657,Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.,2023-Dec-10,Xiao; Blum; Elimova; Kondo; Li,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Princess Margaret Cancer Centre, Toronto, ON, Canada.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
37709297,"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).",2023-Sep,,,sakai-h@med.showa-u.ac.jp.
37701431,The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics.,2023,,,
37699787,Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.,2023-Nov,,,
37682791,Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.,2023-Nov-14,,,
37678672,EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.,2023-Nov,Matsangou; Campbell,"Department of Therapeutic Area-Oncology, Astellas Pharma, Inc., Northbrook.; Department of Late Stage Development, Seagen Inc., Bothell.",daniel.petrylak@yale.edu.
37673858,"Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4.",2023-Sep-06,,,JUNGYUNLEE@yuhs.ac.
37667855,Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.,2023-Nov,Hollmann,"Bristol Myers Squibb, Princeton, NJ, USA.",
37666807,Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.,2023-Sep-04,Baron; Sung,"Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.",eunice.wang@roswellpark.org.
37666264,"First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.",2023-Oct,,,janjigiy@mskcc.org.
37665782,Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.,2023-Nov-02,,,
37656441,Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.,2023-Nov-14,,,
37656420,Rozanolixizumab: First Approval.,2023-Sep,,,dru@adis.com.
37651927,A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.,2023-Oct,,,ninomiya.takashi.se@mail.hosp.go.jp.
37639757,Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.,2023-Nov,,,carmen.criscitiello@ieo.it.
37635052,Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.,2023-Dec,,,marine.gross-goupil@chu-bordeaux.fr.
37620627,Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.,2023-Dec,,,hoa@mskcc.org.
37608616,Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy.,2023,Vasic; Buldun; Ritz; Dickopf; Georges; Spick; Peuker; Meier; Mayer; Brinkmann,"Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.; Reagent Research and Design, Roche Diagnostics GmbH, Penzberg, Germany.; Reagent Research and Design, Roche Diagnostics GmbH, Penzberg, Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.",
37607770,Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.,2023-Aug,,,matthew.galsky@mssm.edu
37605122,"NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases.",2023-Aug-21,,,shkobaya@east.ncc.go.jp.
37603594,Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.,2023-Dec-26,,,
37597578,"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.",2023-Oct,Eli; Frazier; DiPrimeo; Wong,"Clinical Development, Puma Biotechnology, Los Angeles, USA.; Clinical Development, Puma Biotechnology, Los Angeles, USA.; Clinical Development, Puma Biotechnology, Los Angeles, USA.; Clinical Development, Puma Biotechnology, Los Angeles, USA.",jhaverik@mskcc.org.
37597246,Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.,2023-Dec-11,,,
37596517,Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trial.,2023-Aug-18,,,elisabeth.schorb@uniklinik-freiburg.de.
37595359,Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.,2023-Nov-16,,,
37595283,Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.,2023-Nov-23,,,
37595168,Organizational Impact of Immunotherapies in Advanced Cancers in France.,2023-Aug,,,
37595053,Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.,2023-Nov-14,,,
37592104,Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.,2023-Sep,Grossmann,"Merck & Co., Inc., Rahway, NJ, USA.",avanderwalde@westclinic.com.
37589219,Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.,2024-Feb-02,Perini; Saretsky; Bhattacharya; Xu,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",
37587502,Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.,2023-Aug-17,Große-Hovest; Steiner,"Synimmune GmbH, Tübingen, Germany.; Synimmune GmbH, Tübingen, Germany.",helmut.salih@med.uni-tuebingen.de.
37581752,Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.,2023-Oct,Chyla; Sun,"AbbVie, Inc, North Chicago, IL, USA.; AbbVie, Inc, North Chicago, IL, USA.",kizutsu@ncc.go.jp.
37573652,A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy.,2023-Oct,,,ippazio.antonazzo@unimib.it.
37568579,PTHrP Regulates Fatty Acid Metabolism via Novel lncRNA in Breast Cancer Initiation and Progression Models.,2023-Jul-25,,,
37563779,Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.,2023-Dec-06,,,
37562695,Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.,2023-Oct,,,paolo_tarantino@dfci.harvard.edu.
37556095,SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).,2023-Sep,Gallardo Díaz,"Medical Oncology Department, Corporació Sanitària Parc Taulì, Barcelona, Spain.",mariajose.mendezvidal@gmail.com.
37552496,Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.,2023-Dec-26,,,
37548831,First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.,2023-Oct,Li; Gupta; Bushong,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",mnishio@jfcr.or.jp.
37540556,Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.,2023-Oct-13,Abrey; Garcia,"F. Hoffman-La Roche, Ltd., South San Francisco, California.; F. Hoffman-La Roche, Ltd., South San Francisco, California.",
37532934,Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.,2023-Aug,Bellina; Ducarouge; Lengrand; Jelin; Braissand; Bernet; Mehlen,"Netris Pharma, Lyon, France.; Netris Pharma, Lyon, France.; Netris Pharma, Lyon, France.; Netris Pharma, Lyon, France.; Netris Pharma, Lyon, France.; Netris Pharma, Lyon, France. agnes.bernet@lyon.unicancer.fr.; Netris Pharma, Lyon, France. patrick.mehlen@lyon.unicancer.fr.",agnes.bernet@lyon.unicancer.fr.
37532929,Pharmacological targeting of netrin-1 inhibits EMT in cancer.,2023-Aug,Lengrand; Bellina; Ducarouge; Braissand; Mehlen; Bernet,"NETRIS Pharma, Lyon, France.; NETRIS Pharma, Lyon, France.; NETRIS Pharma, Lyon, France.; NETRIS Pharma, Lyon, France.; NETRIS Pharma, Lyon, France. patrick.mehlen@lyon.unicancer.fr.; NETRIS Pharma, Lyon, France. agnes.bernet@lyon.unicancer.fr.",patrick.mehlen@lyon.unicancer.fr.
37532830,Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).,2023-Oct,,,oki.eiji.857@m.kyushu-u.ac.jp.
37531111,Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer.,2023-Aug-01,,,
37530622,Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.,2023-Oct-24,Kuruvilla; Wen; Akyol,"Princess Margaret Cancer Centre, Toronto, ON, Canada.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
37528088,"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.",2023-Aug-01,,,nraje@mgh.harvard.edu.
37526387,"A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar.",2023,Xue,"Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co.,Ltd, Nanjing, China.",
37524953,"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.",2023-Aug,Oh; Park; Moran; Bhattacharya; Arozullah,"Astellas Pharma Global Development, Inc., Northbrook, IL, USA.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.",xurh@sysucc.org.cn.
37519200,Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment.,2024,,,
37511588,Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.,2023-Jul-23,,,
37507543,Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.,2023-Oct,,,denis.collins@dcu.ie.
37506588,"Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.",2023-Sep,Brandely; Tavernaro; Makhloufi; Bendjama,"Transgene S.A., Illkirch-Graffenstaden, France.; Transgene S.A., Illkirch-Graffenstaden, France.; Transgene S.A., Illkirch-Graffenstaden, France.; Transgene S.A., Illkirch-Graffenstaden, France.",christophe.letourneau@curie.fr.
37499954,Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.,2023-Dec,Kaçmaz,"Santen Inc., Emeryville, California.",John_Kempen@meei.harvard.edu.
37495481,Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.,2023-Oct,,,spal@coh.org.
37491373,Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.,2023-Jul-25,Barton; Jones,"Barton Oncology Ltd, Hertfordshire, UK.; UCB Pharma Ltd., Slough, UK.",james.spicer@kcl.ac.uk.
37490286,ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.,2023-Oct-02,Moran; Yang; Arozullah; Park; Raizer,"Astellas Pharma, Inc, Northbrook, Illinois.; Astellas Pharma, Inc, Northbrook, Illinois.; Astellas Pharma, Inc, Northbrook, Illinois.; Astellas Pharma, Inc, Northbrook, Illinois.; Clinical Sciences, Oncology, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts.",
37480164,Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.,2023-Sep,,,
37478883,"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.",2023-Sep-09,,,jychang@mdanderson.org.
37459209,Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis.,2023-Sep-26,,,
37458138,"Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.",2023-Aug,Mohammadi; Brackin; Manvelian; Pordy; Fazio; Geba,"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.",
37451546,Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis.,2023-Aug,Zihlmann; Stiefel,"Geistlich Pharma AG, Wolhusen, Switzerland. Electronic address: carla.zihlmann@geistlich.com.; Geistlich Pharma AG, Wolhusen, Switzerland. Electronic address: Niklaus.Stiefel@geistlich.com.",anna.abbadessa@usc.es.
37451295,"Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.",2023-Sep-02,Kiecker,"Department of Dermatology and Venereology, Vivantes Klinikum Berlin Neukölln, Berlin, Germany; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",dirk.schadendorf@uk-essen.de.
37451291,"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.",2023-Aug,,,laurence.albiges@gustaveroussy.fr.
37446337,"Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer's Disease.",2023-Jul-06,Parrado Fernandez; Juric; Backlund; Dahlström; Madjid; Lidell; Rasti; Sandin; Nordvall; Forsell,"AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.; AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.",
37440214,Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab.,2023-Sep-01,,,
37429302,"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.",2023-Aug,Boudou-Rouquette,"Hôpital Cochin Saint Vincent de Paul, Paris, France.",jean-yves.blay@lyon.unicancer.fr.
37414019,Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.,2023-Jul,,,eterpos@med.uoa.gr.
37403635,Is lirentelimab the 'magic bullet' to fight pathological mast-cell activation in systemic mastocytosis?,2023-Oct-25,,,
37402581,"Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.",2023-Jul,,,jing.li@mdanderson.org.
37399357,"Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.",2023-Jun,Shih; Kobie; Nebozhyn; Cristescu; Cao; Loboda,"Merck & Co Inc, Rahway, New Jersey, USA.; Merck & Co Inc, Rahway, New Jersey, USA.; Merck & Co Inc, Rahway, New Jersey, USA.; Merck & Co Inc, Rahway, New Jersey, USA.; Merck & Co Inc, Rahway, New Jersey, USA.; Merck & Co Inc, Rahway, New Jersey, USA.",kshitara@east.ncc.go.jp.
37398654,Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.,2023,,,
37393762,"Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.",2023-Sep,Xu; Xu; Zhi; Liu; Wang,"Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Biostatistic, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.",caicunzhoudr@163.com.
37390764,Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.,2023-Aug,,,egaron@mednet.ucla.edu.
37389853,Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.,2023-Nov,Morcos; Moss; Austin; Mongay Soler; Childs,"Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.; BAST Inc. Limited, Leicester, UK.; BAST Inc. Limited, Leicester, UK.; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.",
37389844,Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.,2023-Sep-26,,,
37385724,"Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.",2023-Jun,Ansari; Jacquemont; Topletz-Erickson; Zhou; Schmitt,"Seagen Inc, Bothell, Washington, USA.; Seagen Inc, Bothell, Washington, USA.; Seagen Inc, Bothell, Washington, USA.; Seagen Inc, Bothell, Washington, USA.; Seagen Inc, Bothell, Washington, USA.",acoveler@uw.edu.
37385325,Infliximab for vascular involvement in Behçet's syndrome.,2023-Aug,,,vhamuryudan@yahoo.com.
37385069,Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.,2023-Aug,,,marapersano@alice.it.
37379764,Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial.,2023-Aug,,,JRodon@mdanderson.org.
37369081,Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.,2023-Sep-01,Carret; Yu; Guseva; Homet Moreno,"Seagen Inc, Bothell, WA.; Seagen Inc, Bothell, WA.; Astellas Pharma, Northbrook, IL.; Merck & Co Inc, Rahway, NJ.",
37366170,Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.,2023-Oct-05,Walling; Guthrie; Nie; Karp; Jin; Kinney,"Prothena Biosciences Inc, South San Francisco, CA.; Prothena Biosciences Inc, South San Francisco, CA.; Prothena Biosciences Inc, South San Francisco, CA.; Prothena Biosciences Inc, South San Francisco, CA.; Prothena Biosciences Inc, South San Francisco, CA.; Prothena Biosciences Inc, South San Francisco, CA.",
37364568,Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.,2023-Nov-02,,,
37349130,Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis.,2023-Jun,,,mldougan@partners.org
37344701,Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology.,2023-Aug,,,kevin.oconnor@yale.edu.
37339586,Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.,2023-Oct-19,,,
37329889,"First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.",2023-Jul,,,c.j.a.punt@umcutrecht.nl.
37329769,Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia.,2023-Jul,,,pcjohnson@partners.org.
37318242,Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan.,2023,Alkhatib,"PI Pharma Intelligence, Amman, Jordan.",
37315169,Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.,2023-Sep-12,,,
37311055,A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.,2023-Dec-11,,,
37309754,Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR-overexpressed colorectal cancer.,2023-Apr,Singh,"Senior officer, Sun Pharma Laboratories LTD, Mirza-Palasbari road, Kamrup, Assam, 781128, India.",
37308218,Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.,2023-Sep,Palac; Dilley; Liu; Strengholt,"AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.",RFleischmann@dfwra.com.
37307690,Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis.,2023-Aug,Seifer; Hiltl,"Novartis Pharma AG, Basel, Switzerland. Electronic address: gustavo.seifer@gmail.com.; Novartis Pharma AG, Basel, Switzerland.",gustavo.seifer@gmail.com.
37307213,Retrospective characterization of nodal marginal zone lymphoma.,2023-Sep-12,,,
37302750,Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.,2023-Sep,,,alprat@clinic.cat.
37301717,Adjuvant therapy for stage II melanoma: the need for further studies.,2023-Aug,,,paul.lorigan@nhs.net.
37301715,Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.,2023-Aug,,,Tomas.Kirchhoff@nyulangone.org.
37301631,Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using ,2023-Sep,,,mamei@coh.org.
37286557,Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.,2023-Jun-07,,,salvatore.siena@unimi.it.
37285717,Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.,2023-Jun,,,nicolas.girard2@curie.fr.
37282545,Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.,2023-Jul,,,
37273217,"Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.",2023-Jul-01,,,
37270357,Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers.,2023-Sep,,,tmasuishi@aichi-cc.jp.
37270183,Management of immune-related cutaneous adverse events with dupilumab.,2023-Jun,,,markovaa@mskcc.org.
37268756,PARP Inhibitors in Ovarian Cancer: A Review.,2023-Jul,,,Malley@osumc.edu.
37268404,Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum.,2023-Oct,,,sueh916@gmail.com
37258412,"International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.",2023-Jul,,,friedemann.paul@charite.de.
37248753,Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review.,2023-Sep,Morishima,"Oncology Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.",
37248424,Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.,2023-Sep,,,mattymo@alice.it.
37236636,"First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.",2023-May,,,gulleyj@mail.nih.gov.
37235690,Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.,2023-Sep-12,,,
37233452,Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.,2023-Aug-01,,,
37232264,Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.,2023-Aug,,,
37229837,Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.,2023-Jul,,,James.Larkin@rmh.nhs.uk.
37228591,Pembrolizumab-induced optic neuropathy - a case report.,2023,,,
37226798,An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.,2023,Lovell; Sawyers,"MD Anderson Cancer Center, Division of Pharmacy, Houston, TX, USA.; MD Anderson Cancer Center, Division of Pharmacy, Houston, TX, USA.",
37221052,Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.,2023-Sep,,,orhan.aktas@uni-duesseldorf.de
37216614,IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience.,2023-Sep-01,,,
37211045,Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.,2023-Aug,,,isabelle.ray-coquard@lyon.unicancer.fr.
37210008,Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.,2023-Sep,,,rudinc@mskcc.org.
37208512,"Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.",2023-Aug,,,rajn@mskcc.org.
37206279,"A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).",2023-May,Seto; Bates; Lee; Ganti; Han; Chen,"Clinical Development Gilead Sciences, Inc Foster City California USA.; Research, Gilead Sciences, Inc Foster City California USA.; Biomarker Sciences Gilead Sciences, Inc Foster City California USA.; Clinical Pharmacology Gilead Sciences, Inc Foster City California USA.; Biostatistics Gilead Sciences, Inc Foster City California USA.; Clinical Development Gilead Sciences, Inc Foster City California USA.",
37205196,A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials.,2023,,,
37203799,"Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.",2023-Aug,,,
37196485,Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.,2023-Jul,,,boutros.andrea@gmail.com.
37196483,Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours.,2023-Jul,,,jhernando@vhio.net.
37195235,A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.,2023-Aug-15,,,
37188783,Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.,2023-Jun,Robbins,"DNATrix Inc., Carlsbad, CA, USA.",gelareh.zadeh@uhn.ca.
37187201,"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.",2023-Jun,,,ejabbour@mdanderson.org.
37187198,"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.",2023-Jul,Bullinger,"Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germany.",hartmut.doehner@uniklinik-ulm.de.
37184206,10th antibody industrial symposium: new developments in antibody and adoptive cell therapies.,2023,Cornen; Ferré; Reusch; Vicari; Zhang,"Innate Pharma, Marseille, France.; Compugen Ltd, Holon, Israel.; Pharma Technical Development Analytics Biologics, Roche Diagnostics GmbH, Penzberg, Germany.; Calypso Biotech SA, Plan-les-Ouates, Switzerland.; Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.",
37173885,Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment.,2023-Apr-22,,,
37171597,"RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.",2023-Jul,Sabatelli,"Incyte Biosciences International Sàrl, Morges, Switzerland.",Nowakowski.Grzegorz@mayo.edu.
37171397,"High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.",2023-Nov-14,,,
37170241,Potential clinical implications of CD4,2023-May-11,,,d.galati@istitutotumori.na.it.
37166817,Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.,2023-Jul-01,Schumacher; Schinköthe,"Statitistics, Palleos Healthcare GmbH, Wiesbaden, Germany.; CANKADO Service GmbH, Kirchheim bei München, Germany.",
37165980,Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).,2023-Aug,Shen; Tschaika; Roy; Feng; Gao; Aras,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",
37164948,Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.,2023-May-10,Hallin; Chin; Der-Torossian; Yan,"Mirati Therapeutics, Inc., San Diego, CA, 92121, USA.; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA.; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA.; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA.",jakaram@mdanderson.org.
37158938,"First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.",2023-May-08,Kang; Xue; Yang; Yang,"Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.; Department of Clinical Pharmacology, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.; Department of Non-Clinical, Qilu Pharmaceutical Co., Ltd., Jinan, 250001, China.",zhangli@sysucc.org.cn.
37158890,Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.,2023-May-08,,,Narendranath.Epperla@osumc.edu.
37156782,"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.",2023-May-09,,,Tom.Martin@ucsf.edu.
37156551,Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.,2023-May,,,tnowicki@mednet.ucla.edu.
37150651,Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors.,2023-Aug,,,htorres@mdanderson.org.
37149458,Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.,2023-Aug,,,joaquim.bellmunt@gmail.com.
37142661,Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).,2023-Jun,,,eterpos@med.uoa.gr.
37142372,"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.",2023-May,,,bekaii-saab.tanios@mayo.edu.
37142291,"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.",2023-May,Snyder,"Amgen Inc, Thousand Oaks, California, USA.",jason.chesney@louisville.edu.
37141400,"The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer.",2023-Oct-03,,,
37137807,"Atezolizumab plus Bevacizumab after first-line multikinase inhibitors for advanced hepatocellular carcinoma: The concept of ""drug class change"".",2023-Jul,,,csaitta@unime.it.
37134152,Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer.,2023-May-03,Xu; Burkart; Burman; Chong; Barber; Geng; Zhai; Menefee; Polizzi; Eide; Rauch; Rahman; Hamel; Fogassy; Klopp-Savino; Paz; Cubitt; Nangle,"aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; Pangu Biopharma, 26th Floor, Three Exchange Square, 8 Connaught Place, Central, Hong Kong, China.; Pangu Biopharma, 26th Floor, Three Exchange Square, 8 Connaught Place, Central, Hong Kong, China.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.; aTyr Pharma, San Diego, CA 92121, USA.",
37131217,Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.,2023-May-02,,,hkantarjian@mdanderson.org.
37130017,Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.,2023-Jul-13,Thompson; Chakraborty; Marinello,"Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ.; Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ.; Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ.",
37119523,Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.,2023-Jun,Rüschoff; Erb; Naab; Donica; Deurloo,"Targos Molecular Pathology GmbH, Kassel, Germany.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.",
37111346,"Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?",2023-Apr-14,,,
37103927,"Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.",2023-Jun-01,,,
37103916,Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.,2023-Jun-01,,,
37099295,Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.,2023-Apr-03,Gibbs; Tchouakam Kouekam; Johnsson; Esser,"Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Toronto, Ontario, Canada.; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.",
37094988,"Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).",2023-Apr,Lillie; Krige; Carter; Cox; Patel; Parfitt; Powell,"Akamis Bio Ltd, Abingdon, UK.; Akamis Bio Ltd, Abingdon, UK.; Akamis Bio Ltd, Abingdon, UK.; Akamis Bio Ltd, Abingdon, UK.; Akamis Bio Ltd, Abingdon, UK.; Akamis Bio Ltd, Abingdon, UK.; Akamis Bio Ltd, Abingdon, UK.",mfakih@coh.org.
37080222,"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.",2023-May,,,yoon.harry@mayo.edu.
37076395,"RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.",2023-Jul,Graham,"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.",mnishio@jfcr.or.jp.
37074033,"AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas.",2023-Jun,,,
37072748,"The ""Great Debate"" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.",2023-Apr-18,,,paolo.ascierto@gmail.com.
37071094,"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.",2023-Apr-18,Hihara; Soeda,"Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd, Tokyo, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd, Tokyo, Japan.",
37069784,First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.,2023-May,Messinger,"Statistics, Prometris GmbH, Mannheim, Germany.",
37068506,Claudin-18.2 targeting by zolbetuximab: results of SPOTLIGHT in perspective.,2023-May-20,,,h.vanlaarhoven@amsterdamumc.nl.
37068504,"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.",2023-May-20,Yang; Moran; Bhattacharya; Arozullah; Park; Oh,"Astellas Pharma Global Development, Inc, Northbrook, IL, USA.; Astellas Pharma Global Development, Inc, Northbrook, IL, USA.; Astellas Pharma Global Development, Inc, Northbrook, IL, USA.; Astellas Pharma Global Development, Inc, Northbrook, IL, USA.; Astellas Pharma Global Development, Inc, Northbrook, IL, USA.; Astellas Pharma Global Development, Inc, Northbrook, IL, USA.",jajani@mdanderson.org.
37067554,Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.,2023-Aug,Gambotti,"Department of Clinical Research, Institut National Contre Le Cancer (INCa), Paris, France.",elise.toulemonde.etu@univ-lille.fr.
37062953,Update on combined immunotherapy for the treatment of advanced renal cell carcinoma.,2023-Dec-31,,,
37062077,The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.,2023-Jun,,,
37052965,"Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.",2023-Mar,,,s.pignata@istitutotumori.na.it.
37043205,Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer.,2023-Apr-03,,,
37042921,Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.,2023-Jul-25,,,
37042716,Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.,2023-Jul-06,Cantini,"Labcorp Drug Development Inc, Princeton, NJ, USA.",
37038005,Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab.,2023-Apr,,,trevor.pugh@utoronto.ca.
37037952,Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.,2023-Sep,,,kmuro@aichi-cc.jp.
37033984,Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.,2023,,,
37032085,Isolated Adrenocorticotropic Hormone Deficiency Associated with Atezolizumab and Bevacizumab Administration for Treating Hepatocellular Carcinoma: A Case Series.,2023-Nov-15,,,
37028941,Comparative Effects of Domain-Specific Human Monoclonal Antibodies Against LGI1 on Neuronal Excitability.,2023-May,,,christian.geis@med.uni-jena.de.
37026799,A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.,2023-Aug-08,,,
37024664,The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy.,2023-Apr-06,,,kawakami_h@med.kindai.ac.jp.
37023703,Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.,2023-Jul-05,,,
37022706,Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.,2023-Jun-01,Wei; Khan; Miller-Moslin; Roberts,"Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.",
37022687,Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.,2023-Apr-03,Jang; Kim; Lee; Yoon,"Samsung Bioepis, Incheon, Republic of Korea.; Samsung Bioepis, Incheon, Republic of Korea.; Samsung Bioepis, Incheon, Republic of Korea.; Samsung Bioepis, Incheon, Republic of Korea.",
37019386,Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.,2023-Aug,Yang,"Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania.",ablauvelt@oregonmedicalresearch.com.
37018924,Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma.,2023-Jun,,,Georgina.Long@sydney.edu.au.
37016126,"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.",2023-Jul,Bendell,"Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Johanna.bendell@roche.com.",Johanna.bendell@roche.com.
37013954,Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.,2023-Aug-22,,,
37011650,"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.",2023-May,,,toni_choueiri@dfci.harvard.edu.
37011643,"Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.",2023-May,,,wilsonw@nih.gov.
37003980,Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.,2023-Mar-31,,,ogasawaras@chiba-u.jp.
37003279,Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.,2023-May,,,nshort@mdanderson.org.
37000164,"Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.",2023-Jun-13,Ilaria; O'Connell; Peng; Peng; Zizlsperger,"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts.; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts.; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts.; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts.; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts.",
36999533,Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.,2023-Sep-01,Sato,"Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany.",
36997583,"Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.",2023-Mar-30,Hinterberger; Endt; Bathke; Habjan; Heiseke; Heiseke; Schweneker; Von Rohrscheidt; Von Rohrscheidt; Atay; Chaplin; Kalla; Hausmann; Schmittwolf; Lauterbach; Lauterbach; Volkmann; Hochrein; Medina-Echeverz,"Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany. mahi@bavarian-nordic.com.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; GlaxoSmithKline GmbH, Prinzregentenpl. 9, 81675, Munich, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Origenis GmbH, Am Klopferspitz 19A, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Hookipa Pharma Inc, 350 Fifth Avenue, Room/Suite 7240, New York City, NY, USA.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.; Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.",mahi@bavarian-nordic.com.
36996620,Future potential targets of antibody-drug conjugates in breast cancer.,2023-Jun,,,chiara.corti@ieo.it.
36986677,Radioimmune Imaging of α,2023-Mar-02,Wunder,"Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riß, Germany.",
36978142,The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.,2023-Mar-28,Sinn,"Department of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.",jan.kuhlmann@uniklinikum-dresden.de.
36977309,Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.,2023-May-20,,,
36971049,Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+ breast cancer.,2023-May,,,
36970059,"Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia.",2022-Nov,,,
36965007,Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.,2023-Jun,,,
36964928,A novel brick for bispecific antibody construction.,2023-Aug,Ma,"LongBio Pharma Co, Shanghai, China.",
36963232,The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.,2023-May,,,zandbergdp@upmc.edu.
36952231,Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.,2023-Aug-03,,,
36948504,Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).,2023-Mar,,,mba41@Georgetown.edu.
36933320,Anti-TIGIT therapies for solid tumors: a systematic review.,2023-Apr,,,fabrice.barlesi@gustaveroussy.fr.
36928818,Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.,2023-Mar,,,tcascone@mdanderson.org.
36927527,First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).,2023-Mar,Hansen; Spreafico; Ahlers; Chisamore; Schmidt,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Replimune Group Inc, Woburn, Massachusetts, USA.; Merck & Co Inc, Kenilworth, New Jersey, USA.; Merck & Co Inc, Kenilworth, New Jersey, USA.",sophie.postel-vinay@gustaveroussy.fr.
36920329,IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.,2023-May-01,,,
36916728,Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.,2023-May,Pan,"Merck & Co., Inc., Rahway, New Jersey, USA.",
36913694,Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.,2023-May-25,,,
36906542,Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.,2023-Mar-11,,,ogasawaras@chiba-u.jp.
36898292,Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.,2023-Apr,,,ktewari@uci.edu.
36898233,"Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.",2023-May,DiPrimeo; Wong,"Puma Biotechnology Inc., Los Angeles, CA, USA.; Puma Biotechnology Inc., Los Angeles, CA, USA.",faholmesmd@icloud.com.
36895937,Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer-a retrospective cohort study.,2023-Feb-28,,,
36893691,"Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.",2023-Apr,,,v.mueller@uke.de.
36890354,Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.,2023-Jun,,,Stephan.Ortiz@alexion.com.
36889037,Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.,2023-May,Matoba; Noda; Sato; Suminaka; Yamaki,"DNA Chip Research Inc., Tokyo 105-0022, Japan.; Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.; Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.; Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.; Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.",kawakami_h@med.kindai.ac.jp.
36888930,Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.,2023-May-20,Gu; Zhang; Tan; Chao; O'Hear; Ramsingh; Lal,"Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.; Gilead Sciences, Inc, Foster City, CA.",
36883878,Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series.,2023-Apr,,,
36880426,Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.,2023-Apr,,,
36878237,"Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.",2023-Apr,,,bmonk@gog.org.
36875713,Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma.,2022-May,Burnett; Dabovic; Strack,"Molecular Templates, Inc., Jersey City, New Jersey.; Molecular Templates, Inc., Jersey City, New Jersey.; Molecular Templates, Inc., Jersey City, New Jersey.",
36871392,Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer.,2023-Apr,Rudin; Spahn; Li; Cha,"Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: rudinc@mskcc.org.; Genentech, Inc, South San Francisco.; Genentech, Inc, South San Francisco.; Genentech, Inc, South San Francisco.",rudinc@mskcc.org.
36871043,Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.,2023-May,Takenaka; Ozawa,"Clinical Development and Medical Affairs Division, Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.; Clinical Development and Medical Affairs Division, Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.",tyoshino@east.ncc.go.jp.
36868252,"Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.",2023-Apr,,,marc-oliver.grimm@med.uni-jena.de.
36862717,Creation of an ustekinumab external control arm for Crohn's disease using electronic health records data: A pilot study.,2023,,,
36858729,Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.,2023-Mar,Leung,"Bristol Myers Squibb, Princeton, NJ, USA.",lalitha.shankar@nih.gov.
36858723,"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.",2023-Mar,,,sara_tolaney@dfci.harvard.edu.
36852723,Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors.,2023-Jul,Hwang; Fan; Yue; Zhou; Paturel; Andre; Ren; Gibbs; Phipps; Song,"Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, California, USA.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Certara, Princeton, New Jersey, USA.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts, USA.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts, USA.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.",
36842467,MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.,2023-Jul,Waterhouse; Olson; Latven; Yan; Shazer,"US Oncology Network, The Woodlands, Texas; Department of Clinical Research, Oncology Hematology Care, Cincinnati, Ohio; Current affiliation: Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.",kai.he@osumc.edu.
36824125,"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review.",2023,,,
36818675,Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer.,2022,,,
36814222,INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).,2023-Feb-22,,,integrateii.study@sydney.edu.au.
36811382,A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.,2023-Mar-17,,,
36804376,Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.,2023-Feb-20,,,Kathryn.maples@emoryhealthcare.org.
36802176,Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.,2023-Mar,,,
36801605,"Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.",2023-Apr,,,bylicki.olivier@yahoo.fr.
36797356,"A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.",2023-Apr,Rahman; Budha; Wu; Marlow; Yang,"BeiGene USA, Inc., San Mateo, CA, USA.; BeiGene USA, Inc., San Mateo, CA, USA.; BeiGene USA, Inc., San Mateo, CA, USA.; BeiGene USA, Inc., San Mateo, CA, USA.; BeiGene (Beijing) Co., Ltd., Beijing, China.",Jayesh.Desai@petermac.org.
36795388,"Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.",2023-Apr-01,Kaul; Yu; Paranthaman; Bara,"Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.",
36780000,Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16.,2023-Mar,Melief; van der Gracht; Wiekmeijer,"ISA Pharmaceuticals, Oegstgeest, The Netherlands. Melief@isa-pharma.com.; ISA Pharmaceuticals, Oegstgeest, The Netherlands.; ISA Pharmaceuticals, Oegstgeest, The Netherlands.",Melief@isa-pharma.com.
36774933,"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.",2023-Mar-11,Simsek; Spiridigliozzi; Chudnovsky,"Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.; Department of Oncology Late Clinical Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.; Department of Oncology, Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.",motzerr@mskcc.org.
36774931,Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers.,2023-Mar-11,,,thomas.powles1@nhs.net.
36763936,"ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated ",2023-May-10,,,
36746510,"Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors.",2023-Feb,Seto; Zavodovskaya; Hsueh; Zhai; Tarnowski; Jürgensmeier; Stinson; Othman; Chen,"Gilead Sciences Inc, Foster City, California, USA.; Gilead Sciences Inc, Foster City, California, USA.; Gilead Sciences Inc, Foster City, California, USA.; Gilead Sciences Inc, Foster City, California, USA.; Gilead Sciences Inc, Foster City, California, USA.; Gilead Sciences Inc, Foster City, California, USA.; Gilead Sciences Inc, Foster City, California, USA.; Gilead Sciences Inc, Foster City, California, USA.; Gilead Sciences Inc, Foster City, California, USA.",atolcher@nextsat.com.
36746010,Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.,2023-Mar,,,md.velev@gmail.com.
36740590,Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.,2023-Jun-08,,,
36739879,"Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.",2023-Mar,,,thomas.walter@chu-lyon.fr.
36738762,"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.",2023-Apr,,,brian.feagan@alimentiv.com.
36736157,"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.",2023-Mar,Method; Wang,"ImmunoGen, Inc., Waltham, MA, United States. Electronic address: michael.method@immunogen.com.; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: joe.wang@immunogen.com.",lucy.gilbert@mcgill.ca.
36732205,Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.,2023-May,,,ciprian.tomuleasa@umfcluj.ro.
36732204,Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.,2023-May,,,austin.kulasekararaj@nhs.net.
36729213,Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.,2023-Jun,,,shiota.masaki.101@m.kyushu-u.ac.jp.
36727218,The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.,2023,Claus; Ferrara-Koller; Klein,"Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.",
36725094,Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study.,2023-Feb-01,Ranch,"Biostatistics and Pharmacoepidemiology, LEO Pharma A/S, Ballerup, Denmark.",mreilev@health.sdu.dk.
36725084,"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.",2023-Feb,Li; Chang; Fiore; Acevedo,"Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Translational Bioinformatics, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.",neal.ready@duke.edu.
36716415,Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.,2023-Jan,,,
36716220,Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.,2023-Aug-08,,,
36706355,Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.,2023-Apr-13,,,
36702123,Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.,2023-Feb-21,,,dranwaarsaeed1@gmail.com.
36701651,"First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors.",2023-Jan,Shia; Hsu; Pearce,"OBI Pharma Inc, Taipei City, Taiwan.; OBI Pharma Inc, Taipei City, Taiwan.; OBI Pharma USA, Inc, San Diego, CA.",
36696540,Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.,2023-May-23,,,
36690960,Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.,2023-Jan-23,Kanters; Ball; Limbrick-Oldfield,"RainCity Analytics, Vancouver, BC, Canada. skanters@raincity-analytics.com.; Gilead Sciences Canada, Inc., Mississauga, Canada.; RainCity Analytics, Vancouver, BC, Canada.",skanters@raincity-analytics.com.
36689726,Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.,2023-Jun-13,,,
36680880,Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.,2023-Mar,,,Douglas.b.johnson@vumc.org.
36669833,Identification of Hetero-aggregates in Antibody Co-formulations by Multi-dimensional Liquid Chromatography Coupled to Mass Spectrometry.,2023-Jan-31,Kuhne; Heinrich; Winter; Fichtl; Hoffmann; Zähringer; Spitzauer; Meier; Khan; Bonnington; Wagner; Stracke; Reusch; Wegele; Bulau,"Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; Pharma Technical Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.; Pharma Technical Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.",
36669791,"Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.",2023-Jan,Rudin; Hill; Ren; Schmidt,"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA rudinc@mskcc.org.; Tasman Oncology Research Ltd, Southport, Queensland, Australia.; Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.",rudinc@mskcc.org.
36661331,Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma.,2023-Jun-13,,,
36660902,Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.,2023-Apr,Soubret; Buatois; Charoin; Sreckovic; Bucher; Hernández-Sánchez; Gotanda; Jordan; Shinomiya; Ramos; Ramos; Paz-Priel; Sostelly; Sostelly,"Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Genentech, Inc., South San Francisco, California, USA.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Genentech, Inc., South San Francisco, California, USA.; Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA.; Genentech, Inc., South San Francisco, California, USA.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Alnylam Pharmaceuticals, Basel, Switzerland.",
36647206,Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study.,2023-Apr,,,
36641771,Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.,2023-Oct,,,vkazakou@hotmail.com.
36638191,Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases.,2023-Jan-13,Suzuki; Tokumaru; Oshiro,"Pharmaceutical R&D Division, Meiji Seika Pharma Co. Ltd., Tokyo 104-8002, Japan.; Pharmaceutical R&D Division, Meiji Seika Pharma Co. Ltd., Tokyo 104-8002, Japan.; Pharmaceutical R&D Division, Meiji Seika Pharma Co. Ltd., Tokyo 104-8002, Japan.",
36631725,"Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).",2023-Jan-11,de Haas; Lewis; Lambertini; Lopez-Valverde; Boulet,"Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. sanne_lysbet.de_haas@roche.com.; Discovery Oncology, Genentech, Inc., South San Francisco, CA, USA.; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.; Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Product Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd., Basel, Switzerland.",sanne_lysbet.de_haas@roche.com.
36629030,Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.,2023-Mar,,,
36626583,Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.,2023-Apr-20,Bu; Wang; Jiang; Hirata; Lee,"F. Hoffmann-La Roche Ltd, Shanghai, China.; F. Hoffmann-La Roche Ltd, Shanghai, China.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",
36622516,A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine.,2023-Dec,,,peiravianfarzad@gmail.com.
36613644,Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.,2022-Dec-22,,,
36612047,Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends.,2022-Dec-22,,,
36603921,Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma - Authors' reply.,2023-Jan,Burgents; Xu,"Merck & Co, Inc, Rahway, NJ, USA.; Merck & Co, Inc, Rahway, NJ, USA.",thomas.powles1@nhs.net.
36602796,Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.,2023-Jan-03,Beg,"Science 37 Inc, Durham, North Carolina.",
36600561,"Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer.",2022-Dec,Miller; Hu; Mahabhashyam; Jones; Willingham,"Corvus Pharmaceuticals Inc, Burlingame, California, USA rmiller@corvuspharma.com.; Corvus Pharmaceuticals Inc, Burlingame, California, USA.; Corvus Pharmaceuticals Inc, Burlingame, California, USA.; Corvus Pharmaceuticals Inc, Burlingame, California, USA.; Corvus Pharmaceuticals Inc, Burlingame, California, USA.",rmiller@corvuspharma.com.
36576431,"Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.",2023-Feb-08,Ito,"Merck Biopharma Co., Ltd., Tokyo, Japanan affiliate of Merck KGaA.",
36576173,Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.,2023-Apr-06,,,
36568966,"Role of CD36 in cancer progression, stemness, and targeting.",2022,Pérez-Tapia,"National Laboratory for Specialized Services of Investigation Development and Innovation (I+D+i) for Pharma Chemicals and Biotechnological products LANSEIDI-FarBiotec-CONACyT, Mexico City, Mexico.",
36564602,Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.,2023-Apr,Arimitsu,"Department of Oncology, ONO Pharmaceutical Co. Ltd., Osaka, Japan.",kchin@jfcr.or.jp.
36563660,Relatlimab and nivolumab in the treatment of melanoma.,2022-Dec-22,,,james.larkin@rmh.nhs.uk.
36549781,Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.,2022-Dec,Gupta; Lee; Jiang,"Department of Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey, USA.; Division of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey, USA.",brian.rini@vumc.org.
36535121,Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.,2023-Jan,Reinmuth,"Department of Oncology, Asklepios Kliniken GmbH - Asklepios Fachkliniken Muenchen-Gauting, Munich, Germany.",Rolf.Stahel@etop.ibcsg.org.
36529603,"Response to letter entitled: Re: Pathologic Complete Responses, Long-term Outcomes, and Recurrence Patterns in HER2-low vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy.",2023-Feb,,,sbkim3@amc.seoul.kr.
36527976,Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.,2023-Feb,,,casadeigardini@gmail.com.
36527482,"Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients.",2023-Aug,,,sandra.freiberger@usz.ch.
36523162,Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.,2023-Feb,,,
36521030,Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.,2023-Jun-13,,,
36520426,Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.,2023-Mar-01,,,
36512081,"Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.",2023-Jan,Prince,"Epworth Healthcare, East Melbourne, VIC, Australia. miles.prince@petermac.org.",miles.prince@petermac.org.
36511679,Prognostic significance of telomerase reverse transcriptase promoter gen mutations in high grade meningiomas.,2022-Dec-01,,,biomedica@ins.gov.co.
36509000,Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.,2023-Jan,,,H.vanLaarhoven@amsterdamumc.nl.
36504394,Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma.,2023-Jan,,,vperezah12o@outlook.es.
36503738,"Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.",2023-Mar,Fontaine; Hitron; Xu,"Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA.; Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA.; Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA.",mas9313@med.cornell.edu.
36495879,"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.",2023-Jan-14,Hegg,"Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paolo, Brazil.",shurvitz@mednet.ucla.edu.
36493599,"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.",2022-Dec,Palcza; Jha; Chaney; Abraham; Healy,"Clinical Research, Merck & Co., Inc., Rahway.; Clinical Research, Merck & Co., Inc., Rahway.; Clinical Research, Merck & Co., Inc., Rahway.; Clinical Research, Merck & Co., Inc., Rahway.; Clinical Research, Merck & Co., Inc., Rahway.",egarralda@vhio.net.
36485132,Cellular therapy for multiple myeloma: what's now and what's next.,2022-Dec-09,,,
36485086,Management of marginal zone lymphomas.,2022-Dec-09,,,
36483582,Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy.,2022-Nov,Montesion,"Cancer Genomics Research, Foundation Medicine Inc., Cambridge, MA, USA.",
36480191,Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.,2023-Jan-01,Thomas; Hennicken; Coffey,"Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.",
36478334,Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.,2023-Apr,Nakanishi; Furuki; Fukuda; Ueno; Raizer; Arozullah,"Astellas Pharma Inc., Tokyo, Japan.; Astellas Pharma Inc., Tokyo, Japan.; Astellas Pharma Inc., Tokyo, Japan.; Astellas Pharma Inc., Tokyo, Japan.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.",
36473143,Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.,2023-Apr-20,Roberts; Khan; Miller-Moslin; Wei,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
36472635,New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis.,2023-Nov,Jackisch,"Department of Gynecology and Obstetrics, Sana Klinikum Offenbach GmbH, Offenbach, Germany.",carsten.denkert@uni-marburg.de.
36472582,Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.,2023-Jan-01,,,
36470291,"Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.",2023-Feb,,,thierry.andre@aphp.fr.
36463547,"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.",2023-Feb,Zhu; Macharia,"Roche Pharma Product Development China, Shanghai, China.; Oncology Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",xubinghe@medmail.com.cn.
36459673,Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.,2023-Apr-01,Radojcic; Meyers; Qamoos; Qamoos; Ordentlich; Kumar; Kumar; Quaranto; Quaranto; Schmitt; Gu,"Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Kartos Therapeutics, Inc, Redwood City, CA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Aerovate Therapeutics, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.",
36457080,"Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.",2022-Dec-01,,,guillaume.bouguen@chu-rennes.fr.
36455193,"Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an ",2022-Nov,Deegan; Jansen,"Elevation Oncology, Inc, New York, NY.; Elevation Oncology, Inc, New York, NY.",
36455172,"Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.",2022-Nov,,,
36454580,"Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.",2023-Feb-01,Ramos; Feng,"Seagen Inc, Bothell, Washington.; Seagen Inc, Bothell, Washington.",
36451343,A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.,2023-Feb-01,,,
36450381,Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.,2022-Nov,,,Schilling_B@ukw.de.
36450379,Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer.,2022-Nov,Alatorre-Alexander; Höglander; Kaul; Tolson; Hu; Vollan,"Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, Mexico.; F Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, California, USA.; F Hoffmann-La Roche Ltd, Basel, Switzerland.; F Hoffmann-La Roche Ltd, Basel, Switzerland.; F Hoffmann-La Roche Ltd, Basel, Switzerland.",andrea.ardizzoni@aosp.bo.it.
36445410,A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.,2023-Jun,Fein; Wu; Guerreiro; Ren; Shafren; Grose,"CNF Pharma, LLC, New City, NY, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; ImmvirX Pty Ltd, New Lambton Heights, NSW, Australia.; Viralytics Limited, a Wholly Owned Subsidiary of Merck & Co., Inc., Rahway, NJ, USA.",janice.mehnert@nyulangone.org.
36439116,Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data.,2022,,,
36434607,Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?,2022-Nov-25,,,claire.carlier@chu-reims.fr.
36424033,Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis.,2022-Nov,White; Bailey; Warren,"NanoString Technologies Inc, Seattle, Washington, USA.; NanoString Technologies Inc, Seattle, Washington, USA.; NanoString Technologies Inc, Seattle, Washington, USA.",paolo.ascierto@gmail.com.
36417762,Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy.,2023-Jun-13,,,
36416836,Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.,2023-Feb-01,Faller,"Heartland NCORP/Missouri Baptist Medical Center, St Louis.",
36414192,Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.,2023-Feb,Memaj; Nathan; Tran,"Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton.; OneClinical, Bristol Myers Squibb, Princeton.; WW Medical Oncology Department, Bristol Myers Squibb, Princeton.",hossein.borghaei@fccc.edu.
36403579,"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.",2023-Jan,,,aherrera@coh.org.
36401637,Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.,2023-Feb,Stahler,"Department of Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",andreas.jung@lmu.de.
36401133,"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).",2023-Apr,Amaya-Chanaga; Chen; Matsumura,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Department of Oncology, Ono Pharmaceutical Company Ltd., Osaka, Japan.",kenkato@ncc.go.jp.
36400106,"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.",2022-Dec,Elimova,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",fmeric@mdanderson.org.
36394849,Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.,2023-Jan-01,,,
36394299,Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice.,2022,Egli; Heiler; Weber; Steiner; Schwandt; Bray-French; Klein; Fenn; Lotz; Opolka-Hoffmann; Kraft; Petersen; Moser; DeGeer; Siegel; Bessa; Iglesias,"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
36394119,Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment.,2023-Mar,Aida; Hatayama; Shirahase,"Janssen Pharmaceutical K.K., Tokyo, Japan.; Janssen Pharmaceutical K.K., Tokyo, Japan.; Janssen Pharmaceutical K.K., Tokyo, Japan.",
36387057,Spermidine rejuvenates T lymphocytes and restores anticancer immunosurveillance in aged mice.,2022,,,
36385738,Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.,2023-Feb,,,
36385536,"Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.",2023-Mar-14,,,
36383911,Evolving Landscape of Antibody Drug Conjugates in Lymphoma.,None,,,
36383908,Antibody-Drug Conjugates in Myeloid Leukemias.,None,,,
36383907,The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.,None,,,
36383904,Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.,None,,,
36379002,Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.,2023-Feb-01,Saito; Kawaguchi; Kamio,"Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.",
36375132,"Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.",2023-Apr-11,Przespolewski,"Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",
36375046,A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.,2023-Apr-11,,,
36371994,Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study.,2022-Dec,,,m-sawaki@aichi-cc.jp.
36370634,"Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.",2022-Dec,Paul,"Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",jeffrey.bennett@cuanschutz.edu.
36369901,Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.,2023-Mar,Adachi; Fogelman; Marinello,"Merck & Co., Inc., Rahway, New Jersey, USA.; Merck & Co., Inc., Rahway, New Jersey, USA.; Merck & Co., Inc., Rahway, New Jersey, USA.",
36356285,Excellent Response to Fam-Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma With CNS Metastasis: A Case Report.,2022-Nov,,,
36355805,"Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease.",2023-Mar-28,Tanaka; Sanchez-Olle; Albers,"Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",
36351210,Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in ,2023-Jan-20,,,
36348617,Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.,2023-Apr-18,,,
36344672,Targeting HER2-positive breast cancer: advances and future directions.,2023-Feb,,,sandra.swain@georgetown.edu.
36342599,"Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study.",2022-Dec,,,shkondo@ncc.go.jp.
36335780,"Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.",2022-Dec,Gambotti,"Institut National Contre le Cancer (INCa), France.",marie.veron705@gmail.com.
36332187,Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.,2023-Apr-13,,,
36328377,FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.,2022-Nov,Saggi; Lee; Desilva; Bhagavatheeswaran,"Department of Global Regulatory Science, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Global Drug Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.",Toni_Choueiri@dfci.harvard.edu.
36328040,"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.",2022-Nov,,,hartmut.goldschmidt@med.uni-heidelberg.de.
36327527,Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.,2022-Dec,Zhang; Simsek,"Department of Clinical Research, Bristol Myers Squibb, Princeton, NJ, USA.; Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.",andrea.apolo@nih.gov.
36327426,Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.,2023-Feb-20,Alatorre-Alexander; Araujo,"Health Pharma Professional Research, Mexico City, Mexico.; Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil.",
36318439,Resistance to targeted therapies in acute myeloid leukemia.,2023-Feb,,,heuser.michael@mh-hannover.de.
36316061,"First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.",2022-Oct,Janik; Clark; Condamine; Pulini; Chen,"Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.",janice.mehnert@nyulangone.org.
36309837,Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.,2023-Jan-01,Zhou; Walker; Dong,"Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.",
36308296,Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.,2023-Jan-01,Chen; Harnett; Mastey; Li; Gullo; Rietschel,"Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.",
36302562,First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.,2022-Oct,Forgie; Yang; Guo; Chou,"Translational Oncology, Pfizer Inc, San Francisco, California, USA.; Oncology Computational Biology, Pfizer Inc, San Diego, Calfornia, USA.; Clinical Pharmacology, Pfizer Inc, San Diego, California, USA.; Early Oncology Development and Clinical Research, Pfizer Inc, San Francisco, California, USA.",ohamid@theangelesclinic.org.
36300122,SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity.,2022,Antosova; Podzimkova; Augustynkova; Sajnerova; Nedvedova; de Martynoff; Bechard; Moebius; Spisek; Adkins,"Preclinical Department, SOTIO Biotech a.s, Prague, Czechia.; Preclinical Department, SOTIO Biotech a.s, Prague, Czechia.; Preclinical Department, SOTIO Biotech a.s, Prague, Czechia.; Preclinical Department, SOTIO Biotech a.s, Prague, Czechia.; Preclinical Department, SOTIO Biotech a.s, Prague, Czechia.; Cytune Pharma, Nantes, France.; Cytune Pharma, Nantes, France.; Preclinical Department, SOTIO Biotech a.s, Prague, Czechia.; Preclinical Department, SOTIO Biotech a.s, Prague, Czechia.; Preclinical Department, SOTIO Biotech a.s, Prague, Czechia.",
36294316,Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials.,2022-Oct-11,,,
36290837,A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.,2022-Sep-28,Doucette,"Impact Medicom Inc., Toronto, ON M6S 3K2, Canada.",
36289918,Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer.,2022-Oct-21,,,
36289372,Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.,2023-Jan,,,joaquim_bellmunt@dfci.harvard.edu.
36289334,Neoadjuvant relatlimab and nivolumab in resectable melanoma.,2022-Nov,,,rnamaria@mdanderson.org.
36287248,A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.,2023-May-23,,,
36287231,Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.,2023-Apr-25,Raval; Shivhare; Nielsen; Sellam,"Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA.; Data and Statistical Science, Roche Products Ltd, Welwyn Garden City, United Kingdom.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
36283944,"Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease.",2023-Aug,,,Lauranne.Derikx@radboudumc.nl.
36279803,Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.,2022-Dec,,,maapro@genolier.net.
36275782,Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience.,2022,,,
36270753,"Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.",2022-Oct-21,,,ykuboki@east.ncc.go.jp.
36265502,"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.",2022-Nov,,,georgina.long@sydney.edu.au.
36261460,Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant.,2022-Oct-19,Merghoub,"Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.",dengl@mskcc.org.
36261286,Diagnosing myasthenia gravis using orthoptic measurements: assessing extraocular muscle fatiguability.,2023-Feb,,,K.R.Keene@lumc.nl.
36260984,Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?,2022-Oct-18,,,melief@isa-pharma.com.
36260832,NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.,2023-Feb-20,,,
36252998,Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.,2022-Oct,,,sara_tolaney@dfci.harvard.edu.
36252996,Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.,2022-Oct,Glenn; Nesline,"OmniSeq, Inc, Buffalo, New York, USA.; OmniSeq, Inc, Buffalo, New York, USA.",tian.zhang@utsouthwestern.edu.
36252287,Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer.,2022-Nov,,,richard.kim@moffitt.org.
36252154,Treatment of Metastatic Colorectal Cancer: ASCO Guideline.,2023-Jan-20,,,
36251503,"A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.",2023-Feb,,,
36231138,An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.,2022-Oct-10,Ferraù,"Medical Oncology, Ospedale San Vincenzo, 98039 Taormina, Italy.",
36229048,A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).,2023-Feb,,,
36228654,Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.,2023-Apr,,,
36226511,Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study.,2023-Mar,,,
36215121,"Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.",2022-Dec-15,,,
36208496,Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.,2022-Dec,,,casadeigardini@gmail.com.
36206498,Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).,2023-Jan-20,,,
36203123,Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.,2022-Oct-06,,,y-mitsuishi@juntendo.ac.jp.
36202026,Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.,2022-Dec,,,schettini@clinic.cat.
36195556,End-of-life impact of concurrent diabetes mellitus and adrenal insufficiency as immune-related adverse events in an advanced non-small cell lung cancer patient.,2022-Nov,,,
36194906,"Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.",2022-Nov,,,ynakamur@saitama-med.ac.jp.
36191968,Retrospective Analysis of Treatment Pathways in Patients With BRAF,2022-Oct,Schwager; Reichenbach,"Winicker Norimed GmbH - Clinical Research, Berlin, Germany.; Pierre Fabre Pharma GmbH, Freiburg, Germany.",armin.gerger@medunigraz.att.
36191214,"ACBP/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis.",2022-Oct-11,,,
36184373,The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study.,2022-Oct,,,m.r.tannemaat@lumc.nl.
36183651,Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.,2022-Nov,,,markus.moehler@unimedizin-mainz.de.
36183444,A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.,2022-Oct,,,goran.u.carlsson@vgregion.se.
36180954,The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.,2022-Sep-30,,,giuseppe.fornarini@hsanmartino.it.
36166727,Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced ,2023-Jan-10,,,
36164935,Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.,2023-Jan,Kamio; Kikumori; Kamiyama; Fujisaki; Saotome,"Clinical Safety and Pharmacovigilance, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.; Data Intelligence Department, Daiichi Sankyo Co, Ltd., Tokyo, Japan.; Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co, Ltd., Tokyo, Japan.; Clinical Development Department, Daiichi Sankyo Co, Ltd., Tokyo, Japan.; Clinical Development Department, Daiichi Sankyo RD Novare Co, Ltd., Tokyo, Japan.",
36162037,Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).,2023-Jan-20,Schenker; Eigentler; Butler; Re; Bas; de Pril; Braverman; Tenney; Tang,"Oncology Center Sf Nectarie Ltd, Craiova, Romania.; Universitätsklinikum und Medizinische Fakultät Tübingen, Tübingen, and Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Dermatology, Venerology and Allergology, Berlin, Germany.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.",
36162010,Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma.,2023-Jan-20,,,
36153496,"Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.",2022-Sep-24,,,Farastuk.Bozorgmehr@med.uni-heidelberg.de.
36153210,Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety.,2022-Dec,Su; Chen; Hsiang,"Medical Division, Roche Products Ltd, Taipei, Taiwan.; Medical Division, Roche Products Ltd, Taipei, Taiwan.; Medical Division, Roche Products Ltd, Taipei, Taiwan.",yuyunshao@gmail.com.
36140247,Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96.,2022-Sep-01,Boch; Reschke; Igney; Maier; Müller; Das; Rist,"Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.; Boehringer Ingelheim RCV GmbH & Co. KG, 1120 Vienna, Austria.; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.; ViraTherapeutics GmbH, 6063 Rum, Austria.; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.",
36136306,Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.,2022-Nov-01,Sun; Maxwell; Aakhus; Brody,"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.",
36130314,Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents.,2023-Mar-18,,,
36130155,Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Brain Metastases: Real-World Experience.,2022-Sep,,,
36129967,Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.,2022-Dec-02,Mahling,"Novartis Pharma AG, Basel, Switzerland.",
36121672,Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.,2022-Nov-01,,,
36121651,"First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.",2023-Feb-15,Lei; Li; Bao; Chen,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",
36116168,Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.,2022-Nov,,,akhamad@ncc.go.jp.
36112037,Bevacizumab-induced Coagulative Necrosis with Restricted Diffusion.,2022-Sep,,,
36108662,"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.",2022-Oct,,,mary.obrien@rmh.nhs.uk.
36108594,Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis.,2023,Gustovic,"Alexion Pharma GmhB, Zürich, Switzerland.",
36104138,"Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.",2022-Sep-14,Zhang; Askelson; Johansen,"Department of Clinical Research, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey, USA.; US Medical Immunology and Fibrosis, Bristol Myers Squibb, Princeton, New Jersey, USA.",daniel.george@duke.edu.
36099927,"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.",2022-Oct-01,Kiecker,"Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Department of Dermatology and Venereology, Vivantes Klinikum Berlin Neukölln, Berlin, Germany.",dirk.schadendorf@uk-essen.de.
36099926,"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.",2022-Oct-01,,,spal@coh.org.
36098320,"Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.",2022-Jun,,,matthias.ebert@medma.uni-heidelberg.de.
36097345,Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development.,2022-Nov,Hansen,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",
36097216,"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.",2022-Oct,Schulze; Nicholas; Johnson; Grindheim; Hilz; Shames,"Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.",david.carbone@osumc.edu.
36094611,Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).,2022-Nov,Grafe; Eckl,"Medical Center Nordhausen gGmbH, Nordhausen, Germany.; Roche Pharma AG, Grenzach-Wyhlen, Germany.",marc.thill@agaplesion.de.
36092332,A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer.,2022-Aug,,,
36089578,Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.,2022-Sep-11,,,espen.ellingsen@ultimovacs.com.
36088954,"COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.",2022-Nov,,,nicholas.powell@imperial.ac.uk.
36077782,Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era.,2022-Aug-31,,,
36076179,Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.,2022-Sep-08,,,okamoto.isamu.290@m.kyushu-u.ac.jp.
36067452,Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).,2023-Jan-20,Innocenti,"AbbVie Inc, North Chicago, IL.",
36066628,Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study.,2022-Nov,Janssen; Behera; Kellner; Jaeger; Bjorklof,"Medizinische Studiengesellschaft Nord-West GmbH, Westerstede, Germany.; Amgen Research Munich GmbH, Munich, Germany.; Amgen GmbH, Munich, Germany.; Amgen GmbH, Vienna, Austria.; Amgen Europe GmbH, Rotkreuz, Switzerland.",ingodiel@gmail.com.
36055304,"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.",2022-Sep,Burgents; Xu; Imai,"Merck & Co, Inc, Rahway, NJ, USA.; Merck & Co, Inc, Rahway, NJ, USA.; Merck & Co, Inc, Rahway, NJ, USA.",thomas.powles1@nhs.net.
36053786,Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.,2023-Apr-11,,,
36052536,"Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.",2023-Feb,Matsangou; Wu; Campbell; Yamashiro,"Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.; Seagen Inc., Bothell, Washington, USA.; Astellas Pharma, Inc., Tokyo, Japan.",
36050317,Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib.,2022-Sep-01,,,parikh.sameer@mayo.edu.
36048524,Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.,2022-Dec-15,Deng; Fang; Wang; Wang; Zhu; Chen; Min; Yin; Yang; Yang; Chanan-Khan; Zhai; Zhai,"Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma Group, Rockville, Maryland.; Mayo Clinic Cancer Center at St. Vincent's Medical Center Riverside, Jacksonville, Florida.; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma Group, Rockville, Maryland.",
36048457,Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.,2022-Oct-01,Akella; Orford,"Calithera Biosciences, Inc, South San Francisco, California.; Calithera Biosciences, Inc, South San Francisco, California.",
36043457,CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.,2022-Dec,,,
36042175,Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP®.,2022-Aug-05,Seki; Yamada; Ooba; Fujii; Narita; Nakayama; Kitahara; Mendelsohn; Matsuda; Matsuda; Okuzumi,"Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.; Ajinomoto Bio-Pharma Services, San Diego, CA 92121, USA.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.; Ajinomoto Bio-Pharma Services, San Diego, CA 92121, USA.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, 210-8681 Kanagawa, Japan.",
36041086,Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.,2023-Jan-01,Moreno; Yu; Carret,"Merck & Co, Inc, Kenilworth, NJ.; Seagen Inc, Bothell, WA.; Seagen Inc, Bothell, WA.",
36038670,DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment.,2022-Nov,,,Denise.bernhardt@mri.tum.de.
36038669,DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis.,2022-Oct,,,denise.bernhardt@mri.tum.de.
36029653,"MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF",2022-Oct,Tahiri; Gilberg; Irahara,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",jtabernero@vhio.net.
36029651,Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.,2022-Oct,Avery; Sun; Li; Rosales,"Division of Hematology and Oncology, Nebraska Hematology-Oncology, Lincoln, USA.; MacroGenics, Inc., Rockville, USA.; MacroGenics, Inc., Rockville, USA.; MacroGenics, Inc., Rockville, USA.",DocCatenacci@catenacciconsulting.com.
36027558,Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.,2022-Oct-10,Delaney; Fu; Lin; Verret,"Department of Clinical Development, Gilead Sciences Inc, Foster City, CA.; Department of Global Patient Safety, Gilead Sciences Inc, Foster City, CA.; Department of Biostatistics, Gilead Sciences Inc, Foster City, CA.; Department of Clinical Development, Gilead Sciences Inc, Foster City, CA.",
36017743,Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.,2023-Feb,Wolff; Krumm,"Roche Pharma AG, Biometrics & Epidemiology, Grenzach-Wyhlen, Germany.; Roche Pharma AG, Department of Hematology, Grenzach-Wyhlen, Germany.",
36010990,Overcoming Resistance to HER2-Directed Therapies in Breast Cancer.,2022-Aug-18,,,
36007963,Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).,2022-Aug,,,BJohnson6@mdanderson.org.
36007304,Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma.,2022-Sep,,,veronique.bataille@kcl.ac.uk.
36005556,"An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.",2022-Dec-01,Mondal; Rüter; Burkard; Osswald,"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.; BoehringeaBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Rissr Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.",william.g.blum@emory.edu.
35999229,Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.,2022-Aug-23,,,tito.mendoza@nih.gov.
35998004,Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.,2023-Mar,Pico-Navarro; Gafoor; Perschy,"Bavarian Nordic, Inc., Morrisville, NC, USA.; Bavarian Nordic, Inc., Morrisville, NC, USA.; Bavarian Nordic, Inc., Morrisville, NC, USA.",gurup_sonpavde@dfci.harvard.edu.
35995953,Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.,2022-Sep,Mathisen; Shagan; Schleifman; Wang; Yan; Mocci; Mocci; Voong; Fabrizio; Shames; Riehl,"Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; Foundation Medicine, Inc, Cambridge, MA, USA.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; Gilead Sciences, Inc, Foster City, CA, USA.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; Foundation Medicine, Inc, Cambridge, MA, USA.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.",solange.peters@chuv.ch.
35985961,Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study.,2023-Jan,,,lucas.guillo690@gmail.com.
35985446,Potential role of CXCR4 in trastuzumab resistance in breast cancer patients.,2022-Nov-01,,,nancy.shahin@pharma.cu.edu.eg.
35983060,Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.,2022,,,
35977756,Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.,2022-Aug,McCune; Bhagavatheeswaran; Amin; Ünsal-Kaçmaz; Wang; Li; Loehr,"Wellstar Health System Inc, Marietta, Georgia, USA.; Department of Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Clinical Oncology, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Translational Medicine, Clovis Oncology, Inc, Boulder, Colorado, USA.",Karim.FIZAZI@gustaveroussy.fr.
35969830,Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.,2023-Jan-10,,,
35967378,Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.,2022,Ziehn,"Novartis Pharma AG, Basel, Switzerland.",
35967081,Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.,2021,Bléry; Mrabet-Kraiem; Morel; Lhospice; Bregeon; Bonnafous; Gauthier; Rossi; Remark; Cornen; Anceriz; Viaud; Trichard; Carpentier; Joulin-Giet; Grondin; Perrot; Paturel; Morel; Vivier,"Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.",
35964548,Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.,2022-Aug,,,Hope.Rugo@ucsf.edu.
35964471,Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.,2022-Sep,Butler; Lobo; Askelson,"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.",James.Larkin@rmh.nhs.uk.
35959122,Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning.,2022,,,
35954374,COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress.,2022-Jul-29,,,
35953108,Parathyroid hormone-related protein (PTHrP) and malignancy.,2022,,,richard.kremer@mcgill.ca.
35947993,The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.,2023-Jul-05,,,
35947247,Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.,2022-Dec,Kahatt; Luepke-Estefan; Siguero; Fernandez-Teruel; Cullell-Young,"PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.",drilona@mskcc.org.
35947142,Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.,2023-Jan-10,,,
35943588,Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.,2022-Oct,,,Xavier.LELEU@chu-poitiers.fr.
35940825,"Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.",2022-Aug,Hawthorne; Rawls; Yellin; Keler,"Celldex Therapeutics Inc New Haven, New Haven, Connecticut, USA.; Celldex Therapeutics Inc, Hampton, New Jersey, USA.; Celldex Therapeutics Inc, Hampton, New Jersey, USA.; R & D, Celldex Therapeutics Inc, Hampton, New Jersey, USA.",Rachel.sanborn@providence.org.
35940183,"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.",2022-Sep,,,reinhard.dummer@usz.ch.
35927359,Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.,2023-Feb,,,takeh1977@gmail.com.
35922251,"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.",2022-Oct,Li; Mathias; Fury; Lowy; Harnett; Chen,"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",aoaknin@vhio.net.
35922089,Molecular imaging to support cancer immunotherapy.,2022-Aug,,,e.g.e.de.vries@umcg.nl.
35921760,"Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.",2022-Aug,Spreafico; Oliva; Hoffman; Hallett; Maetzel; Giblin; Anido; Kelly; Vickers; Wasserman; Siu,"Princess Margaret Cancer Centre, Toronto, Canada.; Princess Margaret Cancer Centre, Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Princess Margaret Cancer Centre, Toronto, Canada.",eborazanci@honorhealth.com.
35921442,Molecular mechanism for strengthening E-cadherin adhesion using a monoclonal antibody.,2022-Aug-09,Dranow; Phan; Edwards,"UCB Pharma, Bainbridge Island, WA, 98110.; UCB Pharma, Bainbridge Island, WA, 98110.; UCB Pharma, Bainbridge Island, WA, 98110.",
35907009,Real world data on IO-based therapy for metastatic renal cell carcinoma.,2023-Jul,,,bedke@live.com.
35900726,Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.,2022-Sep-01,,,
35897060,"Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.",2022-Jul-27,Sommerhäuser; Kurreck; Stintzing; Hoyer; Kiani; Fruehauf; Stahler; Modest,"Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, Germany.; Department of Hematology, Oncology, and Palliative Care, Klinik Dr. Hancken GmbH, Stade, Germany.; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. dominik.modest@charite.de.",dominik.modest@charite.de.
35896284,Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.,2022-Jul,Chaput,"Faculté de Pharmacie, Université Paris-Saclay, 91400 Orsay, France.",nathalie.chaput@gustaveroussy.fr.
35885987,Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with ,2022-Jul-05,,,
35868630,Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.,2023-Feb-14,,,
35858533,Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study.,2022,Reichert; Thiebach,"Medizinische Studiengesellschaft Nord-West GmbH, Westerstede, Germany.; Roche Pharma AG, Grenzach-Wyhlen, Germany.",
35857577,Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility.,2022-Jul-15,White,"UCB Pharma, Slough SL1 3WE, UK.",
35856239,Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.,2022-Aug,Parreira,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
35852793,Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.,2022-Sep-15,Turpuseema; Purdom; Paskalis; Miskin; Sportelli,"TG Therapeutics, Inc., New York, New York.; TG Therapeutics, Inc., New York, New York.; TG Therapeutics, Inc., New York, New York.; TG Therapeutics, Inc., New York, New York.; TG Therapeutics, Inc., New York, New York.",
35852004,Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.,2023-Jan,Casadebaig; Fox; Kilavuz; Rettby; Dell'Aringa; Taningco; Delarue; Czuczman,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",
35841410,"RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.",2022-Aug,,,nakagawa@med.kindai.ac.jp.
35835137,"Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.",2022-Aug,Llorin-Sangalang; Li,"MEI Pharma, San Diego, CA, USA.; MEI Pharma, San Diego, CA, USA.",zeleneta@mskcc.org.
35820242,Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer.,2022-Sep,,,fjros@vhio.net.
35819310,Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.,2022-Sep,Hoever,"Novartis Pharma AG, Basel, Switzerland.",
35816951,A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).,2022-Aug,Cornfeld; Tian; Catlett; Smith,"Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.",Sheela.Rao@rmh.nhs.uk.
35811461,Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.,2022-Sep-15,,,
35810754,"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.",2022-Aug,,,constantine.tam@alfred.org.au.
35803286,"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.",2022-Aug,Kuruvilla,"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.",nbartlet@wustl.edu.
35798536,Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.,2022-Jul,,,georgina.long@sydney.edu.au.
35794623,"Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.",2022-Jul-07,Laghouati,"Unité Fonctionnelle de Pharmacovigilance, Villejuif, France.",aurelien.marabelle@gustaveroussy.fr.
35793872,Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.,2022-Jul,,,matteo.carlino@sydney.edu.au.
35793409,Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.,2022-Aug-23,Kanhai; Martin,"Medical Affairs, EUSA Pharma, Hemel Hempstead, United Kingdom; and.; Medical Affairs, EUSA Pharma, Hemel Hempstead, United Kingdom; and.",
35789270,Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.,2022-Dec-08,Izquierdo,"Novartis Pharma AG, Basel, Switzerland.",
35779095,Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.,2023-Jan,,,ocearbhr@mskcc.org.
35777186,Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.,2022-Aug,Yao; Jin; Norwood; Hansen,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Princess Margaret Cancer Centre, Toronto, ON, Canada.",Caroline.EVEN@gustaveroussy.fr.
35773363,A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.,2022-Jun-30,Thai; Zavodovskaya; Liu,"Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.",kensei.yamaguchi@jfcr.or.jp.
35768976,Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study.,2022-Aug,Tajima; Kajihara,"Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.; Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.",
35764271,Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.,2022-Oct,Hill; Abdullaev; Memaj; Lei; Dixon,"Medical Oncology, Tasman Oncology Research, Ltd., Southport, Australia.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA.; Oncology Medical Affairs, Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, USA.; Clinical Biomarkers, Translational Medicine, Bristol Myers Squibb, Princeton, USA.; Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, USA.",thierry.andre@aphp.fr.
35763708,Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.,2023-Jan-20,,,
35761123,Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).,2022-Nov,,,japariciou@seom.org.
35759134,A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors.,2022-Oct,Rosales; Arozullah,"Astellas Pharma US, Inc, Northbrook, IL, USA.; Astellas Pharma US, Inc, Northbrook, IL, USA.",nadra@iu.edu.
35749909,Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.,2022-Sep,Mancao,"Oncology Biomarker Development, Genentech Inc., Basel, Switzerland.",lenz@usc.edu.
35746830,"The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.",2022-Oct,Hakimi; Desgraz,"Apellis Pharmaceuticals, Zug, Switzerland.; Apellis Pharmaceuticals, Zug, Switzerland.",
35737383,Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.,2022-Aug-01,Hiegl,"AIO Studien gGmbH Berlin, Germany.",
35734924,"A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.",2022-Nov-01,Fu; Rüter; Burkard; Osswald,"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.",Rami.Komrokji@moffitt.org.
35728876,Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex.,2022-Jun,Izquierdo,"Novartis Pharma AG, Basel, Switzerland.",P.Bouti@sanquin.nl.
35728875,Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with ,2022-Jun,Brase; Gasal; Garrett; Savchenko; Görgün,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.",htawbi@mdanderson.org.
35728379,"Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).",2022-Aug,,,yukinori.ozaki@jfcr.or.jp.
35717989,"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.",2022-Jun-18,,,manali.kamdar@cuanschutz.edu.
35716907,"Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.",2022-Sep,,,Georgina.long@sydney.edu.au.
35714310,"Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).",2022-Aug-15,,,
35710293,"Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.",2022-Jun,,,thomas.marron@mountsinai.org.
35708885,Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.,2022-Aug,Samineni; Wang; Vadhavkar; Rajwanshi; Tandon; Sinha; Salem; Li; Miles,"Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA. samineni.divya@gene.com.; Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.; Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.; VRAY Pharma Consulting, Cupertino, CA, USA.; Roche Products Ltd, Welwyn Garden City, UK.; Roche Products Ltd, Welwyn Garden City, UK.; AbbVie Inc., North Chicago, IL, USA.; Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.; Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.",samineni.divya@gene.com.
35705348,Emotional and physical experiences of people with neovascular age-related macular degeneration during the injection process in Germany: a qualitative study.,2022-Jun-15,,,anne.thier@mhb-fontane.de.
35705312,Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.,2022-Jun,,,lillian.siu@uhn.ca.
35699077,Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.,2022-Aug,Quinson; Crossley; Luecke,"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA.; Boehringer Ingelheim Ltd, Bracknell, UK.; Biostatistics + Data Science Corp., Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",
35696045,Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.,2022-Jul,Huo; Del Tejo; Du; Yang; Betts,"Worldwide Health Economics and Outcomes Research-US Market, Bristol Myers Squibb, Princeton, NJ, USA.; US Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA.; Health Economics and Outcomes Research, Analysis Group, Inc., Los Angeles, CA, USA.; Health Economics and Outcomes Research, Analysis Group, Inc., Los Angeles, CA, USA.; Health Economics and Outcomes Research, Analysis Group, Inc., Los Angeles, CA, USA.",bradley_mcgregor@dfci.harvard.edu.
35690498,OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.,2022-Aug,,,melissa.hardesty@akwcc.com.
35690072,"Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).",2022-Jul,,,neeraj.agarwal@hci.utah.edu.
35688173,"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.",2022-Jul,Zhang; Simsek,"Department of Clinical Research, Bristol Myers Squibb, Princeton, NJ, USA.; Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.",motzerr@mskcc.org.
35688061,Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).,2022-Jun,,,y.sunakawa@marianna-u.ac.jp.
35680043,Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.,2022-Sep,Xu; Jin; Norwood,"Merck & Co., Inc., Rahway, USA.; Merck & Co., Inc., Rahway, USA.; Merck & Co., Inc., Rahway, USA.",maio@unisi.it.
35668304,First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.,2022-Oct,,,kenkato@ncc.go.jp.
35666040,Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.,2023-Jan,,,
35659704,Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.,2022-Jun-03,,,Ahmad.Tarhini@moffitt.org.
35658525,"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.",2023-Jan-20,,,
35655320,A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.,2022-Jun-02,Kakizume; Myers,"Novartis Pharma K.K, Tokyo, Japan.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",chanlam_stephen@cuhk.edu.hk.
35654691,Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF,2022-Sep,Rosé; Reichenbach,"Pierre Fabre Pharma GmbH, Freiburg, Germany.; Pierre Fabre Pharma GmbH, Freiburg, Germany.",sebastian.stintzing@charite.de.
35653981,Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.,2022-Jun,Belani; Zhang,"Pfizer Inc, New York, USA.; Pfizer Inc, New York, USA.",skopetz@mdanderson.org.
35649212,Pertuzumab Plus Trastuzumab for Treatment-Refractory ,2022-May,Narita; Yoshimoto; Namai; Asakawa; Kawakami; Gower-Page; Reyes-Rivera; Patel,"Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.; Roche Products Ltd, Welwyn, Garden City, United Kingdom.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, CA.",
35644725,The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study.,2022-Jul,,,rob@gu.se.
35643855,Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.,2022-Sep,Wang; Neuhof; Vandendries,"Oncology, Pfizer Inc, Cambridge, MA.; Hematology Program, Pfizer Pharma GmbH, Berlin, Germany.; Oncology, Pfizer Inc, Cambridge, MA.",Matthias.Stelljes@ukmuenster.de.
35640928,Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.,2022-May,Desnoyer; Naigeon; Chaput-Gras,"Faculté de Pharmacie, Université Paris-Saclay, Chatenay-Malabray, France.; Faculté de Pharmacie, Université Paris-Saclay, Chatenay-Malabray, France.; Faculté de Pharmacie, Université Paris-Saclay, Chatenay-Malabray, France.",CHAPUT-GRAS.Nathalie@gustaveroussy.fr.
35637412,Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.,2022-Sep,Stintzing; Modest; Kiani; Kahl; Stahler; Held,"Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology, Campus Mitte, Berlin, Germany.; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology, Campus Mitte, Berlin, Germany.; Klinikum Bayreuth GmbH, Bayreuth, Germany.; Department of Hematology, Oncology and Palliative Care, Klinikum Magdeburg gGmbH, Magdeburg, Germany.; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology, Campus Mitte, Berlin, Germany.; linAssess GmbH, Leverkusen, Germany.",laura.fischer@med.uni-muenchen.de.
35636444,"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.",2022-Jul,,,chiaracremolini@gmail.com.
35618285,Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial.,2022-May,,,anaing@mdanderson.org
35613827,Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.,2022-May,,,espen.ellingsen@ultimovacs.com.
35612853,Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.,2022-May-02,Scheuer; Gupta; Hsu,"Roche Products Ltd, Welwyn Garden City, United Kingdom.; Cytel, Inc, Waltham, Massachusetts.; Cytel, Inc, Waltham, Massachusetts.",
35611499,"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.",2022-Jul,,,
35610366,Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.,2022-Sep,,,florazagouri@yahoo.co.uk.
35595632,A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC).,2022-Oct,,,fsabinocba@gmail.com.
35588692,Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.,2022-Jul,Amonkar; Norquist; Wang; Norwood,"Merck & Co., Inc., Rahway NJ, USA. Electronic address: mayur.amonkar@merck.com.; Merck & Co., Inc., Rahway NJ, USA. Electronic address: josephine_norquist@merck.com.; Merck & Co., Inc., Rahway NJ, USA. Electronic address: ruixue.wang@merck.com.; Merck & Co., Inc., Rahway NJ, USA. Electronic address: kevin.norwood@merck.com.",maio@unisi.it.
35582375,Barriers to achieving a cure in lymphoma.,2021,,,
35577503,Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.,2022-May,Watson,"A4P Ltd, Sandwich, UK.",gomez-roca.carlos@iuct-oncopole.fr.
35576957,"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.",2022-Jun,,,cbc1971@yuhs.ac.
35576956,"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.",2022-Jun,Zhang; Shi; Zhang,"Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals, Shanghai, China.",jl.cheng@163.com.
35569281,Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study.,2022-Jul,,,serge.leyvraz@charite.de.
35550060,"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.",2022-Jun,Reece; Jou; Ganetsky; Popa McKiver,"Princess Margaret Cancer Centre, Toronto, ON, Canada.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",mdimop@med.uoa.gr.
35545724,Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.,2022-Sep,Zhu; Phan,"Department of Biostatistics, Gilead Sciences, Inc., Foster City, CA, USA.; Department of Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.",joyce.oshaughnessy@usoncology.com.
35532206,Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma.,2022-Sep,,,
35507334,Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.,2022-Jun-01,,,
35503263,BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.,2022-Jun-15,,,
35493494,Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy.,2022,,,
35489363,"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.",2022-Jun,,,motzerr@mskcc.org.
35481285,Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA).,2022,,,
35471938,Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.,2022-Jun-08,,,
35470385,Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.,2022-Oct-11,Miao; Bunn; Fenton; Fanale; Puhlmann,"Kite Pharma, Santa Monica, CA.; Millennium Pharmaceuticals Inc., Cambridge, MA.; Seagen Inc., Bothell, WA.; Seagen Inc., Bothell, WA.; Seagen Inc., Bothell, WA.",
35468621,Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.,2022-Jun-28,Rueter,"Boehringer Ingelheim Pharma, Biberach, Germany.",
35466275,Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.,2022-Mar-24,,,
35462438,Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors.,2022-Jul,,,
35454826,Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.,2022-Apr-10,,,
35454825,Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab.,2022-Apr-10,,,
35453554,CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review.,2022-Mar-30,,,
35444058,Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.,2022-Apr,,,ntannir@mdanderson.org.
35442707,A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.,2022-Apr-20,Shazer; Der-Torossian,"Mirati Therapeutics Inc., San Diego, CA 92121, USA.; Mirati Therapeutics Inc., San Diego, CA 92121, USA.",
35441907,Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance.,2022-Jun,Yoshizaki; Nakao,"Safety Management Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd., 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan.; Safety Management Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd., 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan.",huemura@med.kindai.ac.jp.
35440667,First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.,2022-Jun,,,eric.vancutsem@uzleuven.be.
35439028,"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.",2022-Aug-01,Nangia; Whitaker,"Omeros Corporation, Seattle, WA.; Omeros Corporation, Seattle, WA.",
35436675,Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.,2022-Jun,,,jtaieb75@gmail.com.
35427833,Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.,2022-May,Schaaf; Waberer,"IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, Germany.; IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, Germany.",GeorgMartin.Haag@med.uni-heidelberg.de.
35427471,"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.",2022-May,,,diazl5@mskcc.org.
35420886,Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.,2022-Jun-20,,,
35418120,Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.,2022-Apr-13,,,anooka@emory.edu.
35414591,Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.,2022-Apr,Cavallo; Peng; Zhang; Baughman; Bonvini; Moore; Goldberg; Arnaldez,"MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.",charu.aggarwal@uphs.upenn.edu.
35410313,Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.,2022-Apr-11,,,miwang@mdanderson.org.
35405088,"De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.",2022-May,,,nadia.harbeck@med.uni-muenchen.de.
35405087,"Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.",2022-May,,,ss-saji@wa2.so-net.ne.jp.
35397434,"Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.",2022-Apr,Habel; Ahrens-Fath; Baumeister; Zurlo,"Glycotope GmbH, Berlin, Germany.; Glycotope GmbH, Berlin, Germany.; Glycotope GmbH, Berlin, Germany.; Glycotope GmbH, Berlin, Germany.",sebastian.ochsenreither@charite.de.
35397432,Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.,2022-Apr,,,ytomita@med.niigata-u.ac.jp.
35396315,Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.,2022-Apr-08,,,ogasawaras@chiba-u.jp.
35390339,"Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.",2022-May,,,yann.vano@aphp.fr.
35389428,Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.,2022-Jun-01,Dervin; Schulze; Darbonne; Yun,"Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.",
35388003,Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.,2022-Apr-06,,,ms.vd.heijden@nki.nl.
35383908,Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.,2022-Jun-01,McHenry; Lee; McCarthy; Ejzykowicz,"Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey.; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey.; Department of Clinical Scientists, Bristol Myers Squibb, Princeton, New Jersey.; Department of Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey.",
35379201,"Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.",2022-Apr-04,,,t.yamamoto@rad.med.tohoku.ac.jp.
35368047,"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).",2022-May,,,gm-k@gmx.de.
35367007,"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.",2022-Apr-30,Chen; Diede; Ahsan; Ibrahim,"Merck & Co, Inc., Kenilworth, NJ, USA.; Merck & Co, Inc., Kenilworth, NJ, USA.; Merck & Co, Inc., Kenilworth, NJ, USA.; Merck & Co, Inc., Kenilworth, NJ, USA.",lukejj@upmc.edu.
35366571,MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.,2022-May,,,schilling_b@ukw.de.
35364421,Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.,2022-May,Gurary; Siegel; Wang,"Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, USA. Electronic address: egurary@gmail.com.; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, USA. Electronic address: abby.siegel@merck.com.; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, USA. Electronic address: jiang.dian.wang@merck.com.",m-kudo@med.kindai.ac.jp.
35362096,"Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.",2022-Jul,,,
35361487,Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.,2022-Aug,Xu; Jin; Norwood,"Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: lei_xu2@merck.com.; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: fan.jin@merck.com.; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: kevin.norwood@merck.com.",ronnie.shapira@sheba.health.gov.il.
35357396,Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.,2022-May-01,Robertson; Adams; Theuer,"TRACON Pharmaceuticals, Inc, San Diego, California.; TRACON Pharmaceuticals, Inc, San Diego, California.; TRACON Pharmaceuticals, Inc, San Diego, California.",
35351371,SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.,2022-Jun,,,astrid.lievre@chu-rennes.fr.
35341664,Keratinocyte apoptosis was present in clinically intact skin in a patient treated with enfortumab vedotin.,2022-May,,,ynakamura-tuk@umin.ac.jp.
35332062,"IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.",2022-Mar,,,TYap@mdanderson.org.
35330715,"Intracranial Metastatic Disease: Present Challenges, Future Opportunities.",2022,,,
35322232,Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.,2022-Mar,Elimova; Kowalyszyn; Poulart; Lei; Xiao; Kondo; Li,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Instituto Multidisciplinario de Oncologia, Clinica Viedma S.A., Viedma, Argentina.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",janjigiy@mskcc.org.
35313167,Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.,2022-May,Kiermaier; Procter; Restuccia,"Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland. Electronic address: astrid.kiermaier@roche.com.; Frontier Science Scotland Ltd., Kincraig, Kingussie, UK. Electronic address: marion.procter@frontier-science.co.uk.; Hoffmann-La Roche Ltd., Basel, Switzerland. Electronic address: eleonora.restuccia@roche.com.",gelber@jimmy.harvard.edu.
35307972,"A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.",2022-Jul,,,
35307254,Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.,2022-May,,,David.PLANCHARD@gustaveroussy.fr.
35305916,Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.,2022-Jun,,,mattymo@alice.it.
35305400,Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.,2022-Apr,Bustillos; Fear; Ganta,"Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",jtabernero@vhio.net.
35304405,Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.,2022-Mar,Gupta; Yao; Han; Ammar; Papillon-Cavanagh; Saggi; McHenry; Ross-Macdonald; Wind-Rotolo,"Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.",motzerr@mskcc.org.
35299035,Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.,2022-Jun,,,f.moinard-butot@icans.eu.
35298698,"First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.",2022-Apr,,,emiliano.calvo@startmadrid.com.
35294723,Novel Approaches for the Treatment of Patients with Richter's Syndrome.,2022-Apr,,,silvia.deaglio@unito.it.
35292755,The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis.,2022-Mar-15,,,chihhsikuo@gmail.com.
35292724,A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.,2022-Apr,,,andrew.armstrong@duke.edu.
35279271,"PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.",2022-Apr,,,julie.delyon@aphp.fr.
35275706,Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.,2022-Jul-01,,,
35273100,Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.,2022-Mar,,,smorello@unisa.it
35272131,How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?,2022-Apr,,,carmen.criscitiello@ieo.it.
35267437,Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group.,2022-Feb-23,,,
35266566,Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.,2022-Jun-01,,,
35264434,Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.,2022-Mar,,,osamae_rahma@dfci.harvard.edu.
35262780,"Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.",2022-Oct,,,kanghj@snu.ac.kr.
35258987,"Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O",2022-May-10,,,
35254550,"A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer.",2022-May,Suna,"Clinical Development Planning Division, Ono Pharmaceutical Co., Ltd., Osaka, Japan.",ykodera@med.nagoya-u.ac.jp.
35247915,Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.,2022-May-13,Frattini,"Cellectis Inc., New York, New York.",
35247334,"A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.",2022-Jul,Ciulla; Gedif; Grosskreutz,"Clearside Biomedical Inc, Alpharetta, Georgia.; Biostatistician, Novartis Pharma Inc (K.G.), Basel, Switzerland.; From the Translational Medicine/Research (S.H.P., C.L.G.); Biostatistician, Novartis Pharma Inc (K.G.), Basel, Switzerland.",stephen.poor@novartis.com.
35246490,Eculizumab versus rituximab in generalised myasthenia gravis.,2022-May,Stascheit; Stascheit; Mergenthaler; Mergenthaler; Meisel; Meisel; Meisel,"Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",Tobias.Ruck@med.uni-duesseldorf.de.
35244756,Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.,2022-May,Fukushima,"Medical Affairs Department, SymBio Pharmaceutical Ltd., Research & Development Division, Tokyo, Japan.",kiguchi-t@umin.ac.jp.
35228755,Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.,2022-Apr,Takahashi; Oka; Higashi,"Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan.; Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan.; Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan.",sarah@skhighlander.us.
35226933,Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II Trial.,2022-Oct,Ibach,"Biostatistik, WiSP Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.",
35226723,"A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia.",2022-Apr-28,McNamara; Meiser; Hom; Oliver,"Novartis Pharma AG, Cambridge, MA; and.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Cambridge, MA; and.; Novartis Pharma AG, Basel, Switzerland.",
35220182,Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.,2022-Apr,,,ojk@doctors.org.uk.
35217575,Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.,2022-Feb,,,dshong@mdanderson.org.
35217573,"Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.",2022-Feb,Albright; Mogg; Ayers; Huang; Lunceford; Cristescu; Cheng,"Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.",Robert_Haddad@dfci.harvard.edu.
35210307,Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.,2022-Feb,Zhang; Johansen,"Department of Clinical Research, Bristol Myers Squibb, Princeton, New Jersey, USA.; US Medical Immunology & Fibrosis, Bristol Myers Squibb, Princeton, New Jersey, USA.",stykodi@fredhutch.org.
35202974,FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.,2022-Apr,Pauligk; Goetze; Al-Batran,"Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt, Germany.; Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt, Germany; Krankenhaus Nordwest, Frankfurt, Germany.; Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt, Germany; Krankenhaus Nordwest, Frankfurt, Germany.",sylvielorenzen@gmx.de.
35193933,ISA101 and nivolumab for HPV-16,2022-Feb,Melief,"ISA Pharmaceuticals, Leiden, The Netherlands.",mcurran@mdanderson.org.
35193932,Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.,2022-Feb,Tang; Tang; Feng; Feng; Yao; Yao,"Medical Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, China.; Medical Department, TopAlliance Biosciences, Inc, Rockville, Maryland, USA.; Medical Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, China.; Medical Department, TopAlliance Biosciences, Inc, Rockville, Maryland, USA.; Medical Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, China.; Medical Department, TopAlliance Biosciences, Inc, Rockville, Maryland, USA.",doctor_sheng@126.com
35190375,Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in ,2022-Feb,McCleland; Kim; Morris; Zou; Shames; Das Thakur; Shankar,"Genentech Inc, South San Francisco, California, USA.; Genentech Inc, South San Francisco, California, USA.; Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, California, USA.; Genentech Inc, South San Francisco, California, USA.; Genentech Inc, South San Francisco, California, USA.; Genentech Inc, South San Francisco, California, USA.",jackwestmd@gmail.com.
35182721,"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.",2022-May,,,luca.gianni@fondazionemichelangelo.org.
35182247,First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.,2022-Apr,Li; Oukessou,"Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ, USA.; Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ, USA.",Tom.John@petermac.org.
35179586,Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.,2022-Feb-01,Hurwitz,"Product Development Oncology, Genentech Inc, South San Francisco, California.",
35176136,Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.,2022-Apr-14,,,
35173725,Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.,2022,,,
35168844,Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.,2022-May,Campbell; Hepp; McKay; Steinberg,"Seagen Inc., Bothell, WA, USA.; Seagen Inc., Bothell, WA, USA.; Astellas Pharma US, Inc., Northbrook, IL, USA.; Astellas Pharma US, Inc., Northbrook, IL, USA.",matthew.galsky@mssm.edu.
35167497,Anti-CD45RC antibody immunotherapy prevents and treats experimental autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome.,2022-Apr-01,Vimond,"AbolerIS Pharma, Nantes, France.",
35158207,First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.,2022-Feb,Nathan,"Bristol Myers Squibb, Princeton, USA.",k.obyrne@qut.edu.au.
35154909,Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.,2022,Lerchen,"Vincerx Pharma GmbH, Leverkusen, Germany.",
35150296,90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.,2022-Apr,Rieger; Lerch; Peuker; Pezzutto; Keller; Scholz,"Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. kathrin.rieger@charite.de.; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.",kathrin.rieger@charite.de.
35144482,Long-term avelumab in advanced non-small-cell lung cancer: summaries and ,2022-Apr,,,
35143285,Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.,2022-Apr-01,,,
35138920,Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.,2022-Feb,Enke; Hurley; Lin; Habeck; Giordano,"Clovis Oncology Inc, Boulder, CO.; Clovis Oncology Inc, Boulder, CO.; Clovis Oncology Inc, Boulder, CO.; Clovis Oncology Inc, Boulder, CO.; Clovis Oncology Inc, Boulder, CO.",
35138529,"Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.",2022-Apr,Pemberton; Sadrolhefazi; Jin,"Boehringer Ingelheim Ltd, Bracknell, UK.; Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada.; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.",tamas.hickish@rbch.nhs.uk.
35138335,Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.,2022-Apr-01,,,
35135447,Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice.,2022,Pavitrakar; Mody,"Division of Biotechnology, Lupin Limited, Pune, India.; Division of Biotechnology, Lupin Limited, Pune, India (Currently associated with Sun Pharma Advanced Research Company Ltd., Vadodara, Gujarat, India).",
35133096,Theragnostics before we found its name.,2021-Dec,,,sergiomodoni@tin.it.
35131863,Soluble PD-L1 as an early marker of progressive disease on nivolumab.,2022-Feb,Ross-Macdonald; Song; Veras; Wind-Rotolo,"Bristol-Myers Squibb Co, Princeton, New Jersey, USA.; Quanterix Corporation, Billerica, Massachusetts, USA.; Quanterix Corporation, Billerica, Massachusetts, USA.; Bristol-Myers Squibb Co, Princeton, New Jersey, USA.",kmmah5@bidmc.harvard.edu.
35131452,Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF,2022-May,Eigentler; Caro; Shah; Yan,"Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Genentech, Inc., South San Francisco, USA.; Genentech, Inc., South San Francisco, USA.; Genentech, Inc., South San Francisco, USA.",caroline.robert@gustaveroussy.fr.
35124183,First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.,2022-May,Zhang; Hu; Balli; Spires,"Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA.; Biostatistics, Bristol Myers Squibb, Princeton, USA.; Translational Medicine, Bristol Myers Squibb, Princeton, USA.; Department of Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, USA.",solange.peters@chuv.ch.
35118423,Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.,2021-Aug,,,
35114169,"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.",2022-May,,,aurelien.marabelle@gustaveroussy.fr.
35108059,Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.,2022-Apr-20,,,
35105689,Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).,2022-Feb,,,setocruise@gmail.com.
35090381,Structural and functional characterization of a monoclonal antibody blocking TIGIT.,2022,Oh; Lee; Choi; Yang,"Department of Research and Early Development, Gc Pharma, Gyeonggi-do, Republic of Korea.; Department of Research and Early Development, Gc Pharma, Gyeonggi-do, Republic of Korea.; Department of Research and Early Development, Gc Pharma, Gyeonggi-do, Republic of Korea.; Department of Research and Early Development, Gc Pharma, Gyeonggi-do, Republic of Korea.",
35089812,"Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.",2022-Apr-20,,,
35089239,Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava.,2022-Jan-28,,,
35086949,Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.,2022-Jan,Polaske; Fields,"Adaptive Biotechnologies Corp, Seattle, Washington, USA.; Adaptive Biotechnologies Corp, Seattle, Washington, USA.",david.page2@providence.org.
35081747,Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.,2022-Apr,Kubisch,"Department of Internal Medicine II, Gastroenterology, Hepatology, Endocrinology, Metabolic Disorders, Oncology, Klinikum Chemnitz gGmbH, Chemnitz, 09116, Germany.",
35078922,Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.,2022-Jan,,,Olivier.Michielin@chuv.ch.
35078146,Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.,2022-Apr,,,mmargeli@iconcologia.net.
35074903,Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.,2022-Jan,Chen,"Personalis Inc, Menlo Park, California, USA.",friedmac@mskcc.org.
35074072,"Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.",2022-Mar,,,miwang@mdanderson.org.
35073148,"Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring ",2022-Mar-01,,,
35072477,Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.,2022-Mar-25,Singh,"SBS Pharma Consulting LLC, Edison, New Jersey 08820, United States.",
35065058,"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.",2022-Mar,Fiaschi; Gupta; Deering; Wang; Wang; Thanigaimani; Mani; Kou; Li; Jankovic; James; Hamon; Cheung; Sims; Miller; Thurston; Lowy,"Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.",thomas.marron@mssm.edu.
35065057,"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.",2022-Mar,,,akaseb@mdanderson.org.
35064011,"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.",2022-Jan,,,aoaknin@vhio.net.
35063943,Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group.,2022-Jun-06,,,ignace.vergote@uz.kuleuven.ac.be.
35063776,Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.,2022-Mar,,,capucine.baldini@gustaveroussy.fr.
35058326,"Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.",2022-Jan,Lépine,"Pharmacokinetics, Excelya on behalf of Sanofi, Alfortville, France.",Johann.de-Bono@icr.ac.uk.
35050711,,2022-Jan,,,
35050320,Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.,2022-Mar-01,Goldmacher,"Merck & Co, Inc, Kenilworth, New Jersey.",
35047671,Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review.,2022,,,
35044810,CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.,2022-Apr-20,,,
35042068,"Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.",2022-Mar,Banna,"(1)Department of Oncology, Ospedale Cannizzaro, 95126 Catania, Province of Catania, Italy. Electronic address: giuseppe.banna@nhs.net.",guruP_Sonpavde@dfci.harvard.edu.
35033994,Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.,2022-Mar,,,demetris.papamichael@bococ.org.cy.
35033226,"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.",2022-Feb,,,Jonathan_Schoenfeld@dfci.harvard.edu.
35032437,"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.",2022-Feb,Blum; Ejzykowicz; Hamilton; Simsek; Zhang,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",d-cella@northwestern.edu.
35030335,"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.",2022-Feb,Takeuchi; Hirashima; Hagihara,"Department of Oncology Clinical Development Planning, Ono Pharmaceutical, Osaka, Japan.; Department of Oncology Clinical Development Planning, Ono Pharmaceutical, Osaka, Japan.; Department of Statistical Analysis, Ono Pharmaceutical, Osaka, Japan.",nboku@ncc.go.jp.
35030036,"Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.",2022-Apr-10,Terol,"Institut d'Investigació Sanitària (INCLIVA), Valencia, Spain.",
35030011,Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for ,2022-May-01,Brase; Green; Haas; Masood; Gasal,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",
35026412,"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.",2022-Apr,Fagniez,"Pharmacokinetics, Dynamics and Metabolism, Sanofi, Chilly-Mazarin, France.",Anas.gazzah@gustaveroussy.fr.
35017151,Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.,2022-Jan,,,hourigan@nih.gov.
35012608,Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.,2022-Jan-10,Carnevali-Ruiz; Carnevali-Ruiz; Carnevali-Ruiz; Fernández-Sousa; Luepke-Estefan; López-Martín; Jimeno,"Pharmamar, Colmenar Viejo, Madrid, Spain.; Pharma Mar. S.A., Colmenar Viejo, Madrid, Spain.; Virology and Inflammation Unit, Pharma Mar, S.A., Colmenar Viejo, Madrid, Spain.; Pharmamar, Colmenar Viejo, Madrid, Spain.; Pharma Mar. S.A., Colmenar Viejo, Madrid, Spain.; Virology and Inflammation Unit, Pharma Mar, S.A., Colmenar Viejo, Madrid, Spain.; Virology and Inflammation Unit, Pharma Mar, S.A., Colmenar Viejo, Madrid, Spain.",Pablo.guisado@quironsalud.es.
35012605,Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.,2022-Jan-10,,,andrew.west@duke.edu.
35012477,Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.,2022-Jan-10,,,lu.weiss@salk.at.
35006344,The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy.,2022-Nov,,,t.gambichler@klinikum-bochum.de.
34990208,Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.,2022-Mar-01,Hansen; Xu; Jin; Norwood,"Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.",
34989133,Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.,2022-Feb,,,
34987165,Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.,2022-Jan-05,,,Wang.Yucai@mayo.edu.
34986342,Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.,2022-Jan-11,,,peter_shaw3@merck.com.
34980789,Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma.,2022-Mar-09,,,
34980131,On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.,2022-Jan-03,Zhang; Zhang; Yang; Shi; Zou,"Genecast Biotechnology Co., Ltd., Wuxi City, China.; Genecast Biotechnology Co., Ltd., Wuxi City, China.; Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.; Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.; Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.",caicunzhou_dr@163.com.
34976826,Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice.,2021,,,
34974985,Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.,2022-Apr,,,jad.chahoud@moffitt.org.
34974527,Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.,2022-Apr,,,thierry.facon@chru-lille.fr.
34974526,Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.,2022-Apr,,,Jeff.Sharman@USONCOLOGY.COM.
34973513,Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.,2022-Feb,,,yanshuo.cao@icloud.com.
34973512,Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma.,2022-Feb,Rosales,"MacroGenics Inc., Rockville, USA.",dcatenac@bsd.uchicago.edu.
34973108,Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.,2022-Feb,,,ytomita@med.niigata-u.ac.jp.
34970853,Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia.,2022-Feb,,,
34959152,Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.,2022-Feb,,,okamotoi@kokyu.med.kyushu-u.ac.jp.
34954044,Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.,2022-Mar,Ramos; Feng,"Seagen Inc., Bothell, USA.; Seagen Inc., Bothell, USA.",giuseppe.curigliano@ieo.it.
34953398,IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.,2022-Feb,,,nicolas.girard2@curie.fr.
34952708,"Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.",2022-Feb,,,P.Harter@kem-med.com.
34949112,The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis.,2022-Jan,,,
34940094,Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.,2021-Dec-20,Bene-Tchaleu; Zhu; Zhang; Cha,"Hoffmann-La Roche Ltd., Mississauga, ON L5N 5M8, Canada.; Genentech, Inc., South San Francisco, CA 94080, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.",
34936940,Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.,2022-Feb,,,mshirasa@ncc.go.jp.
34932394,Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.,2022-Mar-01,Ortuzar Feliu; Ancukiewicz,"Agenus Inc, Waltham, MA.; Agenus Inc, Waltham, MA.",
34928709,"Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).",2022-Apr-01,,,
34928484,"RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.",2022-Jan,,,esnadal@iconcologia.net.
34921960,"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.",2022-Mar,Miao; Bunn; Fenton; Fanale; Puhlmann,"Millennium Pharmaceuticals, Inc, Cambridge, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.; Millennium Pharmaceuticals, Inc, Cambridge, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.; Seagen Inc., Bothell, USA.; Seagen Inc., Bothell, USA.; Seagen Inc., Bothell, USA.",horwitzs@mskcc.org.
34921525,What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.,2022-Jan,Wang,"Novartis Pharma AG, Basel, Switzerland.",
34920291,"Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.",2022-Feb,Ahrens-Fath; Baumeister; Zurlo,"Glycotope GmbH, Berlin, Germany.; Glycotope GmbH, Berlin, Germany.; Glycotope GmbH, Berlin, Germany.",j.ledermann@ucl.ac.uk.
34916725,"Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.",2021-Nov,,,
34914889,"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.",2022-Jan,Schott; Begic; Chen; Neely; Wisniewski; Tschaika,"Helios Klinikum Emil von Behring GmbH, Klinik für Innere Medizin II, Berlin, Germany.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",the@netvigator.com.
34907192,Depletion of central memory CD8,2021-Dec-14,,,hwada@gesurg.med.osaka-u.ac.jp.
34903842,"First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.",2022-Apr,,,d.robbrecht@erasmusmc.nl.
34902530,Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.,2022-Apr,Verret; Ma; Nicholas,"Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.; Product Development Safety, Genentech, Inc., South San Francisco, CA, USA.; Product Development Biostatistics, Genentech, Inc., South San Francisco, CA, USA.",alcheng@ntu.edu.tw.
34896698,Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.,2021-Dec,Gollerkeri; Maharry; Christy-Bittel,"Pfizer Inc, New York, USA.; Pfizer Inc, New York, USA.; Pfizer Inc, New York, USA.",jtabernero@vhio.net.
34893525,"Correspondence on ""G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment"" by Martinez Sanz ",2021-Dec,,,jaume.mora@sjd.es.
34893523,"Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.",2021-Dec,Elboudwarej; Lin; Turner; Zavodovskaya; Inzunza; Liu; Patterson; Zhou; He; Thai; Bhargava; Brachmann,"Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Gilead Sciences, Inc, Foster City, California, USA.",mas9313@med.cornell.edu.
34890214,Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.,2022-Feb-10,Shah; Liu; Trask; Song,"Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",
34871104,Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.,2022-Feb-01,Gillies,"Provenance Biopharmaceuticals, Carlisle, MA.",
34854276,"A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.",2022-Mar-01,Burkard; Osswald; James; Rüter,"Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß.; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß.; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.",william.g.blum@emory.edu.
34843940,Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.,2022-Feb,,,hidet31@med.kindai.ac.jp.
34843570,Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.,2021,,,
34839016,A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.,2022-Feb,,,Rolf.Stahel@etop-eu.org.
34838186,Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.,2022-Jan-10,,,amit.verma@einsteinmed.org.
34834447,Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas.,2021-Oct-26,,,
34826411,"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.",2021-Dec,Jacob,"Adaptive Biotechnologies, Seattle, WA, USA.",zeleneta@mskcc.org.
34818112,Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.,2022-Jan-10,Butler; Bas; Ritchings,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
34816585,The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.,2022-Jun,,,
34815354,"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study.",2021-Nov,,,sara.lonardi@iov.veneto.it.
34810120,Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors.,2022-May,,,dkontoyi@mdanderson.org.
34804027,"Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?",2021,,,
34801354,KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.,2022-Jan,Ghori; Diede; Croydon,"Department of Clinical Oncology, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: razi.ghori@merck.com.; Department of Clinical Oncology, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: scott.diede@merck.com.; Department of Clinical Oncology, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: escroydon@gmail.com.",maio@unisi.it.
34800678,"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer",2022-Feb,Chartash; Lala; Chen; Healy,"Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.; OED-QP2IO, Merck & Co., Inc., Kenilworth, NJ, USA.; BARDS, Merck & Co., Inc., Kenilworth, NJ, USA.; Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.",jiaxin.niu@bannerhealth.com.
34799418,"Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.",2022-Jan,McKenzie; Lee,"Eisai Inc, Woodcliff Lake, New Jersey, USA.; Merck & Co Inc, Kenilworth, New Jersey, USA.",Christian.marth@tirol-kliniken.at.
34799400,Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.,2021-Nov,Stwalley; Moshyk; Ritchings; Re,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",mregan@jimmy.harvard.edu.
34798201,Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.,2022-Apr,Yang; Papp,"Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania.; K Papp Clinical Research and Probity Research, Inc, Waterloo, Ontario, Canada.",ablauvelt@oregonmedicalresearch.com.
34797699,Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.,2022-Jan-10,,,
34794412,"The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.",2021-Nov-18,,,gds35@cam.ac.uk.
34793719,"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.",2021-Dec,,,srandolph@alxoncology.com.
34791816,Radiation recall pneumonitis after COVID-19 vaccination.,2022-Jan,,,
34788412,Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?,2022-Jul-06,Klein,"Cancer Immunotherapy Discovery, Oncology Discovery & Translational AreaRoche Pharma Research & Early Development, Roche Innovation Center, Zurich, Switzerland.",
34784056,Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.,2022-Mar-01,Zhang; Johansen; Leung,"Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.",
34778995,Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.,2022-Jan-01,,,
34774462,Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.,2022-Apr,,,lrosinol@clinic.cat.
34774225,"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.",2021-Dec,Ritchings; Durani; Askelson,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",HTawbi@mdanderson.org.
34764486,Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.,2021-Nov,Asakawa,"Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.",tyoshino@east.ncc.go.jp.
34743703,Contextual reprogramming of CAR-T cells for treatment of HER2,2021-Nov-07,Yang; Li; Turkoz; Chen; Harari-Steinfeld; Bobbin; Stefanson; Choi; Pietrobon; Alphson; Goswami; Balan; Kearney; Patel; Yang; Inel; Vinod; Cesano; Wang; Marincola; Marincola,"Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; ESSA Pharma, South San Francisco, CA, 94080, USA.; ESSA Pharma, South San Francisco, CA, 94080, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA.; Refuge Biotechnologies Inc., Menlo Park, CA, 94025, USA. francesco.marincola1@gilead.com.; Gilead/Kite, Santa Monica, CA, 90404, USA. francesco.marincola1@gilead.com.",stanley.qi@stanford.edu.
34741023,Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2,2021-Nov-05,,,Amy.Clark@pennmedicine.upenn.edu.
34737281,Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.,2021-Nov-04,,,padsharma@mdanderson.org.
34736925,,2022-Jan,,,e.g.e.de.vries@umcg.nl.
34732857,"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.",2022-Mar,,,k.weisel@uke.de.
34730989,Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.,2022-Feb-01,Kulkarni; Norquist; Amonkar; Suryawanshi; Bhagia,"Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.",
34728668,Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.,2021-Nov-02,,,p92c9f20@s.okayama-u.ac.jp.
34715820,Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.,2021-Oct-29,,,nboku@ims.u-tokyo.ac.jp.
34715028,Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.,2021-Nov-08,,,s.quezada@ucl.ac.uk.
34714110,"Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.",2021-Nov,Shapouri; Manzoor; Ravelo; Sail,"Genentech Inc., South San Francisco, CA.; AbbVie Inc., North Chicago, IL.; Genentech Inc., South San Francisco, CA.; AbbVie Inc., North Chicago, IL.",
34710571,Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.,2022-Feb,Jensen; Leiby; Ibrahim,"Merck & Co., Inc., Kenilworth, NJ, USA.; Merck & Co., Inc., Kenilworth, NJ, USA.; Merck & Co., Inc., Kenilworth, NJ, USA.",georgina.long@sydney.edu.au.
34709929,Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.,2021-Dec-20,Panchal; Ching; Tandon; Chyla,"Roche Products Ltd, Welwyn Garden City, United Kingdom.; Adaptive Biotechnologies Corp, Seattle, WA.; Roche Products Ltd, Welwyn Garden City, United Kingdom.; AbbVie Inc, Chicago, IL.",
34709880,Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.,2022-Mar-01,,,
34698902,"4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.",2022-Jan,,,zhengrong.cui@austin.utexas.edu.
34694529,Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.,2021-Nov,Wang; Forgie; Bonato; Jacobs; Chou,"Pfizer Inc., San Francisco, CA, USA.; Pfizer Inc., San Francisco, CA, USA.; Pfizer Inc., San Diego, CA, USA.; Pfizer Inc., New York, NY, USA.; Pfizer Inc., San Francisco, CA, USA.",Siwen.Hu-Lieskovan@hci.utah.edu.
34689001,Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.,2021-Dec,,,chiaracremolini@gmail.com.
34687602,Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.,2021-Dec,,,hkantarjian@mdanderson.org.
34676147,Trial watch: intratumoral immunotherapy.,2021,,,
34675925,Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.,2021,,,
34671037,COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.,2021-Oct-20,,,r.w.sanders@amsterdamumc.nl.
34670169,Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.,2022-Jan,,,Reid_merryman@dfci.harvard.edu.
34663807,Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.,2021-Oct-18,,,KRai@mdanderson.org.
34663640,Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.,2021-Oct,Zhou,"Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd., Beijing, China, an affiliate of Merck KGaA, Beijing, China.",joel.guigay@nice.unicancer.fr.
34663559,Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.,2021-Nov,Kotapati; Moshyk,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",jeffrey.weber@nyulangone.org.
34663250,Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).,2021-Oct-18,,,h.kenmotsu@scchr.jp.
34655533,"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.",2021-Nov,,,thierry.facon@chru-lille.fr.
34654806,Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.,2021-Oct-15,,,zhiwei@njit.edu.
34650833,"An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.",2021,,,
34648895,Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.,2022-Feb,Hucke; Peck-Radosavljevic,"Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology and Nephrology including Centralized Emergency Department (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.; Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology and Nephrology including Centralized Emergency Department (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.",matthias.pinter@meduniwien.ac.at.
34643650,Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial.,2021-Nov-01,Byron; Barry,"Rho Inc, Durham, North Carolina.; Rho Inc, Durham, North Carolina.",
34642329,Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.,2021-Oct-12,,,pbrastianos@mgh.harvard.edu.
34637336,First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.,2022-Jan-10,Abdullaev; Gricar; Ledeine,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
34633575,Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.,2022-Apr,,,a.ono@scchr.jp.
34632569,Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.,2022-Feb,Matsutani,"Osaka laboratory, Repertoire Genesis Incorporation, Ibaraki, Osaka, Japan.",
34627664,The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.,2021-Nov,Goldschmidt; Messayke; Voisin; Laghouati,"Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, F-94800, Villejuif, France. Electronic address: vincent.goldschmidt@gustaveroussy.fr.; Gustave Roussy, Université Paris-Saclay, Unité de Pharmacovigilance, F-94800, Villejuif, France. Electronic address: sabine.messayke@gustaveroussy.fr.; Gustave Roussy, Université Paris-Saclay, Unité de Pharmacovigilance, F-94800, Villejuif, France. Electronic address: alvoisin@hotmail.fr.; Gustave Roussy, Université Paris-Saclay, Unité de Pharmacovigilance, F-94800, Villejuif, France. Electronic address: salim.laghouati@gustaveroussy.fr.",valentine.ruste@live.fr.
34626024,"Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.",2021-Dec,Mann; Garcia-Guzman; Biel,"Department of Clinical Development, Rakuten Medical, Inc, San Mateo, California, USA.; Department of Translational Sciences, Rakuten Medical, Inc, San Diego, California, USA.; Department of Clinical Development, Rakuten Medical, Inc, San Mateo, California, USA.",
34615719,A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.,2022-Jan-01,Couillebault; Guerreiro; Sand-Dejmek,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",s.kuemmel@kem-med.com.
34612846,Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.,2022-Mar-01,Qamra; Summers; Stubbings,"Hoffmann-La Roche Ltd, Mississauga, ON, Canada.; Roche Products Ltd, Welwyn Garden City, United Kingdom.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
34609773,"Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.",2021-Dec,Xiong; Ocampo,"AbbVie Inc., North Chicago, Illinois, USA.; AbbVie Inc., North Chicago, Illinois, USA.",
34609549,Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.,2021-Nov,Gordon; Graham,"Roche Products Ltd, Welwyn Garden City, UK.; Roche Products Ltd, Welwyn Garden City, UK.",ivan.rosas@bcm.edu.
34607519,"A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects.",2022-Feb,Xu; Xue,"Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co.,Ltd, Jiangsu, China.; Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co.,Ltd, Jiangsu, China.",
34607285,First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.,2021-Oct,Memaj; Marimuthu; Zhang; Tran,"Bristol Myers Squibb, Princeton, USA.; Bristol Myers Squibb, Princeton, USA.; Bristol Myers Squibb, Princeton, USA.; Bristol Myers Squibb, Princeton, USA.",m.reck@lungenclinic.de.
34606378,Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.,2022-Jan-01,Ping; Hauns; Arango-Hisijara,"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.",
34599023,Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.,2021-Oct,Diaz-Mejia; Torti; Bruce; Wang; Fortuna; Pugh; Tin; Feeney; Sethi; Aleshin,"Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.",lillian.siu@uhn.ca.
34597975,"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.",2021-Nov,,,ignace.vergote@uzleuven.be.
34593618,Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.,2021-Sep,,,dengl@mskcc.org.
34593617,Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.,2021-Sep,,,ab5147@cumc.columbia.edu
34593565,"ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.",2021-Dec,Lin; Shih; Goble; Grechko; Hume; Maloney,"Molecular Diagnostics, Clovis Oncology, Inc, Boulder, Colorado, USA.; Clinical Operations, Clovis Oncology, Inc, Boulder, Colorado, USA.; Biostatistics, Clovis Oncology, Inc, Boulder, Colorado, USA.; Clinical Development, Clovis Oncology, Ltd, Cambridge, Cambridgeshire, UK.; Clinical Development, Clovis Oncology, Inc, Boulder, Colorado, USA.; Clinical Development, Clovis Oncology, Inc, Boulder, Colorado, USA.",bradley.monk@usoncology.com.
34592180,"Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.",2021-Oct,,,juan.valle@manchester.ac.uk.
34591237,Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181.,2022-Jan,Bhagia,"Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.",kmuro@aichi-cc.jp.
34586548,"Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study.",2021-Dec,Hirata; Hagihara,"Oncology Early Clinical Development Planning, Ono Pharmaceutical Co., Ltd, Osaka, Japan.; Department of Statistical Analysis, Ono Pharmaceutical Co., Ltd, Osaka, Japan.",totorolangdom@yahoo.co.jp.
34582105,Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).,2022-Jan,Bernaards; Ballinger; Bruno; Quarmby; Ruppel; Vilimovskij; Wu; Sternheim,"Product Development Biometrics, Genentech, Inc, South San Francisco, California, USA.; Product Development Oncology, Genentech, Inc, South San Francisco, California, USA.; Clinical Pharmacology, Genentech-Roche, Marseille, France.; BioAnalytical Sciences, Genentech Inc, South San Francisco, California, USA.; BioAnalytical Sciences, Genentech Inc, South San Francisco, California, USA.; Product Development Safety, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Department of Clinical Pharmacology, Genentech Inc, South San Francisco, California, USA.; Product Development Regulatory, Genentech Inc, South San Francisco, California, USA.",
34581902,Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.,2022-Jan,Tanaka; Akamatsu,"Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd, Osaka, Japan.; Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd, Osaka, Japan.",kensei.yamaguchi@jfcr.or.jp.
34581757,Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.,2021-Nov-23,Bournazou; Labriola-Tompkins; Franjkovic; Chesne; Brouwer-Visser; Lechner; Brennan; Nüesch; DeMario; Rüttinger; Kornacker,"Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.",
34581197,"CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.",2021-Dec,Purdum,"Kite Pharma, A Gilead Company, Santa Monica, CA 90404, USA.",
34579528,Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.,2021-Nov-01,Matsuda; Matsuda; Seki; Yamada; Ooba; Takahashi; Fujii; Kawaguchi; Narita; Nakayama; Kitahara; Mendelsohn; Okuzumi,"Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Bio-Pharma Services, 11040 Roselle Street, San Diego, California 92121, United States.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.; Ajinomoto Bio-Pharma Services, 11040 Roselle Street, San Diego, California 92121, United States.; Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.",
34571336,Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.,2021-Nov,Jensen; Diede; Moreno,"Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: erin_jensen2@merck.com.; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: scott.diede@merck.com.; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: blanca.homet.moreno@merck.com.",ohamid@theangelesclinic.org.
34570655,"Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.",2021-Nov-20,Zsíros,"Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.",
34562610,Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.,2022-Jan,,,Rolf.Stahel@etop-eu.org.
34555333,"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.",2021-Oct-09,,,efelip@vhio.net.
34543717,Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.,2021-Dec,Topp; Thiagarajan; De Alwis; Snyder,"Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA. Electronic address: brian.topp@merck.com.; Quantitative Systems Pharmacology, Vantage Research, Chennai, India.; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.; Global Clinical Development, Merck & Co., Inc., Kenilworth, USA.",brian.topp@merck.com.
34542573,Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.,2021-Nov-01,,,
34541620,Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance.,2021-Nov,van Noesel,"Department of Solid Tumors, Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. M.M.vanNoesel@prinsesmaximacentrum.nl.",M.M.vanNoesel@prinsesmaximacentrum.nl.
34534514,"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.",2021-Oct,,,matthew_davids@dfci.harvard.edu.
34533973,Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in ,2022-Jan-01,Graeven,"Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.",
34531249,"Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.",2021-Sep,,,johnliao@uw.edu.
34522051,Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.,2021-Nov,,,wherry@pennmedicine.upenn.edu.
34506214,"Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?",2021-Nov-10,Tanaka; Shimomura; Terakado; Shimizu,"Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.",
34501388,Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group.,2021-Aug-31,,,
34498507,Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.,2022-Mar,Shang; Yountz; Miller; Armstrong,"Alexion Pharmaceuticals, Boston, MA, USA.; Alexion Pharmaceuticals, Boston, MA, USA.; Alexion Pharmaceuticals, Boston, MA, USA.; Alexion Pharmaceuticals, Boston, MA, USA/Rallybio, New Haven, CT, USA.",
34491815,Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.,2021-Nov-20,Dubey; Werneke; Panneerselvam; Curran; Scheffold,"Genentech, Inc, South San Francisco, CA.; Exelixis, Inc, Alameda, CA.; Exelixis, Inc, Alameda, CA.; Exelixis, Inc, Alameda, CA.; Exelixis, Inc, Alameda, CA.",
34488065,First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.,2021-Dec,Grafe; Tomé; Sommer-Joos,"MVZ Nordhausen gGmbh, Praxis Dr Grafe/Brustzentrum der Frauenklinik, Südharz-Klinikum Nordhausen gGmbh, Nordhausen, Germany. Electronic address: andrea.grafe@shk-ndh.de.; St. Vincentius-Kliniken gAG, Karlsruhe, Germany. Electronic address: oliver.tome@vincentius-ka.de.; Roche Pharma AG, Grenzach-Wyhlen, Germany. Electronic address: ann-katrin.sommer@roche.com.",v.mueller@uke.de.
34484202,Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?,2021,Ragsdale,"Medical Affairs, Partner Therapeutics, Inc., Lexington, MA, United States.",
34482179,A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.,2021-Oct,Ahrens-Fath; Dietrich; Baumeister; Zurlo,"Glycotope GmbH, Berlin, Germany.; Glycotope GmbH, Berlin, Germany.; Glycotope GmbH, Berlin, Germany.; Glycotope GmbH, Berlin, Germany.",Konrad.klinghammer@charite.de.
34479034,Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.,2021-Oct,,,David.PLANCHARD@gustaveroussy.fr.
34478664,"Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply.",2021-Sep,,,arjun.balar@nyulangone.org.
34478663,"Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer.",2021-Sep,,,cyrill.rentsch@usb.ch.
34478166,JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.,2022-Jan-01,,,
34477818,Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.,2021-Sep-14,Huang,"Pfizer Inc, Groton, CT; and.",
34477816,Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.,2021-Sep-14,Lee; Kim; Ahn,"Celltrion, Inc., Incheon, South Korea; and.; Celltrion, Inc., Incheon, South Korea; and.; Celltrion, Inc., Incheon, South Korea; and.",
34475514,On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation.,2021-Sep-02,Peters; Rowley; Turner; Humphreys,"UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.",msc@soton.ac.uk.
34473544,"Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).",2021-Nov-20,Takazawa; Takahashi; Namba,"Data Science, Ono Pharmaceutical Co, Ltd, Osaka, Japan.; Oncology Clinical Development Unit, Ono Pharmaceutical Co, Ltd, Osaka, Japan.; Clinical Science, Ono Pharmaceutical Co, Ltd, Osaka, Japan.",
34470722,"Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction.",2022-May,,,michele.milella@univr.it.
34468869,Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.,2022-Jan,Bhagia; Wang; Shih,"Department of Medical Oncology, Merck & Co., Inc, Kenilworth, NJ, USA.; Department of Biostatistics and Research Decision Science, Merck & Co., Inc, Kenilworth, NJ, USA.; Department of Medical Oncology, Merck & Co., Inc, Kenilworth, NJ, USA.",Charles.S.Fuchs@gmail.com.
34465600,Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.,2021-Nov-15,Wang,"Novartis Pharma AG, Basel, Switzerland.",david.rimm@yale.edu.
34458977,Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.,2022-Jan,Stankovic; Maier,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",
34456145,Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.,2022-May,Bene-Tchaleu; Zhu; Zhang; Cha,"F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",DeWong@mednet.ucla.edu.
34454674,"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.",2021-Aug-28,,,jongmu.sun@skku.edu.
34454653,"Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.",2022-Jan,,,maemondo-ma693@aioros.ocn.ne.jp.
34452930,Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.,2021-Aug,Schenker; Hill; de Pril; Lobo,"Oncology Center Sf Nectarie Ltd, Craiova, Romania.; Tasman Oncology Research Ltd, Southport, Queensland, Australia.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",Jeffrey.Weber@nyulangone.org.
34452793,Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.,2021-Nov,Voisin,"Unité Fonctionnelle de Pharmacovigilance, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France.",mramos@clinic.ub.es.
34452745,Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.,2021-Nov,Feliu; Ancukiewicz,"Agenus Inc., Lexington, MA, United States. Electronic address: waldo.ortuzar@agenusbio.com.; Agenus Inc., Lexington, MA, United States. Electronic address: marek.ancukiewicz@agenusbio.com.",Malley@osumc.edu.
34450102,"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.",2021-Sep,,,martin.dreyling@med.uni-muenchen.de.
34438241,Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy.,2021-Oct,,,Carola.Berking@uk-erlangen.de.
34431585,Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance.,2021-Nov,Sakamoto; Akamatsu,"Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Ono Pharmaceutical Co., Ltd., Osaka, Japan.",
34428076,Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.,2021-Oct-01,,,
34418875,Current pharmacological treatment of hepatocellular carcinoma.,2021-Oct,,,mreig1@clinic.cat.
34417444,Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.,2021-Aug-20,Katakam; Knapp; Nielsen; McCord,"Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc., South San Francisco, CA, USA.",franck.morschhauser@chru-lille.fr.
34413166,Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.,2021-Aug,Stankevich; Booth; Yoo; Li; Chen; Okoye; Chen; Mastey; Lowy; Fury,"Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Tarrytown, New York, USA.",danny.rischin@petermac.org.
34408266,Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.,2022-Feb,,,dennis.eichenauer@uk-koeln.de.
34405542,"An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.",2021-Nov,,,
34405395,Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.,2021-Nov,,,
34404686,Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.,2021-Oct,,,lellisen@mgh.harvard.edu
34399710,Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis.,2021-Aug-16,,,yteppei@aichi-cc.jp.
34389874,Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.,2022-Mar,,,hhorinou@ncc.go.jp.
34389618,First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.,2021-Aug,Xyrafas,"Early Development Analytics-Statistics, Novartis Pharma AG, Basel, Switzerland.",spihapau@mdanderson.org.
34389273,Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.,2021-Nov,Buvaylo; Fletcher; Childs,"Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ.; Pharmaceuticals Division, Bayer PLC, Reading, UK.; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ.",matasarm@mskcc.org.
34388022,Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.,2022-Jan-01,,,
34388020,"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).",2021-Nov-10,Coppola; Yang; Al Masud; Ross; Bueno,"AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.",
34380662,"Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers.",2021-Aug,,,jnaidoo1@jhmi.edu.
34371381,Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.,2021-Aug,Valderrama; Norquist; Kher; Shah,"Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, USA.; Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.",eric.vancutsem@uzleuven.be.
34370283,Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.,2021-Sep,,,amitbar@pennmedicine.upenn.edu.
34363762,"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.",2021-Sep,Oza,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",bradley.monk@usoncology.com.
34363528,Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.,2021-Nov,Amonkar; Norquist; Chen; Shih,"Center for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.; Center for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.",eric.vancutsem@uzleuven.be.
34360781,Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.,2021-Jul-27,,,
34344783,Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN.,2022-Feb,,,y_chowers@rambam.health.gov.il.
34344533,Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.,2021-Nov,,,Carmel.pezaro@nhs.net.
34339647,Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.,2021-Aug,,,georgina.long@melanoma.org.au.
34339623,"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.",2021-Sep,,,mjavle@mdanderson.org.
34329577,"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.",2021-Aug,,,agopal@uw.edu.
34327781,Current progress and future perspectives of research on intravascular large B-cell lymphoma.,2021-Oct,,,
34324079,An Integrated Analysis of Dostarlimab Immunogenicity.,2021-Jul-29,Koeck; Potocka,"Certara, Princeton, New Jersey, USA.; Nuventra Pharma Sciences, Durham, North Carolina, USA.",Slu@scholarrock.com.
34314018,Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.,2021-Nov-15,Trudel,"Princess Margaret Cancer Center, Toronto, Ontario, Canada.",
34310716,Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.,2021-Dec-01,Costa,"Pfizer Inc., Porto Salvo, Portugal.",
34304054,"Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.",2021-Sep,,,tatsuro@yamaguchi.email.ne.jp.
34301810,First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.,2021-Jul,,,dangelos@mskcc.org.
34301808,"CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.",2021-Jul,Stroh; Lu,"CytomX Therapeutics Inc, South San Francisco, California, USA.; CytomX Therapeutics Inc, South San Francisco, California, USA.",Rachel.Sanborn@providence.org.
34301751,RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.,2021-Oct-01,,,
34293460,"Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.",2021-Oct,Zhang; Gumuscu; Swaby,"Merck & Co., Inc., Kenilworth, USA.; Merck & Co., Inc., Kenilworth, USA.; Merck & Co., Inc., Kenilworth, USA.",brett.hughes@health.qld.gov.au.
34292792,"Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.",2021-Sep-20,,,
34291369,Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer.,2021-Nov,Iino; Kageyama,"Sumitomo Dainippon Pharma Co., Ltd, Osaka, Japan.; Sumitomo Dainippon Pharma Co., Ltd, Osaka, Japan.",h.taniguchi@aichi-cc.jp.
34284729,Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.,2021-Jul-21,,,steven.grange@chu-rouen.fr.
34273876,"Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.",2021,Shirasuna; Koelsch; Kinugasa; Sugahara; Ohori; Takeuchi; Yoshida,"Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan. Electronic address: kenna.shirasuna@astellas.com.; Drug Discovery Research, Astellas Pharma Inc., 1 Astellas Way, Northbrook, IL 60062, USA.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.",kenna.shirasuna@astellas.com.
34272041,"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.",2021-Aug,Patel; Henschel; Swat; Kaul; Molinero; Patel; Chui,"Genentech, Inc., South San Francisco, USA.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Product Development Safety, Genentech, Inc., South San Francisco.; Oncology Biomarker Development, Genentech, Inc., South San Francisco.; Product Development Data Sciences, Genentech, Inc., South San Francisco, USA.; Genentech, Inc., South San Francisco, USA.",emensla@upmc.edu.
34260265,Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.,2022-Apr-20,Bohac; Bohac; Yurasov; Yurasov; Yakovich; Yakovich; Lu; Lu; Chen; Chen,"Immune Design Corp, South San Francisco, CA.; MacroGenics Inc, Rockville, MD.; Immune Design Corp, South San Francisco, CA.; Nuvation Bio Inc, San Francisco, CA.; Immune Design Corp, South San Francisco, CA.; Replimune Group Inc, Woburn, MA.; Immune Design Corp, South San Francisco, CA.; Seattle Genetics Inc, Bothell, WA.; Immune Design Corp, South San Francisco, CA.; Sangamo Therapeutics Inc, Brisbane, CA.",
34255535,Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.,2021-Sep-10,,,
34253874,Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.,2021-Oct,,,l.vermeulen@amsterdamumc.nl.
34251873,SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.,2021-Sep-10,,,
34244307,Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2,2021-Jul,Soon-Shiong,"ImmunityBio, Inc, Culver City, California, USA.",mitchell_cairo@nymc.edu
34243976,Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.,2021-Sep,,,rpenson@partners.org.
34238257,"Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).",2021-Jul-09,Takata,"Oncology Medical Science Department, Daiichi Sankyo Co., Ltd., 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8426, Japan.",taqnakayama@gmail.com.
34233964,Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.,2021-Jul,,,nicholas.powell@imperial.ac.uk.
34228774,Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.,2021-Aug-10,Lederer; Nivens; Sivapalasingam,"Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.",
34225076,Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.,2021-Aug,,,kevin.punie@uzleuven.be.
34224826,"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.",2021-Oct,Trask; du Toit; Pena-Murillo; Revelant; Klingbiel,"Patient-Centered Outcomes Research, Genentech, Inc., South San Francisco, USA.; Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Global Product Development, Portfolio Clinical Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",David.miles@doctors.org.uk.
34219000,"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.",2021-Aug,Patel; Patre; Morales; Patel; Kaul; Barata,"Product Development Oncology, Genentech, Inc., South San Francisco, USA.; Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Patient-Centered Outcomes Research, Genentech, Inc., South San Francisco, USA.; Product Development Oncology, Genentech, Inc., South San Francisco, USA.; Pharma Development Biostatistics Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",David.miles@doctors.org.uk.
34216247,"First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.",2022-Feb,Englert; Lambert; Parikh; Afar; Vosganian,"AbbVie Deutschland, GmbH & Co KG, Ludwigshafen, Germany.; AbbVie Inc, Redwood City, CA, USA.; AbbVie Inc, Redwood City, CA, USA.; AbbVie Inc, Redwood City, CA, USA.; AbbVie Inc, Redwood City, CA, USA.",a.italiano@bordeaux.unicancer.fr.
34214937,Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).,2021-Aug,Siadak; DeBusk; Ramos; Feng,"Medical Affairs, Seagen, Inc, Bothell, WA, USA.; Health Economics Outcome Research, Seagen Inc., Bothell, WA, USA.; Clinical Development, Seagen Inc., Bothell, WA, USA.; Biometrics, Seagen Inc., Bothell, WA, USA.",v.mueller@uke.de.
34214936,Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.,2021-Aug,,,alexander.menzies@sydney.edu.au.
34213592,The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer.,2021-Oct,Liao; Dutta; Upreti,"Clinical Pharmacology, Modeling and Simulation, Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA, 94080, USA.; Clinical Pharmacology, Modeling and Simulation, Amgen Inc, Thousand Oaks, CA, USA.; Clinical Pharmacology, Modeling and Simulation, Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA, 94080, USA. vupreti@amgen.com.",vupreti@amgen.com.
34185411,Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.,2021-Jun,Somers; Furuuchi; Uenaka,"AD Franchise Special Mission, Eisai Inc., Woodcliff Lake, New Jersey, USA.; Epochal Precision Anti-Cancer Therapeutics (EPAT), Eisai Inc., Exton, Pennsylvania, USA.; Epochal Precision Anti-Cancer Therapeutics (EPAT), Eisai Inc., Exton, Pennsylvania, USA.",
34184418,"Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.",2021-Sep,Gao; Zhao; Wang; Wu,"Clinical Research Center of Luye Pharma Group Ltd, Luye Life Sciences Group, Beijing, 100025, P. R. China.; Clinical Research Center of Luye Pharma Group Ltd, Luye Life Sciences Group, Beijing, 100025, P. R. China.; Clinical Research Center of Luye Pharma Group Ltd, Luye Life Sciences Group, Beijing, 100025, P. R. China.; Clinical Research Center of Luye Pharma Group Ltd, Luye Life Sciences Group, Beijing, 100025, P. R. China.",
34182268,Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.,2021-Aug,,,alexander.menzies@sydney.edu.au.
34180007,Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.,2022-Feb,,,tatyoshi@ncc.go.jp.
34174189,"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.",2021-Aug,Zhang; Yang; Zhang; Zou,"Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals, Shanghai, China.",zhangli@sysucc.org.cn.
34170745,"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.",2021-Oct-01,,,
34169393,Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.,2021-Aug,,,kkalins@emory.edu.
34164224,Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer.,2021-May,,,
34162429,Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.,2021-Jun-23,,,RRJenq@mdanderson.org.
34161001,"[""Immune checkpoint inhibitors in oncology""].",2021-Apr,Vivier,"Centre d'immunologie de Marseille-Luminy, Aix-Marseille Université, CNRS, Inserm, Marseille ; hôpital de La Timone, AP-HM, Marseille immunopole, Marseille ; Innate Pharma, Marseille.",
34156166,"Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT.",2022-Feb,Seronde,"Department of Medical Affairs, Merck Biopharma, Lyon, France.",
34154926,Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.,2021-Dec,Ward; Patre; Chui; Rotmensch; Gupta; Molinero; Li,"Oncology Hematology Care, Cincinnati, OH, USA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA.; Product Development Safety, Genentech Inc, South San Francisco, CA, USA.; Biostatistics, IQVIA-RDS India Pvt Ltd, Mumbai, Maharashtra, India.; Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USA.; Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USA.",ehamilton@tnonc.com.
34153388,"Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort.",2022-Feb,,,charleenardin@hotmail.fr.
34147014,"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.",2021-Jul,Klingbiel; Messeri; Trask; Fredriksson; Machackova,"Pharma Development Biometrics, Biostatistics, F. Hoffmann-La Roche Ltd, Hochstrasse 16, CH-4053 Basel, Switzerland. Electronic address: dirk.klingbiel@roche.com.; PDG Clinical Operations Oncology, F. Hoffmann-La Roche Ltd, Hochstrasse 16, CH-4053 Basel, Switzerland. Electronic address: dimitri.messeri@roche.com.; Patient Centered Outcomes Research, Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: trask.peter@gene.com.; Global Product Development/Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland. Electronic address: judy.fredriksson@roche.com.; Global Product Development/Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland. Electronic address: zuzana.machackova@roche.com.",Joyce.OShaughnessy@usoncology.com.
34146511,"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.",2021-Jul,,,howardj@neurology.unc.edu.
34145579,Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.,2021-Aug,Demaria; Gauthier; Debroas; Vivier,"Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.",
34145536,Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.,2021-Sep,Mascolo; Scavone; Ferrajolo; Rafaniello; Rossi; Capuano,"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy. annamaria.mascolo@unicampania.it.; Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.; Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.; Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.; Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.; Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.",annamaria.mascolo@unicampania.it.
34144111,Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.,2021-Aug,,,tlaidlaw@bwh.harvard.edu.
34143979,Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.,2021-Jul-12,,,lajos.pusztai@yale.edu.
34143970,"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.",2021-Jul,Oza,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",epujade@arcagy.org.
34138471,Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.,2021-Sep-15,,,
34135307,Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.,2021-Jun-16,,,anas.younes@astrazeneca.com.
34135110,Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.,2021-Jun-16,Bissinger; Hage; Wagner; Maser; Brand; Schmittnaegel; Jegg; Cannarile; Klaman; Rieder; Hoves; Ries,"Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany. bissins@gmail.com riescarola@gmx.de.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany. bissins@gmail.com riescarola@gmx.de.",bissins@gmail.com
34125340,Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.,2021-Jul,Pennella; Pennella; Gopalakrishnan; Koch; Baramidze; Barve; Fuentes-Alburo,"Viatris Inc, Canonsburg, PA, USA.; MaxCyte, Inc, Gaithersburg, MD, USA.; Viatris Inc, Bangalore, India.; Viatris Inc, Hannover, Germany.; Golden Fleece 21 Century Health House Ltd, Tbilisi, Georgia.; Viatris Inc, Canonsburg, PA, USA.; Viatris Inc, Canonsburg, PA, USA.",Hope.Rugo@ucsf.edu.
34121358,Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.,2021-Jul,,,
34119801,Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer.,2021-Aug,,,tmasuishi@aichi-cc.jp.
34116144,Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.,2021-Sep,Goldenberg; Hong; Olivo; Itri,"Immunomedics, Inc., Morris Plains, USA; Center for Molecular Medicine and Immunology, Mendham, USA.; Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.; Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.; Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.",shurvitz@mednet.ucla.edu.
34114752,Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.,2022-Feb,,,
34112709,"Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.",2021-Aug-15,Stern,"Roche Pharma Research and Early Development, Roche Innovation Center, Zurich, Switzerland.",rhv@upenn.edu.
34108181,A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.,2021-Sep-01,Porcu; Tayama; Kadel; Yuen; Datye,"Product Development Oncology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Product Development Oncology, Genentech, Inc., South San Francisco, California.; Product Development Oncology, Genentech, Inc., South San Francisco, California.; Product Development Oncology, Genentech, Inc., South San Francisco, California.; Product Development Oncology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.",lawrence.fong@ucsf.edu
34105893,"Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.",2021-Aug,,,
34102137,"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.",2021-Jul-03,Poulart; Cullen; Lei; Xiao; Kondo; Li,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",kshitara@east.ncc.go.jp.
34098908,REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.,2021-Jun-07,,,yoshikagawa@gmail.com.
34097854,"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.",2021-Jun-19,,,philippe.moreau@chu-nantes.fr.
34095713,Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.,2021,Quinn; Espenschied; Mak; Kiedrowski; Lefterova; Nagy,"Guardant Health Inc., Redwood City, CA.; Guardant Health Inc., Redwood City, CA.; Guardant Health Inc., Redwood City, CA.; Guardant Health Inc., Redwood City, CA.; Guardant Health Inc., Redwood City, CA.; Guardant Health Inc., Redwood City, CA.",
34087147,Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply.,2021-Jun,,,jbellmun@bidmc.harvard.edu.
34087138,Unresolved questions regarding the promise of the TPEx regimen - Authors' reply.,2021-Jun,,,joel.guigay@nice.unicancer.fr.
34087137,Unresolved questions regarding the promise of the TPEx regimen.,2021-Jun,,,ishiki-tky@umin.ac.jp.
34083421,Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.,2021-Jun,Li; Li; Chen; Barrows,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",ferrisrl@upmc.edu.
34082019,"Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.",2021-Sep,Kobie; Cristescu; Aurora-Garg; Lu; Shih; Adelberg; Cao,"Merck & Co., Inc., Kenilworth, USA.; Merck & Co., Inc., Kenilworth, USA.; Merck & Co., Inc., Kenilworth, USA.; Merck & Co., Inc., Kenilworth, USA.; Merck & Co., Inc., Kenilworth, USA.; Merck & Co., Inc., Kenilworth, USA.; Merck & Co., Inc., Kenilworth, USA.",kshitara@east.ncc.go.jp.
34080039,Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors.,2021-Sep,Pilla Reddy; Zhou; Sharma; Chen; Vishwanathan; Xu; Ware,"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals Research & Development, AstraZeneca, Cambridge, UK. Venkatesh.Reddy@astrazeneca.com.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals Research & Development, AstraZeneca, Boston, MA, USA.; Quantitative Clinical Pharmacology, AstraZeneca , South San Francisco, CA, USA.; Quantitative Clinical Pharmacology, AstraZeneca , South San Francisco, CA, USA.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals Research & Development, AstraZeneca, Boston, MA, USA.; Quantitative Clinical Pharmacology, AstraZeneca , South San Francisco, CA, USA.; Quantitative Clinical Pharmacology, AstraZeneca , South San Francisco, CA, USA.",Venkatesh.Reddy@astrazeneca.com.
34078817,"Increasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes.",2021,Eshima,Delta-Fly Pharma Inc.,
34077270,Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.,2021-Jul-20,,,
34069354,Current Treatment Options in CLL.,2021-May-19,,,
34062586,[Diagnosis and treatment of HIV-associated lymphoma: Update 202].,2021-Jun,,,
34057394,"The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.",2021-Jun,,,
34051880,"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.",2021-Jul,,,peter.galle@unimedizin-mainz.de.
34051732,Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.,2021-May-29,Brokaw; Le; Scotto; Lord-Bessen; Moshyk; Kotapati,"Bristol Myers Squibb, Princeton, NJ, 08543, USA.; Bristol Myers Squibb, Princeton, NJ, 08543, USA.; Bristol Myers Squibb, Princeton, NJ, 08543, USA.; Bristol Myers Squibb, Princeton, NJ, 08543, USA.; Bristol Myers Squibb, Princeton, NJ, 08543, USA.; Bristol Myers Squibb, Princeton, NJ, 08543, USA.",stephane.dalle@chu-lyon.fr.
34051329,CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.,2021-Sep,Shen; Neely; Tschaika; Wisniewski,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",m-kudo@med.kindai.ac.jp.
34051178,"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.",2021-Jul,,,thomas.powles1@nhs.net.
34051177,"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.",2021-Jul,,,arjun.balar@nyulangone.org.
34050432,A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.,2021-Nov,,,chen_yucherng@lilly.com.
34048680,"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.",2021-Jun,Younes; Liu; Little,"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; AstraZeneca Pharmaceuticals, LP Wilmington, DE, USA.; Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals, Cambridge, MA, USA.; Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals, Cambridge, MA, USA.",strausd@mskcc.org.
34048679,"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.",2021-Jun,,,peter.borchmann@uk-koeln.de.
34041738,Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.,2021-Nov,Jamois; Chavanne; Morcos; McIntyre; Barrett; Lundberg; Zharkov; Boehnke; Frey,"Clinical Pharmacology, Pharmaceutical Sciences, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Clinical Pharmacology, Pharmaceutical Sciences, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Clinical Pharmacology, Pharmaceutical Sciences, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.; Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Clinical Pharmacology, Pharmaceutical Sciences, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.",
34036235,Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.,2021,,,
34036230,Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia.,2021,,,
34023330,Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.,2021-Jul,,,y-tsukita@rm.med.tohoku.ac.jp.
34019819,Chemotherapy de-escalation using an ,2021-Jun,,,jacortes@vhio.net.
34019214,"Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.",2021-Dec,,,atsuji@med.kagawa-u.ac.jp.
34018029,Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.,2021-Jul,Wang; Cheung; Nguyen; Zhou; Styles,"Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.",r.greil@salk.at.
34014607,Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade.,2021-Aug,,,
34009291,Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.,2021-Aug-01,,,
34006498,A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma.,2021-Oct,Perini; Aimone; Naeije,"Merck & Co., Inc., Kenilworth, NJ.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",dmcdermo@bidmc.harvard.edu.
34002026,Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).,2021-Jun,,,liangyang@sysucc.org.cn.
34000246,"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.",2021-Jun,Li; Yoo; Mohan; Coates; Jankovic; Fiaschi; Okoye; Seebach; Thurston; Weinreich; Yancopoulos; Lowy; Bowler; Fury,"Regeneron Pharmaceuticals, Basking Ridge, NJ, USA.; Regeneron Pharmaceuticals, Basking Ridge, NJ, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.",alstrat@med.uoa.gr.
33999652,Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.,2021-Jul-10,,,
33991512,"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.",2021-Jun,Steinberg,"Astellas Pharma, Northbrook, IL, USA.",evanyu@uw.edu.
33989949,Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.,2021-Jun,Moran,"Pfizer Pharma GmbH, Berlin, Germany.",Jean.Bourhis@chuv.ch.
33989559,"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.",2021-Jun,,,agsacco@health.ucsd.edu.
33989558,"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.",2021-Jun,,,paolo.caimi@case.edu.
33989557,"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.",2021-Jun,,,georgina.long@sydney.edu.au.
33989025,Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).,2021-Aug-01,,,
33986126,Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.,2021-May,Klumpp,"Department for Diagnostic and Interventional Radiology, Rems-Murr-Kliniken gGmbH, Winnenden, Germany.",nikolaus.wagner@gmx.de.
33984672,"SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.",2021-Jun,,,abamias@med.uoa.gr.
33976200,Selective and noncovalent targeting of RAS mutants for inhibition and degradation.,2021-May-11,,,Shohei.Koide@nyulangone.org.
33973233,"A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).",2021-Jun,Babanrao Pisal; Izquierdo,"Novartis Healthcare Pvt. Ltd., Hyderabad, India.; Novartis Pharma AG, Basel, Switzerland.",
33972155,CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.,2021-Jul,,,mathieu.rouanne@gustaveroussy.fr.
33970288,"Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.",2021-Sep,Palumbo; Romanus; Cherepanov; Stull; Huang,"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.",faith.davies@nyulangone.org.
33963015,"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.",2021-May,Tarhini; Eroglu; Sondak,"Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA ahmad.tarhini@moffitt.org.; Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA.; Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA.",ahmad.tarhini@moffitt.org.
33963010,Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.,2021-May,,,matteo.carlino@sydney.edu.au.
33961795,"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.",2021-Jun,Yamamoto; Okuda,"Daiichi Sankyo Co, Ltd, Tokyo, Japan.; Daiichi Sankyo Co, Ltd, Tokyo, Japan.",tyoshino@east.ncc.go.jp.
33961018,Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review.,2021-May-11,,,
33951110,Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.,2021,,,
33945288,Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.,2021-Aug-20,,,
33942348,Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.,2021-Aug,Koenigsmann; Maintz,"Onkologisches Ambulanzzentrum am Diakovere Henriettenstift gGmbH, Hannover, Germany.; Medizinisches Versorgungszentrum West GmbH Würselen Hämatologie-Onkologie, Würselen, Germany.",
33942292,Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.,2021-Jul,,,
33938097,Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.,2021-Jul,,,
33937418,Epitope-Based Chicken-Derived Novel Anti-PAD2 Monoclonal Antibodies Inhibit Citrullination.,2021,Aosasa; Hossain; Sakata; Koga; Shigemitsu; Shoya; Yamaguchi; Saito; Kim,"Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.; Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.; Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.; Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.; Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.; Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.; Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.; Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.; Pharma Foods International Co. Ltd., 1-49 Goryo-Ohara, Nishikyo Ku, Kyoto 615-8245, Japan.",
33934059,Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.,2021-Jun,,,a.cortellini@imperial.ac.uk.
33932503,Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.,2021-Aug,Liu; Tesarowski; Lam; Song; Smitt,"Product Development Safety, Genentech, Inc., South San Francisco, USA.; Product Development Oncology, Genentech, Inc., South San Francisco, USA.; Product Development Oncology, Genentech, Inc., South San Francisco, USA.; Product Development Oncology, Genentech, Inc., South San Francisco, USA.; Product Development Oncology, Genentech, Inc., South San Francisco, USA; Seattle Genetics, South San Francisco, USA.",terry.mamounas@orlandohealth.com.
33931498,"Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.",2021-Jun,,,s.pignata@istitutotumori.na.it.
33929895,TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.,2021-Aug-01,Hong; Goswami; Itri,"Immunomedics, a subsidiary of Gilead Sciences, Inc, Morris Plains, NJ.; Immunomedics, a subsidiary of Gilead Sciences, Inc, Morris Plains, NJ.; Immunomedics, a subsidiary of Gilead Sciences, Inc, Morris Plains, NJ.",
33925392,Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome.,2021-Apr-27,,,
33924378,"Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.",2021-Apr-13,Prat; Salon; Allain; Dubreuil; Jean; Lemée; Tabah-Fish; Pipy; Prost; Barret; Coste,"UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France.; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France.; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France.; GamaMabs Pharma, 31106 Toulouse, France.; GamaMabs Pharma, 31106 Toulouse, France.; GamaMabs Pharma, 31106 Toulouse, France.; GamaMabs Pharma, 31106 Toulouse, France.; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France.; GamaMabs Pharma, 31106 Toulouse, France.; GamaMabs Pharma, 31106 Toulouse, France.; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France.",
33921938,Temporal Dominance of B.1.1.7 over B.1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation.,2021-Apr-22,Tseti,"Uni-Pharma S.A., 14564 Kifissia, Greece.",
33910927,Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.,2021-Sep,Zelinger; Shelach,"Lutris-Pharma, Tel Aviv, Israel.; Lutris-Pharma, Tel Aviv, Israel.",aribas@mednet.ucla.edu
33909449,"Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.",2021-Jul-10,,,
33903976,Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products.,2021-May,Allmendinger,"Pharmaceutical Development & Supplies, Pharma Technical Development Biologics Europe, F. Hoffmann-La Roche, Grenzacherstr. 124, CH-4070, Basel, Switzerland. andrea.allmendinger.aa1@roche.com.",andrea.allmendinger.aa1@roche.com.
33901870,Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.,2021-Jun,,,toni_choueiri@dfci.harvard.edu.
33892408,"Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.",2021-Jun,,,miusat1118@niigata-cc.jp.
33892316,Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.,2021-Aug,Pennella; Gopalakrishnan; Koch; Barve,"Viatris Inc, 1000 Mylan Boulevard, Canonsburg, PA, 15317, USA. Electronic address: eduardo.pennella@gmail.com.; Viatris Inc, 10th Floor, Prestige Platina Tech Park, Block 3, Kadubeesanahalli, Outer Ring Road, Bangalore, 560087, India. Electronic address: Unmesh.G@viatris.com.; Viatris Inc, Freundallee 9A, 30173, Hannover, Germany. Electronic address: hans-friedrich.koch@viatris.com.; Viatris Inc, 1000 Mylan Boulevard, Canonsburg, PA, 15317, USA. Electronic address: Abhijit.Barve@viatris.com.",Hope.Rugo@ucsf.edu.
33891472,"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).",2021-Jun-10,Wu; Molinero; Maiya; Khor; Lin,"Biostatistics, Roche (China) Holding Ltd, Shanghai, China.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.",
33883177,"Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.",2021-Jul-01,Bedard; Xyrafas; Gutzwiller; Manenti,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.",giuseppe.curigliano@ieo.it.
33882330,IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy.,2021-Jun,,,rgutzmer@gmx.de.
33878954,Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).,2021-Jun,,,
33872070,Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.,2021-Jul-20,Jensen; Zhao; Pietanza,"Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.",
33871826,Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.,2021-Oct,,,tolba.mf@pharma.asu.edu.eg.
33866430,A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.,2022-Feb,Hummel; Shaw; Liu; Barve; Kothekar,"Viatris Inc, Morgantown, WV, USA.; Viatris Inc, Morgantown, WV, USA.; Viatris Inc, Morgantown, WV, USA.; Viatris Inc, Canonsburg, PA, USA.; Biocon Research Ltd (Now With Sun Pharma Advanced Research Company, Mumbai, India), Bangalore, India.",cornelius.waller@uniklinik-freiburg.de.
33857414,"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.",2021-May,,,andrew.bottomley@eortc.org.
33857412,"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.",2021-May,,,alexander.eggermont@prinsesmaximacentrum.nl.
33856405,"Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.",2021-Jun-01,,,
33849924,Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.,2021-Apr,,,anaing@mdanderson.org
33848462,"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.",2021-May,Soler; Cao; Hiemeyer; Mehra; Childs,"Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Pharmaceuticals Division, Bayer, Berlin, Germany.; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.",matasarm@mskcc.org.
33844595,Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.,2021-Aug-01,,,
33844589,Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?,2021-Jul-10,,,
33837054,IL-6 modulation for COVID-19: the right patients at the right time?,2021-Apr,,,paolo.ascierto@gmail.com.
33836264,Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.,2021-Aug,,,jtabernero@vhio.net.
33836153,"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.",2021-Jun,Chatterjee; Jin; Norwood,"Merck & Co, Inc, Kenilworth, NJ, USA.; Merck & Co, Inc, Kenilworth, NJ, USA.; Merck & Co, Inc, Kenilworth, NJ, USA.",tyap@mdanderson.org.
33835842,Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.,2021-Aug-01,,,
33832464,Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study.,2021-Apr-08,,,rabads@salud.aragon.es.
33829482,"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.",2021-Nov,Bao; Jehl; Marfo; Primatesta; Shete; Trivedi,"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",
33828257,"Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.",2021-Jul,Barton; Restuccia; Procter; Jackisch; Petersen; Petersen,"Barton Oncology Ltd, Croxley Green, Hertfordshire, UK.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Frontier Science (Scotland) Ltd, Kincraig, UK.; Department of Obstetrics and Gynecology, Sana Klinikum Offenbach GmbH, Offenbach, Germany.; Patient-Centered Outcomes Research, Genentech, Inc., South San Francisco, CA, USA.; Digital Health Technologies, Genentech, Inc., South San Francisco, CA, USA.",jose_bines@yahoo.com.
33827906,Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.,2021-Apr,,,alessiocortellini@gmail.com.
33823836,Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).,2021-Apr-06,Nukada,"Medical Affairs, Kyowa Kirin Co. Ltd, Tokyo, Japan.",masahiro.yokoyama@jfcr.or.jp.
33822328,Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.,2021-May,Mollon; Marteau; Martín; Li; Xu,"Ipsen Pharma, Boulogne-Billancourt, France.; Ipsen Pharma, Boulogne-Billancourt, France.; Ipsen Pharma, Barcelona, Spain.; IQVIA Ltd, London, UK.; IQVIA Inc, Beijing, China.",trojan@em.uni-frankfurt.de.
33819461,Pharmacokinetics and Determination of Tumor Interstitial Distribution of a Therapeutic Monoclonal Antibody Using Large-Pore Microdialysis.,2021-Aug,Gertz; Otteneder; Fueth,"Roche Pharma Research and Early Development, Pharmaceutical Science, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Science, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Science, Roche Innovation Center Basel, Basel, Switzerland. Electronic address: matthias.fueth@roche.com.",matthias.fueth@roche.com.
33812497,"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.",2021-May,,,thierry.andre@aphp.fr.
33799233,Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review.,2021-Jun,Winstone; Barham; Hanes; Courmier,"Perscribo Medical Communications Ltd, 7 York Close, Kempshott Rise, Basingstoke, RG22 4PU, UK. Electronic address: jwinstone@perscribo.co.uk.; Perscribo Medical Communications Ltd, 7 York Close, Kempshott Rise, Basingstoke, RG22 4PU, UK.; Amgen Biosimilar Business Unit, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320USA, USA. Electronic address: vhanes@amgen.com.; Amgen Global Health Economics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320USA, USA. Electronic address: dcourmie@amgen.com.",hans-christian.kolberg@mhb-bottrop.de.
33795130,Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma.,2021-Jun,,,lllin@mdanderson.org.
33794441,Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.,2021-May,Brown; Palanca-Wessels; Lisano; Onsum; Bunn; Little; Trepicchio,"Seagen Inc, 21823 30th Drive Southeast, 98021, Bothell, WA, USA. Electronic address: lisaannebr@gmail.com.; Seagen Inc, 21823 30th Drive Southeast, 98021, Bothell, WA, USA. Electronic address: cpalanca@seagen.com.; Seagen Inc, 21823 30th Drive Southeast, 98021, Bothell, WA, USA. Electronic address: jlisano@seagen.com.; Seagen Inc, 21823 30th Drive Southeast, 98021, Bothell, WA, USA. Electronic address: monsum@seagen.com.; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, 40 Landsdowne Street, 02139, Cambridge, MA, USA. Electronic address: Veronica.Bunn@takeda.com.; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, 40 Landsdowne Street, 02139, Cambridge, MA, USA. Electronic address: meredith.little@takeda.com.; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, 40 Landsdowne Street, 02139, Cambridge, MA, USA. Electronic address: bill.trepicchio@takeda.com.",younkim@stanford.edu.
33793049,Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers.,2021-Jun,,,
33792646,"Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.",2021-Jun-01,,,
33788956,The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry.,2021-Jul-15,,,
33787900,Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer.,2022-Mar-08,Wang,"Novartis Pharma AG, Basel, Switzerland.",
33781720,Pharmacokinetics and clinical outcomes of nivolumab administered every 4 weeks in patients with advanced non-small-cell lung cancer: A four-case pilot study.,2021-Jul,,,nkatakami1954@gmail.com.
33771664,Novel adjuvant options for cutaneous melanoma.,2021-Jul,,,alexander.menzies@sydney.edu.au.
33764808,"HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.",2021-May-01,,,
33755863,Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.,2021-May,Ganguli; Sahin; Türeci; Türeci,"Astellas Pharma, Inc, Northbrook, IL, USA.; Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany.; Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany.; CI3 - Cluster of Individualized Immune Intervention; formerly of Ganymed Pharmaceuticals GmbH, Mainz, Germany.",florian.lordick@medizin.uni-leipzig.de.
33747637,BAFF receptor antibody for mantle cell lymphoma therapy.,2021-Mar-05,,,
33744811,Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.,2021-Apr,,,takaota@gifu-u.ac.jp.
33744385,Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.,2021-Jun,,,Richard.Scolyer@health.nsw.gov.au.
33743112,Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.,2021-Jul,Nishiyama,"Medical Information, Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.",nboku@ncc.go.jp.
33741442,"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.",2021-Jun,Goldenberg; Sharkey; Maliakal; Hong; Wegener; Goswami,"Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.",ajo9001@med.cornell.edu.
33739848,Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.,2021-Jul-20,,,
33737428,Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL).,2021-Mar-17,,,tsutani@hiroshima-u.ac.jp.
33737340,Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.,2021-Mar,Morris; Cardona; Mendus; Ballinger,"Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Biometrics, F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; Product Development Oncology, Genentech Inc, South San Francisco, California, USA.; Product Development Oncology, Genentech Inc, South San Francisco, California, USA.",drgandara@ucdavis.edu.
33737339,Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.,2021-Mar,Alatorre-Alexander; Trunzer; Patel; Tolson; Cardona; Perez-Moreno,"Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, Mexico.; Department of Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Basel-Stadt, Switzerland.; Department of Safety Science Oncology, Genentech Inc, South San Francisco, California, USA.; Department of Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Basel-Stadt, Switzerland.; Department of Product Development Biometrics, F. Hoffmann-La Roche Ltd, Basel, Basel-Stadt, Switzerland.; Department of Product Development, Genentech Inc, South San Francisco, California, USA.",andrea.ardizzoni@aosp.bo.it.
33731681,"Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.",2021-Mar-17,,,tkadia@mdanderson.org.
33731480,Targeting loss of heterozygosity for cancer-specific immunotherapy.,2021-Mar-23,,,sbzhou@jhmi.edu
33730455,Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.,2021-Mar-18,,,
33725378,Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR.,2021-Aug,,,
33721560,"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.",2021-Apr,,,jbellmun@bidmc.harvard.edu.
33712274,Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).,2021-May,,,MEBuechel@gmail.com.
33711671,Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.,2021-Apr,,,jsastrev@salud.madrid.org.
33710337,Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.,2021-Mar-23,,,
33709428,"Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.",2021-Jul-15,,,
33707411,Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.,2021-Mar-11,,,kroemer@orange.fr.
33689448,Improving Survival and Predicting Toxicity in Older Patients With DLBCL: A Delicate Balance.,2021-Apr-10,,,
33688022,Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.,2021-Mar,,,davide.melisi@univr.it.
33684370,"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.",2021-Apr,,,joel.guigay@nice.unicancer.fr.
33683919,Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.,2021-Apr-20,Lin; Selvaggi; Baudelet; Baden; Pandya; Doshi,"Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",
33683501,"A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.",2021-Aug,Quinson; Maier; Smith,"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.",Jennifer_Brown@dfci.harvard.edu.
33667669,IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.,2021-Jun,,,LacoutuM@mskcc.org.
33648347,Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.,2021-Apr,Dong; Blin; Rodrik-Outmezguine; Passos,"Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.; Novartis Pharma AG, Basel, CH-4056, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.",
33622518,Pituitary enlargement following ipilimumab without long term endocrine dysfunction.,2021-Dec,,,d.morganstein@ic.ac.uk.
33621109,ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.,2021-Apr-20,Czuczman; Hersey; Kilcoyne; Russo; Hudak; Zhang; Wade,"Clinical Research and Development, Celgene Corporation, Summit, NJ.; Translational Development, Precision Medicine and Companion Diagnostics, Celgene Corporation, Summit, NJ.; Clinical Research and Development, Celgene Corporation, Summit, NJ.; Clinical Research and Development, Celgene Corporation, Summit, NJ.; Clinical Research and Development, Celgene Corporation, Summit, NJ.; Clinical Research and Development, Celgene Corporation, Summit, NJ.; Department of Statistical Programming, Celgene Corporation, Overland Park, KS.",
33615628,First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors.,2021-Apr,,,
33615402,First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis.,2021-Mar,,,pgarcaalfonso@gmail.com.
33613875,Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.,2021-Feb,,,
33610734,FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.,2021-May,Türeci; Bazin; Maurus; Arozullah; Park,"Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany; CI3 - Cluster of Individualized Immune Intervention, Mainz, Germany; formerly of Ganymed Pharmaceuticals GmbH.; Department of Clinical Pharmacology and Chemotherapy, Russian Oncology Research Center n. a. N.N. Blokhin, Moscow, Russia.; Formerly of Ganymed Pharmaceuticals GmbH, Mainz, Germany.; Astellas Pharma Global Development, Inc., Northbrook, USA.; Astellas Pharma Global Development, Inc., Northbrook, USA.",albatran.salah@khnw.de.
33607404,Siglec and anti-Siglec therapies.,2021-Jun,Weigle,"Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str. 65, 88397, Biberach/Riss, Germany.",p.r.crocker@dundee.ac.uk.
33602695,Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.,2021-Feb,,,kzsaito@dokkyomed.ac.jp.
33602684,"Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.",2021-May-15,Wang; Paccagnella; Nguyen; Sleight; Vandendries; Neuhof; Laird,"Pfizer Inc., Cambridge, Massachusetts.; Pfizer Inc., Groton, Connecticut.; Navigate BioPharma Services, Inc., a Novartis subsidiary, Carlsbad, California.; Pfizer Inc., Groton, Connecticut.; Pfizer Inc., Cambridge, Massachusetts.; Pfizer Pharma GmbH, Berlin, Germany.; Pfizer Inc., San Francisco, California.",hkantarjian@mdanderson.org.
33601293,Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.,2021-Apr,Looman; Kundu,"Pharmaceutical Development, AbbVie, Hoofddorp, the Netherlands. Electronic address: jim.looman@abbvie.com.; Statistics, AbbVie Inc, North Chicago, IL, USA. Electronic address: madan_g.kundu@yahoo.com.",paul.clement@uzleuven.be.
33597560,Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy.,2021-Feb-17,,,dmitrii.bychkov@helsinki.fi.
33591468,The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.,2021-May,Steinberg; Sugg; Tudor,"Astellas Pharma Inc., Northbrook, USA.; Astellas Pharma Inc., Northbrook, USA.; Pfizer Inc., San Francisco, USA.",ian_krop@dfci.harvard.edu.
33591324,A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.,2021-Feb-23,,,
33589425,PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability.,2021-Jul,,,akr2164@cumc.columbia.edu.
33588870,Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.,2021-Feb-15,Costa,"Pfizer Inc, Porto Salvo, Portugal.",paolo.ascierto@gmail.com.
33580363,"Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.",2021-Sep,,,kjetil.boye@rr-research.no.
33577729,Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.,2021-Mar-25,,,
33576088,Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.,2021-May,,,
33574401,Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial.,2021-Feb-11,,,anaing@mdanderson.org.
33568521,Targeted immunotherapy for HER2-low breast cancer with 17p loss.,2021-Feb-10,Kulke; Hechler; Pahl,"Heidelberg Pharma Research GmbH, Ladenburg 68526, Germany.; Heidelberg Pharma Research GmbH, Ladenburg 68526, Germany.; Heidelberg Pharma Research GmbH, Ladenburg 68526, Germany.",xz48@iu.edu
33556898,A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma,2021-Apr,Lee; Rizzo; Moshyk; Rao; Kotapati,"US Health Economics and Outcome Research, Metastatic Melanoma, Bristol Myers Squibb, Princeton, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA.; Worldwide Health Economics and Outcomes Research, Melanoma, Bristol Myers Squibb, Princeton, USA.; US Health Economics and Outcome Research, Metastatic Melanoma, Bristol Myers Squibb, Princeton, USA.; Worldwide Medical, Melanoma, Bristol Myers Squibb, Princeton, USA.",Ahmad.Tarhini@moffitt.org.
33555941,Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.,2021-Apr-20,,,
33551068,"BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.",2020,,,hbando@aichi-cc.jp.
33544407,A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.,2021-Feb,Hamada; Makris,"Taiho Oncology, Inc, Princeton, New Jersey, USA.; Stathmi, Inc, New Hope, Pennsylvania, USA.",
33541735,Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.,2021-Apr,,,Kimberly-leslie@uiowa.edu.
33539946,Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331,2021-May,Fairchild; Baudelet; Pandya; Doshi; Chang,"Clinical Development, Bristol Myers Squibb, Princeton, USA.; Global Drug Development, Biometrics & Data Sciences, Bristol Myers Squibb, Princeton, USA.; Translational Pathology, Bristol Myers Squibb, Princeton, USA.; Translational Medicine, Bristol Myers Squibb, Princeton, USA.; Translational Bioinformatics, Bristol Myers Squibb, Princeton, USA.",David.spigel@sarahcannon.com.
33539215,Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.,2021-May-01,Procter; Restuccia; Monturus,"Frontier Science Scotland Ltd, Kincraig, Kingussie, United Kingdom.; Hoffmann-La Roche Ltd, Basel, Switzerland.; Hoffmann-La Roche Ltd, Basel, Switzerland.",
33538797,A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.,2021-Feb-04,Samineni; Jiang; Punnoose; Spielewoy,"Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; F. Hoffmann-La Roche Ltd., Basel, Switzerland; and.",
33538237,Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.,2021-Nov,Williams,"Oxford PharmaGenesis Ltd, Oxford, UK.",
33533655,KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.,2021-Apr,Bordia; Bhagia; Shih; Desai,"Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.",
33531690,Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.,2021-Apr,Bilbruck,"Envision Pharma Group, Horsham, UK.",azhu@mgh.harvard.edu.
33527228,Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.,2021-Aug,,,ikesue@kcho.jp.
33523334,"A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.",2021-Aug,Quinson; Maier,"Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.",carmelo.carlostella@hunimed.eu.
33516050,Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.,2021-Mar,,,Ithar.gataa@aphp.fr.
33515422,SEOM clinical guideline in ovarian cancer (2020).,2021-May,,,andres.redondos@uam.es.
33513313,"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.",2021-Jul-20,Xu; Piperdi; Samkari,"Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.",
33512481,Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.,2021-May-13,Bolen; Mattiello; Huet; Nielsen; Oestergaard,"Bioinformatics & Computational Biology, Genentech Inc., South San Francisco, CA.; Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Faculté de Pharmacie de Lyon, Université Claude Bernard Lyon-1, Lyon, France.; Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and.",
33492774,R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.,2021-Feb,,,
33483590,"Circulating long non-coding RNAs HOTAIR, Linc-p21, GAS5 and XIST expression profiles in diffuse large B-cell lymphoma: association with R-CHOP responsiveness.",2021-Jan-22,,,aya.elabd@gmail.com.
33482769,Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.,2021-Jan-22,Dai; Jandial,"Global Development (Oncology), Amgen Inc., One Amgen Center Drive, MS 38-2-B, Thousand Oaks, CA, 91320-1799, USA.; Global Development (Oncology), Amgen Inc., One Amgen Center Drive, MS 38-2-B, Thousand Oaks, CA, 91320-1799, USA.",emanuela.palmerini3@unibo.it.
33480963,Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.,2021-Apr-01,Nordstrom; Bonvini; Koenig; Edlich; Hong; Rock,"MacroGenics, Inc, Rockville, Maryland.; MacroGenics, Inc, Rockville, Maryland.; MacroGenics, Inc, Rockville, Maryland.; MacroGenics, Inc, Rockville, Maryland.; MacroGenics, Inc, Rockville, Maryland.; MacroGenics, Inc, Rockville, Maryland.",
33465293,"Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy.",2021-Mar,González-García; Pierre; Pierre; Dubois; Baverel; Baverel,"Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK.; Clinical Pharmacology & Safety Sciences, AstraZeneca, Gaithersburg, Maryland, USA.; Clinical Pharmacology, EMD Serono, Billerica, Massachusetts, USA.; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK.; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK.; Clinical Pharmacology, Hoffmann-La Roche Research and Early Development, Roche Innovation Center, Basel, Switzerland.",
33464651,C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.,2020-Nov,Grossi; Tan; Di Casoli; El Mehdi; Deschatelets; Francois,"Apellis Pharmaceuticals, Waltham, Massachusetts, USA.; Lisa Tan Pharma Consulting Ltd, Cambridge, UK.; Apellis Pharmaceuticals, Waltham, Massachusetts, USA.; Apellis Pharmaceuticals, Waltham, Massachusetts, USA.; Apellis Pharmaceuticals, Waltham, Massachusetts, USA.; Apellis Pharmaceuticals, Waltham, Massachusetts, USA.",
33463028,Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.,2021-Feb,Hansen,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",
33462883,IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.,2021-Apr,Nakagawa; Kawakami,"Chugai Pharmaceutical co., Ltd, Tokyo, Japan.; Chugai Pharmaceutical co., Ltd, Tokyo, Japan.",
33461835,The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).,2021-Feb-12,,,jennifer.whitaker@bcm.edu.
33451345,"A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.",2021-Jan-15,Schlieker,"External statistician on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG., Staburo GmbH & Co. KG., Munich, Germany.",p.schmid@qmul.ac.uk.
33448893,Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.,2021-Jun,Feng; Cannan; Fellague-Chebra,"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma S.A.S., Paris, France.",
33442538,Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.,2020-Dec,,,
33440157,Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma.,2021-Jan-12,,,wolchokj@mskcc.org.
33439693,"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).",2021-Feb-20,Alatorre-Alexander; Lam; McCleland; Deng; Phan,"Health Pharma Professional Research, Mexico City, Mexico.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.",
33439261,"Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer.",2021-Jan-04,Ramagopalan; Pisoni; Rathore; Ray; Sammon,"Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma International Informatics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Strategic Insights & Advance Analytics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; PHMR Ltd, London, United Kingdom.",
33431630,Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.,2021-Jan,Kopp; Kelkenberg; Pieper; Hadaschick; Battke; Biskup,"CeGaT GmbH, Tuebingen, Germany.; CeGaT GmbH, Tuebingen, Germany.; CeGaT GmbH, Tuebingen, Germany.; CeCaVa GmbH & Co KG, Tuebingen, Germany.; CeGaT GmbH, Tuebingen, Germany.; CeGaT GmbH, Tuebingen, Germany.",Saskia.Biskup@humangenetik-tuebingen.de.
33428680,CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.,2021,Piazza; Warren; Smith; Ren; White; Elliott; Cesano; Beechem,"NanoString® Technologies, Inc., Seattle, Washington, United States of America.; NanoString® Technologies, Inc., Seattle, Washington, United States of America.; NanoString® Technologies, Inc., Seattle, Washington, United States of America.; NanoString® Technologies, Inc., Seattle, Washington, United States of America.; NanoString® Technologies, Inc., Seattle, Washington, United States of America.; NanoString® Technologies, Inc., Seattle, Washington, United States of America.; ESSA Pharma, South San Francisco, California, United States of America.; NanoString® Technologies, Inc., Seattle, Washington, United States of America.",
33419847,Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin,2021-Jan,Distelrath; Busch-Liles,"Joint Practices for Urology and Oncology, Wilhelmshaven, previously, MVZ Osthessen GmbH, Fulda, Germany.; Roche Pharma AG, Grenzach, Germany.",marcus.schmidt@unimedizin-mainz.de.
33415580,The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.,2021-Jun,,,anaing@mdanderson.org.
33412465,Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.,2021-Mar,Perini,"Merck & Co, Inc, 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA. Electronic address: rodolfo.perini@merck.com.",mba41@georgetown.edu.
33410885,Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.,2021-Mar-01,,,
33403729,Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.,2021-Mar,,,
33400034,"Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.",2021-Feb,,,sandra.swain@georgetown.edu.
33399087,ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial.,2021-Feb,,,c.oing@uke.de.
33399081,ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.,2021-Feb,,,matteo.lambertini@unige.it.
33394273,Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?,2021-Apr,,,n.i.bouwer@asz.nl.
33392974,Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.,2021-Mar,Sakamoto; Nishimura,"Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Co. Ltd., 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8668, Japan.; Pharmacovigilance, Takeda Development Center Japan, Takeda Pharmaceutical Co. Ltd., Osaka, Japan.",miyako.hoshino@takeda.com.
33382918,"A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.",2021-May,Woo; Lee,"GC Pharma, Yongin, Korea.; GC Pharma, Yongin, Korea.",
33369704,Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.,2021-Jan,,,domenica.lorusso@policlinicogemelli.it.
33361337,"KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in ",2020-Dec,Ghori; Diede; Croydon,"Department of Clinical Oncology, Merck & Co Inc, Kenilworth, New Jersey, USA.; Department of Clinical Oncology, Merck & Co Inc, Kenilworth, New Jersey, USA.; Department of Clinical Oncology, Merck & Co Inc, Kenilworth, New Jersey, USA.",pier.ferrucci@ieo.it.
33360855,Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.,2021-Feb,Lin; Ibrahim; Diede,"Department of Clinical Oncology, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA. Electronic address: jianxin_lin@merck.com.; Department of Clinical Oncology, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA. Electronic address: nageatte.ibrahim@merck.com.; Department of Clinical Oncology, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA. Electronic address: scott.diede@merck.com.",caroline.robert@gustaveroussy.fr.
33357482,"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.",2021-Jan,,,saad.usmani@atriumhealth.org.
33357452,Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.,2021-Feb-08,,,ssrivas2@fredhutch.org.
33345417,Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes.,2021-Feb,Kodama; Yoshikawa,"Japan Lifeline Co., Ltd., Toda, Japan.; Japan Lifeline Co., Ltd., Toda, Japan.",
33343209,Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.,2020-Nov,,,
33323821,Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients.,2020-Dec-14,Liu,"Department of Medical Affairs, Beijing Novartis Pharma Company Limited, Shanghai 201203, China.",
33309774,Cobimetinib plus atezolizumab in BRAF,2021-Mar,Rooney; Voulgari; Troutman; Pitcher; Guo; Yan; Castro; Mulla,"Genentech, Inc., South San Francisco, USA.; Roche Products Ltd, Welwyn Garden City, UK.; Genentech, Inc., South San Francisco, USA.; Hoffmann-La Roche Ltd., Mississauga, Canada.; Genentech, Inc., South San Francisco, USA.; Genentech, Inc., South San Francisco, USA.; Genentech, Inc., South San Francisco, USA.; Hoffmann-La Roche Ltd., Mississauga, Canada.",helgogas@gmail.com.
33307201,Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy.,2021-Mar,,,Mario.sznol@yale.edu.
33303745,Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.,2020-Dec-10,,,christos.sotiriou@bordet.be.
33301613,One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.,2021-Mar,Ogawa; Yu; Ortiz,"Alexion Pharmaceuticals, Inc., Boston, MA, USA.; Alexion Pharmaceuticals, Inc., Boston, MA, USA.; Alexion Pharmaceuticals, Inc., Boston, MA, USA.",
33290361,Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.,2021-Jan,,,
33289953,A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma.,2021-Mar,Jie; Croitoru; Poondru,"Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.",
33288749,PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.,2020-Dec-07,Butler,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",aribas@mednet.ucla.edu.
33284946,International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.,2020-Dec-08,,,
33276076,"Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.",2021-Mar,Siddiqi; Li; Cyrus; Chackerian; Chain; Altura,"MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, USA.; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.",CBC1971@yuhs.ac.
33275769,Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.,2020-Dec-08,,,
33275723,Immunotherapy with cells.,2020-Dec-04,,,
33273230,Mycosis Fungoides Unmasked by Dupilumab Treatment in a Patient With a History of Atopic Dermatitis.,2021-Oct-01,,,
33268819,"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.",2021-Mar,Li,"QED Therapeutics Inc., San Francisco, CA, USA.",Sameek.Roychowdhury@osumc.edu.
33257382,Nivolumab for malignant peritoneal mesothelioma.,2020-Nov-30,,,nobufujimot@gmail.com.
33256829,Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.,2020-Nov-30,Sorensen,"IMRIS Inc., Minnetonka, MN, USA.",nlin@partners.org.
33249761,Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.,2021-Jan,,,
33249059,"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",2021-Mar,,,
33246931,Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.,2020-Nov,Saggi; McHenry,"Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey, USA.",laurence.albiges@gustaveroussy.fr.
33239098,"Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report.",2020-Nov-26,,,soonishi@aichi-cc.jp.
33234846,Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).,2021-Feb-01,van Dijck; Lobo; Hogg,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",
33219142,Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.,2021-Feb-09,,,Vera.bril@utoronto.ca.
33208490,"Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer.",2020-Nov,,,andres.cervantes@uv.es.
33203854,Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).,2020-Nov-17,,,SHurvitz@mednet.ucla.edu.
33188713,Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.,2021-Mar,,,
33176725,Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.,2020-Nov-11,Kuesters; Overkamp; Belleville,"Merrimack Pharmaceuticals, Cambridge, MA, USA.; Oncologianova GmbH, Recklinghausen, Germany.; ClinSol GmbH & Co KG, Würzburg, Germany.",peter.fasching@fau.de.
33176232,"Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).",2020-Dec,,,paul.cottu@curie.fr.
33171127,Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.,2020-Nov-09,,,Solange.Peters@chuv.ch.
33170461,"Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3).",2021-Jan,Kodani,"Department of Oncology, Ono Pharmaceutical Co., Ltd., Osaka, Japan.",masanobu.takahashi.a7@tohoku.ac.jp.
33168461,Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.,2021-Sep,Pavlova; Thiebach; de Ducla; Fear,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma AG, Grenzach-Wyhlen, Germany.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",jens.bedke@med.uni-tuebingen.de.
33167735,First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.,2021-Feb,Cao; Lu; Bhagia; Shih,"Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.",
33161240,"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.",2020-Dec,Jacob; Jegg; Michielin; Christen; Watson; Cannarile; Klaman; Abiraj; Ries; Weisser; Rüttinger,"Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany. Electronic address: wolfgang.jacob@roche.com.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; A4P Ltd, Sandwich, UK.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.",wolfgang.jacob@roche.com.
33160886,Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus.,2021-Jan,,,aurelien.amiot@aphp.fr.
33158772,Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.,2021-Feb,Leoni; Dale; Herr,"Kyowa Kirin Pharmaceutical Development, Inc, Princeton, NJ.; Kyowa Kirin Pharmaceutical Development, Inc, Princeton, NJ.; Kyowa Kirin, Inc, Bedminster, NJ.",pierluigi.porcu@jefferson.edu.
33154570,"FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.",2021-Feb,Held,"ClinAssess GmbH, Leverkusen, Germany.",Volker.heinemann@med.uni-muenchen.de.
33152119,STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.,2021-Mar-15,Agbor-Tarh; Izquierdo; Granit,"Frontier Science (Scotland) Ltd, Kingussie, UK.; Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland.; Academix Bio Ltd, Jerusalem, Israel.",
33148620,FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.,2020-Nov,,,earandaa@seom.org.
33146741,"Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.",2021-Jan,Paccaly; Li; Rietschel; Sims,"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",skitano@ncc.go.jp.
33144458,Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers.,2020,,,yamagu.toshifumi@gmail.com.
33136585,Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.,2021-Mar-01,,,
33136521,CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.,2020,Jost; Darowski; Challier; Pulko; Hanisch; Xu; Mössner; Bujotzek; Klostermann; Umana; Klein,"Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.; Roche Innovation Center Munich, Roche Pharma Research & Early Development , Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research & Early Development , Penzberg, Germany.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development , Schlieren, Switzerland.",
33128769,Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.,2021-Jan,Kuruvilla,"Princess Margaret Cancer Centre, Toronto, Canada.",
33119048,Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.,2020-Dec-01,Gruber; Rao; Hogan; Accomando; Ostertag; Montellano; Kheoh; Kabbinavar; Kabbinavar,"Formerly Tocagen Inc, San Diego, California.; Formerly Tocagen Inc, San Diego, California.; Formerly Tocagen Inc, San Diego, California.; Formerly Tocagen Inc, San Diego, California.; Formerly Tocagen Inc, San Diego, California.; Formerly Tocagen Inc, San Diego, California.; Formerly Tocagen Inc, San Diego, California.; Formerly Tocagen Inc, San Diego, California.; Puma Biotechnology, Los Angeles, California.",
33109233,Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.,2020-Oct-27,Agbor-Tarh; Izquierdo,"Frontier Science (Scotland) Ltd, Kincraig, UK.; Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland.",serena.dicosimo@istitutotumori.mi.it.
33098704,The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.,2021-Feb,,,
33097971,A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).,2021-Feb,,,k-shinozaki@hph.pref.hiroshima.jp.
33097687,Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.,2020-Oct-23,,,sloni01@emory.edu.
33097612,Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.,2020-Oct,Jacob; Jegg; Cannarile; Watson; Babitzki; Korski; Klaman; Teixeira; Hoves; Ries; Meneses-Lorente; Michielin; Christen; Rüttinger; Weisser,"Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; A4P Ltd, Sandwich, UK.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.; Roche Innovat Ctr Munich Oncol Discovery Pharma, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.",jean-pascal.machiels@uclouvain.be.
33096610,The Circular Life of Human CD38: From Basic Science to Clinics and Back.,2020-Oct-21,,,
33095031,Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.,2021-May,Ramagopalan; Pisoni; Zenin; Rathore; Ray,"Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma International Informatics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Data Science & Advanced Analytics, Roche Moscow Ltd, Moscow, Russian Federation.; Strategic Insights & Advance Analytics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
33091125,Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.,2020-Oct-27,,,
33090268,"A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.",2021-Feb,,,katarzyna.jerzak@sunnybrook.ca.
33087895,Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.,2021-Feb,,,Prachi_Bhave@yahoo.com.
33087150,Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.,2020-Oct-21,,,f.perrone@istitutotumori.na.it.
33078867,PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.,2020-Oct-20,,,
33072116,Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.,2020,Zhang,"West China-Frontier Pharma Tech Co., Ltd. (WCFP), Chengdu, China.",
33067614,A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).,2021-Mar-25,Brivio; Lopez-Yurda; Ammerlaan; Thano; van der Sluis; den Boer; Sleight; Zwaan,"Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Pfizer Inc, Groton, CT.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.",
33064988,"A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.",2020-Oct-15,,,patrick_ott@dfci.harvard.edu.
33059764,"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.",2020-Oct-15,,,jorge.cortes@augusta.edu.
33054054,Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.,2020-Sep-01,Bolen; Klanova; He; Tong; Paulson; Kim; Fingerle-Rowson; Nielsen; Oestergaard,"Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, CA, USA.; Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, CA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Department of Biostatistics, Product Development, Genentech Inc., South San Francisco, CA, USA.; Department of Biostatistics, Product Development, Genentech Inc., South San Francisco, CA, USA.; Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
33046869,Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.,2020-Dec,,,JGao1@mdanderson.org.
33046621,"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.",2020-Oct,Rasmussen; Juan; Wong; Soman; Smit; Nagorsen,"Amgen Inc, Thousand Oaks, California, USA.; Amgen Inc, Thousand Oaks, California, USA.; Amgen Inc, South San Francisco, California, USA.; Amgen Inc, Thousand Oaks, California, USA.; Amgen Inc, Thousand Oaks, California, USA.; Amgen Inc, Thousand Oaks, California, USA.",kyri.papadopoulos@startsa.com.
33046558,Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.,2021-Jul,,,s.kanis@erasmusmc.nl.
33046516,Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive ,2021-Feb-15,,,yuh@mskcc.org.
33037118,"Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.",2020-Oct,Pennock,"EMD Serono, Inc, Rockland, Massachusetts, USA; a business of Merck KGaA, Darmstadt, Germany.",andrea.apolo@nih.gov.
33037117,Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.,2020-Oct,Siu,"Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ontario, Canada lillian.siu@uhn.ca.",lillian.siu@uhn.ca.
33031633,HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor.,2020-Nov,,,
33031626,Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies.,2021-Feb,Tajima; Tokushige; Ishihara,"Novartis Pharma KK, Tokyo, Japan.; Novartis Pharma KK, Tokyo, Japan.; Novartis Pharma KK, Tokyo, Japan.",
33022066,Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.,2020-Oct-13,Huang; Prathikanti; Cohen; Elstrom; Reed; Schneider,"BeiGene USA, Inc., San Mateo, CA; and.; BeiGene USA, Inc., San Mateo, CA; and.; BeiGene USA, Inc., San Mateo, CA; and.; BeiGene USA, Inc., San Mateo, CA; and.; BeiGene USA, Inc., San Mateo, CA; and.; BeiGene USA, Inc., San Mateo, CA; and.",
33020648,"Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.",2020-Oct,Masood; Brase; Gasal,"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",Reinhard.Dummer@usz.ch.
33020241,,2020-Oct,Jorritsma-Smit; Lub-de Hooge,"Department of Clinical Pharmacy and Pharmacology, UMCG, Groningen, Groningen, Netherlands.; Department of Clinical Pharmacy and Pharmacology, UMCG, Groningen, Groningen, Netherlands m.n.de.hooge@umcg.nl.",m.n.de.hooge@umcg.nl.
33016109,The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany.,2020-Oct,Dünzinger; Launonen; Thuresson,"Roche Pharma AG, Grenzach-Wyhlen, 79639, Germany.; F. Hoffman-La Roche Ltd, Basel, 4070, Switzerland.; F. Hoffman-La Roche Ltd, Basel, 4070, Switzerland.",
33015996,Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study.,2020-Nov,,,
33015525,Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.,2020,,,
33012782,A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.,2021-Jan,Tang; Tang,"Clinical Pharmacology and Safety Assessment, AstraZeneca, One Medimmune Way, 101 ORD, 2001D, Gaithersburg, MD, 20878, USA.; Clinical Pharmacology and Safety Assessment, AstraZeneca, One Medimmune Way, 101 ORD, 2001D, Gaithersburg, MD, 20878, USA.",Ben.Creelan@moffitt.org.
33012455,Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.,2020-Nov,,,jbruix@clinic.cat.
33010459,TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma.,2021-Jan,,,Laurence.ALBIGES@gustaveroussy.fr.
33003481,Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation.,2020-Sep-29,,,
33001135,Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.,2020-Nov-01,Knox; Neely; Shen; Wisniewski; Anderson,"Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Department of Immuno-Oncology, Biomarkers, and Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey.; Department of Immuno-Oncology, Oncology, and Immunology, Bristol Myers Squibb, Princeton, New Jersey.; Department of Clinical Research, Bristol Myers Squibb, Princeton, New Jersey.; Department of Clinical Research, Bristol Myers Squibb, Princeton, New Jersey.",
32999042,An Antibody-Tumor Necrosis Factor Fusion Protein that Synergizes with Oxaliplatin for Treatment of Colorectal Cancer.,2020-Dec,,,dario.neri@pharma.ethz.ch.
32992341,Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.,2021-Mar-11,,,
32989806,Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database.,2021-Feb,Sellner; Ratsch; Basic,"Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.",
32976938,A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.,2020-Dec,,,Rolf.Stahel@etop-eu.org.
32975869,"Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.",2020-Dec,,,
32975815,Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.,2020-Dec-15,,,
32973129,Bone morphogenetic protein 7 promotes resistance to immunotherapy.,2020-Sep-24,,,MACortez@mdanderson.org.
32969597,Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.,2020-Nov,,,
32946924,"Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.",2020-Dec,Goldenberg; Sharkey; Maliakal; Hong; Goswami; Wegener,"Clinical Development, Immunomedics, Inc., Morris Plains, USA.; Clinical Development, Immunomedics, Inc., Morris Plains, USA.; Clinical Development, Immunomedics, Inc., Morris Plains, USA.; Clinical Development, Immunomedics, Inc., Morris Plains, USA.; Clinical Development, Immunomedics, Inc., Morris Plains, USA.; Clinical Development, Immunomedics, Inc., Morris Plains, USA.",kk2693@cumc.columbia.edu.
32933335,Anti-CD20 treatment for B-cell malignancies: current status and future directions.,2021-Feb,Klein; Jamois; Nielsen,"Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland.; Clinical Pharmacology, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel , Basel, Switzerland.; Product Development Oncology, F. Hoffmann-La Roche Ltd , Basel, Switzerland.",
32932518,Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.,2021-Feb-25,,,
32926507,First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.,2020-Dec,Ebiana,"Merck & Co., Inc., Kenilworth, NJ, USA.",
32917410,PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.,2020-Nov,Fury; Feng; Stankevich; Li; Yama-Dang; Yoo; Lowy; Mathias; Fury,"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",Danny.Rischin@petermac.org.
32916308,Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.,2020-Dec,,,jwelsh@mdanderson.org.
32916126,Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.,2020-Oct-12,,,catherine.grasso@cshs.org.
32914866,Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.,2020-Nov-15,Lin; Pietanza; Piperdi,"Merck & Co, Inc, Kenilworth, New Jersey.; Merck & Co, Inc, Kenilworth, New Jersey.; Merck & Co, Inc, Kenilworth, New Jersey.",
32910710,Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.,2020-Nov-20,Waterhouse; Li; Aanur,"The US Oncology Network/Oncology Hematology Care, Cincinnati, OH.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.",
32910151,Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.,2020-Nov-01,,,
32907924,Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.,2020-Sep,Zhou,"Merck Serono Pharmaceutical R&D Co, Beijing, China; an affiliate of Merck KGaA, Darmstadt, Germany.",claire.verschraegen@osumc.edu.
32905959,Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.,2020-Oct,Fear; Di Nucci; de Ducla,"F Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: simon.fear@roche.com.; Genentech, Inc., South San Francisco, CA, USA. Electronic address: di-nucci.flavia@gene.com.; F Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: sabine.de_ducla@roche.com.",yohann.loriot@gustaveroussy.fr.
32897497,Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.,2021-Apr,Sánchez,"Medical Department, Roche Farma S.A., Madrid, Spain.",ignacioduranmartinez@gmail.com.
32894785,Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.,2020-Dec,Hoffmann,"ICH Study Center GmbH & Co KG, Hamburg, Germany.",
32894101,Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.,2020-Sep-07,,,sebastian.hultin@doctors.org.uk.
32893992,Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.,2021-Jun,Hayashi; Tanaka,"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",
32890812,Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?,2020-Oct,,,kkaehler@dermatology.uni-kiel.de.
32886753,"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.",2020-Sep-08,Kiessling; Massow; Woltering; Snipes; Ke; Langdon,"Union Chimique Belge (UCB) Pharma, Monheim-am-Rhein, Germany.; Union Chimique Belge (UCB) Pharma, Monheim-am-Rhein, Germany.; Union Chimique Belge (UCB) Pharma, Monheim-am-Rhein, Germany.; UCB Pharma, Raleigh, NC.; UCB Pharma, Slough, United Kingdom.; PTx Solutions Ltd, London, United Kingdom.",
32885904,Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.,2020-Nov,,,
32880602,"Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.",2020-Oct-01,,,
32880601,"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.",2020-Oct-01,Kher; Shah; Kang,"Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, New Jersey.; Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, New Jersey.; Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, New Jersey.",
32878811,Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.,2020-Sep,Tajima; Isaacs,"Novartis Pharma K.K., Tokyo, Japan.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A.",hminami@med.kobe-u.ac.jp.
32870269,"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.",2021-Feb-04,Martín-Regueira; Sumbul; Samakoglu; Tang,"Bristol Myers Squibb, Princeton, NJ; and.; Bristol Myers Squibb, Princeton, NJ; and.; Bristol Myers Squibb, Princeton, NJ; and.; Bristol Myers Squibb, Princeton, NJ; and.",
32865652,Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.,2020-Dec,Kerioui; Krieter; Bruno,"Clinical Pharmacology, Genentech/Roche, Paris, France.; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany.; Clinical Pharmacology, Genentech/Roche, Marseille, France.",francois.mercier@roche.com.
32863385,Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.,2020-Nov,,,tmasuishi@aichi-cc.jp.
32859260,Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report.,2020-Aug-28,,,maximilian.higer@unimedizin-mainz.de.
32857420,Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.,2020-Oct,,,
32847985,Durvalumab activity in previously treated patients who stopped durvalumab without disease progression.,2020-Aug,,,siddharth.sheth@med.unc.edu.
32847969,Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction.,2020-Nov,Sahin; Klein,"Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Zurich, Switzerland.",charles.dumontet@chu-lyon.fr.
32847933,Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.,2020-Nov-01,Kauh; Novosiadly,"Hutchison MediPharma International (US) Inc., Florham Park, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.",autiok@mskcc.org.
32822287,"Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.",2021-Jan-01,Kenny; Sarp; Izquierdo; Williams,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom.",
32822275,Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.,2021-Jan-01,,,
32820271,A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.,2021-Apr,,,matthew_davids@dfci.harvard.edu.
32819972,Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.,2020-Aug,,,eric.deutsch@gustaveroussy.fr.
32819447,"Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.",2020-Aug-20,,,k.weisel@uke.de.
32817068,Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.,2020-Aug,,,azhu@mgh.harvard.edu.
32816895,Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).,2020-Nov-01,,,Diane.DaSilva@med.usc.edu.
32812370,Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.,2021-Jan,Chen; Haughey; Vandendries; Ruiz-Garcia,"Pfizer Inc, New York, New York, USA.; Pfizer Inc, San Diego, California, USA.; Pfizer Inc, Cambridge, Massachusetts, USA.; Pfizer Inc, San Diego, California, USA.",
32812243,Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma.,2020-Nov,Hatsumichi; Namba,"Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Ono Pharmaceutical Co., Ltd., Osaka, Japan.",
32810220,A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.,2020-Aug-25,Davis; Lasher; Izquierdo; Banerjee,"Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharma AG, Basel, Switzerland; and.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",
32810157,"Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.",2020,,,
32805058,Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.,2020-Nov,Wang; Neuhof; Vandendries,"Pfizer Inc, Cambridge, MA, USA.; Pfizer Pharma GmbH, Berlin, Germany.; Pfizer Inc, Cambridge, MA, USA.",
32795284,Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.,2020-Aug-14,,,c.dickhoff@amsterdamumc.nl.
32789773,Controversies in the treatment of RAS wild-type metastatic colorectal cancer.,2021-Apr,,,earandaa@seom.org.
32785666,Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.,2020-Dec-03,Samineni; Punnoose; Szafer-Glusman; Spielewoy; Mobasher; Kornacker,"Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland; and.; Genentech, Inc., South San Francisco, CA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland; and.",
32771306,The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.,2020-Sep,,,vsubbiah@mdanderson.org.
32770720,Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).,2021-Jan,Afar; Parikh; Engelhardt; Englert; Lambert; Kasichayanula; Mensing; Menon; Vosganian,"Oncology Early Development, AbbVie, Inc., Redwood City, California, USA.; Clinical Pharmacology and Pharmacometrics, AbbVie, Inc., Redwood City, California, USA.; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.; Data and Statistical Sciences, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.; Oncology Early Development, AbbVie, Inc., Redwood City, California, USA.; Clinical Pharmacology and Pharmacometrics, AbbVie, Inc., Redwood City, California, USA.; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.; Oncology Early Development, AbbVie, Inc., Redwood City, California, USA.",
32770608,Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.,2020-Dec,,,
32769965,Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.,2020-Aug-07,Wang; Vandendries; Neuhof,"Pfizer Inc, Cambridge, MA, 02139, USA.; Pfizer Inc, Cambridge, MA, 02139, USA.; Pfizer Pharma GmbH, 10785, Berlin, Germany.",Daniel_Deangelo@dfci.harvard.edu.
32767806,R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.,2020-Oct,,,
32763109,"Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.",2020-Oct,Irahara; Donica,"Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Development Biostatistics Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.",andres.redondos@uam.es.
32757302,A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.,2020-Oct-15,Schmidt; Bitman; Munugalavadla; Izumi; Patel,"Merck & Co, Inc, North Wales, Pennsylvania.; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.",
32753547,Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.,2020-Aug,,,mark_awad@dfci.harvard.edu.
32747302,Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.,2020-Oct,,,Sylvain.manfredi@chu-dijon.fr.
32741971,"First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours.",2020-Oct,,,jmartinliberal@gmail.com.
32730586,A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.,2020-Nov-19,Schwarz; Alland; Strassz; Prier; Choe-Juliak,"Affimed GmbH, Heidelberg, Germany.; Affimed, Inc., New York, NY; and.; Affimed GmbH, Heidelberg, Germany.; Affimed GmbH, Heidelberg, Germany.; Affimed, Inc., New York, NY; and.",
32710922,Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.,2020-Dec,Wadhawan; Boyd; Tang; Shen; Tschaika; Neely,"Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",bsangro@unav.es.
32705363,Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.,2021-Jan,,,hhorinou@ncc.go.jp.
32692850,Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia.,2020-Jul-28,,,
32690620,Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR).,2020-Jul,Yada,"Ono Pharmaceutical Co., Ltd, Osaka, Osaka, Japan.",okishio.kyoichi.hj@mail.hosp.go.jp.
32673417,"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.",2020-Sep-15,McHenry; Saggi,"Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey.; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey.",
32672795,Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.,2020-Aug-01,Lin; Homet Moreno; Ibrahim,"Merck & Co, Inc, Kenilworth, New Jersey.; Merck & Co, Inc, Kenilworth, New Jersey.; Merck & Co, Inc, Kenilworth, New Jersey.",
32671831,COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.,2020-Nov,,,
32669858,Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.,2020,,,
32661118,Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.,2020-Jul,McHenry; Saggi,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",motzerr@mskcc.org.
32661116,The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.,2020-Jul,,,madhav.v.dhodapkar@emory.edu.
32640047,Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.,2020-Nov,Wilson; Gustovic,"Alexion Pharmaceuticals, Inc., Boston, MA, USA.; Alexion Pharma GmbH, Zürich, Switzerland.",
32634611,"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial",2020-Oct,Peña-Murillo; Yilmaz; Donica,"Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Personalized Healthcare, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Pharma Development and Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland.",filippo.montemurro@ircc.it.
32632305,NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?,2020-Sep,,,akamat@mdanderson.org.
32629391,Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.,2020-Jul,,,maemondo-ma693@aioros.ocn.ne.jp.
32620755,Cancer immunotherapy comes of age and looks for maturity.,2020-Jul-03,,,cjune@upenn.edu.
32620640,Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer.,2020-Jul,Grafe; Hitschold; Lattrich,"Health Care Center Nordhausen gGmbH, Nordhausen, Germany.; Klinikum Worms gGmbH, Worms, Germany.; Roche Pharma AG, Grenzach, Germany.",Lars.Hanker@uksh.de.
32616555,A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.,2020-Jul,,,graffj@ohsu.edu.
32610172,Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?,2020-Sep,Solas,"Aix Marseille Univ, APHM, INSERM 1207, IRD 190, UVE, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, F-13005 Marseille, France.",paul.gougis@aphp.fr.
32606164,Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer.,2020,,,kawakami_h@med.kindai.ac.jp.
32603414,CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.,2020-Nov-19,,,
32601377,A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.,2021-Mar,Zhu; Popa McKiver,"Bristol-Myers Squibb, Princeton, NJ, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.",ansell.stephen@mayo.edu.
32594779,"A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.",2020-Jul,Wei; Ou; Zhang; Jin,"Anhui Province Key Laboratory of Gene Engineering Pharmaceutical, Anhui Anke Biotechnology (Group) Co., Ltd ., Anhui, China.; United-Power Pharma Tech Co., Ltd , Beijing, China.; National and Local Joint Engineering Research Center for Precision Cancer Therapy Technology and Products, Anhui Anke Biotechnology (Group) Co., Ltd , Anhui, China.; National and Local Joint Engineering Research Center for Precision Cancer Therapy Technology and Products, Anhui Anke Biotechnology (Group) Co., Ltd , Anhui, China.",
32587360,Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.,2020-Sep,,,viktor.gruenwald@uk-essen.de.
32583948,Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma.,2020-Nov,Xu; Sun,"Janssen Research and Development, Raritan, Princeton, New Jersey, USA.; Janssen Research and Development, Raritan, Princeton, New Jersey, USA.",
32576578,Identification of MicroRNAs With ,2020,Weidle; Nopora,"Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany adam.nopora@roche.com weidle49@t-online.de.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany adam.nopora@roche.com weidle49@t-online.de.",adam.nopora@roche.com
32567084,Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.,2020-Aug-15,,,
32554615,"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.",2020-Jun,Okoye; Mathias; Jankovic; Stankevich; Booth; Li; Lowy; Fury,"Regeneron Pharmaceuticals, Inc, London, UK.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Basking Ridge, New Jersey, USA.; Regeneron Pharmaceuticals, Inc, Basking Ridge, New Jersey, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.",danny.rischin@petermac.org.
32554313,Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.,2020-Sep,,,bcybulskatopa@vp.pl.
32544980,Pembrolizumab in relapsed or refractory Richter syndrome.,2020-Jul,Chatterjee; Orlowski; Marinello,"Merck & Co., Inc, Kenilworth, NJ, USA.; Merck & Co., Inc, Kenilworth, NJ, USA.; Merck & Co., Inc, Kenilworth, NJ, USA.",
32534809,Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.,2020-Sep,,,mfrumovitz@mdanderson.org.
32533228,Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2).,2020-Sep,Männikkö,"Pharma Ltd, Turku, Finland.",Rades.Dirk@gmx.net.
32526634,"Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).",2020-Aug,,,dsakai@cfs.med.osaka-u.ac.jp.
32519026,A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.,2020-Aug,Ochi,"Ono Pharmaceutical Co., Ltd, Osaka, Japan.",huemura@med.kindai.ac.jp.
32516414,ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.,2020-Jun-09,,,
32515086,Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance.,2020-Aug,,,
32505213,"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.",2020-Jun-06,Liu; Bolen; Knapp; Sahin; Sellam,"Roche Pharma Development, Shanghai, China.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",Lsehn@bccancer.bc.ca.
32503946,Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.,2020-Jun,Hosein; Simsek; Simsek,"Oncology Clinical Development, Bristol-Myers Squibb Co, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol-Myers Squibb Co, Princeton, New Jersey, USA.; Department of Biostatistics, Bristol-Myers Squibb Co, Princeton, New Jersey, USA.",paolo.ascierto@gmail.com.
32503572,Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.,2020-Jun-05,,,NShort@mdanderson.org.
32502876,Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.,2020-Jul,Prince; Wang; Lisano; Richhariya; Feliciano; Zhu; Bunn; Little; Zagadailov; Dalal,"Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8066, Australia. Electronic address: miles.prince@petermac.org.; Seattle Genetics, Inc., Bothell, WA, USA. Electronic address: ywang@seagen.com.; Seattle Genetics, Inc., Bothell, WA, USA. Electronic address: jlisano@seagen.com.; Seattle Genetics, Inc., Bothell, WA, USA. Electronic address: arichhariya@seagen.com.; Seattle Genetics, Inc., Bothell, WA, USA. Electronic address: felicianojoseph1@gmail.com.; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. Electronic address: Yanyan.Zhu@takeda.com.; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. Electronic address: Veronica.Bunn@takeda.com.; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. Electronic address: meredith.little@takeda.com.; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. Electronic address: erin.zagadailov@gmail.com.; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. Electronic address: mehul.dalal@takeda.com.",reinhard.dummer@usz.ch.
32501471,Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression.,2021-Jan-09,Martin; Laux; Franz; Fuchs; Weigle,"Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str. 65, 88397 Biberach/Riss, Germany.; Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str. 65, 88397 Biberach/Riss, Germany.; Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str. 65, 88397 Biberach/Riss, Germany.; Biotherapeutics Discovery, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str. 65, 88397 Biberach/Riss, Germany.; Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str. 65, 88397 Biberach/Riss, Germany.",
32497736,Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.,2020-Sep,,,eric.vancutsem@uzleuven.be.
32484460,PD-1 blockade inhibits osteoclast formation and murine bone cancer pain.,2020-Jul-01,Liao,Department of Pharmacology and Cancer Biology.,
32478814,A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.,2020-Jun-11,,,
32472503,"Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.",2020-Aug,,,murtuza.bharmal@emdserono.com.
32472087,Near IR responsive targeted integrated lipid polymer nanoconstruct for enhanced magnolol cytotoxicity in breast cancer.,2020-May-29,,,rihabosman@pharma.asu.edu.eg.
32470440,Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.,2020-Jun,,,thanarajasingam.gita@mayo.edu.
32464632,The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.,2020,,,n2furuya@marianna-u.ac.jp.
32463456,Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.,2020-Jul-01,,,
32459600,"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.",2020-Sep-01,Avery; Liang; Patel; Quah,"Nebraska Hematology Oncology, Lincoln, NE.; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA.; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA.; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA.",
32457999,Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?,2020-Jul-02,,,
32454069,Are we ready to accept intermediate outcome measures in clinical cancer trials?,2020-Aug,,,Viktor.Gruenwald@UK-Essen.de.
32449174,"Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.",2020-Nov,Ortiz; Rottinghaus; Aguzzi; Gao,"Alexion Pharmaceuticals, Inc., Boston, MA, USA.; Alexion Pharmaceuticals, Inc., Boston, MA, USA.; Alexion Pharmaceuticals, Inc., Boston, MA, USA.; Alexion Pharmaceuticals, Inc., Boston, MA, USA.",
32449093,Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.,2021-Jan,,,d.morganstein@ic.ac.uk.
32449003,Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).,2020-Oct,Greeve,"St. Vincenz-Krankenhaus Paderborn, Paderborn, Germany.",dominik.modest@charite.de.
32448949,Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.,2020-Sep,Tokushige; Fujita,"Novartis Pharma K.K., Toranomon Minato-ku, Tokyo, Japan.; Novartis Pharma K.K., Toranomon Minato-ku, Tokyo, Japan.",hidekigt@med.hokudai.ac.jp.
32444867,Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.,2021-Feb,,,mdimop@med.uoa.gr.
32437528,Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms.,2020-Jun-01,O'Dowd; Dedi; Topia; Griffin; McMillan; Marshall; Lightwood,"UCB Pharma, 208-216 Bath Road, Berkshire, UK.; UCB Pharma, 208-216 Bath Road, Berkshire, UK.; UCB Pharma, 208-216 Bath Road, Berkshire, UK.; UCB Pharma, 208-216 Bath Road, Berkshire, UK.; UCB Pharma, 208-216 Bath Road, Berkshire, UK.; UCB Pharma, 208-216 Bath Road, Berkshire, UK.; UCB Pharma, 208-216 Bath Road, Berkshire, UK.",
32437507,Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.,2020-Jul-01,Carleton; Tatsuoka; Taitt; Zwirtes,"Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.",
32434789,Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy.,2020-May,,,michael.t.serzan@gunet.georgetown.edu.
32432798,Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study.,2020-Dec,Mendelsohn; Parno; Rozzo; Davidson; Gupta,"Sun Pharmaceutical Industries, Inc, Princeton, NJ, USA.; Sun Pharmaceutical Industries, Inc, Princeton, NJ, USA.; Sun Pharmaceutical Industries, Inc, Princeton, NJ, USA.; Sun Pharmaceutical Industries, Inc, Princeton, NJ, USA.; Mediprobe Research, Inc, London, ON, Canada.",
32432649,Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.,2020-Jul-01,,,
32422505,Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab.,2020-Jul,,,miyauchi@rm.med.tohoku.ac.jp.
32418993,Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?,2020-Jul,,,vincent.cheung@doctors.org.uk.
32414862,Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.,2020-May,,,dangelos@mskcc.org.
32409691,A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.,2020-Dec,Lendvai,"Janssen Pharmaceuticals, Titusville, NJ, USA.",jmikhael@myeloma.org.
32404868,Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.,2020-Dec,Jiao; Tangirala,"Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.",nshore@gsuro.com.
32404569,Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy.,2020-Jun-20,,,
32387454,Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy,2020-Aug,,,georgina.long@sydney.edu.au.
32386593,"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.",2020-May-09,Martin; Ding; Pellet; Mpofu; Pricop,"Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharma, Basel, Switzerland.; Novartis Pharma, Basel, Switzerland.; Novartis Pharmaceuticals, East Hanover, NJ, USA.",iain.mcinnes@glasgow.ac.uk.
32378440,Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.,2020-Aug,Wang; Neuhof; Vandendries,"Global Product Development - Oncology, Pfizer Inc, Cambridge, MA, USA.; Pfizer Pharma GmbH, Berlin, Germany.; Global Product Development - Oncology, Pfizer Inc, Cambridge, MA, USA.",
32377821,Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.,2020-Aug,,,Laila.Koenig@med.uni-heidelberg.de.
32376855,"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.",2020-Dec,Reece,"Princess Margaret Cancer Centre, Toronto, ON, Canada.",davids.siegel@hackensackmeridian.org.
32358520,Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.,2020-May-01,Paci; Paci; Seck; Chaput,"Institut Gustave Roussy, Pharmacology and Drug Analysis Department, Villejuif, F-94805, France.; Université Paris-Saclay, Faculté de Pharmacie, Chatenay-Malabry, F-92296, France.; Institut Gustave Roussy, Pharmacology and Drug Analysis Department, Villejuif, F-94805, France.; Université Paris-Saclay, Faculté de Pharmacie, Chatenay-Malabry, F-92296, France. nathalie.chaput@gustaveroussy.fr.",nathalie.chaput@gustaveroussy.fr.
32354934,Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab ,2020,,,b07m1050z@yahoo.co.jp.
32352498,A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.,2020-Jun-01,,,
32339648,Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.,2020-Aug,,,toni_choueiri@dcfi.harvard.edu.
32338867,Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.,2020-Jun-19,,,
32332851,Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts.,2020-Apr-24,,,solitd@mskcc.org.
32330241,"A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).",2020-Apr-28,,,
32325490,"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.",2020-Aug-20,,,
32314038,Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.,2020-Dec,Trask; Hänel; Knapp; Liu,"Genentech Inc., South San Francisco, CA, USA.; Klinikum Chemnitz gGmbH, Chemnitz, Germany.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",a.davies@southampton.ac.uk.
32311799,Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.,2020-Aug,Moorahrend; Gaillard,"Zentrum für Hämatologie und Onkologie MVZ GmbH, Porta Westfalica, Germany.; Roche Pharma AG, Medical Affairs, Grenzach-Wyhlen, Germany.",
32305093,"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.",2020-Apr-18,Izumi; Munugalavadla; Patel; Wang; Wong,"Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.",john.byrd@osumc.edu.
32305010,A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.,2020-May,Lala; Li; de Alwis; Sinha; Mayawala; Chartash; Aboshady; Jain,"Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.; Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.; Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.; Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.; Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.; Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.; Clinical Safety and Risk Management, Merck & Co., Inc., Kenilworth, NJ, USA.; Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: lokesh_jain@merck.com.",lokesh_jain@merck.com.
32298807,Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.,2020-Jul,,,david.porter@pennmedicine.upenn.edu.
32296919,PD-1,2020-Aug,,,marcel.trefny@unibas.ch.
32294530,"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.",2020-Jul,,,ferrrl@UPMC.EDU.
32286687,Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.,2020-Jul-01,Song; Trask,"Genentech, Inc., South San Francisco, California.; Genentech, Inc., South San Francisco, California.",
32280859,Synthesis and Biological Evaluation of Antibody Drug Conjugates Based on an Antibody Expression System: Conamax.,2020-Apr-07,Tawfiq; Matsuda; Mendelsohn,"Ajinomoto Bio-Pharma Services, 11040 Roselle St, San Diego, California 92121, United States.; Ajinomoto Bio-Pharma Services, 11040 Roselle St, San Diego, California 92121, United States.; Ajinomoto Bio-Pharma Services, 11040 Roselle St, San Diego, California 92121, United States.",
32277531,Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.,2020-Jun,Yamamoto,"Oncology Clinical Development Planning 1, Ono Pharmaceutical Co. Ltd, Osaka, Japan.",
32276179,Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.,2020-May,,,alexis.cortot@chru-lille.fr.
32275086,Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study.,2020-Jun,Takatsu; Ootaki,"Medical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan.; R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.",
32273276,Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.,2020-Jul-15,Brockstedt,"Aduro Biotech Inc., Berkeley, California.",dle@jhmi.edu.
32271900,The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.,2020-Apr-14,,,
32271377,Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.,2020-May-01,,,
32269140,Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.,2020-Apr,Engelsberg,"Pfizer Oncology, Pfizer Pharma, Berlin, Germany.",jwwalker@ualberta.ca.
32259868,[Systemic therapy for metastatic urothelial carcinoma - Current status and what comes after checkpoint inhibitors?].,2020-Aug,,,
32259228,Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.,2020-Apr-07,Abdul Razak,"Princess Margaret Cancer Center, Toronto, Ontario, Canada.",
32256049,A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.,2020,Zou; Zhang; Luo; Lahn; Kallender; Mannucci; Somma,"Jiangsu Hengrui Medicine Co. Ltd, Shanghai, People's Republic of China.; Jiangsu Hengrui Medicine Co. Ltd, Shanghai, People's Republic of China.; Jiangsu Hengrui Medicine Co. Ltd, Shanghai, People's Republic of China.; Incyte Biosciences International Sarl, Geneva, Switzerland.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Biosciences International Sarl, Geneva, Switzerland.; Incyte Biosciences International Sarl, Geneva, Switzerland.",
32253666,Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?,2020-May,,,suzumiya@med.shimane-u.ac.jp.
32252684,"Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.",2020-Apr-06,Sent,"Klinikum Leverkusen gGmbH, Am Gesundheitspark 11, 51375, Leverkusen, Germany.",manuscript@iomedico.com.
32248071,Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.,2020-May,,,eleftheria.chorti@uk-essen.de.
32248069,Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab.,2020-May,,,yui1783@yokohama-cu.ac.jp.
32247642,"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.",2020-Jul,Netzer,"Department of Pharmacy, Villejuif, France.",jean-marie.michot@gustaveroussy.fr.
32244252,Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.,2020-Jul-02,,,
32236950,A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.,2020-Sep,Werner; Vincent; Khanna,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma S.A.S, Paris, France.; Novartis Pharma S.A.S, Paris, France.",
32233107,Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.,2020-Jul,Ding; Quach; Hashimoto; Schiff; Piault-Louis,"Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Roche Products Ltd, Welwyn Garden City, UK.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.",
32232481,Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.,2020-Jun-18,Higley,"CCS Associates, Inc., San Jose, CA.",
32221017,Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.,2020-Mar,,,teresa.amaral@med.uni-tuebingen.de.
32215194,Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.,2020,,,
32209338,"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.",2020-Jun,Broadhurst,"Plus-Project Ltd, Alderley Park, UK.",lpazaresr@seom.org.
32207067,Malignancy Rates in Brodalumab Clinical Studies for Psoriasis.,2020-Jun,,,alice.gottlieb@mountsinai.org.
32205463,"A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.",2020-Jul-01,,,postowm@mskcc.org.
32203207,Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.,2020-May,Werner,"Novartis Pharma AG, Basel, Switzerland.",evandro.azambuja@bordet.be.
32203138,"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.",2021-Jan,,,montesinos_pau@gva.es.
32201234,ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.,2020-May,,,David.PLANCHARD@gustaveroussy.fr.
32194183,Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.,2020-Aug,,,mmizokami@hospk.ncgm.go.jp.
32192809,Atypical extended immune-related neutropenia in patient treated with pembrolizumab.,2020-May,,,pierreantoine.laurain@gmail.com.
32189108,'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.,2020-Jul,Fujita; Fujita; O'Brien,"Alnylam Pharmaceuticals, 675 West Kendall Street, Cambridge, MA, 02142, USA.; Formerly Alexion Pharmaceuticals, 121 Seaport Boulevard, Boston, MA, 02210, USA.; Alexion Pharmaceuticals, 121 Seaport Boulevard, Boston, MA, 02210, USA.",john.vissing@regionh.dk.
32188704,Phase 2 study of pembrolizumab in patients with advanced rare cancers.,2020-Mar,,,anaing@mdanderson.org.
32188412,Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.,2020-Mar-18,,,ngaisa@ukaachen.de.
32180219,The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.,2020-May,Eckert; Ping; Co; Beaupre; Neuenburg,"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.",
32179633,"A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.",2020-Mar,Wu; Sun,"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.",anaing@mdanderson.org.
32179448,"Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy.",2020-May,van Noesel; van Rijn; Caron,"Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; IPODD, Pharma Development Oncology, Hoffmann-La Roche, Switzerland.",andrea.ferrari@istitutotumori.mi.it.
32178964,Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.,2020-May,Patel; Henschel; Chui,"Genentech, Inc., South San Francisco, USA.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, USA.",Sylvia.Adams@nyulangone.org.
32173464,"Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.",2020-Jul,,,lpazares@seom.org.
32172489,Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.,2020-Oct,Quinson; von Wangenheim; Burkard; Berk,"Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT, 06877, USA.; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.; ClinTriCare GmbH & Co. KG, Untere Illereicher Str. 10, 89281, Altenstadt, Germany.",Norbert.Schmitz@ukmuenster.de.
32169873,Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.,2020-Mar,,,anna.minchom@icr.ac.uk.
32161368,"Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.",2020-Apr,Buschke; Fuertig; Schmid; Goeldner; Strelkowa; Huang,"Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach an der Riß, Germany.; Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach an der Riß, Germany.; Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach an der Riß, Germany.; Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str. 65, Biberach an der Riß, Germany.; Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str. 65, Biberach an der Riß, Germany.; Medical Department, Boehringer Ingelheim Taiwan Ltd, 12F, No. 2, Sec 3, Minsheng East Road, Taipei, Taiwan.",jdebono@icr.ac.uk.
32160365,Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.,2020-May,,,
32152503,"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.",2020-Apr,,,Namrata.vijayvergia@fccc.edu.
32145474,Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.,2020-Apr,,,akawazoe@east.ncc.go.jp.
32142673,Boosting Cytotoxic Antibodies against Cancer.,2020-Mar-05,Gauthier; Vivier,"Innate Pharma Research Laboratories, Innate Pharma, Marseille, France. Electronic address: laurent.gauthier@innate-pharma.fr.; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France; Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France; APHM, Hôpital de la Timone, Service d'Immunologie, Marseille-Immunopôle, Marseille, France.",laurent.gauthier@innate-pharma.fr.
32139298,"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.",2020-Apr,Vishwanathan,"Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Boston, USA.",geoffrey_oxnard@dfci.harvard.edu.
32139017,"High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.",2020-Mar,,,eemanasanch@mdanderson.org.
32114502,"Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.",2020-Feb,Munugalavadla; Patel; Tao,"Acerta Pharma LLC, Redwood City, California, USA.; Acerta Pharma LLC, Redwood City, California, USA.; Acerta Pharma LLC, Redwood City, California, USA.",moverman@mdanderson.org.
32114283,Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.,2020-Apr,,,benjamin.besse@gustaveroussy.fr.
32113942,European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.,2020-Mar,Eggermont,"Princess Máxima Center, 3584 Utrecht, the Netherlands.",alstrat2@gmail.com.
32107948,A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.,2020-Jul,Stefanelli; Vincent,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma S.A.S., Paris, France.",
32107609,Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.,2020-Jun,,,m-kudo@med.kindai.ac.jp.
32099495,Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.,2019,,,
32089494,Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?,2020-Mar,Broutin; Delahousse,"Gustave Roussy Cancer Campus, Department of Pharmacology, Villejuif, F-94805, France. Electronic address: sophie.broutin@gustaveroussy.fr.; Gustave Roussy Cancer Campus, Department of Pharmacology, Villejuif, F-94805, France. Electronic address: julia.delahousse@gustaveroussy.fr.",olivier.mir@gustaveroussy.fr.
32085669,Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.,2020-Feb-18,Izquierdo,"Novartis Pharmaceutical, 4002 Basel, Switzerland.",
32071431,Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.,2020-Aug,Ibach,"WiSP Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.",carmen.herling@uk-koeln.de.
32067497,Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.,2020-Jun,,,
32066647,Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).,2020-Feb,,,hidet31@med.kindai.ac.jp.
32063602,New survival standards for advanced melanoma.,2020-Apr,,,samra.turajlic@rmh.nhs.uk.
32054831,Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.,2020-Feb-13,Skacel; Labotka; Palumbo,"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.",mdimop@med.uoa.gr.
32053137,Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.,2020-May-01,,,
32052473,Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.,2020-May,Lathers; Liu; Neely; Suryawanshi,"Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.",
32047001,,2020-Jun-01,Brase; Rangwala; Gasal,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.",g.middleton@bham.ac.uk.
32037061,"Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.",2020-Mar,Delahousse; Blondel; Broutin,"Gustave Roussy Cancer Campus, Department of Pharmacology, Villejuif, F-94805, France. Electronic address: julia.delahousse@gustaveroussy.fr.; Gustave Roussy Cancer Campus, Department of Pharmacology, Villejuif, F-94805, France. Electronic address: louis.blondel@gustaveroussy.fr.; Gustave Roussy Cancer Campus, Department of Pharmacology, Villejuif, F-94805, France. Electronic address: sophie.broutin@gustaveroussy.fr.",angelo.paci@gustaveroussy.fr.
32037060,"Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.",2020-Mar,Broutin; Delahousse,"Gustave Roussy Cancer Campus, Department of Pharmacology, Villejuif, F-94805, France. Electronic address: sophie.broutin@gustaveroussy.fr.; Gustave Roussy Cancer Campus, Department of Pharmacology, Villejuif, F-94805, France. Electronic address: julia.delahousse@gustaveroussy.fr.",aude.desnoyer@gustaveroussy.fr.
32031899,"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.",2020-Apr-01,Wu; Zuo; Melhem-Bertrandt,"Astellas Pharma, Northbrook, IL.; Astellas Pharma, Northbrook, IL.; Astellas Pharma, Northbrook, IL.",
32027862,"Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.",2020-Mar,Gibson; Kanhai,"Medical Affairs, EUSA Pharma, Hemel Hempstead, UK.; Medical Affairs, EUSA Pharma, Hemel Hempstead, UK.",vanrheefrits@uams.edu.
32013269,The Role of Immune Checkpoint Blockade in Uveal Melanoma.,2020-Jan-29,,,
31999003,Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (,2020-Jun,,,
31994178,Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.,2020-May,Stefanelli; Vincent; Govindaraju,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma S.A.S, Paris, France.; Novartis Healthcare Pvt. Ltd., Hyderabad, India.",
31986450,ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.,2020-Mar,Diede; Elgadi; Meyers,"Merck & Co., Inc., Kenilworth, NJ, USA.; Boehringer-Ingelheimm Pharma GmbH, Germany.; Syndax Pharmaceuticals, USA.",andy1pearson@btinternet.com.
31978225,High total metabolic tumor volume at baseline predicts survival independent of response to therapy.,2020-Apr-16,,,
31978221,The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.,2020-Mar-19,Sostelly; Higginson; Dieckmann; Anzures-Cabrera; Shinomiya; Jordan; Biedzka-Sarek; Klughammer; Bucher,"Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.; Roche Products Ltd, Welwyn, United Kingdom.; Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.; Roche Products Ltd, Welwyn, United Kingdom.; Chugai Pharmaceutical, Tokyo, Japan.; Roche Diagnostics GmbH, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.",
31959756,Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.,2020-Jan-20,,,alprat@clinic.cat.
31958290,Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.,2020-Jan,,,egaron@mednet.ucla.edu.
31953696,"A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.",2020-Feb,Takasuka,"Oncology Lifecycle Management Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",toi@kuhp.kyoto-u.ac.jp.
31933266,Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.,2019-Feb,Nakayama,"Healthcare Policy and CSR, Astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan. hiroki.nakayama@astellas.com.",hiroki.nakayama@astellas.com.
31927716,"Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.",2020-Mar,Hanes,"Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, USA.",hans-christian.kolberg@mhb-bottrop.de.
31927165,Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.,2020-Feb,,,leec@mskcc.org.
31926048,Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report.,2020-Jul,,,
31924513,Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.,2020-Apr,Procter; Restuccia; Zardavas; Suter,"Frontier Science, Kincraig, United Kingdom.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; The Breast International Group, Brussels, Belgium; Bristol-Myers Squibb, Princeton, NJ.; Roche Pharma, Bern, Switzerland.",jose_bines@yahoo.com.
31915195,Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.,2020-Mar,Gulrajani; Frigault; Hamdy; Izumi; Munugalavadla; Quah; Wang,"Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.",jennifer.woyach@osumc.edu.
31904483,"ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.",2020-Mar-31,,,mark.barok@helsinki.fi.
31896945,A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.,2019-Dec,Poulin-Costello; Gillesby,"Amgen Canada, Inc., Mississauga, ON.; Amgen Canada, Inc., Mississauga, ON.",
31895407,Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.,2020-Apr-01,,,
31883418,Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.,2020-Mar,,,
31881856,Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.,2019-Dec-27,,,ykuboki@east.ncc.go.jp.
31863227,A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.,2020-May,Sameshima,"Medical Oncology, Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.",nboku@ncc.go.jp.
31852955,CD8,2019-Dec-18,,,Catharina.Gross@ukmuenster.de.
31850514,"Presence, function, and regulation of IL-17F-expressing human CD4",2020-Apr,Maroof; Marshall; Cole,"UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.",
31842958,"Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.",2019-Dec-16,,,teresa.troiani@unicampania.it.
31839434,Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting.,2020-May,,,sigbjorn.berentsen@haugnett.no.
31837576,Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.,2020-Feb,,,JanB.Vermorken@uza.be.
31821456,Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.,2019-Dec-10,Jansson; Akbari; Chen; Quadri; Parfionovas,"Takeda Pharmaceuticals International Co, Cambridge, MA; and.; Takeda Pharmaceuticals International Co, Cambridge, MA; and.; Takeda Pharmaceuticals International Co, Cambridge, MA; and.; Takeda Pharmaceuticals International Co, Cambridge, MA; and.; Takeda Pharmaceuticals International Co, Cambridge, MA; and.",
31811017,Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.,2020-Mar-01,,,aherrera@coh.org.
31801940,Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.,2019-Dec-04,Stefanelli; Hoever,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",m.h.vanoers@amc.uva.nl.
31801624,A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.,2019-Dec-04,Chen; Huang; Davis; Toffalorio; Thall,"Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, Milan, Italy.; Pfizer Inc, La Jolla, CA, USA.",ecohen@ucsd.edu.
31792460,Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.,2019-Dec,,,eliezerm_vanallen@dfci.harvard.edu.
31791418,Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.,2019-Dec-02,,,veronica.aedo-lopez@chuv.ch.
31790983,Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.,2020-Jan,Wang; Laird; Vandendries; Neuhof; Nguyen; Dakappagari,"Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, San Francisco, CA, USA.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Pharma GmbH, Berlin, Germany.; Navigate BioPharma Services, Inc, a Novartis Subsidiary, Carlsbad, CA, USA.; Navigate BioPharma Services, Inc, a Novartis Subsidiary, Carlsbad, CA, USA.",ejabbour@mdanderson.org.
35100719,Atypical ,2019-Dec,,,
31782999,Holistic cost-effectiveness analysis of anticancer drug regimens in Japan.,2020-Feb,,,gr0434fx@ed.ritsumei.ac.jp.
31766279,Biological Background of Resistance to Current Standards of Care in Multiple Myeloma.,2019-Nov-13,,,
31761899,Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.,2020-Feb,,,glopes@med.miami.edu.
31753727,"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.",2020-Jan,,,daniel.petrylak@yale.edu.
31729982,"Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.",2019-Nov-15,Shreay,"Gilead Sciences, Inc., Foster City, CA, USA.",marco.montillo@ospedaleniguarda.it.
31727874,Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.,2019-Nov-14,,,bvantine@wustl.edu.
31723167,Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.,2019-Nov-13,,,chachagot-a-mail@hotmail.co.jp.
31718669,Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.,2019-Nov-12,,,yonarita@ncc.go.jp.
31705176,[,2020-Apr,,,c.menke@amsterdamumc.nl.
31703593,Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.,2019-Nov-08,,,tgajewsk@medicine.bsd.uchicago.edu.
31699438,Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.,2019-Nov,Abhyankar; Song; Signorovitch; Zhao; Yao,"Acerta Pharma, San Francisco, CA, United States.; Analysis Group, Inc., Los Angeles, CA, United States.; Analysis Group, Inc., Boston, MA, United States.; Analysis Group, Inc., Boston, MA, United States.; Analysis Group, Inc., Boston, MA, United States.",claire.telford@astrazeneca.com.
31697308,"Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.",2020-Jan-01,Meniawy; Patah; Wang; Liu; Bajaj; Siu,"Linear Clinical Research Ltd, Nedlands, Australia.; Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.; Bras and Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",
31693267,Application of proteometric approach for identification of functional mutant sites to improve the binding affinity of anticancer biologic trastuzumab with its antigen human epidermal growth factor receptor 2.,2020-Feb,Balakrishnan,"Biotechnology Division, R&D Centre, Orchid Pharma Ltd. (Formerly known as Orchid Chemicals and Pharmaceuticals Ltd.), Chennai, India.",
31686616,Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.,2019,,,
31682550,Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.,2020-Jan-01,Hansen,"Princess Margaret Cancer Center, Toronto, Ontario, Canada.",
31678267,A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel.,2020-Jan,Potthoff; McBlane; Spindeldreher; Sickert,"Novartis Pharma AG, Basel, Switzerland. Electronic address: bernd.potthoff@novartis.com.; Novartis Pharma AG, Basel, Switzerland.; Integrated Biologix GmbH, Basel, Switzerland.; Hoffmann-La Roche Ltd., Basel, Switzerland.",bernd.potthoff@novartis.com.
31676670,Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.,2020-Feb-15,,,Ronan.Kelly@BSWHealth.org.
31676542,Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance.,2019-Nov,,,nfsaba@emory.edu.
31672768,How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.,2020-Apr-01,Fowler; Mezzi; Scott,"Amgen, Inc., Thousand Oaks, California.; Amgen, Inc., Thousand Oaks, California.; Amgen, Inc., Thousand Oaks, California.",adam.cohen@uphs.upenn.edu.
31664934,Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.,2019-Oct-29,,,koji-y@nms.ac.jp.
31651359,Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.,2019-Oct-24,Zhou,"Merck Serono Pharmaceutical R&D Co, Beijing, China.",vaishamu@karmanos.org.
31638948,Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.,2019-Oct-21,,,hshouji@ncc.go.jp.
31623687,Monalizumab: inhibiting the novel immune checkpoint NKG2A.,2019-Oct-17,André; Zerbib; Vivier,"Innate Pharma Research Labs, Innate Pharma, Marseille, France.; Innate Pharma Research Labs, Innate Pharma, Marseille, France.; Innate Pharma Research Labs, Innate Pharma, Marseille, France. Vivier@ciml.univ-mrs.fr.",T.van_Hall@lumc.nl.
31622733,Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.,2020-Feb,,,Jhanelle.Gray@moffitt.org.
31621810,Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.,2019-Dec-01,,,
31621094,Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.,2020-Jan,Guan; Hill; Kwei; Liu,"Department of Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.; Department of Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.; Department of Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.; Department of Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.",
31620980,"Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.",2019-Dec,Segui-Palmer; Hanes,"Corporació Sanitària Parc Taulí, Sabadell, Spain.; Amgen Inc, 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.",hans-christian.kolberg@mhb-bottrop.de.
31620931,Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial.,2020-Feb,Asakawa; Kawakami,"Clinical Information and Intelligence Department, Chugai Pharmaceutical Co., Ltd, 2-1-1, Nihonbashi-Muromachi, Chuo-ku, Tokyo, Japan.; Clinical Science & Strategy Department, Chugai Pharmaceutical Co., Ltd, 2-1-1, Nihonbashi-Muromachi Chuo-ku, Tokyo, Japan.",kshitara@east.ncc.go.jp.
31606656,Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.,2019-Nov,,,AmalAbdel-Aziz@pharma.asu.edu.eg.
31573746,"Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.",2019-Nov,,,
31563517,"Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.",2019-Nov,,,anaing@mdanderson.org.
31562490,'Stealth' corporate innovation: an emerging threat for therapeutic drug development.,2019-Nov,,,lambris@pennmedicine.upenn.edu.
31557826,ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin.,2019-Sep-25,,,cirofrancescoruggier@libero.it.
31554815,Metabolomic adaptations and correlates of survival to immune checkpoint blockade.,2019-Sep-25,Jin; Horak; Wind-Rotolo,"Bristol-Myers Squibb, Princeton, NJ, 08540, USA.; Bristol-Myers Squibb, Princeton, NJ, 08540, USA.; Bristol-Myers Squibb, Princeton, NJ, 08540, USA.",Toni_Choueiri@dfci.harvard.edu.
31548805,Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.,2019-Aug,Christofides,"impactMedicom Inc., Toronto, ON.",
31548348,"ImmunoPET, [",2019-Dec-15,,,shui@coh.org.
31540976,Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.,2019-Dec-15,Quigley; Gao; Spires; Reilly,"Bristol-Myers Squibb (BMS), Redwood City, California and Princeton, New Jersey.; Bristol-Myers Squibb (BMS), Redwood City, California and Princeton, New Jersey.; Bristol-Myers Squibb (BMS), Redwood City, California and Princeton, New Jersey.; Bristol-Myers Squibb (BMS), Redwood City, California and Princeton, New Jersey.",jwelsh@mdanderson.org.
31537908,"Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.",2019-Oct,,,roldano.fossati@marionegri.it.
31537528,Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.,2019-Nov-28,Srivastava; Hether,"Adaptive Biotechnologies Corporation, Seattle, WA.; Adaptive Biotechnologies Corporation, Seattle, WA.",
31526159,DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.,2019,Sustmann; Dickopf; Regula; Kettenberger; Mølhøj; Gassner; Weininger; Fenn; Manigold; Kling; Künkele; Schwaiger; Bossenmaier; Lauer; Brinkmann; Schaefer; Klein,"Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Discovery Oncology, Roche Innovation Center Basel , Basel , Switzerland.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Discovery Oncology, Roche Innovation Center Basel , Basel , Switzerland.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Small Molecule Research, Roche Innovation Center Basel , Basel , Switzerland.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Roche Pharma Research and Early Development (pRED), Discovery Oncology, Roche Innovation Center Zurich , Schlieren , Switzerland.",
31511065,Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.,2019-Sep-12,,,Emily.Gallagher@mssm.edu.
31502117,"First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.",2019-Oct,Tanigawa,"Bayer Yakuhin, Ltd., Osaka, Japan.",sbkim3@amc.seoul.kr.
31501610,A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.,2019-Sep,,,luca.piccoli@irb.usi.ch.
31481761,Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.,2019-Oct,,,kroemer@orange.fr.
31462735,MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.,2020-Feb,Spielewoy; Fingerle-Rowson; Mundt; Wassner-Fritsch,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",c.pott@med2.uni-kiel.de.
31461377,Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.,2019-Oct-20,,,
31444589,A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.,2020-Aug,Melhem-Bertrandt; Inoue; Akazawa; Kadokura,"Astellas Pharma Global Development, Northbrook, IL, USA.; Astellas Pharma, Inc., Tokyo, Japan.; Astellas Pharma, Inc., Tokyo, Japan.; Astellas Pharma, Inc., Tokyo, Japan.",s.takahashi-chemotherapy@jfcr.or.jp.
31443721,ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.,2019-Aug-23,Dubreuil; Barret; Prost,"GamaMabs Pharma SA, Centre Pierre Potier, F-31106, Toulouse, France.; GamaMabs Pharma SA, Centre Pierre Potier, F-31106, Toulouse, France.; GamaMabs Pharma SA, Centre Pierre Potier, F-31106, Toulouse, France.",thierry.chardes@inserm.fr.
31436395,Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.,2019-Oct,Mueller; Vandendries; Loberiza; Böhme,"Ingress-Health HWM GmbH, Wismar, Germany.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, Pharma GmbH, Berlin, Germany.; Pfizer Deutschland GmbH, Berlin, Germany.",
31427204,"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.",2019-Oct,McHenry; Mekan,"Bristol-Myers Squibb, Princeton, NJ, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.",motzerr@mskcc.org.
31422216,Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.,2019-Sep,Jayaprakash; Li,"Bristol-Myers Squibb, 3401 Princeton Pike, Lawrenceville 08648, NJ, USA. Electronic address: Vijayvel.Jayaprakash@bms.com.; Bristol-Myers Squibb, 3401 Princeton Pike, Lawrenceville 08648, NJ, USA. Electronic address: Li.Li6@bms.com.",nfsaba@emory.edu.
31422028,Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.,2019-Oct,Agrawal; Li; Penrod,"Bristol-Myers Squibb, Princeton, NJ, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.",scott.antonia@duke.edu.
31420414,Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.,2019-Sep,,,domenica.lorusso@policlinicogemelli.it.
31419253,Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.,2019,,,
31412935,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.",2019-Aug-14,Hasegawa; Kakurai; Kamiyama; Nakata; Nakamura; Sakaki,"Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.",kshitara@east.ncc.go.jp.
31409671,Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.,2019-Oct-03,Lin; Kim; Nahar; Balakumaran,"Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and.; Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and.; Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and.; Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and.",
31391510,Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.,2019-Aug-07,,,peter.steinberger@meduniwien.ac.at.
31377477,Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.,2019-Sep,Holmes; Sarp,"Frontier Science (Scotland) Ltd, Grampian View, Kincraig, Kingussie, United Kingdom.; Novartis Pharma AG, Oncology Development Unit, Basel, Switzerland.",jens.huober@uniklinik-ulm.de.
31373648,Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.,2019-Aug-02,,,
31368160,Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.,2019-Sep,Dolado; Donica,"Pharma Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
31366914,A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma.,2019-Jul-31,Asvadi; Campbell; Dunn,"Aurobindo Pharma Ltd, Hyderabad, AP, India.; Minomic International Ltd, Sydney, NSW, Australia.; HaemaLogiX Pty Ltd, Sydney, NSW, Australia.",aspencer@netspace.net.au.
31356140,Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.,2019-Oct-10,Melhem-Bertrandt,"Astellas Pharma, Northbrook, IL.",
31355940,"C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.",2020-Jan,,,
31353840,Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.,2019-Sep,Sumiyoshi,"Oncology Clinical Development Planning, Ono Pharmaceutical Co., Ltd, Osaka, Japan.",
31350344,"Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.",2019-Oct,Bartz; Fukuchi; Ohtsuka; Lange; Gruner; Watanabe; Hayashi; Oda; Kawaida; Komori; Kashimoto; Wirtz; Mayer; Redondo-Müller; Saito; Takahashi; Hanzawa; Imai; Hanai; Agatsuma; Bange; Abraham,"U3 Pharma GmbH/Daiichi-Sankyo, Martinsried, Germany.; Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; U3 Pharma GmbH/Daiichi-Sankyo, Martinsried, Germany.; U3 Pharma GmbH/Daiichi-Sankyo, Martinsried, Germany.; Modality Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; U3 Pharma GmbH/Daiichi-Sankyo, Martinsried, Germany.; U3 Pharma GmbH/Daiichi-Sankyo, Martinsried, Germany.; U3 Pharma GmbH/Daiichi-Sankyo, Martinsried, Germany.; Analytical & Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.; Global Project Management Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; U3 Pharma GmbH/Daiichi-Sankyo, Martinsried, Germany.; U3 Pharma GmbH/Daiichi-Sankyo, Martinsried, Germany. abraham@lead-discovery.de.",abraham@lead-discovery.de.
31348579,"Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.",2019-Sep,,,
31347292,A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.,2019-Sep,Firdaus; Kapoun; Holmgren; Zhou; Dupont,"Oncology Hematology Cancer, Inc., Cincinnati, Ohio.; Oncomed Pharmaceuticals Inc, Redwood City, California.; Oncomed Pharmaceuticals Inc, Redwood City, California.; Oncomed Pharmaceuticals Inc, Redwood City, California.; Oncomed Pharmaceuticals Inc, Redwood City, California.",
31340866,"First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.",2019-Jul-24,Yokochi; Ito,"IDAC Theranostics Inc., Bunkyo-ku, Tokyo, Japan.; IDAC Theranostics Inc., Bunkyo-ku, Tokyo, Japan.",koujim@rs.tus.ac.jp.
31332464,CTLA-4 antibody ipilimumab negatively affects CD4,2019-Aug,,,peter.steinberger@meduniwien.ac.at.
31331919,Adjuvant low-dose rituximab and plasma exchange for acquired TTP.,2019-Sep-26,,,
31331917,Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.,2019-Sep-26,Knapp; Ping; Beaupre; Neuenburg,"Mid Ohio Oncology/Hematology, Inc, Columbus, OH.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and.",
31326578,Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.,2019-Sep,,,dario.neri@pharma.ethz.ch.
31325530,Humanized anti-CD271 monoclonal antibody exerts an anti-tumor effect by depleting cancer stem cells.,2019-Oct-01,Wada,"Research Unit/Innovative Medical Science, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa, Japan.",tamaikeiichi@med.tohoku.ac.jp.
31317218,Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.,2019-Aug,,,stephen_hodi@dfci.harvard.edu.
31314918,Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.,2019-Nov,,,
31308062,Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.,2019-Oct-15,Butler; Azim; Ramsahai,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Innate Pharma, Research and Development, Marseille, France.; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",lseymour@ctg.queensu.ca.
31285591,Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).,2019-Jul,,,okieiji@surg2.med.kyushu-u.ac.jp.
31284184,The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.,2019-Sep,Izquierdo,"Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland.",elda.tagliabue@istitutotumori.mi.it.
31267201,Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.,2019-Nov,Ammann; Hieke-Schulz,"Roche Pharma AG, Grenzach-Wyhlen, Germany.; Roche Pharma AG, Grenzach-Wyhlen, Germany.",kschwamborn@tum.de.
31255687,Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.,2019-Oct-01,Hagemann; Sommer; Ellinger-Ziegelbauer; Wirnitzer; Wengner; Linden; Mumberg,"Bayer AG, Pharma, Preclinical Research, Berlin, Germany.; Bayer AG, Pharma, Preclinical Research, Berlin, Germany.; Bayer AG, Pharma, Translational Science, Wuppertal, Germany.; Bayer AG, Pharma, Translational Science, Wuppertal, Germany.; Bayer AG, Pharma, Preclinical Research, Berlin, Germany.; Bayer AG, Pharma, Preclinical Research, Wuppertal, Germany.; Bayer AG, Pharma, Preclinical Research, Berlin, Germany.",katrine.wickstroem@bayer.com.
31246283,Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.,2019-Sep-15,Jayaprakash; Lynch; Li,"Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.",
31240302,"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.",2019-Sep-01,Maurus; Gold; Krivoshik; Arozullah; Park,"Formerly of Ganymed GmbH (AG), Mainz, Germany.; Formerly of Ganymed GmbH (AG), Mainz, Germany.; Astellas Pharma, Inc., Northbrook, USA.; Astellas Pharma, Inc., Northbrook, USA.; Astellas Pharma, Inc., Northbrook, USA.",tureci@uni-mainz.de.
31233395,Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.,2019-Oct,,,
31217355,Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.,2019-Jun-20,,,
31213507,Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.,2019-Sep,,,dario.neri@pharma.ethz.ch.
31208944,"Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.",2019-Aug,,,matthew_davids@dfci.harvard.edu.
31199595,Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.,2019-Aug,,,
31195996,Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.,2019-Jun-13,Berrak; He,"Eisai Inc. (former employees), Woodcliff Lake, NJ, USA.; Eisai Inc. (former employees), Woodcliff Lake, NJ, USA.",lschwartzberg@westclinic.com.
31187176,Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.,2019-Jul,,,angela.yenny@mh-hannover.de.
31164456,"A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.",2019-Aug,Won,"GC Pharma, Yongin, Korea.",bangyj@snu.ac.kr.
31155232,Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.,2019-Jun-13,Gauthier; Morel; Anceriz; Rossi; Blanchard-Alvarez; Grondin; Trichard; Cesari; Sapet; Bosco; Rispaud-Blanc; Guillot; Cornen; Habif; Caraguel; Arrufat; Remark; Morel; Vivier,"Innate Pharma, Marseille, France. Electronic address: laurent.gauthier@innate-pharma.fr.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France; Aix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, Marseille, France; Service d'Immunologie, Marseille Immunopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France. Electronic address: vivier@ciml.univ-mrs.fr.",laurent.gauthier@innate-pharma.fr.
31145415,Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.,2019-Jul-01,Chou; Davda; Forgie; Li; Jacobs; Kazazi,"Pfizer Inc, South San Francisco, California.; Pfizer Inc, La Jolla, California.; Pfizer Inc, South San Francisco, California.; Pfizer Inc, Cambridge, Massachusetts.; Pfizer Inc, New York, New York.; Pfizer Inc, South San Francisco, California.",
31140655,Epidermolysis bullosa: Advances in research and treatment.,2019-Oct,,,
31140580,Comparison of microbial and transient expression (tobacco plants and plant-cell packs) for the production and purification of the anticancer mistletoe lectin viscumin.,2019-Sep,Melmer; Lentzen; Bührmann,"Pharmedartis GmbH, Aachen, Germany.; MELEMA Pharma GmbH, Hamburg, Germany.; Pharmedartis GmbH, Aachen, Germany.",
31138521,Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.,2019-Jul,,,rxp278@case.edu.
31124055,"Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.",2020-Apr,Sato; Nakai; Inatani,"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",nbryamam@ncc.go.jp.
31116985,Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.,2019-May-21,Perrot; Giraudon-Paoli; Augier; Docquier; Courtois; Déjou; Jecko; Rispaud-Blanc; Gauthier; Rossi; Chanteux; Gourdin; Bastid; Morel; Vivier; Paturel,"Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; OREGA Biotech, 69130 Ecully, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; OREGA Biotech, 69130 Ecully, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; OREGA Biotech, 69130 Ecully, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France; Aix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France; Service d'Immunologie, Marseille Immunopôle, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: vivier@ciml.univ-mrs.fr.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France. Electronic address: carine.paturel@innate-pharma.fr.",vivier@ciml.univ-mrs.fr.
31112622,Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study.,2019-Sep,Ternant; Paintaud,"Service de Pharmacologie Médicale, CHRU de Tours, Tours, France.; Service de Pharmacologie Médicale, CHRU de Tours, Tours, France.",
31101691,Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.,2020-Mar,,,
31101647,A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.,2019-May-28,,,
31097627,Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.,2019-Oct,Frömming; Dümmler; Riecke; Baumann; Beyer; Vauléon,"NOXXON Pharma, Berlin, Germany.; NOXXON Pharma, Berlin, Germany.; NOXXON Pharma, Berlin, Germany.; NOXXON Pharma, Berlin, Germany.; NOXXON Pharma, Berlin, Germany.; NOXXON Pharma, Berlin, Germany.",gobbi@unige.it.
31093770,Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).,2020-Feb,Nukada; Nomura,"Medical Affairs, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan.; Medical Affairs, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan.",masahiro.yokoyama@jfcr.or.jp.
31092853,Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma.,2019-May-15,,,nharder@definiens.com.
31092773,Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.,2019,,,
31089249,Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.,2019-Oct,von Wangenheim; Ursula Kress; Blum,"Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.",Stephan.Stilgenbauer@uniklinik-ulm.de.
31087200,Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.,2020-Jan,Tanimoto,"Oncology Clinical Development Planning, Oncology Clinical Development Unit, ONO Pharmaceutical Co., Ltd., Osaka, Japan.",nboku@ncc.go.jp.
31077164,AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany.,2019-May-10,Gaillard,"F. Hoffmann-La Roche Ltd, Product Development Medical Affairs, Grenzacherstrasse, 4070, Basel, Switzerland.",studien@onkologie-goslar.de.
31053571,GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.,2019-May-14,,,
31050355,"Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.",2019-Sep,Buchheit; Frey; Fingerle-Rowson; Jamois,"Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.",
31048302,Venetoclax: R-CHOP rocket booster?,2019-May-02,,,
31043824,Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.,2019-Apr,,,
31034598,A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.,2019-Jul-15,Heyburn; Weil; Wang,"Morphotek, Inc, Exton, Pennsylvania.; Morphotek, Inc, Exton, Pennsylvania.; Morphotek, Inc, Exton, Pennsylvania.",
31021392,Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.,2019-Jul-01,,,
30995478,Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer.,2019-Apr-16,,,merghout@mskcc.org.
30995176,"Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.",2019-Jun-01,,,
30991144,Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.,2019-Sep-25,,,neri@pharma.ethz.ch.
30988393,Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).,2019-May,,,alessandra.curioni@usz.ch.
30986472,High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates.,2019-Jun-15,Ding,"Formulation and Analysis Laboratory, Hisun Pharma (Hangzhou) Co. Ltd., Hangzhou 311404, China.",zhanzhou@zju.edu.cn.
30976844,Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.,2019-Jun,McConnell,"Frontier Science (Scotland), Grampian View, Kincraig, Inverness-Shire, PH21 1NA, UK.",garg.amit@gene.com.
30971227,Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.,2019-Apr-10,Lommelé; Wang,"Alexion Pharma GmbH, Giesshübelstrasse 30, 08045, Zurich, Switzerland.; Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA, 02210, USA.",menne.jan@mh-hannover.de.
30968729,The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?,2019-May,,,
30967392,Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.,2019-Apr-09,,,
30959557,Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.,2019-Jun,Hatsumichi,"Ono Pharmaceutical Co., Ltd., Osaka, Japan.",
30954729,Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents.,2019-Jun,,,Mreagan@mmc.org.
30952672,PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.,2019-Jul-04,,,
30929841,Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.,2019-Feb,Saum,"Roche Pharma AG, Grenzach-Wyhlen, Germany.",nvanderv@tulane.edu.
30927036,Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.,2019-Jun,,,Fernando.rivera@scsalud.es.
30925943,Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.,2019-Mar-29,Roder; Meyer; Asmellash; Oliveira; Roder; Grigorieva,"Biodesix Inc, Boulder, CO, USA.; Biodesix Inc, Boulder, CO, USA.; Biodesix Inc, Boulder, CO, USA.; Biodesix Inc, Boulder, CO, USA.; Biodesix Inc, Boulder, CO, USA.; Biodesix Inc, Boulder, CO, USA. julia.grigorieva@biodesix.com.",julia.grigorieva@biodesix.com.
30925912,Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.,2019-Mar-29,,,elisabeth.schorb@uniklinik-freiburg.de.
30911859,Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.,2019-Jul,Savage; Wang; Dalal; Shah,"Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.; Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.; Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.; Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.",bangyj@snu.ac.kr.
30905021,Eculizumab improves fatigue in refractory generalized myasthenia gravis.,2019-Aug,Wang; O'Brien; Patra,"Formerly of Alexion Pharmaceuticals, Inc., New Haven, CT, USA.; Alexion Pharmaceuticals, Inc., New Haven, CT, USA.; Alexion Pharmaceuticals, Inc., New Haven, CT, USA.",hennande@rm.dk.
30899984,"Rituximab dosing in hematological malignancies: an old question, revisited.",2019-Sep,Morcos; Boehnke,"Clinical Pharmacology, Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center, New York, 430 East 29th Street, 10016, New York City, NY, USA. peter.morcos@roche.com.; Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",peter.morcos@roche.com.
30899264,Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.,2019,Rowley; Bhatta; Sherington; Cutler; Humphreys,"UCB Pharma, Slough, United Kingdom.; UCB Pharma, Slough, United Kingdom.; UCB Pharma, Slough, United Kingdom.; UCB Pharma, Slough, United Kingdom.; UCB Pharma, Slough, United Kingdom.",
30897176,Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.,2019,Ducret; James; Wilson; Feilke; Tebbe; Dybowski; Elschenbroich; Klammer; Friess; Bossenmaier; Dietmann; Schaab; Ceppi,"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; A4P Consulting Ltd, Sandwich, United Kingdom.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Evotec (München) GmbH, Munich, Germany.; Evotec (München) GmbH, Munich, Germany.; Evotec (München) GmbH, Munich, Germany.; Evotec (München) GmbH, Munich, Germany.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Evotec (München) GmbH, Munich, Germany.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.",
30895346,A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.,2019-Jun,,,mettu002@mc.duke.edu.
30894515,"Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.",2019-Mar-20,Trudel,"Princess Margaret Cancer Centre, Toronto, ON, Canada. Suzanne.Trudel@uhn.ca.",Suzanne.Trudel@uhn.ca.
30894212,Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.,2019-Mar-20,Zhao; Newton; Maleski; Leopold,"Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA.; Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA.; Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA.; Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA.",geoffrey.t.gibney@gunet.georgetown.edu.
30891877,Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.,2019-May,,,
30886344,Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.,2019-Apr,Ciampricotti; Ooi; Rüttinger; Ries,"Molecular Pharmacology Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.",k.d.visser@nki.nl.
30866056,Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.,2019-Jul,Jamois; Buchheit; Frey; Fingerle-Rowson,"Department of Clinical Pharmacology, F. Hoffmann-La Roche, Roche Innovation Center Basel, Switzerland.; Department of Clinical Pharmacology, F. Hoffmann-La Roche, Roche Innovation Center Basel, Switzerland.; Department of Clinical Pharmacology, F. Hoffmann-La Roche, Roche Innovation Center Basel, Switzerland.; Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland.",
30863922,Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.,2019-Jun,,,tomas.kirchhoff@nyumc.org.
30862692,Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.,2019-Jun-15,Campbell; Bradburry; Rodrik-Outmezguine,"Frontier Science (Scotland) Ltd, Kingussie, United Kingdom.; Frontier Science (Scotland) Ltd, Kingussie, United Kingdom.; Novartis Pharma AG, Basel, Switzerland.",michail.ignatiadis@bordet.be.
30862645,Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.,2019-Jun-27,Klein; Huang; Jiang; Mobasher,"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; F-Hoffmann-La Roche Ltd, Mississauga, ON, Canada.; Genentech Inc, South San Francisco, CA.; Genentech Inc, South San Francisco, CA.",
30857956,"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.",2019-Apr,Beattie; Blotner; Stone; Schulze; Cuchelkar,"Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.",fmeric@mdanderson.org.
30850561,Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.,2019-Sep,Purdum,"Kite Pharma, Inc., Santa Monica, California, USA apurdum@kitepharma.com.",apurdum@kitepharma.com.
30846506,Targeting CD20 takes the backseat in CLL.,2019-Mar-07,,,
30832606,"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.",2019-Mar-04,Saraf; Thanigaimani; Cheng,"Merck & Co., Inc., 8000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.; Merck & Co., Inc., 8000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.; Merck & Co., Inc., 8000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.",mehnerja@cinj.rutgers.edu.
30824549,Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.,2019-Mar,Neri,"Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland. dario.neri@pharma.ethz.ch.",dario.neri@pharma.ethz.ch.
30816957,"Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.",2019-May-01,,,
30811063,Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.,2019-Jun,Le Louedec; Lafont; Allal; Becher; Chatelut; Thomas,"Laboratory of Pharmacology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.; Laboratory of Pharmacology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.; Laboratory of Pharmacology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.; Service de Pharmacologie et Immunoanalyse, Laboratoire d'Etude du Métabolisme des Médicaments, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Institut National de la Recherche Agronomique, Université Paris Saclay, Gif-sur-Yvette, France.; Laboratory of Pharmacology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.; Laboratory of Pharmacology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.",
30806748,First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.,2019-May,,,benjamin.weide@med.uni-tuebingen.de.
30782667,Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8,2019-Apr,,,dario.neri@pharma.ethz.ch
30762274,Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.,2019-Jun,,,
30758227,Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?,2019-Apr,Hilberg; Barrueco,"Boehringer Ingelheim RCV GmbH & Co. KG, A-1121, Vienna, Austria.; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, CT 06877, USA.",
30737616,Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.,2019-Jul,,,ashimomu@ncc.go.jp.
30737226,Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.,2019-Feb-12,,,
30733496,Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.,2019-Feb-07,,,chachagot-a-mail@hotmail.co.jp.
30731178,Incidence and risk of developing photosensitivity with targeted anticancer therapies.,2019-Oct,Chaudhari,"Department of Dermatology, Bay Area Corpus Christi Medical Center, Corpus Christi, Texas.",lacoutum@mskcc.org.
30730897,Protective immunity by an engineered DNA vaccine for Mayaro virus.,2019-Feb,Reed; Ramos; Kim; Humeau,"Inovio Pharmaceuticals, Plymouth Meeting, PA, United States of America.; Inovio Pharmaceuticals, Plymouth Meeting, PA, United States of America.; Inovio Pharmaceuticals, Plymouth Meeting, PA, United States of America.; Inovio Pharmaceuticals, Plymouth Meeting, PA, United States of America.",
30730104,Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.,2019-Mar,,,
30725389,"A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.",2019-Oct,Anand; Chu; Lackey; Reyno,"Agensys, Inc., Santa Monica, CA, USA.; Agensys, Inc., Santa Monica, CA, USA.; Agensys, Inc., Santa Monica, CA, USA.; Agensys, Inc., Santa Monica, CA, USA.",morrism@mskcc.org.
30711970,Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study.,2019-Feb,Häckl,"Roche Pharma AG Germany, Grenzach-Wyhlen, Germany.",wolfgang.schultze-seemann@uniklinik-freiburg.de
30709633,"Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.",2019-Mar,,,everardo.saad@iddi.com.
30693419,Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.,2019-Mar,,,senthiljrajappa@gmail.com.
30682108,Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART.,2019,,,
30676622,Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.,2019-Mar-01,Chand,"currently at Global Development, AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland.",
30670497,irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.,2019-Apr-01,Horak; Wind-Rotolo; Ishii,"Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.; Bristol-Myers Squibb, Princeton, New Jersey.",ssignoretti@partners.org.
30665463,A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.,2019-Jan-21,Müller; Gébleux; Briendl; Hell; Wolter; Beerli; Grawunder,"Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharma GmbH and Co. KG, Birkendorfer Str. 65, 88400, Biberach an der Riss, Germany.; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.",alfred.zippelius@usb.ch.
30651126,Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.,2019-Jan-16,,,Ulrich.Keilholz@charite.de.
30648616,The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer.,2020-Apr,,,hermann.gram@novartis.com.
30638416,Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.,2019-Jun,Gibson; Begum; Koblbauer; Dranitsaris; McEwan; Pritchard,"a Wickenstones Ltd , Didcot , UK.; a Wickenstones Ltd , Didcot , UK.; a Wickenstones Ltd , Didcot , UK.; b Augmentium Pharma Consulting Inc. , Toronto , Canada.; d Health Economics and Outcomes Research Ltd , Cardiff , UK.; a Wickenstones Ltd , Didcot , UK.",
30623420,Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).,2019-Jul-15,,,
30623276,"A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.",2019-Oct,Nakai; Ikezawa; Nakajima,"Eisai Co. Ltd., Tokyo, Japan.; Eisai Co. Ltd., Tokyo, Japan.; Eisai Co. Ltd., Tokyo, Japan.",t.aramaki@scchr.jp.
30618179,KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.,2019-Mar,,,
30605211,Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.,2019-Mar-01,,,
30589930,Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.,2019-Mar-01,,,
30579890,Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.,2019-Jan-20,,,neri@pharma.ethz.ch.
30578679,High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis.,2019-Mar,Fuchs; Sawas; Staedler; Schubert; D'Andrea; Piali; Frei,"Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases (I3) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases (I3) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, BiOmics, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases (I3) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases (I3) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases (I3) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases (I3) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.",
30573690,A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.,2019-Apr-01,,,asingh@mednet.ucla.edu
30570649,"Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.",2019-Apr-01,Liu; Lunceford; Kang; Bhagia,"Clinical Research, Merck & Co Inc, Kenilworth, New Jersey.; Clinical Research, Merck & Co Inc, Kenilworth, New Jersey.; Clinical Research, Merck & Co Inc, Kenilworth, New Jersey.; Clinical Research, Merck & Co Inc, Kenilworth, New Jersey.",
30543899,Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin.,2019-Jun,,,neri@pharma.ethz.ch.
30523122,DUO delivers for duvelisib.,2018-Dec-06,,,
30522922,"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.",2019-Jan-19,Hua; Little; Rao; Woolery; Manley,"Millennium Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company.; Millennium Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company.; Seattle Genetics, Inc, Bothell, WA, USA.; Seattle Genetics, Inc, Bothell, WA, USA.; Seattle Genetics, Inc, Bothell, WA, USA.",horwitzs@mskcc.org.
30506519,"A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).",2019-Mar,,,nboku@ncc.go.jp.
30506110,A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.,2019-Feb,Bouhlel; Lauer; Liste Hermoso; Nüesch; Shing,"Global Pharma Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Global Pharma Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, USA.",elisabet.lidbrink@sll.se.
30504313,Where does PD-1 blockade fit in HL therapy?,2018-Nov-30,,,
30504308,Where to start? Upfront therapy for follicular lymphoma in 2018.,2018-Nov-30,,,
30503213,Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.,2018-Dec-13,André; Denis; Soulas; Bourbon-Caillet; Lopez; Arnoux; Bléry; Bonnafous; Gauthier; Morel; Rossi; Remark; Breso; Bonnet; Habif; Boyer-Chammard; Zerbib; Dodion; Ghadially; Morel; Vivier,"Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France. Electronic address: pascale.andre@innate-pharma.fr.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; MedImmune, Ltd., Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France; Aix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France; Service d'Immunologie, Marseille Immunopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: vivier@ciml.univ-mrs.fr.",pascale.andre@innate-pharma.fr.
30501868,"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.",2018-Dec,,,wilsonw@mail.nih.gov.
30515672,"Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.",2019-Jul,Shimizu; Watanabe,"Merck Serono Co., Ltd, Tokyo, Japan.; Merck Serono Co., Ltd, Tokyo, Japan.",tdoi@east.ncc.go.jp.
30498056,"Rituximab in neurological disease: principles, evidence and practice.",2019-Feb,,,anu.jacob@thewaltoncentre.nhs.uk.
30488098,Prognostic value of baseline metabolic tumor volume measured on ,2019-Apr,,,schoderh@mskcc.org.
30465228,Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.,2019-Aug,,,b.pennington@sheffield.ac.uk.
30455380,Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.,2019-Jan-31,Trunzer; Fingerle-Rowson; Humphrey,"Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Pharma Development Oncology, Roche Products Ltd, Welwyn, United Kingdom.",
30448772,NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.,2019-Aug,Bonnafous; Lhospice,"Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.",
30429890,Ultrasound molecular imaging as a non-invasive companion diagnostic for netrin-1 interference therapy in breast cancer.,2018,Goldschneider; Mehlen,"Netris Pharma, 69008 Lyon, France.; Netris Pharma, 69008 Lyon, France.",
30429032,Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.,2018-Nov,Bachman; Saraf; Raftopoulos,"Merck & Co., Inc., Kenilworth, NJ, USA.; Merck & Co., Inc., Kenilworth, NJ, USA.; Merck & Co., Inc., Kenilworth, NJ, USA.",sgadgeel@med.umich.edu.
30420754,Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.,2018-Dec,,,ywang59@mdanderson.org.
30417277,Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.,2019-Feb,Papp,"K Papp Clinical Research and Probity Medical Research Inc., Waterloo, ON, Canada.",aprilarmstrong@post.harvard.edu.
30401604,Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison.,2019-Jul,Dinet,"Ipsen Pharma SAS, 65 quai Georges Gorse, Boulogne-Billancourt, Ile-de-France, France. Electronic address: postmaster@jeromedinet.com.",camillo.porta@unipv.it.
30393621,Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?,2018-Sep,Dempke; Dale,"SaWo-Oncology Ltd, Cambridge, UK.; LightSwift Pharma Ltd, Cheshire, UK.",
30383184,Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.,2019-Feb-01,Wildsmith,"Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.",
30373595,Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.,2018-Oct-30,,,hojinkim@ncc.re.kr.
30357775,Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.,2018-Nov,,,
30350178,Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.,2018-Dec,Goeldner; Sadrolhefazi,"Boehringer Ingelheim Pharma GmbH and Co. KG, Global BDS, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.; Boehringer Ingelheim (Canada) Ltd./Ltee, 5180 South Service Road, Burlington, ON, L7L 5H4, Canada.",delord.jean-pierre@iuct-oncopole.fr.
30348216,Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.,2018-Oct-22,Knox; Berghorn; Yang,"Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, M5G 1Z5, Canada.; Oncology - Global Clinical Research, Bristol-Myers Squibb, Princeton, NJ, 08541, USA.; Oncology - Global Clinical Research, Bristol-Myers Squibb, Princeton, NJ, 08541, USA.",Asim.Amin@carolinashealthcare.org.
30347025,Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.,2019-Mar-01,Chang; Zhang; Iizuka; Foster; Molinero; Funke,"Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.",
30335191,Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.,2019-Jan-15,Schuehly,"Novartis Pharma AG, Basel, Switzerland.",
30326862,Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.,2018-Oct-16,,,ymiyoshi@hyo-med.ac.jp.
30317410,Novel Immunotherapies for T Cell Lymphoma and Leukemia.,2018-Dec,,,mruella@upenn.edu.
30309874,A new triple threat to CLL.,2018-Oct-11,,,matthew_davids@dfci.harvard.edu.
30309758,"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.",2018-Nov,Fingerle-Rowson; Zhu; Nielsen; Sahin,"Pharma Development Clinical Oncology, F Hoffmann-La Roche, Basel, Switzerland.; Pharma Development Biometrics Biostatistics, F Hoffmann-La Roche, New York, NY, USA.; Pharma Development Clinical Oncology, F Hoffmann-La Roche, Basel, Switzerland.; Pharma Development Clinical Oncology, F Hoffmann-La Roche, Basel, Switzerland.",judith.trotman@health.nsw.gov.au.
30301790,Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).,2018-Oct-09,Cutler; Avogadri-Connors; Lalani; Bryce,"Puma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.; Puma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.; Puma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.; Puma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.",filippo.montemurro@ircc.it
30297909,Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.,2018-Nov,,,jwargo@mdanderson.org.
30282824,Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.,2018-Oct-04,,,
30275242,Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.,2018-Dec,Moran; Hsiang; Stephens,"R&D and Pharmaceutical Services, Cancer Genetics, Inc., Los Angeles, California.; R&D and Pharmaceutical Services, Cancer Genetics, Inc., Los Angeles, California.; R&D and Pharmaceutical Services, Cancer Genetics, Inc., Los Angeles, California.",y.suna0825@gmail.com.
30268483,EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.,2018-Oct,Jacob; Ceppi; Weisser; James,"Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; 4P Consulting Ltd, Sandwich, UK.",jymama@ncc.re.kr.
30245864,Preparing for the incoming wave of biosimilars in oncology.,2018,,,
30242306,Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.,2019-Jan-01,ElGabry; Chang; Sarkar; Grossman; Grossman; O'Hear; Fassò; Molinero,"Ventana Medical Systems, Inc, Tucson, Arizona.; Genentech, Inc, South San Francisco, California.; now with Bellicum Pharmaceuticals, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; now with Bellicum Pharmaceuticals, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.",
30239818,Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.,2018-Dec-01,Fujii; Taniguchi; Suzuki,"Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, Japan.",
30238401,SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.,2019-Jan,,,cnsternberg@corasternberg.com.
30231890,Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.,2018-Sep-19,O'Neal; Feng; Feng; Jacobs; Jacobs; Roberts; Roberts; Braun; Braun; Bach,"CoreLab Partners (now known as Bioclinica), Princeton, NJ, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Atara Biotherapeutics, Inc, San Francisco, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Pfizer Inc., New York, NY, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Kite Pharma, Inc., Santa Monica, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Pharmacyclics, Sunnyvale, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.",jacob.engellau@med.lu.se.
30219280,Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.,2018-Dec,Moran; Hsiang; Stephens,"R&D and Pharmaceutical Services, Cancer Genetics, Inc, Los Angeles, CA.; R&D and Pharmaceutical Services, Cancer Genetics, Inc, Los Angeles, CA.; R&D and Pharmaceutical Services, Cancer Genetics, Inc, Los Angeles, CA.",y.suna0825@gmail.com.
30202085,"Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.",2018-Sep,Long; Ebbinghaus; Ibrahim; Butler,"Merck & Co., Inc, Kenilworth, NJ, USA.; Merck & Co., Inc, Kenilworth, NJ, USA.; Merck & Co., Inc, Kenilworth, NJ, USA.; Princess Margaret Cancer Centre, Toronto, ON, Canada.",ohamid@theangelesclinic.org.
30201522,Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.,2019-Feb-15,,,dario.neri@pharma.ethz.ch.
30194079,Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (,2018,Lehrer; Rheinstein,"Fermata Pharma, Inc., New York, NY, U.S.A. steven@fermatapharma.com.; Severn Health Solutions, Severna Park, MD, U.S.A.",steven@fermatapharma.com.
30184451,Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.,2018-Sep-06,,,
30178193,Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.,2018-Dec,McKendrick; Kudlac; Oukessou; Zyczynski; Davis,"PRMA Consulting Ltd, Fleet, Hampshire, UK. jmckendrick@prmaconsulting.com.; PRMA Consulting Ltd, Fleet, Hampshire, UK.; Bristol-Myers Squibb, Princeton, NJ, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.",jmckendrick@prmaconsulting.com.
30177994,Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.,2018-Dec-01,Das-Gupta; Truman; Truman; Donica; Smoljanovic,"F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Products Pty Ltd, Sydney, New South Wales, Australia.; Now with OzBiostat Pty Ltd, Manly, New South Wales, Australia.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",
30177462,"Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.",2018-Nov,,,teww@mskcc.org.
30167847,Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.,2018-Nov,,,takeh1977@gmail.com.
30130439,"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.",2018-Oct,Smith; Kiessling; Lledo-Garcia; Dixon; Christodoulou; Catley; Atherfold; D'Hooghe; Finney; Greenslade; Hailu; Kevorkian; Lightwood; Meier; Munro; Qureshi; Sarkar; Shaw; Tewari; Turner; Tyson; West; Shaw; Brennan,"a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.; a UCB Pharma , Slough , UK.",
30128047,Molecular imaging of T cell co-regulator factor B7-H3 with ,2018,Kotsuma; Hirotani; Senaldi,"Quantitative Clinical Pharmacology & Translational Sciences, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.; Biologics & Immuno-Oncology Laboratories, Daiichi-Sankyo Co., Ltd., Tokyo, Japan.; Department of Translational Medicine and Clinical Pharmacology, Daiichi-Sankyo Pharma Development, Edison, NJ, USA.",
30082475,Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.,2018-Dec-15,Venkatakrishnan; Zhou; Sheldon-Waniga; Leonard,"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.; Bluebird Bio, Cambridge, Massachusetts (previously Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited).; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.",kevin.kelly@med.usc.edu.
30080132,Patient monitoring programs in oncology pharmacy practice: A survey of oncology pharmacists in Atlantic Canada.,2019-Jun,Dranitsaris,"4 Augmentium Pharma Consulting Inc., Toronto, Canada.",
30056611,First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.,2019-Feb,Zwick-Wallasch; Jansen; Vandell; Senaldi,"U3 Pharma GmbH, 82152, Martinsried, Germany.; Daiichi Sankyo Development Ltd., Gerrards Cross, SL9 0BG, UK.; Daiichi Sankyo Inc., 211 Mt Airy Rd, Basking Ridge, NJ, 07290, USA. avandell@dsi.com.; Daiichi Sankyo Inc., 211 Mt Airy Rd, Basking Ridge, NJ, 07290, USA.",avandell@dsi.com.
30054281,Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3,2019-Feb-15,,,PadSharma@mdanderson.org.
30044476,Diagnosis and treatment of follicular lymphoma: an update.,2018,Baumann; Konermann,"Roche Pharma (Schweiz) AG, Reinach, Switzerland.; Roche Pharma (Schweiz) AG, Reinach, Switzerland.",
30039480,Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.,2019-Jan,Shimono; Matsuda,"Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan.; Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan.",itoshu@yokohama-cu.ac.jp.
29996914,"Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).",2018-Jul-11,,,paolo.ascierto@gmail.com.
29971465,Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.,2018-Sep,,,dario.neri@pharma.ethz.ch.
29959568,Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.,2019-Jan,Matsuda; Shimono,"Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan.; Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan.",hirookda@saitama-med.ac.jp.
29952259,Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy.,2019,Barre; Rougé; Benoist,"Universite de Toulouse, Pharma-Dev, Institut de Recherche pour le Developpement (IRD) UMR 152, Faculte des Sciences Pharmaceutiques, F-31062 Toulouse, Cedex 09, France.; Universite de Toulouse, Pharma-Dev, Institut de Recherche pour le Developpement (IRD) UMR 152, Faculte des Sciences Pharmaceutiques, F-31062 Toulouse, Cedex 09, France.; Universite de Toulouse, Pharma-Dev, Institut de Recherche pour le Developpement (IRD) UMR 152, Faculte des Sciences Pharmaceutiques, F-31062 Toulouse, Cedex 09, France.",
29944978,Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.,2018-Jul,Jacob; James; Hasmann; Weisser,"Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany. Electronic address: wolfgang.jacob@roche.com.; A4P Consulting Ltd, Discovery Park, Sandwich, UK.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.",wolfgang.jacob@roche.com.
29929977,"Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment.",2019-Apr,,,
29915982,A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.,2018-Sep,Xu; Xu; Ravva; Dang; Laurent; Adessi; McIntyre; Meneses-Lorente; Mercier,"Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center New York, New York, USA.; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc, Rahway, USA.; Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center New York, New York, USA.; Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center New York, New York, USA.; Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Drug Safety Licensing, Roche Innovation Center Basel, Basel, Switzerland.; Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center Welwyn, Welwyn, UK.; Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center Welwyn, Welwyn, UK.; Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland. francois.mercier@roche.com.",francois.mercier@roche.com.
29905573,Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.,2018-Aug-31,Apostolou; Skepner; Trojer,"Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.; Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.",
29882016,"Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.",2018-Aug,Silva; Hackl; Quadt; Demanse; Duval,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",jrodon@vhio.net.
29878225,"Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.",2019-Jan-01,Izquierdo,"Novartis Pharma AG, Basel, Switzerland.",
29867498,The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain.,2018,Gorham; Nicholson; Corradini,"Department of CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Department of CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Department of CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",
29852043,Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.,2018-Sep-01,Huttunen,"4Pharma, Turku, Finland.",
29808014,Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.,2018-Jul,,,Ian.Chau@rmh.nhs.uk.
29804638,"A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.",2018-Aug,,,aghajanc@mskcc.org.
29800117,Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.,2018-Jun-01,,,
29799960,Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.,2018-Jun-01,Foley,"Skin & Cancer Foundation Inc, Carlton, Victoria, Australia.",
29712896,"Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.",2018-May-01,,,iida@med.nagoya-cu.ac.jp.
29707140,A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.,2018-Apr-03,Marie; André; Paturel; Zerbib,"Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.",
29700710,HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.,2018-Sep,,,tsurutani_j@med.kindai.ac.jp.
29654069,Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.,2018-Jul,Moisan; Michielin; Jacob; Kronenberg; Wilson; Avignon; Gérard; Benmansour; McIntyre; Meneses-Lorente; Hasmann; Weisser; Adessi,"Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland. annie.moisan@roche.com.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, UK.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, UK.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Development Safety Science, Drug Licensing and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",annie.moisan@roche.com.
29648580,"Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.",2018-Jun-01,Abrey,"F. Hoffmann-La Roche, Pharma Division, Product Development Oncology, Basel, Switzerland.",michael.weller@usz.ch.
29587321,[Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma].,2018-Apr,,,
29568913,A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer.,2018-May,,,
29566260,Ixekizumab-treatment-emergent photosensitive cutaneous eruption.,2018-Nov,Anthony; Rajgopal Bala; Goh; Foley,"Skin & Cancer Foundation Inc. Carlton, Victoria, Australia.; Skin & Cancer Foundation Inc. Carlton, Victoria, Australia.; Skin & Cancer Foundation Inc. Carlton, Victoria, Australia.; Skin & Cancer Foundation Inc. Carlton, Victoria, Australia.",
29556919,Recent advances in medical therapy for metastatic urothelial cancer.,2018-Aug,,,takeshi.yuasa@jfcr.or.jp.
29545095,"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.",2018-Apr,,,marina.garassino@istitutotumori.mi.it.
29544445,Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.,2018-Mar-15,Clemens; Al-Sakaff; Auclair; Nüesch; Holloway; Shing,"Innere Medizin I, Klinikum Mutterhaus der Borromäerinnen gGmbH, Feldstraße 16, 54290, Trier, Germany.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.; Genentech, Inc., Global Pharma Development, 1 DNA Way, South San Francisco, CA, 94080, USA.",v.mueller@uke.de.
29543932,Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.,2018-May-10,Jang; Levitan; Wang; Rosales; Dalal,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Merck & Co, Inc, Kenilworth, New Jersey.; Merck & Co, Inc, Kenilworth, New Jersey.; Merck & Co, Inc, Kenilworth, New Jersey.; Merck & Co, Inc, Kenilworth, New Jersey.",
29501977,Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).,2018-Apr,Sandermann,"Biostatistics, Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.",markus.moehler@unimedizin-mainz.de.
29500245,Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity.,2018-Apr-15,,,nicole.joller@immunology.uzh.ch
29487979,The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.,2018-May,Müller,"Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400, Biberach an der Riss, Germany.",heinz.laeubli@unibas.ch.
29470536,Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.,2018,,,
29466990,Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes.,2018-Feb-21,Lajoie; Courbebaisse,"GICC 'Groupe Innovation et Ciblage Cellulaire', Université de Tours, Equipe FRAME - Fc Récepteurs, Anticorps et MicroEnvironnement, 37032, Tours, France.; Bertin Pharma Orléans, 45071, Orléans, France.",emilie.allard@univ-tours.fr.
29464396,"Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.",2018-Jun,,,atsuji@med.kagawa-u.ac.jp.
29464112,"Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.",2018,Baumeister; Danielczyk; Dietrich; Goletz; Zurlo; Salzberg,"Immunomonitoring, Glycotope GmbH, Berlin, Germany.; R&D, Glycotope GmbH, Berlin, Germany.; Clinical Development, Glycotope GmbH, Berlin, Germny.; R&D, Glycotope GmbH, Berlin, Germany.; Clinical Development, Glycotope GmbH, Berlin, Germany.; Pharma Brains AG, Basel, Switzerland.",
29442540,Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.,2018-Jun-10,,,
29439857,"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.",2018-Mar,,,mba41@georgetown.edu.
29438784,"Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.",2018-Apr-10,,,anja.schmid@pharma.ethz.ch.
29436940,Biomarker threshold adaptive designs for survival endpoints.,2018,Dong; Ke; Rong,"b Amgen Inc ., Thousand Oaks , California , USA.; b Amgen Inc ., Thousand Oaks , California , USA.; d Astellas Pharma US, Inc ., Los Angeles , California , USA.",
29431699,"Combined BRAF, EGFR, and MEK Inhibition in Patients with ",2018-Apr,Jung; Brase; Bettinger; Mookerjee; Rangwala,"Amgen Inc., Thousand Oaks, California.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.",rbcorcoran@partners.org.
29423521,Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.,2018-Apr-12,,,
29423515,Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.,2018-Apr-01,Ding; Kaiser; Fassò; O'Hear,"Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.",
29419437,"Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.",2018-Apr,Bernhardt; Kellershohn; Messeri; Osborne,"Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Medical Affairs, Roche Pharma AG, Grenzach-Wyhlen, Germany.; Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland.",veronique.leblond@aphp.fr.
29393986,Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.,2018-May,Marquardt; Kellershohn,"Roche Pharma AG, Grenzach-Wyhlen, Germany.; Roche Pharma AG, Grenzach-Wyhlen, Germany.",
29378660,Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.,2018-Jan-29,,,rinib2@ccf.org.
29349598,"Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.",2018-Oct,Michielin; Jacob; Adessi; Moisan; Meneses-Lorente; Racek; James; Ceppi; Hasmann; Weisser,"Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany. wolfgang.jacob@roche.com.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development (pRED), Roche Innovation Center Welwyn, Welwyn Garden City, UK.; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; A4P Consulting Ltd, Sandwich, UK.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.",wolfgang.jacob@roche.com.
29327061,EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.,2018-Aug-01,,,
29310623,Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study.,2018-Jan-08,Schleif,"Roche Pharma AG, Emil-Barell-Str. 1, D-79639, Grenzach-Wyhlen, Germany.",peter.dall@klinikum-lueneburg.de.
29308327,Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.,2018,Mayer; Wirtz,"U3 Pharma GmbH, Planegg, Germany.; U3 Pharma GmbH, Planegg, Germany.",
29284010,Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.,2017,Abdul Razak; Gould; Saraf; Stein,"Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, Canada.; Department of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.; Department of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.; Department of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.",
29280043,Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).,2018-Apr,Bradbury; Campbell; Izquierdo,"Frontier Science (Scotland) Ltd., Grampian View, Kingussie, PH21 1NA, UK.; Frontier Science (Scotland) Ltd., Grampian View, Kingussie, PH21 1NA, UK.; Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Klybeckstrasse, 4057, Basel, Switzerland.",evandro.azambuja@bordet.be.
29259203,The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.,2017-Dec-19,Ravichandran,"Advanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Frederick, MD, 21701, USA.",wiestnea@nhlbi.nih.gov.
29253068,Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.,2018-Mar-01,Kuruvilla; Wu; Fan; Louveau; Voi,"Princess Margaret Cancer Centre, Toronto, Canada.; Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, USA.; Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, USA.; Novartis Pharma, Paris, France.; Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, USA.",witzig.thomas@mayo.edu.
29244528,"Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.",2018-Mar-10,,,
29241550,Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope.,2017-Dec-12,,,nese.kurtyilmaz@umassmed.edu.
29227816,"The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.",2018-Jan,Campbell; Izquierdo,"Frontier Science (Scotland) Ltd., Kincraig, UK.; Novartis Pharma AG, Basel, Switzerland.",serena.dicosimo@istitutotumori.mi.it.
29222268,Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?,2017-Dec-08,,,
29211295,Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).,2018-Feb-15,,,
29209955,Acalabrutinib: First Global Approval.,2018-Jan,,,dru@adis.com.
29198055,Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.,2018-Apr,Urban; Mouhaër; Tomaso; Massacesi,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, Rueil-Malmaison, France.; Syros Pharmaceuticals, Watertown, MA, USA.; Novartis Pharmaceuticals Corporation, Rueil-Malmaison, France.",barbara.pistilli@gustaveroussy.fr.
29180606,Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies ,2018-Mar-01,,,lkwak@coh.org
29174181,"Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.",2018-Feb,Hilton; Garcia,"Biostatistics Oncology, Pharma Development, F. Hoffmann-La Roche Ltd, Building 663, Hochstrasse, Basel, 4070, Switzerland.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, 4070, Switzerland.",david.miles@doctors.org.uk.
29172757,Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.,2017-Nov,,,
29123255,Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.,2017-Dec-05,,,
29110849,Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.,2017-Nov,Miller; Freiwald; Fan; Wang; Chand,"Foundation Medicine, Inc., 150 Second Street, Cambridge, MA, USA. Electronic address: vmiller@foundationmedicine.com.; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach, Germany. Electronic address: matthias.freiwald@boehringer-ingelheim.com.; Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT, USA. Electronic address: jean.fan@boehringer-ingelheim.com.; Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT, USA. Electronic address: bushi.wang@boehringer-ingelheim.com.; Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT, USA. Electronic address: vikramkchand@gmail.com.",leora.horn@vanderbilt.edu.
29071414,"A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.",2017-Dec,,,tdoi@east.ncc.go.jp.
29070415,"Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.",2017-Oct-25,,,neri@pharma.ethz.ch.
29061295,"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.",2017-Dec-23,,,peter.borchmann@uni-koeln.de.
29043496,Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.,2018-Feb,Tao; Yu; Khaznadar; Tajima; Shibata; Seki,"Roche (China) Holding Ltd, Building 11, 1100 Longdong Avenue, Shanghai, 201203, China.; Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, 4070, Switzerland.; Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.",terufumikato@gmail.com.
29040265,Analysis of peripheral B cells and autoantibodies against the anti-nicotinic acetylcholine receptor derived from patients with myasthenia gravis using single-cell manipulation tools.,2017,Makino; Nakamura; Terakawa; Muneoka; Nagahira,"Drug Discovery Technology Function, Asubio Pharma Co., LTD, Kobe, Japan.; Regenerative Medicine Field, Asubio Pharma Co., LTD, Kobe, Japan.; Immunology & Inflammatory Disease Field, Asubio Pharma Co., LTD, Kobe, Japan.; Immunology & Inflammatory Disease Field, Asubio Pharma Co., LTD, Kobe, Japan.; Immunology & Inflammatory Disease Field, Asubio Pharma Co., LTD, Kobe, Japan.",
29030633,The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.,2017-Oct-13,,,horitano@yokohama-cu.ac.jp.
28983557,Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.,2018-Mar-01,,,
28982916,The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.,2017-Oct,,,nakahama_kenji@outlook.jp.
28982322,PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.,2018-Feb-12,Dong,"Jinan Taorui Pharma & Tech Co., Ltd., Jinan, Shandong 250101, China.",
28975219,Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.,2018-Mar-01,,,
28950297,A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.,2017-Nov-01,Crowell; Li; Senderowicz; Stone,"Department of Medicine, Cerulean Pharma Inc., Waltham.; Department of Medicine, Cerulean Pharma Inc., Waltham.; Department of Medicine, Cerulean Pharma Inc., Waltham.; Department of Medicine, Cerulean Pharma Inc., Waltham.",vossm@mskcc.org.
28936560,Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).,2018-May,,,gioncology2006@yahoo.co.jp.
28935843,"Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.",2017-Nov,Osborne; Smith,"PDMA Operations (Biometrics), F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.",p.lugtenburg@erasmusmc.nl.
28923573,"Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).",2017-Nov,Turri; Urban,"Novartis Pharma SAS, Rueil Malmaison, France.; Novartis Pharma AG, Basel, Switzerland.",Sibylle.Loibl@gbg.de.
28866758,Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.,2017-Dec,Gibson; Koblbauer; Begum; Dranitsaris; McEwan,"Wickenstones Ltd, Oxford, UK. Eddie@wickenstones.com.; Wickenstones Ltd, Oxford, UK.; Wickenstones Ltd, Oxford, UK.; Augmentium Pharma Consulting Inc., Toronto, Canada.; Health Economics and Outcomes Research Ltd, Cardiff, UK.",Eddie@wickenstones.com.
28845710,Combination therapy with the type II anti-CD20 antibody obinutuzumab.,2017-Oct,Klein; Bacac; Umana; Fingerle-Rowson,"a Roche Pharmaceutical Research & Early Development , Roche Innovation Center Zurich , Zurich , Switzerland.; a Roche Pharmaceutical Research & Early Development , Roche Innovation Center Zurich , Zurich , Switzerland.; a Roche Pharmaceutical Research & Early Development , Roche Innovation Center Zurich , Zurich , Switzerland.; b Pharma Development Clinical Oncology , F. Hoffmann-La Roche Ltd , Basel , Switzerland.",
28838937,Daratumumab combinations: what can we learn?,2017-Aug-24,,,
28819703,Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.,2017-Dec,Wise; Kraynyak; Sardesai; Joseph Kim,"Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.",dweiner@wistar.org.
28817755,Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.,2018-Jan-01,,,
28817753,Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.,2017-Sep-14,Sridhar,"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",
28810837,Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.,2017-Aug-15,,,sylvie.negrier@lyon.unicancer.fr.
28807568,Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.,2017-Nov-01,Wiltzius; Sievers,"Kite Pharma, Inc., Santa Monica, CA 90404, USA.; Kite Pharma, Inc., Santa Monica, CA 90404, USA.",kochendj@mail.nih.gov.
28781291,A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.,2017-Oct-12,,,
28744667,Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.,2017-Sep,,,allen.cohn@usoncology.com.
28735068,Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery.,2017-Sep,Keitel; Lattrich; Jackisch,"Roche Pharma AG, Grenzach-Wyhlen, Germany.; Roche Pharma AG, Grenzach-Wyhlen, Germany.; Sana Klinikum Offenbach GmbH, Offenbach, Germany.",barinoff.jana@googlemail.com.
28733442,,2017-Oct-15,Thomas; Jacob; Abiraj; Adessi; Meneses-Lorente; James; Weisser,"Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom.; A4P Consulting Ltd, Sandwich, United Kingdom.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.",e.g.e.de.vries@umcg.nl.
28716814,Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.,2017-Nov,Wulhfard,"Philochem AG, Otelfingen, Switzerland. neri@pharma.ethz.ch sarah.wulhfard@philochem.ch.",neri@pharma.ethz.ch
28625777,Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.,2017-Sep,Al-Sakaff; Lauer; Shing,"F. Hoffmann-La Roche Ltd, Global Pharma Development, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Biostatistics, Basel, Switzerland.; Genentech, Inc., Global Pharma Development, South San Francisco, CA, USA.",joseph.gligorov@aphp.fr.
28608499,Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.,2017-Sep,Bedrosian; Cole,"Alexion Pharma International, New Haven, Connecticut, USA.; Alexion Pharma International, Lexington, Massachusetts, USA.",
28600477,Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.,2017-Sep-01,Prieur; Joubert,"Accompagnement Pharma, Luxembourg, Luxembourg. a.prieur@accompagnementpharma.com.; Accompagnement Pharma, Luxembourg, Luxembourg.",a.prieur@accompagnementpharma.com.
28600476,Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.,2017-Sep-15,Jacob; Wilson; Thomas; Ceppi; Meneses-Lorente; James; Vega-Harring; Dua; Nguyen; Steiner; Adessi; Michielin; Bossenmaier; Weisser,"Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany. wolfgang.jacob@roche.com.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom.; A4P Consulting Ltd, Discovery Park, Sandwich, United Kingdom.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Molecular Systems Inc., Pleasanton, California.; Roche Molecular Systems Inc., Pleasanton, California.; Roche Molecular Systems Inc., Pleasanton, California.; Pharma Research and Early Development, Roche Innovation Center, Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center, Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.",wolfgang.jacob@roche.com.
28600350,Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.,2017-Oct,Voisin,"Institut Gustave Roussy, Unité Fonctionnelle de Pharmacovigilance, Villejuif, France.",
28581356,Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.,2017-Jul-13,,,
28578404,A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients.,2017-Jun-02,Becher; Becher; Ciccolini; Imbs; Marin; Ghettas; Pruvost; Junot; Lacarelle,"Service de Pharmacologie et d'Immunoanalyse (SPI), CEA, INRA, Université Paris-Saclay, 91191, Gif sur Yvette, France.; Groupe de Pharmacologie Clinique & Oncologique (GPCO)-Unicancer, 101 rue de Tolbiac, 75013, Paris, France.; Groupe de Pharmacologie Clinique & Oncologique (GPCO)-Unicancer, 101 rue de Tolbiac, 75013, Paris, France. joseph.ciccolini@univ-amu.fr.; Groupe de Pharmacologie Clinique & Oncologique (GPCO)-Unicancer, 101 rue de Tolbiac, 75013, Paris, France.; Groupe de Pharmacologie Clinique & Oncologique (GPCO)-Unicancer, 101 rue de Tolbiac, 75013, Paris, France.; Service de Pharmacologie et d'Immunoanalyse (SPI), CEA, INRA, Université Paris-Saclay, 91191, Gif sur Yvette, France.; Service de Pharmacologie et d'Immunoanalyse (SPI), CEA, INRA, Université Paris-Saclay, 91191, Gif sur Yvette, France.; Service de Pharmacologie et d'Immunoanalyse (SPI), CEA, INRA, Université Paris-Saclay, 91191, Gif sur Yvette, France.; Groupe de Pharmacologie Clinique & Oncologique (GPCO)-Unicancer, 101 rue de Tolbiac, 75013, Paris, France.",joseph.ciccolini@univ-amu.fr.
28554253,Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.,2018-Jan,,,
28546521,"Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.",2018-Apr,,,
28529321,Colorectal cancer drugs market.,2017-Aug,Cassidy; Syed,"FirstWord Pharma, PSL Group, 75 Davies Street, London W1K 5JN, UK.; FirstWord Pharma, PSL Group, 75 Davies Street, London W1K 5JN, UK.",
28523951,Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe.,2017-Jun,Trollope; Johnson,"Mundipharma International Limited,194 Science ParkMilton Road, Cambridge CB4 0AB, UK.; Mundipharma International Limited,194 Science ParkMilton Road, Cambridge CB4 0AB, UK.",
28523933,The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.,2017-Jul,Ehneß,"Novartis Pharma GmbH, Nuernberg, Germany.",
28507002,Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.,2017-Jul,Dubreuil; Barret; Prost,"GamaMabs Pharma SA, Centre Pierre Potier, Toulouse, France.; GamaMabs Pharma SA, Centre Pierre Potier, Toulouse, France.; GamaMabs Pharma SA, Centre Pierre Potier, Toulouse, France.",thierry.chardes@inserm.fr.
28499022,Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.,2017-Nov-29,,,
28497320,Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.,2017-Jun,Meneses-Lorente; McIntyre; Thomas,"Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, Hertfordshire, AL7 1TW, UK. georgina.meneses-lorente@roche.com.; Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, Hertfordshire, AL7 1TW, UK.; Roche Pharma AG, Grenzach-Wyhlen, Germany.",georgina.meneses-lorente@roche.com.
28467975,ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.,2017-Jul-11,Gerdes,"Roche Pharma Research & Early Development, Roche Innovation Center Zürich, Schlieren, Switzerland.",
28453187,PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.,2017-Apr-28,,,
28427157,"The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.",2017-Jun-06,Fontayne; Barret; Dubreuil; Abache; de Romeuf; Terrier; Verhaeghe; Gaucher; Prost,"LFB Biotechnologies, Loos, F-59120, France.; GamaMabs Pharma, Toulouse cedex, F-31106, France.; GamaMabs Pharma, Toulouse cedex, F-31106, France.; LFB Biotechnologies, Loos, F-59120, France.; LFB Biotechnologies, Loos, F-59120, France.; LFB Biotechnologies, Loos, F-59120, France.; LFB Biotechnologies, Loos, F-59120, France.; LFB Biotechnologies, Loos, F-59120, France.; GamaMabs Pharma, Toulouse cedex, F-31106, France.",
28421390,"Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.",2017-Aug,Zhang; Fujita,"Novartis Pharma K.K., Tokyo, Japan.; Novartis Pharma K.K., Tokyo, Japan.",khatake@jfcr.or.jp.
28402142,Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns.,2017-Sep,,,
28399902,Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.,2017-Apr-11,Ridolfi; Noel-Baron; Ringeisen,"Novartis Pharma SAS, Rueil-Malmaison, France.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",toi@kuhp.kyoto-u.ac.jp.
28382562,Biomarkers to predict prognosis and response to checkpoint inhibitors.,2017-Aug,,,takeshi.yuasa@jfcr.or.jp.
28376188,Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.,2017-Aug-01,Holmes; Izquierdo,"Frontier Science (Scotland) Ltd., Kincraig, UK.; Novartis Pharma AG, Basel, Switzerland.",
28375706,"Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.",2017-May-01,,,
28368335,Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.,2017-Apr-02,,,miyamotoyuji@gmail.com.
28363909,A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic ,2017-Jun,Spreafico; Avsar; Chatterjee; Tan; Maharry; Demuth,"Princess Margaret Cancer Centre, Toronto, Canada.; Novartis Pharmaceutical Corporation, East Hanover, New Jersey.; Novartis Pharmaceutical Corporation, East Hanover, New Jersey.; Novartis Pharmaceutical Corporation, East Hanover, New Jersey.; Array BioPharma Inc., Boulder, Colorado.; Novartis Pharma AG, Basel, Switzerland.",j.schellens@nki.nl.
28288980,Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.,2017-May-11,Klein,"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.",
28283736,Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).,2017-Apr,,,nyamazaki@ncc.go.jp.
28282035,Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.,2017-Mar-10,Bleickardt,"Oncology Clinical Development, Bristol-Myers Squibb, Princeton, NJ, USA.",
28264791,More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.,2017-Apr,,,
28263892,In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies.,2017-Dec,Brennan; Kiessling,"UCB Pharma, 208 Bath Road, Slough SL1 3WE, UK. Electronic address: frank.brennan@ucb.com.; UCB Pharma, 208 Bath Road, Slough SL1 3WE, UK.",frank.brennan@ucb.com.
28236978,Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.,2017-Mar,Hirotani; Chen; Copigneaux,"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.; Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ 08837, USA.; Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ 08837, USA.",yonesaka@sakai.med.kindai.ac.jp.
28236583,Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP,2017-Apr,,,peter.borchmann@uni-koeln.de.
28223062,"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.",2017-Apr,,,ceng@mdanderson.org.
28222590,Novel Tumor Pretargeting System Based on Complementary l-Configured Oligonucleotides.,2017-Apr-19,Vonhoff; Klussmann; Bethge,"NOXXON Pharma AG , 10589 Berlin, Germany.; NOXXON Pharma AG , 10589 Berlin, Germany.; NOXXON Pharma AG , 10589 Berlin, Germany.",
28216573,A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.,2017-Feb-14,Pieczykolan; Jelen,"Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland. jerzy.pieczykolan@celonpharma.com.; Research and Development Department, Pure Biologics Ltd., 54-427 Wroclaw, Poland. filip@purebiologics.com.",aniaserwotka@wp.pl.
28204866,Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.,2017-May,,,jan.marsal@med.lu.se.
28192159,PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab' antibody fragment after pulmonary delivery in three different species.,2017-Apr-15,Heywood,"UCB Pharma, Slough, UK.",rita.vanbever@uclouvain.be.
28186126,Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.,2017-Feb-10,Schütte; Keil; Yildiriman; Borodina; Lange; Wierling; Becker; Welte; Regan; Silvestrov; Kessler; Garin-Chesa; Reinhard; Regenbrecht; Henderson; Lange; Hoffmann; Lehrach,"Alacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.; Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Robert-Roessle-Str. 10, 13125 Berlin, Germany.; Alacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.; Alacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.; Bayer Pharma AG, Müllerstraße 178, 13353 Berlin, Germany.; Alacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.; Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Robert-Roessle-Str. 10, 13125 Berlin, Germany.; CPO-Cellular Phenomics&Oncology, Berlin-Buch GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany.; Bayer Pharma AG, Müllerstraße 178, 13353 Berlin, Germany.; CPO-Cellular Phenomics&Oncology, Berlin-Buch GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany.; Alacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.; Boehringer Ingelheim RCV GmbH &Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Wien, Austria.; Eli Lilly and Company, Lilly Research Laboratories, Oncology Translational Research, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.; CPO-Cellular Phenomics&Oncology, Berlin-Buch GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany.; Bayer Pharma AG, Global External Innovation &Alliances, Müllerstraße 178, 13353 Berlin, Germany.; Alacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.; Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Robert-Roessle-Str. 10, 13125 Berlin, Germany.; Alacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.",
28174294,"Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.",2017-Feb,Keitel,"Roche Pharma AG, Grenzach-Wyhlen, Germany.",peter.dall@klinikum-lueneburg.de.
28167454,Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.,2017-Mar,,,kilian.wistuba-hamprecht@uni-tuebingen.de.
28154831,Targeting ,2017,Fleurence; Fougeray; Birklé,"Inserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France; CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.; Inserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France; CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.; Inserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France; CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.",
28121547,Oncology pharma costs to exceed $150 billion by 2020.,2016-Oct,,,
28111429,"Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.",2017-Oct,Soldatenkova; Depenbrock; Orlando,"Lilly Deutschland GmbH, Bad Homburg, Germany.; Lilly Deutschland GmbH, Bad Homburg, Germany.; Eli Lilly Interamerica Inc., Buenos Aires, Argentina.",
28096534,Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.,2017-Oct,Rueter,"Boehringer Ingelheim Pharma GmbH &Co. KG, Biberach/Riss, Germany.",
28078656,Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.,2017-Feb,Jacobs; Ewesuedo; Lula; Zacharchuk,"Pfizer Inc, Pfizer Essential Health, 235 East 42nd Street, New York, NY, 10017-5755, USA. ira.jacobs@pfizer.com.; Pfizer Inc, Biosimilars Development, Cambridge, MA, USA.; Envision Pharma Group, London, UK.; Pfizer Inc, Biosimilars Development, Cambridge, MA, USA.",ira.jacobs@pfizer.com.
28056114,Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.,2017-Sep-01,,,
28013222,Generation and characterization of monoclonal antibodies against human LGR6.,2017-Apr-01,,,
28004361,"A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.",2017-Feb,Klein; Oya; Fingerle-Rowson,"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Oncology Lifecycle Management Department, Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.; Pharma Development Oncology, F. Hoffmann La-Roche Ltd, Basel, Switzerland.",ktobinai@ncc.go.jp.
27979383,"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.",2017-Jan-21,Waterkamp; Ballinger; Kowanetz; He; Chen; Sandler,"Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.",drgandara@ucdavis.edu.
27942917,LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.,2017-Jan,Kakizume; Tajima; Takeuchi; Maacke,"Novartis Pharma K.K., Tokyo, Japan.; Novartis Pharma K.K., Tokyo, Japan.; Novartis Pharma K.K., Tokyo, Japan.; Novartis Pharma K.K., Tokyo, Japan.",s.takahashi-chemotherapy@jfcr.or.jp.
27918764,"Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.",2017-May-01,Chen; Hack; Bruey; Smith; McCaffery; Shames; Phan,"Biostatistics Department, Roche (China) Holdings Ltd, Shanghai, China.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.",
27903862,Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.,2016-Nov-30,,,onur.boyman@uzh.ch.
27872953,A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.,2017-Jan,Uttenreuther-Fischer; Pemberton; Pelling; Schnell,"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Boehringer Ingelheim Ltd, Bracknell, UK.; Boehringer Ingelheim Ltd, Bracknell, UK.; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",james.spicer@kcl.ac.uk.
27863175,Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.,2016-Nov,Mueller; Wagg; Phipps; Boetsch; Ribba,"Pharma Research and Early Development, Roche Innovation Centre Munich, Munich, Germany.; Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation, Welwyn Garden City, UK.; Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Centre Munich, Munich, Germany.",
27817944,Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.,2017-Jan,Hubeaux; Quah; Bais,"Biostatistics Oncology, Pharma Development, F. Hoffmann-La Roche, Building 670, Malzgasse 30, 4070 Basel, Switzerland.; Global Development BioOncology, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.; Global Development BioOncology, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.",david.miles@doctors.org.uk.
27807766,Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.,2016-Dec,Jacobs; Petersel; Shane; Ng; Kirchhoff; Finch; Lula,"Global Established Pharma Medicines Development Group, Pfizer Inc., 235 East 42nd Street, New York, NY, 10017-5755, USA. ira.jacobs@pfizer.com.; Global Established Pharma Medicines Development Group, Pfizer Inc., 235 East 42nd Street, New York, NY, 10017-5755, USA.; Outcomes and Evidence, Global Health and Value, Pfizer Inc., New York, NY, USA.; Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, MA, USA.; Global Technology Services, Biotechnology and Aseptic Sciences, Pfizer Inc., Chesterfield, MO, USA.; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA.; Envision Pharma Group, London, UK.",ira.jacobs@pfizer.com.
27550944,"The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",2016-Nov,Mattie; Raitano; Morrison; Morrison; An; Capo; Verlinsky; Leavitt; Ou; Nadell; Aviña; Guevara; Malik; Moser; Duniho; Coleman; Li; Pereira; Doñate; Joseph; Challita-Eid; Benjamin; Stover,"Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California. mmattie@agensys.com.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Seattle Genetics, Inc., Bothell, Washington.; Seattle Genetics, Inc., Bothell, Washington.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Seattle Genetics, Inc., Bothell, Washington.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.",mmattie@agensys.com.
27797971,"An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.",2016-Nov-01,Grebennik,"Kyowa Hakko Kirin Pharma, Inc., Princeton, New Jersey.",wolchokj@mskcc.org.
27543601,Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.,2016-Nov-01,Sommer; Kopitz; Schatz; Nising; Mahlert; Lerchen; Stelte-Ludwig; Hammer; Greven; Schuhmacher; Braun; Zierz; Wittemer-Rump; Harrenga; Dittmer; Reetz; Apeler; Jautelat; Ziegelbauer; Kreft,"Bayer Pharma AG, Berlin, Germany. anette.sommer@bayer.com.; Bayer Pharma AG, Berlin, Germany.; Bayer Pharma AG, Berlin, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Berlin, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Berlin, Germany.; Bayer Pharma AG, Berlin, Germany.; Bayer Pharma AG, Berlin, Germany.; Bayer Intellectual Property GmbH, Monheim, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Berlin, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Wuppertal, Germany.; Bayer Pharma AG, Berlin, Germany.; Bayer Pharma AG, Berlin, Germany.",anette.sommer@bayer.com.
27641143,Romosozumab Treatment in Postmenopausal Women with Osteoporosis.,2016-Oct-20,,,
27698113,Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.,2016-Oct-18,Emerson; Yusko; Vignali; Robins,"Adaptive Biotechnologies, Seattle, WA 98102.; Adaptive Biotechnologies, Seattle, WA 98102.; Adaptive Biotechnologies, Seattle, WA 98102.; Adaptive Biotechnologies, Seattle, WA 98102; Fred Hutchinson Cancer Research Center, Seattle, WA 98102.",padsharma@mdanderson.org
27787547,Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.,2017-Jul-01,Fall; Wilhelm,"Wilex AG, Munich, Germany6Therawis Pharma GmbH, Munich, Germany.; Wilex AG, Munich, Germany6Therawis Pharma GmbH, Munich, Germany.",
27129177,Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.,2016-Jun-21,Hsu Schmitz; Lefebvre; Akimov,"Early Clinical Biostatistics, Oncology, Novartis Pharma AG, Basel, Switzerland.; Translational Clinical Oncology, Novartis Pharma AG, Basel, Switzerland.; Oncology Global Development, Novartis Pharma AG, Basel, Switzerland.",
27533633,The efficacy of anti-PD-1 agents in acral and mucosal melanoma.,2016-Nov-15,,,shoushta@mskcc.org.
27733243,"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.",2016-Nov,Harbison; Lin; Tschaika; Azrilevich,"NIVO/IPI LCM Biomarkers, Bristol-Myers Squibb, Princeton, NJ, USA.; Clinical Biostatistics, Bristol-Myers Squibb, Princeton, NJ, USA.; Global Clinical Research/Oncology, Bristol-Myers Squibb, Princeton, NJ, USA.; Global Clinical Research/Oncology, Bristol-Myers Squibb, Princeton, NJ, USA.",padsharma@mdanderson.org.
27729618,Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.,2016-Nov-08,,,
27724870,"SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.",2016-Oct-10,Na,"Present Address: Novartis Pharma, Stein, Switzerland.",Christoph.Rochlitz@usb.ch.
27698437,Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies.,2016-Oct-04,Perro; Freytag; Gerdes,"Roche Innovation Center Zurich, Roche Pharma Research &Early Development, Wagistrasse 18,8952 Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research &Early Development, Wagistrasse 18,8952 Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research &Early Development, Wagistrasse 18,8952 Schlieren, Switzerland.",
27622751,"Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.",2016-Dec,,,mcarthuh@mskcc.org.
27602494,Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.,2016-Oct-18,Gerdes,"Department of Roche Pharma Research and Early Development, Roche Innovation Center Zürich, Schlieren, Switzerland.",
27578890,TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.,2016-Oct,Castoldi; Schanzer; Panke; Jucknischke; Neubert; Croasdale; Scheuer; Auer; Klein; Niederfellner; Kobold; Sustmann,"pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Munich, Germany.; pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Munich, Germany.; pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Munich, Germany.; pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Munich, Germany.; pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Munich, Germany.; pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Munich, Germany.; pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Munich, Germany.; pRED, Roche Pharma Research & Early Development, Roche Large Molecule Research, Roche Innovation Center, Munich, Nonnenwald 2, 82377 Penzberg, Germany.; pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Zuerich, Switzerland, Wagistrasse 18, 8952 Schlieren.; pRED, Roche Pharma Research & Early Development, Roche Innovation Center, Munich, Germany.; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Lindwurmstraße 2a, 80337 Munich, Germany, Member of the German Center for Lung Research (DZL).; pRED, Roche Pharma Research & Early Development, Roche Large Molecule Research, Roche Innovation Center, Munich, Nonnenwald 2, 82377 Penzberg, Germany.",
27529514,Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.,2016-Sep-06,Thomas; Koehler; Ooi; Birzele; Belousov,"Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.",
27523608,The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity.,2016-Aug-25,McHale,"New Medicines, UCB Pharma, Slough SL1 3WE, UK.",erm1000@medschl.cam.ac.uk.
27507056,"First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.",2016-Nov-29,Rüttinger; Weigand; Cannarile; Heil; Brewster; Walz; Nayak; Guarin; Meresse,"Pharma Research & Early Development, Roche Innovation Center, Penzberg, Germany.; Pharma Research & Early Development, Roche Innovation Center, Penzberg, Germany.; Pharma Research & Early Development, Roche Innovation Center, Penzberg, Germany.; Pharma Research & Early Development, Roche Innovation Center, Penzberg, Germany.; Pharma Research & Early Development, Roche Innovation Centre, Welwyn, UK.; Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.",
27472034,Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.,2017-Jan,Selby; Benson; Engstrom; Sajosi; Bonthapally,"d Takeda UK Ltd , Buckinghamshire , UK.; d Takeda UK Ltd , Buckinghamshire , UK.; e Takeda Pharma AB , Stockholm , Sweden.; f Millennium Pharmaceuticals Inc. , Cambridge , MA , USA ,a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.; f Millennium Pharmaceuticals Inc. , Cambridge , MA , USA ,a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.",
27462398,ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.,2016,,,
27457310,Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.,2016-Aug,Eliasof; Garmey; Jayaraman; Senderowicz; Tellez; Hennessy; Piscitelli,"Cerulean Pharma Inc., Waltham.; Cerulean Pharma Inc., Waltham.; Cerulean Pharma Inc., Waltham.; Cerulean Pharma Inc., Waltham.; Cerulean Pharma Inc., Waltham.; Cerulean Pharma Inc., Waltham.; Cerulean Pharma Inc., Waltham.",naomi.haas@uphs.upenn.edu.
27422720,"A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.",2016-Oct,,,tdoi@east.ncc.go.jp.
27402103,Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.,2016-Dec,,,takeshi.yuasa@jfcr.or.jp.
27401244,BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.,2016-Oct-15,Sasse; Vossen; Chen; Van Sant; Ball; Keating; Krivoshik,"Astellas Pharma Global Development, Northbrook, Illinois.; Astellas Pharma Global Development, Northbrook, Illinois.; Astellas Pharma Global Development, Northbrook, Illinois.; Astellas Pharma Global Development, Northbrook, Illinois.; Astellas Pharma Global Development, Northbrook, Illinois.; Astellas Pharma Global Development, Northbrook, Illinois.; Astellas Pharma Global Development, Northbrook, Illinois.",a-benson@northwestern.edu.
27400222,Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.,2016-Aug,,,
27349978,Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.,2016-Jun,,,
27342991,Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.,2017-Mar,,,matt_milowsky@med.unc.edu.
27325647,"Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.",2016-Aug-01,Peters; Brown; Jayaraman; Rohde; Lazarus; Eliasof,"Cerulean Pharma Inc., Waltham, Massachusetts.; Cerulean Pharma Inc., Waltham, Massachusetts.; Cerulean Pharma Inc., Waltham, Massachusetts.; Cerulean Pharma Inc., Waltham, Massachusetts.; Cerulean Pharma Inc., Waltham, Massachusetts.; Cerulean Pharma Inc., Waltham, Massachusetts.",robert.kerbel@sri.utoronto.ca.
27317172,"Optimized Lentiviral Transduction Protocols by Use of a Poloxamer Enhancer, Spinoculation, and scFv-Antibody Fusions to VSV-G.",2016,Thirion,"SIRION Biotech GmbH, Am Klopferspitz 19, 82152, Martinsried, Germany. thirion@sirion-biotech.de.",natasa.anastasov@helmholtz-muenchen.de.
27277600,Systemic therapy in metastatic renal cell carcinoma.,2017-Feb,,,bedke@live.com.
27243803,Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.,2016-Sep-01,Jiang; Waxman,"Global Biometric Sciences, Bristol-Myers Squibb, Princeton, New Jersey.; Global Clinical Research, Bristol-Myers Squibb, Princeton, New Jersey.",
27217584,IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.,2016-Jul-01,Desbois; Béchard,"Gustave Roussy, Laboratoire d'Immunomonitoring en Oncologie, Villejuif F-94805, France; Centre National de la Recherche Scientifique, Unité Mixte de Service 3655, Villejuif F-94805, France; INSERM, US23, Villejuif, F-94805, France; INSERM, Centre d'Investigation Clinique Biothérapie 1428, Villejuif F-94805, France; Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre F-94276, France; Cytune Pharma, Nantes F-44300, France;; Cytune Pharma, Nantes F-44300, France;",nathalie.chaput@gustaveroussy.fr.
27216274,"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.",2016-Jul,,,barbara.eichhorst@uk-koeln.de.
27208905,HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.,2016-Jul,Jackisch; Crepelle-Fléchais; Heinzmann; Shing,"Sana Klinikum Offenbach GmbH, Department of Obstetrics and Gynecology & Breast Cancer and Gynecology Cancer Center, Starkenburgring 66, D-63069, Offenbach, Germany. Electronic address: christian.jackisch@sana.de.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.; Genentech, Inc., Global Pharma Development, 1 DNA Way, South San Francisco, CA, 94080, USA.",christian.jackisch@sana.de.
27203743,The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.,2016-Jun-14,Dubreuil; Mondon,"GamaMabs Pharma SA, Centre Pierre Potier, ONCOPOLE, BP 50624, France.; LFB Biotechnologies, 59000, Lille, France.",
27189072,Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.,2016-May-18,Smith; Robida; Acosta; Vennapusa; Mistry; Martin; Yates; Hnatyszyn,"Companion Diagnostics Pharma Services, Assay Development, Ventana Medical Systems Inc., Roche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.; Companion Diagnostics Pharma Services, Assay Development, Ventana Medical Systems Inc., Roche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.; Companion Diagnostics Pharma Services, Assay Development, Ventana Medical Systems Inc., Roche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.; Companion Diagnostics Pharma Services, Pathology Office, Ventana Medical Systems Inc., Roche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.; Companion Diagnostics Pharma Services, Pathology Office, Ventana Medical Systems Inc., Roche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.; Companion Diagnostics, Project Management Office, Ventana Medical Systems Inc., Roche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.; Companion Diagnostics, Pharma Services, Clinical Services Management, Ventana Medical Systems Inc., Roche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.; Companion Diagnostics Pharma Services, CDx CAP/CLIA Lab Operations, Ventana Medical Systems Inc., Roche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA. james.hnatyszyn@roche.com.",james.hnatyszyn@roche.com.
27180926,Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.,2016-Jul,Gong; Huang; Papavassilis; Fox,"Beijing Novartis Pharma Co Ltd, Shanghai, China.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",peter.vandeKerkhof@radboudumc.nl.
27172791,Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.,2016-Jul-05,Cochonneau; Fougeray; Terme; Dorvillius; Birklé,"OGD2 Pharma, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.; OGD2 Pharma, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.; OGD2 Pharma, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.",
27169993,Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.,2016-Oct-01,,,benjamin.weide@med.uni-tuebingen.de.
27122234,Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys.,2016-Oct,Campbell; Noda; Verlinsky; Snyder; Fujita; Murakami; Fushiki; Miyoshi; Lacayo; Cabral; Yang; Stover; Joseph,"Agensys Inc., an affiliate of Astellas Pharma Inc., 1800 Stewart St, Santa Monica, CA, 90404, USA. dean.campbell@agensys.com.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan.; Agensys Inc., an affiliate of Astellas Pharma Inc., 1800 Stewart St, Santa Monica, CA, 90404, USA.; Agensys Inc., an affiliate of Astellas Pharma Inc., 1800 Stewart St, Santa Monica, CA, 90404, USA.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan.; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan.; Agensys Inc., an affiliate of Astellas Pharma Inc., 1800 Stewart St, Santa Monica, CA, 90404, USA.; Agensys Inc., an affiliate of Astellas Pharma Inc., 1800 Stewart St, Santa Monica, CA, 90404, USA.; Agensys Inc., an affiliate of Astellas Pharma Inc., 1800 Stewart St, Santa Monica, CA, 90404, USA.; Agensys Inc., an affiliate of Astellas Pharma Inc., 1800 Stewart St, Santa Monica, CA, 90404, USA.; Agensys Inc., an affiliate of Astellas Pharma Inc., 1800 Stewart St, Santa Monica, CA, 90404, USA.",dean.campbell@agensys.com.
27081038,"Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.",2016-May-31,Guarin; Bröske; Baehner; Brewster; Walz; Michielin; Runza; Meresse,"Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research & Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.; Pharma Research & Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.; Pharma Research & Early Development, Roche Innovation Centre, Welwyn, UK.; Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research & Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.; Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.",
27060634,"Immunocytokines for cancer treatment: past, present and future.",2016-Jun,,,neri@pharma.ethz.ch.
27052654,Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.,2016-Jul,Patre; de Haas; Xu,"Pharma Development Oncology.; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, USA.",mmartin@geicam.org.
27037558,KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.,2016-Aug,Collomb; Sicard; Bonnafous; Dujardin; Kadin,"Innate Pharma, Marseille, F-13276, France.; Innate Pharma, Marseille, F-13276, France.; Innate Pharma, Marseille, F-13276, France.; Innate Pharma, Marseille, F-13276, France.; Roger Williams Medical Center, Providence, RI, U.S.A.",
27037412,"RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",2016-May,Brünker; Wartha; Friess; Grau-Richards; Waldhauer; Koller; Weiser; Majety; Runza; Niu; Packman; Feng; Daouti; Hosse; Mössner; Weber; Herting; Scheuer; Sade; Shao; Liu; Wang; Xu; Vega-Harring; Klein; Bosslet; Umaña,"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, New York.; Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, New York.; Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, New York.; Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, New York.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.; Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.; Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.; Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. pablo.umana@roche.com.",pablo.umana@roche.com.
27032301,"Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.",2016-May,,,bertuccif@ipc.unicancer.fr.
27017616,"Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.",2016-May,Yoshiba; Jansen; Matsushima; Chen; Mendell,"Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa, Tokyo, 140-8710, Japan. yoshiba.satoshi.s8@daiichisankyo.co.jp.; Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Development, Ltd, Gerrards Cross, UK.; Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa, Tokyo, 140-8710, Japan.; Biostatistics and Data Management, Daiichi Sankyo Pharma Development, Edison, NJ, USA.; Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Pharma Development, Edison, NJ, USA.",yoshiba.satoshi.s8@daiichisankyo.co.jp.
27013443,Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.,2016-Jun-09,Rueter,"Medicine Oncology, Boehringer Ingelheim Pharma GmbH, Biberach/Riss, Germany; and.",
26984378,"XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.",2016,Schanzer; Wartha; Moessner; Hosse; Moser; Croasdale; Trochanowska; Shao; Wang; Shi; Weinzierl; Rieder; Bacac; Ries; Kettenberger; Schlothauer; Friess; Umana; Klein,"a Roche Pharma Research and Early Development, Roche Innovation Center Munich , Nonnenwald, Penzberg , Germany.; a Roche Pharma Research and Early Development, Roche Innovation Center Munich , Nonnenwald, Penzberg , Germany.; b Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Wagistrasse, Schlieren , Switzerland.; b Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Wagistrasse, Schlieren , Switzerland.; b Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Wagistrasse, Schlieren , Switzerland.; a Roche Pharma Research and Early Development, Roche Innovation Center Munich , Nonnenwald, Penzberg , Germany.; b Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Wagistrasse, Schlieren , Switzerland.; c Pharma Research and Early Development, Roche Innovation Center Shanghai , Cai Lun Road, Shanghai , China.; c Pharma Research and Early Development, Roche Innovation Center Shanghai , Cai Lun Road, Shanghai , China.; c Pharma Research and Early Development, Roche Innovation Center Shanghai , Cai Lun Road, Shanghai , China.; b Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Wagistrasse, Schlieren , Switzerland.; a Roche Pharma Research and Early Development, Roche Innovation Center Munich , Nonnenwald, Penzberg , Germany.; b Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Wagistrasse, Schlieren , Switzerland.; a Roche Pharma Research and Early Development, Roche Innovation Center Munich , Nonnenwald, Penzberg , Germany.; a Roche Pharma Research and Early Development, Roche Innovation Center Munich , Nonnenwald, Penzberg , Germany.; a Roche Pharma Research and Early Development, Roche Innovation Center Munich , Nonnenwald, Penzberg , Germany.; a Roche Pharma Research and Early Development, Roche Innovation Center Munich , Nonnenwald, Penzberg , Germany.; b Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Wagistrasse, Schlieren , Switzerland.; b Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Wagistrasse, Schlieren , Switzerland.",
26979130,Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.,2016-Aug,Fingerle-Rowson; Humphrey; de Costa; Iglesias,"Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Pharma Development Clinical Science, Roche Products Limited, Welwyn Garden City, UK.; Roche Pharmaceutical Research and Early Development (pRED), Pharmaceutical Sciences (PS), Roche Innovation Centre Basel, Basel, Switzerland.; Roche Pharmaceutical Research and Early Development (pRED), Pharmaceutical Sciences (PS), Roche Innovation Centre Basel, Basel, Switzerland.",
26976985,First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.,2016-Mar,Kiewitz; Klawitter,"Roche Pharma AG, Grenzach, Germany.; Roche Pharma AG, Grenzach, Germany.",andreas.schneeweiss@med.uni-heidelberg.de.
26976423,Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.,2016-May-10,,,ulrich.herrlinger@ukb.uni-bonn.de.
26972355,Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer.,2016-Mar-14,,,
26940768,Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a.,2016-Jun,Kotsuma; Hasegawa; Senaldi,"Translational Medicine and Clinical Pharmacology Department, Daiichi-Sankyo Co., Ltd., Tokyo, Japan.; Biologics Pharmacology Research Laboratories, Daiichi-Sankyo Co., Ltd., Tokyo, Japan.; Department of Translational Medicine and Clinical Pharmacology, Daiichi-Sankyo Pharma Development, Edison, New Jersey; and.",andrew.scott@onjcri.org.au.
26912427,A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.,2016-Jun,Müller,"Research Department Biology and Chemistry, Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen-PSI, Switzerland.",neri@pharma.ethz.ch.
26893500,The safety of vedolizumab for ulcerative colitis and Crohn's disease.,2017-May,Sankoh; Fox; Parikh; Milch; Abhyankar,"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.; Takeda Global Research and Development Centre (Europe) Ltd., London, UK.",
26886011,First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.,2016-Jun,,,
26876171,Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.,2016-Feb-23,Klein; Ries,"Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Zurich, 8952 Zurich, Switzerland.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Oncology Discovery, 82377 Penzberg, Germany.",federico.caligaris@airc.it.
26875184,Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.,2016-Feb,,,norahh@med.umich.edu.
26871714,"Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.",2016-Feb-12,,,
26864324,"Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.",2016,Scheuer; Thomas; Hanke; Sam; Osl; Weininger; Baehner; Seeber; Kettenberger; Schanzer; Brinkmann; Weidner; Regula; Klein,"a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; b Roche Innovation Center Zurich, Roche Pharma Research and Early Development , Wagistrasse 18, Schlieren , Switzerland.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; a Roche Innovation Center Penzberg, Roche Pharma Research and Early Development , Nonnenwald 2, Penzberg , Germany.; b Roche Innovation Center Zurich, Roche Pharma Research and Early Development , Wagistrasse 18, Schlieren , Switzerland.",
26863569,ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.,2016-Mar-01,,,
26857688,A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.,2016-Aug,Steinberg; Keating; Sasse; Jie,"d Astellas Pharma , Northbrook , IL , USA ;; d Astellas Pharma , Northbrook , IL , USA ;; d Astellas Pharma , Northbrook , IL , USA ;; d Astellas Pharma , Northbrook , IL , USA ;",
26830079,Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis.,2016-Feb,Iwamoto; Umino; Aoki; Yamane; Hamada; Shimada,"Life Science Research Center, SHIMADZU Corporation, Kanda-Nishiki-cho, Chiyoda-ku, Tokyo 101-8448, Japan.; Life Science Research Center, SHIMADZU Corporation, Kanda-Nishiki-cho, Chiyoda-ku, Tokyo 101-8448, Japan.; Life Science Research Center, SHIMADZU Corporation, Kanda-Nishiki-cho, Chiyoda-ku, Tokyo 101-8448, Japan.; CMIC Pharma Science Co., Ltd., Shibaura, Minato-ku, Tokyo 105-0023, Japan.; Division of Clinical Pharmacology, National Cancer Center, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.; Life Science Research Center, SHIMADZU Corporation, Kanda-Nishiki-cho, Chiyoda-ku, Tokyo 101-8448, Japan. Electronic address: t-shima@shimadzu.co.jp.",t-shima@shimadzu.co.jp.
26822398,"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.",2016-Mar,Goeldner; Uttenreuther-Fischer,"Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.",bhxu@hotmail.com.
26721894,Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.,2016-May,André; Bléry; Wagtmann,"Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.",loredana.ruggeri@unipg.it.
26716992,The INNs and outs of antibody nonproprietary names.,2016,Jones; Carter; Holgate; Hötzel; Popplewell; Clark; Lowe; Smith; Lambert; Reilly; Haurum; Schirrmann; Steegmaier; Davies; McCafferty; Baker,"a Antitope Ltd. (part of Abzena Plc.), Babraham Research Campus , Cambridge CB22 3AT , UK.; b Genentech Inc., 1 DNA Way , South San Francisco , CA 94080 , USA.; a Antitope Ltd. (part of Abzena Plc.), Babraham Research Campus , Cambridge CB22 3AT , UK.; b Genentech Inc., 1 DNA Way , South San Francisco , CA 94080 , USA.; e UCB Pharma., 208 Bath Road , Slough SL1 3WE , UK.; i Clark Antibodies Ltd., 11 Wellington Street , Cambridge CB1 1HW , UK.; j MedImmune Ltd., Milstein Building, Granta Park , Cambridge CB21 6GH , UK.; l Gilead Sciences Inc ., Foster City , CA 94404 , USA.; m ImmunoGen Inc., 830 Winter Street , Waltham , MA 02451-1477 , USA.; o Opsona Therapeutics Ltd., 2nd Floor, Ashford House , Tara Street , Dublin 2 , Ireland.; p F-Star Biotechnology Ltd., Babraham Research Campus , Cambridge CB22 3AT , UK.; s Yumab GmbH. , Rebenring , 38106 Braunschweig , Germany.; u Roche Pharmaceutical Research and Early Development,. Large Molecule Research, Roche Innovation Center Penzberg , 82377 Penzberg , Germany.; ab Lilly Biotechnology Center San Diego , CA 92121 , USA.; ae Iontas Ltd., Babraham Research Campus , Cambridge CB22 3AT , UK.; a Antitope Ltd. (part of Abzena Plc.), Babraham Research Campus , Cambridge CB22 3AT , UK.",
26691837,"Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial.",2016-Feb,Morita; Tanaka; Nomoto,"Clinical Research Planning Department, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan. jun.morita@meiji.com.; Clinical Research Planning Department, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan.; Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.",jun.morita@meiji.com.
26666258,Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.,2016-Jun,,,bruce.cree@ucsf.edu.
26655846,A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.,2016-May-01,,,laura.goff@Vanderbilt.edu.
26655425,"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.",2016-Jan,,,mathias.rummel@innere.med.uni-giessen.de.
26633908,Intensive Immunofluorescence Staining Methods for Low Expression Protein: Detection of Intestinal Stem Cell Marker LGR5.,2015-Oct-29,Yamazaki; Kato; Funahashi; Suzuki,"Research Division, Chugai Pharmaceutical Co., Ltd. , 1-135, Komakado, Gotemba, Shizuoka 412-8513, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd. , 1-135, Komakado, Gotemba, Shizuoka 412-8513, Japan.; Forerunner Pharma Research Co., Ltd. , 4-2-16, Komaba, Meguro-ku, Tokyo 153-8904, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd. , 1-135, Komakado, Gotemba, Shizuoka 412-8513, Japan.",
26581243,Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy.,2016-May-15,Gonzalez-Nicolini; Herter; Lang; Waldhauer; Bacac; Roemmele; Bommer; Freytag; van Puijenbroek; Umaña; Gerdes,"Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. christian.gerdes@roche.com.",christian.gerdes@roche.com.
26578779,Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.,2015-Nov-17,,,ikrop@partners.org
26567113,"Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.",2016-Jun,Desai; Mahmood; Mendell,"Daiichi-Sankyo Pharma Development, Edison, NJ, USA.; Daiichi-Sankyo Pharma Development, Edison, NJ, USA.; Daiichi-Sankyo Pharma Development, Edison, NJ, USA.",alockhar@dom.wustl.edu.
26565404,Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.,2015-Nov-13,Klein,"Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.",
26527790,"Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.",2015-Dec-10,,,jean.bourhis@chuv.ch.
26526566,Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.,2016-Jan,,,neri@pharma.ethz.ch.
26507836,"Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.",2016-Jun,Zhang; Bristow; Kaito; Strout,"Kyowa Hakko Kirin Pharma, Inc., Princeton, NJ, USA.; Kyowa Hakko Kirin Pharma, Inc., Princeton, NJ, USA.; Kyowa Hakko Kirin Pharma, Inc., Princeton, NJ, USA.; Kyowa Hakko Kirin Pharma, Inc., Princeton, NJ, USA.",sarantopoulo@uthscsa.edu.
26472752,"Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.",2016-Jan-07,Fingerle-Rowson; Tyson; Hirata,"F. Hoffmann-La Roche, Pharma Development Oncology, Basel, Switzerland;; F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom;; Genentech Inc., South San Francisco, CA; and.",
26472043,Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis.,2016-Jul,Kobayashi; Shoji; Togo,"i UCB Pharma , Shinjuku-ku , Tokyo , Japan .; i UCB Pharma , Shinjuku-ku , Tokyo , Japan .; i UCB Pharma , Shinjuku-ku , Tokyo , Japan .",
26463709,"First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.",2016-Feb-15,Jacob; Thomas; Ceppi; Meneses-Lorente; James; Adessi; Michielin; Abiraj; Bossenmaier; Weisser,"Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany. wolfgang.jacob@roche.com.; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom.; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.",wolfgang.jacob@roche.com.
26450879,Targeting the tumor niche to treat cancer.,2015-Oct-20,,,padsharma@mdanderson.org.
26447188,Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.,2015-Dec-10,Fingerle-Rowson; Wassner-Fritsch,"Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.",
26426340,Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?,2015,,,
26361971,"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.",2015-Oct,Graeven; Hinke,"Kliniken Maria Hilf GmbH, Department of Hematology, Oncology and Gastroenterology, Mönchengladbach, Germany.; WiSP Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.",hegewisch@t-online.de.
26358523,Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.,2015-Oct-06,,,
26341962,Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany.,2015-Nov,Wohlfarth,"Roche Pharma AG, Grenzach-Wyhlen, Germany.",peter.dall@klinikum-lueneburg.de.
26294742,Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.,2015-Nov,,,neri@pharma.ethz.ch.
26284426,A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice.,2015-Nov,Otto; Särnefält; Ljungars; Wolf; Rohde-Schulz; Fuchs; Schkoldow; Mattsson; Vonk; Harrenga; Freiberg,"TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; TRG Oncology and Gynaecological Therapy (C.O., S.W., B.R.-S., I.F., J.S.), and Department of Research and Clinical Sciences Statistics (R.V.), Bayer Pharma AG, 13342 Berlin, Germany; Department of Protein Engineering (A.S., A.L., M.M.), BioInvent International AB, Soelvegatan 41, SE-223 70 Lund, Sweden; and Department of Global Biologics (A.H., C.F.), Bayer Pharma AG, Aprather Weg 18a, 42113 Wuppertal, Germany.",
26264832,"Multifunctional liposomes having target specificity, temperature-triggered release, and near-infrared fluorescence imaging for tumor-specific chemotherapy.",2015-Oct-28,Hiramatsu; Kitagawa; Otani,"R&D Center, Katayama Chemical Industries Co. LTD, 4-1-7 Ina, Minoh, Osaka 562-0015, Japan.; R&D Center, Katayama Chemical Industries Co. LTD, 4-1-7 Ina, Minoh, Osaka 562-0015, Japan.; R&D Center, Katayama Chemical Industries Co. LTD, 4-1-7 Ina, Minoh, Osaka 562-0015, Japan.",kono@chem.osakafu-u.ac.jp.
26254483,Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.,2016-Jan,,,mam.suzuki@teijin.co.jp.
26253764,A common glycan structure on immunoglobulin G for enhancement of effector functions.,2015-Aug-25,Tsai; Chu; Liu; Lai; Shivatare; Wang; Chao; Wang; Shih; Zeng; You; Liao; Tu; Lin; Chuang; Tsai; Huang; Lin,"CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; Genomics Research Center, Academia Sinica, Taipei 115, Taiwan; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;; CHO Pharma Inc., Taipei 11503, Taiwan;",chwong@gate.sinica.edu.tw
26208478,Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.,2015-Sep-22,,,
26190254,Obinutuzumab in hematologic malignancies: lessons learned to date.,2015-Nov,Klein,"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. Electronic address: christian.klein.ck1@roche.com.",tmi@manchester.ac.uk.
26137564,"Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.",2015-Mar,Mendell; Freeman; Feng; Hettmann; Schneider; Blum; Ruhe; Bange; Nakamaru; Chen; Tsuchihashi; Copigneaux; Beckman,"Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA.; Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA.; Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA.; U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany.; U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany.; U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany.; U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany.; U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany.; Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.; Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA.; Daiichi Sankyo, Inc., Two Hilton Court, Parsippany, NJ 07054, USA.; Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA.; Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA.",
26123628,Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.,2015-Aug,Piwko,"CHP Pharma Inc, 20 Maimonides Court, Thornhill, ON, L4J 4X8, Canada, cpiwko@chppharma.com.",cpiwko@chppharma.com.
26115796,"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.",2015-Aug,,,aribas@mednet.ucla.edu.
26106084,Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA).,2015-Oct,Bader; Zajac; Friess; Ruge; Rieder; Thomas,"From the ‡Pharma Research & Early Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377, Penzberg, Germany;; §Pharma Research & Early Development, Roche Innovation Centre Welwyn, 6 Falcon Way, Shire Park, Welwyn Garden City, Herts, AL7 1TW, United Kingdom;; From the ‡Pharma Research & Early Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377, Penzberg, Germany;; From the ‡Pharma Research & Early Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377, Penzberg, Germany;; From the ‡Pharma Research & Early Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377, Penzberg, Germany;; ‖Roche Pharma AG, Emil-Barell-Str. 1, 79639, Grenzach-Wyhlen, Germany michael.pawlak@nmi.de marlene.thomas@roche.com.",michael.pawlak@nmi.de
26092818,"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.",2015-Jul,Rao; Pacaud; Taran,"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",shurvitz@mednet.ucla.edu.
26075403,Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.,2015,Boehm,"Novartis Pharma AG, Postfach, CH-4002, Basel, Switzerland.",
26071796,Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.,2015-Oct,Austin; Wang; Greenberg; Shiratori,"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Daiichi Sankyo Pharma Development, Edison, NJ, USA.; Daiichi Sankyo Pharma Development, Edison, NJ, USA.; Daiichi Sankyo Pharma Development, Edison, NJ, USA.",alcheng@ntu.edu.tw.
26030924,A Linear Epitope in the N-Terminal Domain of CCR5 and Its Interaction with Antibody.,2015,,,
26017283,90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts.,2015,Suga; Saito; Hino; Kasahara,"SANKYO LABO SERVICE Co., Ltd., Edogawaku, Tokyo, Japan.; FUJIFILM RI Pharma Co., Ltd., SAMMU-CITY, CHIBA, Japan.; FUJIFILM RI Pharma Co., Ltd., SAMMU-CITY, CHIBA, Japan.; FUJIFILM RI Pharma Co., Ltd., SAMMU-CITY, CHIBA, Japan.",
25999435,A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.,2015-Sep-15,Andre; Zerbib,"Innate Pharma, Marseille, France.; Innate Pharma, Marseille, France.",Don.benson@osumc.edu.
25943534,"Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.",2015-Sep,Stewart; Morrow; Marcus; Poon; Watkins; Mullins; Chodorge; Andrews; Bannister; Dick; Crawford; Parmentier; Alimzhanov; Foltz; Buchanan; Bedian; Wilkinson; McCourt,"MedImmune Ltd, Cambridge, United Kingdom. StewartR@medimmune.com.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; MedImmune Ltd, Cambridge, United Kingdom.; Abbvie Inc, Worcester, Massachusetts. Previously AstraZeneca Ltd.; Acceleron Pharma, Inc, Cambridge, Massachusetts. Previously Astrazeneca Ltd.; Amgen Inc, Burnaby, British Columbia, Canada.; MedImmune Ltd, Cambridge, United Kingdom.; AstraZeneca Ltd, Waltham, Massachusetts.; MedImmune Ltd, Cambridge, United Kingdom.; Kymab Ltd, The Bennet Building, Babraham Research Campus, Cambridge, United Kingdom. Previously MedImmune Ltd.",StewartR@medimmune.com.
25935650,Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling.,2015-May-03,Diefenbach,"Boehringer-Ingelheim Pharma GmbH, Biberach, Germany. claudia.diefenbach@boehringer-ingelheim.com.",jhk@nordicbioscience.com.
25934707,"AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",2015-Jul,Pereira; Guevara; Verlinsky; Hsu; Aviña; Karki; Abad; Yang; Moon; Malik; An; Morrison; Challita-Eid; Doñate; Joseph; Stover,"Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California. dpereira@agensys.com.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.; Agensys Inc., an Affiliate of Astellas Pharma Inc., Santa Monica, California.",dpereira@agensys.com.
25907615,Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin.,2016,Koch,"c Department of Medical Affairs , Takeda Pharma Ges.m.b.H , Vienna , Austria.",
25884529,Vedolizumab for the treatment of moderately to severely active ulcerative colitis.,2015-Apr,,,
25851632,RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.,2015-Jul,Anak; Gogov; Louveau,"Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma, Novartis Oncology BDM, Paris, France.",alain.ravaud@chu-bordeaux.fr.
25761109,Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.,2015,,,
25750312,"Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.",2015-Mar,Beck; Davidson; Brandt; Rizvi,"Highlands Oncology Group, Fayetteville, AR, U.S.A.; Leavey Cancer Center, Northridge, CA, U.S.A.; Novartis Pharma AG, Postfach, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A.",jrhecht@mednet.ucla.edu.
25702049,"Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.",2015-Apr,Meneses-Lorente,"Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, UK.",
25694444,Combined treatment strategies for microtubule stabilizing agent-resistant tumors.,2015-Apr,,,martin.pruschy@usz.ch.
25605368,"Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.",2015-Mar-19,Dwyer; Zhang; Kurman; Ballerini; Liu,"Kyowa Hakko Kirin Pharma Inc, Princeton, NJ;; Kyowa Hakko Kirin Pharma Inc, Princeton, NJ;; Kyowa Hakko Kirin Pharma Inc, Princeton, NJ;; Kyowa Hakko Kirin Pharma Inc, Princeton, NJ;; ReSearch Pharmaceutical Services, Inc, Fort Washington, PA; and.",
25601342,"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.",2015-Feb,,,jbradley@radonc.wustl.edu.
25537159,"A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.",2015-Apr,Arantes; Uttenreuther-Fischer; Solca,"Boehringer Ingelheim do Brasil QF Ltd, Santo Amaro, São Paulo.; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.",rimawi@bcm.edu.
25524310,Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.,2015-Feb-15,Eliasof; Garmey; Lazarus; Peters,"Cerulean Pharma Inc., Cambridge, Massachusetts.; Cerulean Pharma Inc., Cambridge, Massachusetts.; Cerulean Pharma Inc., Cambridge, Massachusetts.; Cerulean Pharma Inc., Cambridge, Massachusetts.",robert.kerbel@sri.utoronto.ca
25510242,Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.,2015-Feb,Andre; Morel,"Research & Development, Innate Pharma, Marseille, France.; Research & Development, Innate Pharma, Marseille, France.",t.mutis@vumc.nl.
25480118,Immunotherapy in prostate cancer: review of the current evidence.,2015-May,Fernández-García,"Pharma Mar S.A., Avenida de los Reyes, 1, Colmenar Viejo, Madrid, Spain, eva.m.fernandez.garcia@gmail.com.",eva.m.fernandez.garcia@gmail.com.
25459946,An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab.,2015-Jan,Stubenrauch; Wessels; Essig; Vogel; Waltenberger; Hansbauer; Koehler; Heinrich,"Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Large Molecule Bioanalytical Research & Assay Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377 Penzberg, Germany. Electronic address: kay-gunnar.stubenrauch@roche.com.; Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Large Molecule Bioanalytical Research & Assay Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377 Penzberg, Germany.; Roche Diagnostics GmbH, Roche Professional Diagnostic R&D, Nonnenwald 2, D-82377 Penzberg, Germany.; Roche Diagnostics GmbH, Roche Professional Diagnostic R&D, Nonnenwald 2, D-82377 Penzberg, Germany.; Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Starnberger See, Germany.; Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Starnberger See, Germany.; Roche Pharma Research and Early Development (pRED), Oncology, Translational Medicine Group, Roche Innovation Center Penzberg, Nonnenwald 2, 82377 Penzberg, Germany.; Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Large Molecule Bioanalytical Research & Assay Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377 Penzberg, Germany.",kay-gunnar.stubenrauch@roche.com.
25456838,Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.,2015-Jun,Slimane; Kelkouli,"Oncology Department, Novartis Pharma, Paris, France.; Oncology Department, Novartis Pharma, Paris, France.",a.thieryvuillemin@mac.com.
25398804,Quantum dots-bevacizumab complexes for in vivo imaging of tumors.,2014,Papalois,"Experimental and Research Center, ELPEN Pharma, Athens, Greece.",mgazouli@med.uoa.gr.
25370464,Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.,2015-Jun-15,Uttenreuther-Fischer; Temple; Pelling; Schnell,"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Boehringer Ingelheim Ltd., Bracknell, United Kingdom.; Boehringer Ingelheim Ltd., Bracknell, United Kingdom.; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",alistair.ring@rmh.nhs.uk.
25361998,"IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.",2014-Nov-01,Viaud; Joly; Chanteux; Gauthier; Bonnafous; Rossi; Bléry; Paturel; Sicard,"INNATE PHARMA, Marseilles, France.; INNATE PHARMA, Marseilles, France.; INNATE PHARMA, Marseilles, France.; INNATE PHARMA, Marseilles, France.; INNATE PHARMA, Marseilles, France.; INNATE PHARMA, Marseilles, France.; INNATE PHARMA, Marseilles, France.; INNATE PHARMA, Marseilles, France.; INNATE PHARMA, Marseilles, France. helene.sicard@innate-pharma.fr anne.marie-cardine@inserm.fr.",helene.sicard@innate-pharma.fr
25287822,Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.,2014-Nov-10,,,csaura@vhio.net.
25209423,Optimal design of clinical trials with biologics using dose-time-response models.,2014-Dec-30,,,
25143487,Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.,2014-Oct-02,Lei; Wassner-Fritsch,"Pharma Development Biostatistics, Roche Products, Welwyn Garden City, United Kingdom;; Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland; and.",
25123819,Can we unlock the potential of IGF-1R inhibition in cancer therapy?,2014-Oct,,,helen.king@stcatz.ox.ac.uk.
25111131,Current issues of RNAi therapeutics delivery and development.,2014-Dec-10,,,dirk.haussecker@gmail.com.
25101331,Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.,2014-Jul,,,scientificprousjournals@thomsonreuters.com.
25085789,89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.,2014-Aug-01,Akimov; Fernandez-Ibarra,"Novartis Pharma AG, Basel, Switzerland and Novartis Pharmaceuticals, Cambridge, Massachusetts.; Novartis Pharma AG, Basel, Switzerland and Novartis Pharmaceuticals, Cambridge, Massachusetts.",c.p.schroder@umcg.nl.
25073100,A fibrin-specific monoclonal antibody from a designed phage display library inhibits clot formation and localizes to tumors in vivo.,2014-Oct-23,,,alessiaputelli@pharma.ethz.ch.
24925479,Monoclonal antibodies to murine thrombospondin-1 and thrombospondin-2 reveal differential expression patterns in cancer and low antigen expression in normal tissues.,2014-Sep-10,,,neri@pharma.ethz.ch.
24916506,PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.,2014-Jul-17,Weisser; Yeh; Duchateau-Nguyen; Palermo; Nguyen; Shi; Stinson; Yu; Valente; Wenger; Dornan,"Roche Pharma Research and Early Development, Penzberg, Germany;; Biostatistics, Genentech Inc., South San Francisco, CA;; F. Hoffman-La Roche Ltd., Basel, Switzerland;; F. Hoffman-La Roche Ltd., Basel, Switzerland;; F. Hoffman-La Roche Ltd., Basel, Switzerland;; Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;; Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;; Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;; BioOncology, Genentech Inc., South San Francisco, CA; and.; Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;",
24906181,Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization.,2014-Oct,,,
24870719,ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.,2014,Abiraj; Bossenmaier; Thomas; Hölzlwimmer; Friess,"Pharma Research & Early Development (pRED); F. Hoffmann-La Roche AG; Basel, Switzerland.; Pharma Research & Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany.; Pharma Research & Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany.; Pharma Research & Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany.; Pharma Research & Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany.",
24859229,Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.,2014,Yasri,"OriBase Pharma; Cap Gamma; Parc Euromédecine; Montpellier, France.",
24828661,"Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.",2014-Jun,,,
24827808,"Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.",2014-Jun,,,n.schmitz@asklepios.com.
24795343,Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.,2014-Jun,,,neri@pharma.ethz.ch.
24795141,The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.,2014-Jun,,,neri@pharma.ethz.ch.
24662970,Influence of glycosylation pattern on the molecular properties of monoclonal antibodies.,2014,Zheng; Bantog; Bayer; Patapoff,"Late Stage Pharmaceutical Development; Genentech Inc.; South San Francisco, CA USA; Formerly at Oceanside Pharma Technical Development; Genentech Inc.; Oceanside, CA USA.; Formerly at Oceanside Pharma Technical Development; Genentech Inc.; Oceanside, CA USA; Department of Chemistry Development; Illumina Inc.; San Diego, CA USA.; Formerly at Oceanside Pharma Technical Development; Genentech Inc.; Oceanside, CA USA; Biotherapeutics Development Unit; Novartis Inc.; San Diego, CA USA.; Early Stage Pharmaceutical Development; Genentech Inc.; South San Francisco, CA USA.",
24589717,"Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.",2014,Reichert; Bléry; Laurén,"Reichert Biotechnology Consulting, LLC; Framingham, MA USA.; Innate Pharma; Marseille, France.; Regeneron Pharmaceuticals, Inc.; Tarrytown, NY USA.",
24563615,"Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment response.",2014-Jan,Scheuer; Strobel,"Discovery Oncology, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, Germany.; Discovery Oncology, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, Germany.",
24529991,Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.,2014-Mar-20,van Dieck; Schmid; Heindl; Dziadek; Schraeml; Gerg; Massoner; Engel; Tiefenthaler; Vural; Stritt; Tetzlaff; Soukupova; Kopetzki; Bossenmaier; Thomas; Klein; Mertens; Heller; Tacke,"Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Glycart AG, 8952 Schlieren, Switzerland.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Pharma Research and Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.; Roche Professional Diagnostics, Roche Diagnostics GmbH, 82377 Penzberg, Germany. Electronic address: michael.tacke@roche.com.",michael.tacke@roche.com.
24520328,Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.,2014,Terme; Dorvillius; Chaumette; Birklé,"ATLAB Pharma, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France ; INSERM U.892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France ; CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.; ATLAB Pharma, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.; INSERM U.892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France ; CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France ; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.; INSERM U.892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France ; CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France ; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.",
24492295,Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.,2014,Weigand; Bergstrom; Nayak,"Discovery Oncology; Pharma Research and Early Development; Roche Diagnostics Gmb; Penzberg, Germany.; Oncology Translational Imaging; Pharma Research and Early Development; F Hoffmann-La Roche Ltd; Basel, Switzerland.; Oncology Translational Imaging; Pharma Research and Early Development; F Hoffmann-La Roche Ltd; Basel, Switzerland.",
24487095,A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development.,2014-Mar-17,Neri,"ETH Zurich, Department of Chemistry and Applied Biosciences, Wolfgang-Pauli-Strasse 10, 8093 Zurich, Switzerland. Electronic address: neri@pharma.ethz.ch.",tim.fugmann@philochem.ch.
24486595,"Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.",2014-Apr-01,Kaneko,"Authors' Affiliation: Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, Japan.",
24470511,Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.,2014-Apr-01,,,
24465541,"Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).",2014,,,
24443618,Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.,2014-Jan-15,,,
24423618,"World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.",2014,,,
24386306,Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.,2013,Kawai; Yamada-Okabe,"Research Division, Forerunner Pharma Research Co. Ltd., Tokyo, Japan.; Research Division, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan.",
24384233,Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.,2014-Feb-20,,,dario.neri@pharma.ethz.ch.
24362366,"Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.",2014-Mar,Hinke; Hinke,"Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.; Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.",
24336633,The translational potential for target validation and therapy using intracellular antibodies in oncology.,2013,Weidle,"Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Im Nonnenwald 2, D-82372 Penzberg, Germany. ulrich.weidle@roche.com.",ulrich.weidle@roche.com.
24304419,Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.,2014-Sep,Herting,"Discovery Oncology, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH , Penzberg , Germany.",
24253022,New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).,2014-Mar,,,
24188818,Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.,2013-Nov-10,Lambertini,"Novartis Pharma AG, CH-4057 Basel, Switzerland. Electronic address: chiara.lambertini@novartis.com.",chiara.lambertini@novartis.com.
24092417,Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.,2015-Jan,de Longueville,"UCB Pharma SA, Brussels, Belgium.",
24061648,Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.,2013-Dec,,,elengyel@uchicago.edu.
23974006,RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.,2013-Oct-15,Yin,"Authors' Affiliations: Roche Pharma Research and Early Development, Nutley, New Jersey; Roche Diagnostics GmbH, Pharma Research & Early Development, Nonnenwald, Penzberg, Germany; and Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland.",
23953030,"A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).",2013-Nov,,,g.middleton@bham.ac.uk.
23908588,Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin.,2013-Aug,Weber,"Pharma Research and Early Development, Discovery Oncology, Roche Diagnostics GmbH, Penzberg, Germany. thomas.weber.tw7@roche.com",thomas.weber.tw7@roche.com
23893924,The emerging role of new protein scaffold-based agents for treatment of cancer.,2013,Weidle,"Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany. ulrich.weidle@roche.com",ulrich.weidle@roche.com
23873847,Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.,2013-Oct,Herter,"Corresponding Author: Christian Klein, Roche Pharma Research and Early Development, Roche Glycart AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland. christian.klein.ck1@roche.com.",christian.klein.ck1@roche.com.
23780344,"RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.",2013-Aug-15,Mirschberger,"Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany. brigit.bossenmaier@roche.com",brigit.bossenmaier@roche.com
23743569,"Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.",2013-Jul-15,,,Kimmie_Ng@dfci.harvard.edu
23641698,A personal perspective of the development and validation of a phase-specific antibody-drug conjugate cytotoxicity potency assay.,2013-May,Wilson,"Pharma Solutions, Piramal Healthcare Limited, Earls Road, Grangemouth, Stirlingshire, FK3 8XG, UK. robert.wilson@piramal.com",robert.wilson@piramal.com
23433739,"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.",2013-Apr-06,,,mathias.rummel@innere.med.uni-giessen.de
23331696,Kinase dysfunction and kinase inhibitors.,2013-Feb,,,cheryl.london@cvm.osu.edu
23285246,"ADH IB expression, but not ADH III, is decreased in human lung cancer.",2012,Mutka,"N30 Pharmaceuticals, Inc., Boulder, Colorado, United States of America. sarah.mutka@n30pharma.com",sarah.mutka@n30pharma.com
23211638,Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.,2013,Klein,"Discovery Oncology, Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland. christian.klein.ck1@roche.com",christian.klein.ck1@roche.com
23096716,The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.,2013-Mar,,,dario.neri@pharma.ethz.ch.
22787117,Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.,2012-Oct,Kita,"Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan.",
22777824,Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist.,2012-Sep-01,Weigand,"Discovery Oncology, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany. Stefan.weigand@roche.com",Stefan.weigand@roche.com
22641239,Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.,2012-Sep,,,blairegerdie@mac.com
22553195,A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.,2012-Oct,Vincent,"Agensys Inc., An Affiliate of Astellas Pharma Inc., Santa Monica, USA.",morrism@mskcc.org.
22528864,"Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies.",2013-Feb,Poeschinger,"Roche Diagnostics GmbH, pRED, Pharma Research & Early Development, DTA Oncology, Nonnenwald 2, 82377 Penzberg, Germany. thomas.poeschinger@roche.com",thomas.poeschinger@roche.com
22464987,Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.,2012-Oct-15,Croasdale,"Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, D-82372 Penzberg, Germany.",
22421340,The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.,2012-Mar-31,,,
21980036,Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer.,2011,Weidle,"Roche Diagnostics, Division Pharma, Im Nonnenwald, Penzberg, Germany. ulrich.weidle@roche.com",ulrich.weidle@roche.com
21898590,Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.,2011-Dec,,,smith.matthew@mgh.harvard.edu
21815704,Receptor kinase inhibitors target NSCLC: two antibodies and a small-molecule MET inhibitor.,2011-Aug-01,Yee,"inThought Research, Wolters Kluwer Pharma Solutions, Yardley, PA, USA. david.yee@wolterskluwer.com",david.yee@wolterskluwer.com
21668044,Ipilimumab: first global approval.,2011-May-28,Cameron,"RD Insight, Wolters Kluwer Pharma Solutions, Auckland, New Zealand.",
21536919,Bispecific digoxigenin-binding antibodies for targeted payload delivery.,2011-May-17,Metz,"Roche Pharma Research and Early Development, Biologics Engineering, D-82377 Penzberg, Germany.",
21443276,Trials define anti-tumor effects of anti-resorptive agents: denosumab ahead of zoledronate 2 to 1.,2011-Apr-01,Weintraub,"inThought Research, Wolters Kluwer Pharma Solutions, Yardley, Pennsylvania 19067, USA. ben.weintraub@wolterskluwer.com",ben.weintraub@wolterskluwer.com
21378200,"Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.",2011-Nov,Brendel; Krätzschmar; Loembé; Christensen,"Department of Pharmacokinetic Analysis, Bayer HealthCare AG, Wuppertal, Germany.; Department of Pharmacokinetic Analysis, Bayer HealthCare AG, Wuppertal, Germany.; Bayer Schering Pharma, Mijdrecht, The Netherlands.; Bayer Pharmaceuticals Inc., Montville, USA.",e.e.voest@umcutrecht.nl.
21364752,Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines.,2011-Feb-18,Franke,"Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany.",
21156962,Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer.,2010,Weidle,"Roche Diagnostics, Division Pharma, Im Nonnenwald 2, Penzberg, Germany. ulrich.weidle@roche.com",ulrich.weidle@roche.com
21154164,"IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers.",2010-Dec,,,Evren.Alici@ki.se
21050974,Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?,2010-Nov-09,,,
21034418,Endoglin-targeted cancer therapy.,2011-Jan,,,ben.seon@roswellpark.org
20828971,A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.,2011-Jan-05,Winter,"Analytical Development, Bayer Schering Pharma AG, Müllerstr. 178, 13353 Berlin, Germany. jonas.winter@bayerhealthcare.com",jonas.winter@bayerhealthcare.com
20694021,Research and development of next generation of antibody-based therapeutics.,2010-Sep,Li,"Novartis Pharma AG, Cambridge, MA 02139, USA.",
20551248,Cancer-related issues of CD147.,2010,Weidle,"Roche Diagnostics, Division Pharma, D-82377 Penzberg, Germany. ulrich.weidle@roche.com",ulrich.weidle@roche.com
20494963,"Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma.",2010-Dec,Marillonnet; Kandzia; Thieme; Nickstadt; Herz; Fröde; Lenz; Butler-Ransohoff; Klimyuk; Gleba,"Icon Genetics GmbH, Halle, Germany.; Icon Genetics GmbH, Halle, Germany.; Icon Genetics GmbH, Halle, Germany.; Icon Genetics GmbH, Halle, Germany.; Icon Genetics GmbH, Halle, Germany.; Icon Genetics GmbH, Halle, Germany.; Bayer Schering Pharma, Wuppertal, Germany.; Bayer Innovation GmbH, Duesseldorf, Germany.; Icon Genetics GmbH, Halle, Germany.; Icon Genetics GmbH, Halle, Germany. Electronic address: gleba@icongenetics.de.",gleba@icongenetics.de.
20190561,Catumaxomab: clinical development and future directions.,2010,Linke,"Fresenius Biotech GmbH, Munich, Germany.",
20179216,"Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.",2010-Mar-01,Hammer,"Bayer Schering Pharma AG, Global Drug Discovery, Berlin, Germany. stefanie.hammer@bayerhealthcare.com",stefanie.hammer@bayerhealthcare.com
20127951,Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.,2010-Feb-15,,,
20068403,"Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.",2009,,,thierry.wurch@pierre-fabre.com
20044598,L1-CAM as a target for treatment of cancer with monoclonal antibodies.,2009-Dec,Weidle,"Roche Diagnsotics GmbH, Division Pharma, D 82372 Penzberg, Germany. ulrich.weidle@roche.com",ulrich.weidle@roche.com
19934333,Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.,2009-Dec-15,Scheuer,"Roche Diagnostics GmbH, Pharma Research Penzberg, Penzberg, Germany.",
19712009,Economic burden of follicular non-Hodgkin's lymphoma.,2009,Foster,"Abt Bio-Pharma Solutions, Inc., Lexington, Massachusetts, USA. talia.foster@abtbiopharma.com",talia.foster@abtbiopharma.com
19685053,The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer.,2009-Dec,Dredge,"Progen Pharmaceuticals Ltd, PO Box 2403, Toowong, Brisbane, QLD 4066, Australia. keithd@progen-pharma.com",keithd@progen-pharma.com
19561305,Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo.,2009-Aug-04,Sola,"Innate-Pharma, 13009 Marseille, France.",
19553639,"Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.",2009-Sep-24,Romagné,"Innate-Pharma SA, Marseille, France. Francois.romagne@innate-pharma.fr",Francois.romagne@innate-pharma.fr
19414332,"Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers.",2009-Apr,Weidle,"Roche Diagnostics GmbH, Pharma Research, D-82377 Penzberg, Germany. ulrich.weidle@roche.com",ulrich.weidle@roche.com
19061730,[Contribution of radioimmunotherapy to the treatment of lymphoma].,2008,,,nathalie.padoin@lrb.aphp.fr
18767949,Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine.,2008-Sep,Luby,"MGI Pharma, 35 Hartwell Avenue, Lexington, MA 02421, USA. thomas.luby@mgipharma.com",thomas.luby@mgipharma.com
18535935,"Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.",2008-Jun,Shen,"ImClone Systems Inc, 180 Varick Street, New York, NY 10014 USA.",
18279418,Three-year follow-up of malignancies in tacrolimus-treated renal recipients--an analysis of European multicentre studies.,2008,Cowlrick,"Astellas Pharma GmbH, Medical Affairs, Munich, Germany. ivor.cowlrick@eu.astellas.com",ivor.cowlrick@eu.astellas.com
18200068,Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.,2008-Mar,Pühler,"Therapeutic Research Group Oncology, Bayer Schering Pharma AG, Berlin, Germany.",
18158780,Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.,2007-Dec,Moffett,"ProScan Rx Pharma Inc, Montréal, Québec, Canada. smoffett@proscanrxpharma.com",smoffett@proscanrxpharma.com
17261171,Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis.,2007,,,eveline.trachsel@pharma.ethz.ch
17214744,"Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.",2007-Mar,Hanada,"Pharmacology Research Laboratories, Drug Research Division, Dainippon Sumitomo Pharma Co., Ltd, 3-1-98, Kasugadenaka, Konohana-ku, Osaka 554-0022, Japan. mitsuharu-hanada@ds-pharma.co.jp",mitsuharu-hanada@ds-pharma.co.jp
21901074,Targeted brain tumor treatment-current perspectives.,2007,,,
17117720,Current stumbling blocks in oncology drug development.,2007,Gimmi,"Global Pharma Development, Medical Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Claude.Gimmi@Roche.com",Claude.Gimmi@Roche.com
17073521,"Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.",2006,,,
16612145,Characterization of antibodies to CA 125 that bind preferentially to the cell-associated form of the antigen.,2006,Singleton,"Department of Immunotherapeutics, Purdue Pharma, L.P., Cranbury, NJ, USA.",
16596472,TGFbeta in cancer and other disease - AACR special conference in cancer research.,2006-Apr,Jachimczak,"Antisense Pharma GmbH, Josef-Engert-Strasse 9, D-93053 Regensburg, Germany. jachimczak@t-online.de",jachimczak@t-online.de
16434088,Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.,2006-Sep,Masters,"Purdue Pharma, L.P., Immunotherapeutics Department, 6 Cedar Brook Drive, Cranbury, NJ 08512, USA.",
16398611,"Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer.",2005-Dec,Berger,"Purdue Pharma, L.P., Immunotherapeutics Department, Cranbury, NJ, USA.",
15943563,Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4).,2005-Jun,Chen,"Department of Immunotherapeutics, Discovery Research, Purdue Pharma, LP, Cranbury, New Jersey, USA. charlie.chen2@sanofipasteur.com",charlie.chen2@sanofipasteur.com
15541284,A new immunofluorostaining method using red fluorescence of PerCP on formalin-fixed paraffin-embedded tissues.,2004-Oct,Niki,"Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan.",
15180497,Novel approaches for targeted cancer therapy.,2004-Jun,,,uri@pharma.mcgill.ca
15157394,[CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].,2004-Apr,,,
15122339,JNK activation is critical for Aplidin-induced apoptosis.,2004-Jun-10,Cuadrado,"Pharma Mar SA, E-28770 Colmenar Viejo, Madrid, Spain.",
14562030,Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner.,2003-Oct-20,Hosokawa,"Pharmaceuticals Research Division, Mitsubishi Pharma Coporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan.",
12908776,From conventional to stealth liposomes: a new frontier in cancer chemotherapy.,2003,,,luigi.cattel@unito.it
12899647,"Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.",2003,,,
12630290,Targeting protein kinases in cancer therapy.,2002-Sep,Fabbro,"Oncology Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. doriano.fabbro@pharma.novartis.com",doriano.fabbro@pharma.novartis.com
11990467,Targeted delivery of tissue factor to tumor neovasculature for cancer therapy.,2001,,,neri@pharma.anbi.ethz.ch
11920682,Expression and targeting of the tight junction protein CLDN1 in CLDN1-negative human breast tumor cells.,2002-Apr,Hoevel,"Roche Diagnostics GmbH, Pharma Research Oncology, Department of Cell Analytics, Penzberg, Germany.",
11521716,Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.,2001,,,heidi.lane@pharma.novartis.com
11323162,Assessment of biotechnology products for therapeutic use.,2001-Mar-31,Sims,"Novartis Pharma AG, WSH2881, Auhafen, 4132 Muttenz, Basel, Switzerland. jennifer.sims@pharma.novartis.com",jennifer.sims@pharma.novartis.com
11259992,Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.,2001-Feb,Tanswell,"Department of Pharmacokinetics and Drug Metabolism, Boehringer Ingelheim Pharma KG, Biberach, Germany. paul.tanswell@bc.boehringer-ingelheim.com",paul.tanswell@bc.boehringer-ingelheim.com
10855790,"Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.",1999,Schlaeppi,"Core Technology, Novartis Pharmaceuticals, Novartis Limited, Basle, Switzerland. jean-marc.schlaeppi@pharma.novartis.com",jean-marc.schlaeppi@pharma.novartis.com
10363565,"Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor.",1999,Schlaeppi,"Novartis Pharmaceuticals, Core Technology Department, Novartis Limited, Basel, Switzerland. jean-marc.schlaeppi@pharma.novartis.com",jean-marc.schlaeppi@pharma.novartis.com
10029083,Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library.,1999-Feb-15,Geiser,"Novartis Pharma AG, Core Technology Area, Basel, Switzerland. martin.geiser@pharma.novartis.com",martin.geiser@pharma.novartis.com
10023696,Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.,1999-Jan-15,,,
9804890,Functional and physical association of a cell surface phospholipid and interleukin-2 receptor p55(alpha) subunits.,1998-Nov-11,,,uri@pharma.mcgill.ca
8623459,Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation.,1996-Apr,Kovarik,"Sandoz Pharma Ltd., Basle, Switzerland.",
8722416,Monoclonal antibodies in tumor therapy.,1996,Matzku,"E. Merck KGaA, Pharma Preclinical Research, Darmstadt, Germany.",
7490449,Establishment and evaluation of MRK16-magnetic cell sorting assays for detecting low expression of multidrug resistance P-glycoprotein using human leukemia cell lines and peripheral blood cells from healthy donors.,1995-Nov-16,Okochi,"Pharma Research and Development Division, Hoechst, Japan Ltd., Saitama, Japan.",
7511316,Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.,1994,Karamitopoulou,"Sandoz Pharma Ltd., Department of Toxicology, Basle, Switzerland.",
8106147,Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.,1993-Nov-15,Iwahashi,"Pharma Research Laboratories, Hoechst Japan LTD., Saitama.",
8431517,Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer.,1993,Kuijpers,"AKZO Pharma Division, Organon International BV, Oss, The Netherlands.",
8337939,p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies.,1993,Karamitopoulou,"Sandoz Pharma Ltd., Department of Toxicology, Basel, Switzerland.",
1718127,Granular cell brain tumors of the laboratory rat: an immunohistochemical approach.,1991,Perentes,"Sandoz Pharma Ltd., Department of Toxicology, Basle, Switzerland.",
2098110,Immunotoxin construction with a ribosome-inactivating protein from barley.,1990,,,
2519205,[Novel neutral glycolipid associated with adult T-cell leukemia and its pathological biochemistry].,1989-Mar,Ono,"Laboratory for Cell Biology, Pharma Research Laboratories, Hoechst Japan, Ltd., Kawagoe.",
